STIC Search Report
EIC 1700

STIC Database Tracking Number: 176724

TO: Ben Sackey
Location: REM 5B31
Art Unit : 1626
January 25, 2006

Case Serial Number: 10/654112

From: Ross Shipe
Location: EIC 1700
REMSEN 4B31
Phone: 571/272-6018
Ross.Shipe@uspto.gov

Search Notes

Examiner Sackey:

Please review the attached search results.
If you have any questions or if you would like to refine the search query, please feel free to contact me at any time.

Thanks you for using EIC 1700 search services!

Ross Shipe (ASRC)
Technical Information Specialist

FOR OFFICIAL USE ONLY

ACCESS DB # 176724

PLEASE PRINT CLEARLY

MNs fulltext

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: BEN SACKEY Examiner #: 73489 Date: 1/14/06

Art Unit: 1626 Phone Number: 2-0704 Serial Number: 10/654,112

Location (Bldg/Room#): REM 5B31 (Mailbox #): _____ Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Modulation of CCR4 function

Inventors (please provide full names): Tassie Collins et al.

Earliest Priority Date: 5/23/01

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

A method of treating a CCR4-mediated disease in a subject comprising the administration of a compd of formula (1) claim 1 $Ar^1 - X - Ar^2$ wherein:

Ar^1 is phenyl and naphthyl

X is -N(R)- or -C(O)S-

Ar^2 is substituted thiazolyl

or

formula (1) of claim 80 wherein

N is naphthyl, Y is NH, Z is -N; X is -S-, Thanks

R^1 is C_{1-8} alkyl, H, halogen, CN, CO_2R, $CONR'R''$,

R^2 ✓ ✓ ✓ ✓ ✓ ✓ ✓

****

STAFF USE ONLY

Searcher: ROS

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: 1/25/06

Searcher Prep & Review Time: 30

Online Time: 180

Type of Search

_____ NA Sequence (#)

_____ AA Sequence (#)

2 Structure (#)

_____ Bibliographic

_____ Litigation

_____ Fulltext

_____ Other

Vendors and cost where applicable

✓ STN _____ Dialog

_____ Questel/Orbit _____ Lexis/Nexis

_____ Westlaw _____ WWW/Internet

___ In-house sequence systems

___ Commercial ___ Oligomer ___ Score/Length

___ Interference ___ SPDI ___ Encode/Transl

_____ Other (specify)

```
=> d his full

     FILE 'REGISTRY' ENTERED AT 09:25:17 ON 25 JAN 2006
                ACT SAC112/A
L1              STR
L2              SCR 1839
L3              SCR 1842
L4              SCR 2043
L5              SCR 1918
L6              STR
L7   (    341980)SEA SSS FUL L6 AND L2 NOT (L3 OR L4 OR L5)
L8         28391 SEA SUB=L7 SSS FUL L1


     FILE 'HCAPLUS' ENTERED AT 09:25:47 ON 25 JAN 2006
L9          1532 SEA ABB=ON  PLU=ON  L8
L10          762 SEA ABB=ON  PLU=ON  CCR4
L11       435105 SEA ABB=ON  PLU=ON  TREAT? (L) (CONDITION# OR DISEASE#)
L12          561 SEA ABB=ON  PLU=ON  CCR4 (L) CHEMOKINE (L) RECEPTOR#
L13        41743 SEA ABB=ON  PLU=ON  PSORIAS## OR DERMATAT? OR ASTHMA?
L14            3 SEA ABB=ON  PLU=ON  L9 AND L10
L15            2 SEA ABB=ON  PLU=ON  L9 AND L11 AND L12
L16          149 SEA ABB=ON  PLU=ON  L9 AND L11
L17           28 SEA ABB=ON  PLU=ON  L9 AND L11 AND L13
L18        13027 SEA ABB=ON  PLU=ON  CHEMOKINE (L) RECEPTOR#
L19            3 SEA ABB=ON  PLU=ON  L9 AND L11 AND L18
L20            2 SEA ABB=ON  PLU=ON  L9 AND L18 AND L13
L21            5 SEA ABB=ON  PLU=ON  L9 AND L18
L22          552 SEA ABB=ON  PLU=ON  L9 AND (BSU OR BIOL OR PAC OR
                 THU)/RL
L23            5 SEA ABB=ON  PLU=ON  L9 AND (BSU OR BIOL OR PAC OR
                 THU)/RL  AND L18
L24           39 SEA ABB=ON  PLU=ON  L9 AND (BSU OR BIOL OR PAC OR
                 THU)/RL  AND L13
L25            5 SEA ABB=ON  PLU=ON  L14 OR L15 OR L19 OR L20 OR L21 OR
                 L23
L26           37 SEA ABB=ON  PLU=ON  (L17 OR L24) NOT L25
L27        13651 SEA ABB=ON  PLU=ON  RECEPTOR (L) MODULATOR#
L28        77983 SEA ABB=ON  PLU=ON  INFLAMMAT? (L) (CONDITION# OR
                 DISEASE#)
L29           12 SEA ABB=ON  PLU=ON  L9 AND L27
L30           19 SEA ABB=ON  PLU=ON  (L17 OR L24) AND (L28 OR L27) NOT
                 L25
L31           10 SEA ABB=ON  PLU=ON  L29 NOT (L19 OR L25)
L32           24 SEA ABB=ON  PLU=ON  L30 OR L25

     FILE 'CAOLD' ENTERED AT 09:56:29 ON 25 JAN 2006
L33          127 SEA ABB=ON  PLU=ON  L8
L34            0 SEA ABB=ON  PLU=ON  L33 AND CCR4
L35            0 SEA ABB=ON  PLU=ON  L33 AND CHEMOKINE AND RECEPTOR#
L36            0 SEA ABB=ON  PLU=ON  L33 AND PHARMAC?/SC,SX
L37            0 SEA ABB=ON  PLU=ON  L33 AND TREAT?/TI
L38            0 SEA ABB=ON  PLU=ON  L33 AND CCR4/TI
L39            0 SEA ABB=ON  PLU=ON  L33 AND CHEMOKINE/TI


=> file reg
FILE 'REGISTRY' ENTERED AT 10:21:46 ON 25 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

=> d l32 que stat
L1 STR



VAR G1=22/19-3 20-13/20-3 19-13
VAR G2=18/14/16
VAR G3=H/AK
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 14
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L2 SCR 1839
L3 SCR 1842
L4 SCR 2043
L5 SCR 1918
L6 STR



REP G1=(0-3) A
VAR G2=18/14/16
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 14
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L7 (341980) SEA FILE=REGISTRY SSS FUL L6 AND L2 NOT (L3 OR L4 OR L5)
L8 28391 SEA FILE=REGISTRY SUB=L7 SSS FUL L1
L9 1532 SEA FILE=HCAPLUS ABB=ON PLU=ON L8
L10 762 SEA FILE=HCAPLUS ABB=ON PLU=ON CCR4
L11 435105 SEA FILE=HCAPLUS ABB=ON PLU=ON TREAT? (L) (CONDITION# OR DISEASE#)
L12 561 SEA FILE=HCAPLUS ABB=ON PLU=ON CCR4 (L) CHEMOKINE (L) RECEPTOR#
L13 41743 SEA FILE=HCAPLUS ABB=ON PLU=ON PSORIAS## OR DERMATAT? OR ASTHMA?

```
L14           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND L10
L15           2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND L11 AND L12
L17          28 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND L11 AND L13
L18       13027 SEA FILE=HCAPLUS ABB=ON  PLU=ON  CHEMOKINE (L) RECEPTOR#

L19           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND L11 AND L18
L20           2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND L18 AND L13
L21           5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND L18
L23           5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND (BSU OR BIOL OR
                PAC OR THU)/RL  AND L18
L24          39 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND (BSU OR BIOL OR
                PAC OR THU)/RL  AND L13
L25           5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L14 OR L15 OR L19 OR
                L20 OR L21 OR L23
L27       13651 SEA FILE=HCAPLUS ABB=ON  PLU=ON  RECEPTOR (L) MODULATOR#

L28       77983 SEA FILE=HCAPLUS ABB=ON  PLU=ON  INFLAMMAT? (L) (CONDITIO
                N# OR DISEASE#)
L30          19 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L17 OR L24) AND (L28
                OR L27) NOT L25
L32          24 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L30 OR L25


=> file hcaplus
FILE 'HCAPLUS' ENTERED AT 10:22:26 ON 25 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


=> d l32 1-24 ibib abs hitstr hitind

L32  ANSWER 1 OF 24  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:1265299  HCAPLUS
DOCUMENT NUMBER:          144:22939
TITLE:                    Preparation of bicyclic heterocycles,
                          particularly pyrimido[2,1-c][1,4]oxazine-2-
                          carboxamides, as HIV integrase inhibitors
INVENTOR(S):              Naidu, B. Narasimhulu; Banville, Jacques;
                          Beaulieu, Francis; Connolly, Timothy P.;
                          Krystal, Mark R.; Matiskella, John D.; Ouellet,
                          Carl; Plamondon, Serge; Remillard, Roger;
                          Sorenson, Margaret E.; Ueda, Yasutsugu; Walker,
                          Michael A.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 156 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------
     --------
     US 2005267105         A1    20051201    US 2005-126891
                                                                   200505
                                                                   11
     WO 2005118593         A1    20051215    WO 2005-US16473
                                                                   200505
                                                                   12
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,
```

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC,
NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005267132 A1 20051201 US 2005-138726
200505
26

US 2005267131 A1 20051201 US 2005-138773
200505
26

WO 2005118589 A1 20051215 WO 2005-US18567
200505
27

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC,
NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2005118590 A1 20051215 WO 2005-US18568
200505
27

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC,
NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-575513P P
200405
28

US 2004-603371P P
200408
20

US 2005-126891 A
200505
11

US 2005-138726 A
200505
26

US 2005-138773 A
200505
26

GI



I



II



II

AB The invention is related to the prepn. of title compds. I [R1 = C1-6(Ar1)alkyl, C1-6(Ar1)oxyalkyl, C1-6(Ar1)hydroxyalkyl, etc.; R2 = H, alkyl, OH, alkyloxy; Ar1 = (un)substituted Ph, naphthyl, benzothiophenyl, etc.; X-Y-Z = C(R3)2OC(R3)2, C(R3)2OC(R3)2C(R3)2, C(R3)2C(R3)2C(R3)2C(R3)2; R3 = H, alkyl], and their pharmaceutically acceptable salts or solvates which inhibit HIV integrase and prevent viral integration into human DNA. The invention is also related to the pharmaceutical compns. comprising pyrimidinones I, and methods of using them for treating HIV infection and AIDS. Thus, reacting ester II (prepn. given) with 4-fluorobenzylamine in DMF/ethanol in the presence of TEA at 90° gave amide III in 82% yield. Selected I displayed IC50 values in the range of 0.002-0.1 μM for the inhibition of HIV integrase activity. II demonstrated synergistic or additive-synergistic HIV antiviral activity when used in combination with other antiviral agents, e.g., zidovudine, indinavir, T-20, etc.

IT **870560-23-9P**, N-[[4-Fluoro-2-[(2-thiazolyl)amino]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(drug candidate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

RN 870560-23-9 HCAPLUS

CN Pyrimido[2,1-c][1,4]oxazine-2-carboxamide, N-[[4-fluoro-2-(2-thiazolylamino)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo- (9CI) (CA INDEX NAME)



IT **870562-87-1P**, 4-Fluoro-2-[(thiazol-2-yl)amino]benzonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)
RN 870562-87-1 HCAPLUS
CN Benzonitrile, 4-fluoro-2-(2-thiazolylamino)- (9CI) (CA INDEX NAME)



IC ICM A61K031-538
ICS C07D491-04
INCL 514230500; 544105000
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(CCR5, CCR5 inhibitors and HIV attachment inhibitors; combination therapy agents; prepn. of bicyclic heterocycles for use in combination therapy for treating HIV infection)
IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(CXCR4, CXCR4 inhibitors and HIV budding or maturation inhibitors; combination therapy agents; prepn. of bicyclic heterocycles for use in combination therapy for treating HIV infection)
IT 3056-17-5, Stavudine 7481-89-2, Zalcitabine 30516-87-1, Zidovudine 69655-05-6, Didanosine 127779-20-8, Saquinavir 129618-40-2, Nevirapine 134678-17-4, Lamivudine 136470-78-5, Abacavir 136817-59-9, Delavirdine 143491-57-0, Emtricitabine 147127-20-6, Tenofovir 150378-17-9, Indinavir 154598-52-4, Efavirenz 155213-67-5, Ritonavir 159519-65-0, Enfuvirtide 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 192725-17-0, Lopinavir 198904-31-3, Atazanavir
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(combination therapy agent; prepn. of bicyclic heterocycles for use in combination therapy for treating HIV infection)

IT 870559-67-4P, N-[[2-[3-[(Dimethylamino)carbonyl]-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-68-5P, N-[[4-Fluoro-2-[3-[[(methylsulfonyl)amino]carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-69-6P 870559-71-0P, N-[[2-[3-[(4-Acetyl-1-piperazinyl)carbonyl]-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-73-2P, N-[[4-Fluoro-2-[3-[[(2-hydroxyethyl)(methyl)amino]carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-74-3P, N-[[4-Fluoro-2-[3-[[[(4-fluorophenyl)sulfonyl]amino]carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-75-4P, N-[[4-Fluoro-2-[3-[(4-methyl-1-piperazinyl)carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-76-5P, N-[[2-[3-[[[2-(Dimethylamino)ethyl]amino]carbonyl]-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-77-6P, N-[[2-[3-[[[2-(Dimethylamino)ethyl](methyl)amino]carbonyl]-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-78-7P, N-[[4-Fluoro-2-[3-[[(2-hydroxyethyl)amino]carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-79-8P, N-[(4-Fluoro-2-iodophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-80-1P, N-[(5-Fluoro[1,1'-biphenyl]-2-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-81-2P, N-[[4-Fluoro-2-(3-pyridinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-82-3P, N-[[4-Fluoro-2-(2-methoxy-3-pyridinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-83-4P, N-[[4-Fluoro-2-(6-methoxy-3-pyridinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-84-5P, N-[[2-(1,2-Dihydro-2-oxo-3-pyridinyl)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-85-6P, N-[[2-(1,6-Dihydro-6-oxo-3-pyridinyl)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-86-7P, N-[[2-(1,6-Dihydro-6-oxo-2-pyridinyl)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-87-8P, N-[[4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-88-9P, N-[[4-Fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-89-0P, N-[[2-Fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-90-3P, N-[[4-Fluoro-2-(1,2,3-thiadiazol-4-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-91-4P, N-[[4-Fluoro-2-(1H-pyrazol-3-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-92-5P, N-[[4-Fluoro-2-(5-methyl-2-oxazolyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-

carboxamide 870559-93-6P, N-[[2-(Ethylamino)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-94-7P, N-[(2-Ethynyl-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-95-8P, N-[[4-Fluoro-2-(3-hydroxy-1-propynyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-96-9P, N-[[4-Fluoro-2-[3-[(methylsulfonyl)oxy]-1-propynyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-98-1P 870559-99-2P, N-[[4-Fluoro-2-[3-(methylsulfonyl)-1-propynyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-00-2P, N-[[4-Fluoro-2-[3-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)-1-propynyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-01-3P 870560-02-4P, N-[(4-Fluoro-2-hydroxyphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(drug candidate; prepn. of bicyclic heterocycles)

IT 870558-24-0P, N-[(4-Fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide
RL: ADV (Adverse effect, including toxicity); **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(drug candidate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

IT 870560-07-9P, N-[[4-Fluoro-2-(methylthio)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-20-6P, 3-Hydroxy-9,9-dimethyl-N-[[2-(methylthio)phenyl]methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-55-7P, N-[(2-Bromophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-16-3P, N-[(4-Fluorophenyl)methyl]-3-hydroxy-9-[2-(methylthio)ethyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

IT 870557-73-6P, N-[(4-Fluorophenyl)methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-76-9P, N-[(4-Fluoro-3-methylphenyl)methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-80-5P, N-[[4-Fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-83-8P, N-[(4-Fluorophenyl)methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-87-2P, N-[(4-Fluoro-3-methylphenyl)methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-90-7P, N-[(3,4-Dichlorophenyl)methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-95-2P, N-[(3-Chloro-4-fluorophenyl)methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-98-5P, N-[(3,4-Dimethylphenyl)methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide

870558-02-4P, N-[[4-Fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-05-7P, 9-Ethyl-N-[(4-fluorophenyl)methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-08-0P, 9-Ethyl-N-[(4-fluoro-3-methylphenyl)methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-09-1P, N-[(3,4-Dichlorophenyl)methyl]-9-ethyl-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-10-4P, N-[(3,4-Dimethylphenyl)methyl]-9-ethyl-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-12-6P, N-[(3-Chloro-4-fluorophenyl)methyl]-9-ethyl-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-14-8P, 9-Ethyl-N-[[4-fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-16-0P, 9-Ethyl-N-[[4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-19-3P, N-[(4-Fluorophenyl)methyl]-3-hydroxy-9-(1-methylethyl)-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-22-8P, N-[(4-Fluoro-3-methylphenyl)methyl]-3-hydroxy-9-(1-methylethyl)-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-27-3P, N-[(4-Fluoro-3-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-30-8P, N-[[4-Fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-33-1P, N-[[2-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-36-4P, N-[[4-Fluoro-2-(4-morpholinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-39-7P, N-[[2-Fluoro-4-(4-morpholinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-42-2P, N-[3-(3,4-Dichlorophenyl)propyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-45-5P, N-[3-(4-Fluorophenyl)propyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-49-9P, N-[[4-Fluoro-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-51-3P, N-[(3,5-Difluoro-2-pyridinyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-54-6P, N-[(5-Chloropyridin-2-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-56-8P, N-[(3-Bromo-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-59-1P, N-[(3,4-Dimethylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-62-6P, N-[(3-Chloro-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-65-9P, N-[(3,4-Difluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-68-2P, N-[(4-Chlorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-73-9P, N-[(2,4-Difluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-79-5P, N-[(2-Chloro-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-83-1P, N-[(2,4-Dimethylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-

carboxamide 870558-87-5P, N-[(3,5-Dimethylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-90-0P, N-[(4-Fluoro-2-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-94-4P, N-[(4-Fluoro-1-naphthalenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-98-8P, N-[(4-Fluoro-2-methoxyphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-01-6P, 9,9-Diethyl-N-[(4-fluorophenyl)methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-04-9P, 9,9-Diethyl-N-[(4-fluoro-3-methylphenyl)methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-07-2P, N-[(4-Fluorophenyl)methyl]-4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870559-10-7P, N-[(4-Fluoro-3-methylphenyl)methyl]-4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870559-14-1P, N-[[4-Fluoro-2-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-18-5P, 5-Fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]benzoic acid methyl ester 870559-23-2P, 5-Fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]benzoic acid 870559-27-6P, N-[[4-Fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-31-2P, N-[[2-[(Cyclopropylamino)carbonyl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-35-6P, N-[[4-Fluoro-2-[[(2-hydroxyethyl)amino]carbonyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-39-0P, N-[[4-Fluoro-2-[(4-morpholinyl)carbonyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-44-7P, N-[[4-Fluoro-2-(1H-imidazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-48-1P, N-[[5-Fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-52-7P, N-[[3-Fluoro-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-54-9P, N-[[3-Fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-56-1P, N-[[4-Fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-58-3P, N-[[2-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-60-7P, N-[(2-Bromo-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-62-9P, 1H-1,2,4-Triazole-3-carboxylic acid 1-[5-fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl]methyl ester 870559-64-1P, 1-[5-Fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl]-1H-1,2,4-Triazole-3-carboxylic acid 870559-65-2P, N-[[4-Fluoro-2-[3-[(4-morpholinyl)carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-

tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-03-5P, N,N-Dimethylcarbamic acid 5-fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl ester 870560-04-6P, N-[[4-Fluoro-2-[2-(methylamino)-2-oxoethoxy]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-05-7P, N-[[2-[2-(Dimethylamino)-2-oxoethoxy]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-06-8P, 4-Morpholinecarboxylic acid 5-fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl ester 870560-08-0P, N-[[4-Fluoro-2-(methylsulfonyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-09-1P, N-[[4-Fluoro-2-(methylsulfinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-11-5P 870560-12-6P, 3-Hydroxy-9,9-dimethyl-4-oxo-N-[[3-[3-(trifluoromethyl)-3-diaziridinyl]phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-13-7P, 3-Hydroxy-9,9-dimethyl-4-oxo-N-[[3-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-14-8P, N-[[4-Fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-15-9P, N-[[4-Fluoro-2-(1-methyl-1H-tetrazol-5-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-16-0P, N-[[2-[(Dimethylamino)sulfonyl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-17-1P, N-[[4-Fluoro-2-[(methylamino)sulfonyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-18-2P, N-[[2-(Aminosulfonyl)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-19-3P, N-[[2-[(1-Azetidinyl)sulfonyl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-21-7P, 3-Hydroxy-9,9-dimethyl-N-[[2-(methylsulfinyl)phenyl]methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-22-8P, 3-Hydroxy-9,9-dimethyl-N-[[2-(methylsulfonyl)phenyl]methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide **870560-23-9P**, N-[[4-Fluoro-2-[(2-thiazolyl)amino]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-24-0P, N-[[4-Fluoro-2-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-25-1P, N-[[4-Fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870560-26-2P, N-[[4-Fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870560-27-3P, 9,9-Diethyl-N-[[4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-28-4P, 9,9-Diethyl-N-[[4-fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-29-5P, N-[[4-Fluoro-2-(2-oxo-1-piperidinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-30-8P, 3-Hydroxy-9,9-dimethyl-4-oxo-N-[[2-(2-oxo-3-oxazolidinyl)phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-

c][1,4]oxazine-2-carboxamide 870560-31-9P, 3-Hydroxy-9,9-dimethyl-4-oxo-N-[[2-(2-oxo-1-azetidinyl)phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-32-0P, N-[[4-Fluoro-2-(2-oxo-1-pyrrolidinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-33-1P, N-[[4-Fluoro-2-(hexahydro-2-oxo-1H-azepin-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-34-2P, N-[4-Fluoro-2-(2-oxoazetidin-1-yl)benzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-35-3P, N-[4-Fluoro-2-(2-oxooxazolidin-3-yl)benzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-36-4P, N-[[4-Fluoro-2-[(2R)-2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-37-5P, N-[[2-[(2R)-2-[(Acetyloxy)methyl]-5-oxo-1-pyrrolidinyl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-38-6P, N-[[4-Fluoro-2-[(2S)-2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-39-7P, (R)-N-[2-[2-[(Dimethylamino)methyl]-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-40-0P, (R)-N-[2-[2-(Azidomethyl)-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-41-1P, (R)-N-[2-[2-(Aminomethyl)-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-42-2P, N-[(2-Amino-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-43-3P, N-[[2-(Acetylamino)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-44-4P, N-[[2-[(Acetyl)(methyl)amino]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-45-5P, N-[2-(2,5-Dioxo-2H-pyrrol-1(5H)-yl)benzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-46-6P, N-[(Benzo[b]thien-7-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-47-7P, N-[(1,1-Dioxidobenzo[b]thien-7-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-48-8P, N-[(2,3-Dihydro-1,1-dioxidobenzo[b]thien-7-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-49-9P 870560-50-2P 870560-51-3P 870560-52-4P 870560-53-5P 870560-54-6P 870560-56-8P 870560-57-9P 870560-58-0P 870560-59-1P 870560-60-4P 870560-61-5P 870560-62-6P 870560-63-7P 870560-64-8P 870560-65-9P 870560-66-0P 870560-67-1P 870560-68-2P 870560-69-3P 870560-70-6P 870560-71-7P 870560-72-8P 870560-73-9P 870560-74-0P 870560-75-1P 870560-76-2P 870560-77-3P 870560-78-4P 870560-79-5P 870560-80-8P 870560-81-9P 870560-82-0P 870560-83-1P 870560-84-2P 870560-85-3P 870560-86-4P 870560-87-5P 870560-88-6P 870560-89-7P 870560-90-0P 870560-91-1P 870560-92-2P 870560-93-3P 870560-94-4P 870560-95-5P 870560-96-6P 870560-97-7P 870560-98-8P 870560-99-9P 870561-00-5P 870561-01-6P 870561-02-7P 870561-03-8P 870561-04-9P 870561-05-0P 870561-06-1P 870561-07-2P 870561-08-3P 870561-09-4P, N-[(4-Fluoro-2,5-dibromophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-

tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-10-7P, N-[[4-Fluoro-2-(methylsulfonyl)phenyl]methyl]-4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-Pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870561-11-8P, 9,9-Diethyl-N-[[4-fluoro-2-(methylsulfonyl)phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-12-9P, N-[[2-[(Dimethylamino)sulfonyl]-4-fluorophenyl]methyl]-4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870561-13-0P, N-[[2-[(Dimethylamino)sulfonyl]-4-fluorophenyl]methyl]-9,9-diethyl-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-14-1P, 4,7,8,10-Tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-N-[[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]methyl]-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870561-15-2P, 3-Hydroxy-9,9-diethyl-4-oxo-N-[[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-17-4P, N-[(4-Fluorophenyl)methyl]-3-hydroxy-9-[2-(methylsulfonyl)ethyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-18-5P, N-[[4-Fluoro-2-(3-methyl-5-isoxazolyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-19-6P, N-[[2-((2Z)-3-Amino-1-oxo-2-butenyl)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-20-9P, N-[[2-(3-Bromo-5-isoxazolyl)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-21-0P, [5-Fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl]phosphonic acid diethyl ester 870561-22-1P, N-[(4-Fluorophenyl)methyl]-3-hydroxy-N-methoxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-23-2P, 3-Hydroxy-9,9-dimethyl-4-oxo-N-[[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-24-3P, 3-Hydroxy-9,9-dimethyl-4-oxo-N-[[2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-25-4P, 3-Hydroxy-9,9-dimethyl-4-oxo-N-(3-phenylpropyl)-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-26-5P 870561-27-6P 870561-28-7P 870561-29-8P 870561-30-1P 870561-31-2P 870561-32-3P 870561-33-4P 870561-34-5P 870561-35-6P 870561-36-7P 870561-37-8P 870561-38-9P 870561-39-0P 870561-40-3P 870561-41-4P 870561-42-5P 870561-43-6P 870561-44-7P 870561-45-8P 870561-46-9P 870561-47-0P 870561-48-1P 870561-49-2P 870561-50-5P 870561-51-6P 870561-52-7P 870561-53-8P 870561-54-9P 870561-55-0P 870561-56-1P 870561-57-2P 870561-58-3P 870561-59-4P 870561-60-7P 870561-61-8P 870561-62-9P 870561-63-0P 870561-64-1P 870561-65-2P 870561-66-3P 870561-67-4P 870561-68-5P, 3-Hydroxy-9,9-dimethyl-N-[[2-(4-morpholinyl)phenyl]methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-69-6P, 4-[2-[[[(3-Hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester 870561-70-9P, 3-Hydroxy-9,9-dimethyl-N-[[2-(1-methylethoxy)phenyl]methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-71-0P, 3-Hydroxy-9,9-dimethyl-N-[[3-(1-methylethoxy)phenyl]methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-72-1P, 3-[[[(3-Hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]benzoic acid methyl ester 870561-73-2P, N-[(4-Cyanophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-

4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-74-3P, N-[(3-Chloro-2-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-75-4P, N-[(2,3-Dihydro-1,4-benzodioxin-5-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-76-5P, N-[(3,4-Dihydro-2H-1,5-benzodioxepin-6-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-77-6P, N-[(2,5-Dimethylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-78-7P, N-[(5-Chloro-2-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-79-8P, N-[(2,4-Dichlorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-80-1P, N-[(4-Chloro-2-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(drug candidate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

IT 870561-81-2P, N-[(2-Chloro-6-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-82-3P, N-[(6-Chloro-2-fluoro-3-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-83-4P, N-[(2,6-Difluoro-3-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-84-5P, N-[(2,3-Difluoro-4-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-85-6P, N-[(4-Chloro-2-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-86-7P, N-[(2-Chloro-6-fluoro-3-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-87-8P, 3-Hydroxy-9,9-dimethyl-N-[(1-methyl-1H-indol-4-yl)methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-88-9P, N-[[4-Fluoro-2-(2-oxo-1-azetidinyl)phenyl]methyl]-4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870561-89-0P, [5-Fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl]phosphonic acid dimethyl ester 870561-90-3P, [5-Fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl]phosphonic acid monoethyl ester
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(drug candidate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

IT 450-88-4P, 1-Bromo-4-fluoro-2-methoxybenzene 2339-57-3P, 5-Fluoro-2-methylbenzenesulfonamide 10133-24-1P, 7-(Bromomethyl)benzo[b]thiophene 14315-15-2P, 7-Methylbenzo[b]thiophene 16630-62-9P, 2-[2-(Methylthio)ethyl]-1,3-dioxolane 25699-87-0P, 2-(1H-1,2,4-Triazol-1-yl)benzonitrile 34451-66-6P, 2-Ethyl-2-hydroxybutanenitrile 67938-76-5P, (5-Chloropyridin-2-yl)methanamine 91905-69-0P, (2,2-Diethoxyethyl)(o-tolyl)sulfane 162845-02-5P, 3-(3-Bromomethylphenyl)-3-trifluoromethyl-3H-diazirine 186590-01-2P, 4-Fluoro-2-hydroxybenzonitrile 190198-07-3P, 4-Fluoro-2-(imidazol-1-yl)benzonitrile 191014-55-8P,

4-Fluoro-2-methoxybenzonitrile 217661-27-3P, 2-(Bromomethyl)-5-fluorobenzonitrile 353265-76-6P, 2-(2-Oxooxazolidin-3-yl)benzonitrile 410545-49-2P, (4-Fluoro-2-methylsulfanylbenzyl)amine 410545-71-0P, 5-Fluoro-2-methyl-N,N-dimethylbenzenesulfonamide 410545-72-1P, 2-Bromomethyl-5-fluoro-N,N-dimethylbenzenesulfonamide 410545-73-2P, 2-Azidomethyl-5-fluoro-N,N-dimethylbenzenesulfonamide 410545-74-3P, 2-(Aminomethyl)-5-fluoro-N,N-dimethylbenzenesulfonamide 449758-80-9P, 5-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzonitrile 503293-06-9P, 2-(Benzyloxy)-4-fluorobenzonitrile 554448-62-3P, 4-Morpholino-2-fluorobenzonitrile 791071-00-6P, 2-(1,1-Dioxo-[1,2]thiazinan-2-yl)benzonitrile 864054-89-7P, (5-Fluoro-2-methylphenyl)(morpholino)methanone 869591-69-5P, 4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzonitrile 869591-70-8P, 4-(1H-1,2,4-Triazol-1-yl)-2-fluorobenzonitrile 869591-76-4P, 4-Fluoro-2-(2H-1,2,3-triazol-2-yl)benzonitrile 869591-78-6P, [2-(1,1-Dioxo-[1,2]thiazinan-2-yl)benzyl]amine hydrochloride 869591-79-7P, 4-Fluoro-2-(1,1-dioxo-[1,2]thiazinan-2-yl)benzonitrile 869591-80-0P, [4-Fluoro-2-(1,1-dioxo-[1,2]thiazinan-2-yl)phenyl]methanamine hydrochloride 869591-84-4P, 4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzonitrile 869591-85-5P, 4-Fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)benzonitrile 869591-92-4P, [3-Fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methanamine 870561-91-4P, 2-(Azidomethyl)-5-fluorobenzenesulfonamide 870561-93-6P, 2-[2-(Methylthio)ethoxy]acetic acid 870561-94-7P, Methyl 2-[2-(methylthio)ethoxy]acetate 870561-95-8P, 2-[2-(Methylthio)ethoxy]acetamidine hydrochloride 870561-96-9P, Ethyl 5-benzyloxy-2-[[2-(methylthio)ethoxy]methyl]-6-oxo-1,6-dihydropyrimidine-4-carboxylate 870561-97-0P, Ethyl 5-benzyloxy-2-[[2-(dimethylsulfonium)ethoxy]methyl]-6-oxo-1,6-dihydropyrimidine-4-carboxylate iodide 870561-98-1P, Ethyl 3-benzyloxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870561-99-2P, 3-(Benzyloxy)-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylic acid 870562-00-8P, Ethyl 3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-01-9P, 2-[2-(Methylthio)ethoxy]propanoic acid 870562-02-0P, Methyl 2-[2-(methylthio)ethoxy]propanoate 870562-03-1P, 2-[2-(Methylthio)ethoxy]propanamidine hydrochloride 870562-04-2P, Ethyl 5-benzyloxy-2-[1-[2-(methylthio)ethoxy]ethyl]-6-oxo-1,6-dihydropyrimidine-4-carboxylate 870562-05-3P, Ethyl 5-benzyloxy-2-[1-[2-(dimethylsulfonium)ethoxy]ethyl]-6-oxo-1,6-dihydropyrimidine-4-carboxylate iodide 870562-06-4P, Ethyl 3-(benzyloxy)-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-07-5P, Ethyl 3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-08-6P, 3-Benzyloxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylic acid 870562-09-7P, 4-(Methylthio)-2-[2-[(trimethylsilyl)oxy]ethoxy]butane nitrile 870562-10-0P 870562-11-1P, Ethyl 5-(benzyloxy)-2-[1-(2-hydroxyethoxy)-3-(methylthio)propyl]-6-oxo-1,6-dihydropyrimidine-4-carboxylate 870562-12-2P, Ethyl 3-(benzyloxy)-9-[2-(methylthio)ethyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-13-3P, 3-(Benzyloxy)-9-[2-(methylthio)ethyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylic acid 870562-14-4P, 2-(2-Chloroethoxy)-2-methylpropanenitrile 870562-15-5P, Ethyl 2-(2-ethoxy-2-oxoethyl)-8,8-dimethyl-2,5,6,8-tetrahydro-[1,2,4]oxadiazolo[3,2-c][1,4]oxazine-2-carboxylate 870562-16-6P, Ethyl 3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-17-7P, Ethyl

3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-18-8P, 3-(Benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylic acid 870562-19-9P, 2-(2-Chloroethoxy)-2-ethylbutanenitrile 870562-20-2P 870562-21-3P, Ethyl 9,9-diethyl-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-22-4P, 2-(3-Chloropropoxy)-2-methylpropanenitrile 870562-23-5P, Ethyl 2-[2-(3-chloropropoxy)propan-2-yl]-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylate 870562-24-6P, 3-(Benzyloxy)-10,10-dimethyl-4-oxo-6,7,8,10-tetrahydro-4H-pyrimido[2,1-c][1,4]oxazepine-2-carboxylic acid 870562-25-7P, Ethyl 3-hydroxy-10,10-dimethyl-4-oxo-6,7,8,10-tetrahydro-4H-pyrimido[2,1-c][1,4]oxazepine-2-carboxylate 870562-26-8P, (4-Fluoronaphthalen-1-yl)methanamine hydrochloride 870562-27-9P, Methyl 2-(aminomethyl)-5-fluorobenzoate trifluoroacetate 870562-29-1P, 2-Aminomethyl-5-fluoro-N-methylbenzamide trifluoroacetate 870562-30-4P, 2-(Aminomethyl)-N-cyclopropyl-5-fluorobenzamide trifluoroacetate 870562-31-5P, [2-(Bromomethyl)-5-fluorophenyl](morpholino)methanone 870562-32-6P, [2-(Azidomethyl)-5-fluorophenyl](morpholino)methanone 870562-33-7P, [2-(Aminomethyl)-5-fluorophenyl](morpholino)methanone hydrochloride 870562-34-8P, 5-Fluoro-2-methyl-N-methylbenzenesulfonamide 870562-35-9P, 2-Bromomethyl-5-fluoro-N-methylbenzenesulfonamide 870562-36-0P, 2-Azidomethyl-5-fluoro-N-methylbenzenesulfonamide 870562-37-1P, 2-(Aminomethyl)-5-fluoro-N-methylbenzenesulfonamide hydrochloride 870562-38-2P, 2-Bromomethyl-5-fluorobenzenesulfonamide 870562-39-3P, 2-(Aminomethyl)-5-fluorobenzenesulfonamide hydrochloride 870562-40-6P, 5-(2-Bromo-5-fluorophenyl)-2-methyl-2H-tetrazole 870562-42-8P, 4-Fluoro-2-(2-methyl-2H-tetrazol-5-yl)benzonitrile 870562-43-9P 870562-44-0P, 3-(m-Tolyl)-3-trifluoromethyl-3H-diazirine 870562-46-2P 870562-47-3P 870562-48-4P 870562-49-5P 870562-50-8P, 4-Fluoro-2-morpholinobenzonitrile 870562-51-9P 870562-52-0P 870562-53-1P, 2-Fluoro-4-(2H-1,2,3-triazol-2-yl)benzylamine 870562-54-2P 870562-55-3P, 2-Fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzonitrile 870562-56-4P, 2-Fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)benzonitrile 870562-57-5P 870562-58-6P 870562-59-7P 870562-60-0P, [4-Fluoro-2-(1H-imidazol-1-yl)phenyl]methanamine hydrochloride 870562-61-1P, 1-(2-Cyano-5-fluorophenyl)-1H-1,2,4-triazole-3-carboxylic acid methyl ester 870562-62-2P, Methyl 1-[2-(aminomethyl)-5-fluorophenyl]-1H-1,2,4-triazole-3-carboxylate 870562-63-3P, 3-Fluoro-2-(1,1-dioxo-[1,2]thiazinan-2-yl)benzonitrile 870562-64-4P, [3-Fluoro-2-(1,1-dioxo-[1,2]thiazinan-2-yl)benzyl]amine hydrochloride 870562-65-5P, 3-Fluoro-2-(1,2,4-triazol-1-yl)benzonitrile 870562-66-6P 870562-67-7P 870562-68-8P, (3,5-Difluoropyridin-2-yl)methanamine hydrochloride 870562-69-9P, 2-[(1,3-Dioxoisoindolin-2-yl)methyl]-5-fluorobenzonitrile 870562-70-2P, tert-Butyl (2-cyano-4-fluorobenzyl)carbamate 870562-72-4P, 2-(Aminomethyl)-5-fluorobenzonitrile trifluoroacetate 870562-73-5P, (2,5-Dibromo-4-fluorophenyl)methanamine 870562-74-6P, 2-(Aminomethyl)-5-fluorobenzenamine hydrochloride 870562-75-7P, 4-Fluoro-2-(2-oxopyrrolidin-1-yl)benzonitrile 870562-76-8P 870562-77-9P, 4-Fluoro-2-(2-oxopiperidin-1-yl)benzonitrile 870562-78-0P, 4-Fluoro-2-(2-oxoazepan-1-yl)benzonitrile 870562-79-1P, N-(2-Cyano-5-fluorophenyl)-N-methylacetamide 870562-80-4P, 2-(2-Oxoazetidin-1-yl)benzonitrile 870562-81-5P, 4-Fluoro-2-(2-oxooxazolidin-3-yl)benzonitrile 870562-82-6P, 3-[2-(Aminomethyl)-5-fluorophenyl]oxazolidin-2-one hydrochloride 870562-83-7P, 4-Fluoro-2-(2-oxoazetidin-1-yl)benzonitrile 870562-84-8P, 1-[2-(Aminomethyl)-5-fluorophenyl]azetidin-2-one

hydrochloride 870562-85-9P, (R)-2-[2-[[(tert-Butyldimethylsilyl)oxy]methyl]-5-oxopyrrolidin-1-yl]-4-fluorobenzonitrile 870562-86-0P, (S)-2-[2-[[(tert-Butyldimethylsilyl)oxy]methyl]-5-oxopyrrolidin-1-yl]-4-fluorobenzonitrile **870562-87-1P**, 4-Fluoro-2-[(thiazol-2-yl)amino]benzonitrile 870562-88-2P, 4-Fluoro-2-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]benzonitrile 870562-89-3P, 1-[2-(Aminomethyl)-5-fluorophenyl]piperidin-2-one hydrochloride 870562-90-6P, (4-Fluoro-2-methoxybenzyl)amine hydrochloride 870562-91-7P, 4-Fluoro-2-[2-(morpholino)-2-oxoethoxy]benzonitrile 870562-92-8P, 2-[2-(Aminomethyl)-5-fluorophenoxy]-1-morpholinoethanone hydrochloride 870562-93-9P, Dimethylcarbamic acid 2-cyano-5-fluorophenyl ester 870562-94-0P, Dimethylcarbamic acid 2-aminomethyl-5-fluorophenyl ester hydrochloride 870562-95-1P, (2-Hydroxy-4-fluorobenzyl)amine hydrochloride 870562-96-2P, Benzo[b]thiophen-7-ylmethanamine hydrochloride 870562-97-3P, N-[4-Fluoro-2-(methylcarbamoyl)benzyl]-3-benzyloxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870562-98-4P, N-(4-Fluorobenzyl)-3-(benzyloxy)-9-[2-(methylthio)ethyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870562-99-5P, 3-(Benzyloxy)-2-[(6-fluoro-1-oxoisoindolin-2-yl)carbonyl]-9,9-dimethyl-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one 870563-00-1P, N-[4-Fluoro-2-(methylcarbamoyl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-01-2P, N-(4-Fluoro-2-hydroxybenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-02-3P 870563-03-4P, N-[4-Fluoro-2-(2-oxoazetidin-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-04-5P, N-[(Benzo[b]thiophen-7-yl)methyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-05-6P, N-[4-Fluoro-2-(methylcarbamoyl)benzyl]-3-(benzyloxy)-10,10-dimethyl-4-oxo-6,7,8,10-tetrahydro-4H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870563-06-7P, N-(4-Fluorobenzyl)-3-(benzyloxy)-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-07-8P, N-[4-Fluoro-2-(methylcarbamoyl)benzyl]-3-(benzyloxy)-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-08-9P, N-[4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl]-3-(benzyloxy)-9-ethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-10-3P, N-[4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-11-4P, N-[2-Fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-12-5P 870563-13-6P, N-[2-(Cyclopropylcarbamoyl)-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-14-7P, N-[4-Fluoro-2-(morpholine-4-carbonyl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-15-8P, N-[4-Fluoro-2-[2-(morpholino)-2-oxoethoxy]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-16-9P, Dimethylcarbamic acid 2-[[[(3-benzyloxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]-5-fluorophenyl ester 870563-17-0P, N-[4-Fluoro-2-(2-oxopyrrolidin-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-18-1P, N-[4-Fluoro-2-(2-oxoazepan-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-19-2P, N-[2-(2-Oxooxazolidin-3-yl)benzyl]-3-(benzyloxy)-9,9-

dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-20-5P, N-[2-(2-Oxoazetidin-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-21-6P, N-[4-Fluoro-2-[(thiazol-2-yl)amino]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-22-7P, N-[4-Fluoro-2-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-23-8P, N-[4-Fluoro-2-(2-oxooxazolidin-3-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-24-9P, (R)-N-[2-[2-[[(tert-Butyldimethylsilyl)oxy]methyl]-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-25-0P, (S)-N-[2-[2-[[(tert-Butyldimethylsilyl)oxy]methyl]-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-26-1P, N-[4-Fluoro-2-(N-methylacetamido)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-27-2P, N-(2-Amino-4-fluorobenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-28-3P, N-[2-(Ethylamino)-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-30-7P, N-(4-Fluorobenzyl)-3-(benzyloxy)-N-methoxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-31-8P, N-[4-Fluoro-2-(1,2,3-thiadiazol-4-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-33-0P, N-[4-Fluoro-2-(5-methyloxazol-2-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-35-2P, N-(4-Fluoro-2-iodobenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-36-3P, N-[4-Fluoro-2-(2-methoxypyridin-3-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-37-4P, N-(4-Fluoro-2-phenylbenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-38-5P, N-[4-Fluoro-2-(1H-pyrazol-3-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-39-6P, N-[4-Fluoro-2-[2-(trimethylsilyl)ethynyl]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-40-9P, N-(2-Ethynyl-4-fluorobenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-41-0P, N-[4-Fluoro-2-(3-methylisoxazol-5-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-42-1P, N-[2-(3-Bromoisoxazol-5-yl)-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-43-2P, N-[4-Fluoro-2-(3-hydroxyprop-1-ynyl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-44-3P, 3-[2-[[[[3-(Benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorophenyl]prop-2-ynyl methanesulfonate 870563-45-4P, N-[2-[3-(Dimethylamino)prop-1-ynyl]-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-46-5P, N-[4-Fluoro-2-[3-(methylthio)prop-1-ynyl]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-47-6P, N-[4-Fluoro-2-[3-(methylsulfonyl)prop-1-ynyl]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-48-7P,

Diethyl [2-[[[[3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorophenyl]phosphonate 870563-49-8P, Ethyl hydrogen [2-[[[[3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorophenyl]phosphonate 870563-50-1P, N-(2-Acetamido-4-fluorobenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-51-2P, 2-[[[[3-(Benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorobenzoic acid 870563-52-3P, N-[2-[(2-Hydroxyethyl)carbamoyl]-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-53-4P, (R)-N-[4-Fluoro-2-[2-(hydroxymethyl)-5-oxopyrrolidin-1-yl]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-54-5P, (R)-[1-[2-[[[[3-(Benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorophenyl]-5-oxopyrrolidin-2-yl]methyl acetate 870563-55-6P, (R)-[1-[2-[[[[3-(Benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorophenyl]-5-oxopyrrolidin-2-yl]methyl methanesulfonate 870563-56-7P, (R)-N-[2-[2-(Azidomethyl)-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-57-8P, N-[(1,1-DioxoBenzo[b]thiophen-7-yl)methyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-63-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

IT 9068-38-6
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(non/nucleoside HIV reverse transcriptase inhibitors; combination therapy agents; prepn. of bicyclic heterocycles for use in combination therapy for treating HIV infection)

IT 52350-85-3, HIV integrase
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(of HIV inhibitors; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

L32 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1242755 HCAPLUS
DOCUMENT NUMBER: 143:472565
TITLE: Methods of **treating conditions** associated with an Edg-7 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 352,579.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2005261298	A1	20051124	US 2003-390428	200303 14
WO 2003062392	A2	20030731	WO 2003-US1881	200301 21
WO 2003062392	A3	20050120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 2002-350446P	P	200201 18
	WO 2003-US1881	A1	200301 21
	US 2003-352579	B2	200301 27
	US 2002-350445P	P	200201 18
	US 2002-350447P	P	200201 18
	US 2002-350448P	P	200201 18

AB In one aspect, the present invention provides a method for modulating an Edg-7 **receptor** mediated biol. activity in a cell. A cell expressing the Edg-7 **receptor** is contacted with a **modulator** of the Edg-7 **receptor** which is capable of modulating an Edg-7 **receptor** mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-7 **receptor** mediated biol. activity in a subject. A therapeutically effective amt. of a **modulator** of the Edg-7 **receptor** is administered to the subject.

IT **353771-45-6P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

RN 353771-45-6 HCAPLUS

CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT **569656-05-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)
RN 569656-05-9 HCAPLUS
CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IC ICM A61K031-498
ICS A61K031-4709; A61K031-455; A61K031-426; A61K031-382; A61K031-165
INCL 514249000; 514355000; 514310000; 514309000; 514437000; 514622000; 514443000; 514369000
CC 1-6 (Pharmacology)
Section cross-reference(s): 28
ST antitumor Edg7 **receptor** **modulator** prepn **inflammation** lung **disease** therapy; phenoxyacetate deriv prepn Edg7 **modulator** **asthma** heart **disease** therapy
IT Animal cell line
(A431; Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)
IT Dopamine **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(D2(long); Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG (endothelial differentiation gene); Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL**

(Biological study)
(EDG-1 (endothelial differentiation gene 1); Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-2 (endothelial differentiation gene 2); Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-3 (endothelial differentiation gene 3); Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-4 (endothelial differentiation gene 4); Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-5 (endothelial differentiation gene 5); Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-6 (endothelial differentiation gene 6); Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-7 (endothelial differentiation gene 7); Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-8 (endothelial differentiation gene 8); Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Angiogenesis
Anti-**inflammatory** agents
Anti-ischemic agents
Antiasthmatics
Antitumor agents
Apoptosis
Asthma
Cardiovascular agents
Cardiovascular system, **disease**
Cell migration
Cell proliferation
Combination chemotherapy
Cytotoxic agents
Fibroblast
Human
Inflammation

Ischemia
Kidney, neoplasm
Lung, **disease**
Lung, neoplasm
Mammary gland, neoplasm
Myoblast
Neuron
Ovary, neoplasm
Pancreas, neoplasm
Peritoneum, neoplasm
Platelet (blood)
Platelet activation
Prostate gland, neoplasm
Stomach, neoplasm
Thyroid gland, neoplasm
Uterus, neoplasm
Wound healing
(Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT Muscarinic **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT Carbohydrates, biological studies
Nucleic acids
Organic compounds, biological studies
Proteins
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT Animal cell line
(HT-1080; Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT Animal cell line
(HTC; Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT Animal cell line
(HUVEC; Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT Histamine **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(H1; Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT Calcium channel
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(L-type; Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT Animal cell line
(MDA-MB-231; Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT Animal cell line
(OV202, CAOV-3, MDA-MB-453; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Respiratory distress syndrome
(adult; Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT Antiarteriosclerotics

(antiatherosclerotics; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Atherosclerosis
(atherogenesis; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Immune system
(autoimmune response; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Biological transport
(calcium; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Lysophosphatidic acids
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(cell proliferation stimulated by; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Carcinoma
Pheochromocytoma
(cell; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Uterus, neoplasm
(cervix; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Intestine, neoplasm
(colon; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Intestine, neoplasm
(colorectal; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Eye
(cornea, transcorneal freezing; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Burn
(cutaneous; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Uterus, neoplasm
(endometrium; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Epithelium
(epithelial cell; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Sarcoma
(fibrosarcoma, cell; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Carcinoma
(hepatocellular, cell; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Liver, neoplasm
(hepatoma, cell; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Phosphatidylinositols
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(hydrolysis; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Neoplasm

(invasiveness; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Neoplasm
(metastasis; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Ovary
(ovarian cell; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Actins
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(polymn.; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Intestine, neoplasm
(small; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Interleukin 8
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(synthesis; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT 5-HT **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(type 5-HT1; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Angiotensin **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(type AT2; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Endothelin **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(type ETA; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Adrenoceptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(α1; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Adrenoceptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(α2; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT Adrenoceptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(β-; Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT 60-92-4, CAMP 127464-60-2, VEGF
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(Edg-7 **modulators** for **treating conditions** assocd. with Edg-7 **receptor**)

IT 40622-01-3P, 2,3-Bis(4-Methoxyphenyl)quinoxaline-6-carboxylic acid
66085-59-4P 306764-68-1P 312501-62-5P 331945-22-3P
353771-45-6P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)

(Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT 91-56-5, 1H-Indole-2,3-dione 108-31-6, Maleic anhydride, reactions 108-38-3, 1,3-Dimethylbenzene, reactions 119-80-2 619-05-6, 3,4-Diaminobenzoic acid 1226-42-2, 4,4'-Dimethoxybenzil 4506-71-2, Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[B]thiophene-3-carboxylate 5242-26-2 64900-65-8, 2-Chlorobenzenesulfonyl isocyanate 82799-44-8 **569656-05-9** 569656-06-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT 7741-54-0P 76293-13-5P, 2,4-Dimethylthioxanthen-9-one 569656-29-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

IT 7440-70-2, Calcium, biological studies
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(transport; Edg-7 **modulators** for **treating** **conditions** assocd. with Edg-7 **receptor**)

L32 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1016895 HCAPLUS
DOCUMENT NUMBER: 143:415586
TITLE: G-Protein-Coupled Receptor Affinity Prediction Based on the Use of a Profiling Dataset: QSAR Design, Synthesis, and Experimental Validation
AUTHOR(S): Rolland, Catherine; Gozalbes, Rafael; Nicolaie, Eric; Paugam, Marie-France; Coussy, Laurent; Barbosa, Frederique; Horvath, Dragos; Revah, Frederic
CORPORATE SOURCE: Cerep, Rueil-Malmaison, 92500, Fr.
SOURCE: Journal of Medicinal Chemistry (2005), 48(21), 6563-6574
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A QSAR model accounting for "av." G-protein-coupled receptor (GPCR) binding was built from a large set of exptl. standardized binding data (1939 compds. systematically tested over 40 different GPCRs) and applied to the design of a library of "GPCR-predicted" compds. Three hundred and sixty of these compds. were randomly selected and tested in 21 GPCR binding assays. Positives were defined by their ability to inhibit by more than 70% the binding of ref. compds. at 10 μM. A 5.5-fold enrichment in positives was obsd. when comparing the "GPCR-predicted" compds. with 600 randomly selected compds. predicted as "non-GPCR" from a general collection. The model was efficient in predicting strongest binders, since enrichment was greater for higher cutoffs. Significant enrichment was also obsd. for peptidic GPCRs and receptors not included to develop the QSAR model, suggesting the usefulness of the model to design ligands binding with newly identified GPCRs, including orphan ones.

IT **412008-22-1**
RL: **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a

profiling dataset)
RN 412008-22-1 HCAPLUS
CN 2-Thiazolamine, N-(4-chloro-1-naphthalenyl)-4-(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)



CC 1-3 (Pharmacology)
Section cross-reference(s): 27, 28
IT Adenosine receptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(A1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)
IT Adenosine receptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(A2A, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)
IT Bradykinin receptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(B2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)
IT Cholecystokinin receptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(CCKA, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)
IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(CCR1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled **receptor** affinity prediction based on use of a profiling dataset)
IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(CCR2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled **receptor** affinity prediction based on use of a profiling dataset)
IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)

(CCR3, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled **receptor** affinity prediction based on use of a profiling dataset)

IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(**CCR4**, ligands; 0QSAR design, synthesis, and exptl. validation of G-protein-coupled **receptor** affinity prediction based on use of a profiling dataset)

IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(CCR5, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled **receptor** affinity prediction based on use of a profiling dataset)

IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(CXCR1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled **receptor** affinity prediction based on use of a profiling dataset)

IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(CXCR2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled **receptor** affinity prediction based on use of a profiling dataset)

IT Dopamine receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(D1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(D1A, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(D2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(D2(short), ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(D3, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(D4, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a

profiling dataset)

IT GABA receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(GABAB, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT G protein-coupled receptors
Hormone receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(GHS-R (growth hormone secretagogue receptor), ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Histamine receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(H1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Histamine receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(H2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT G protein-coupled receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(MCH-1R (melanin concg. hormone receptor 1), ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Muscarinic receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(M1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Muscarinic receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(M2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Muscarinic receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(M3, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT G protein-coupled receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Vasopressin receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(V1a, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Neuropeptide Y receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(Y1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Calcitonin gene-related peptide receptors
Somatostatin receptors
VIP receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Pituitary hormone receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(melanocortin receptor 1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Pituitary hormone receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(melanocortin receptor 3, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Pituitary hormone receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(melanocortin receptor 4, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 5-HT receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 5-HT1A, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 5-HT receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 5-HT1B, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 5-HT receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 5-HT1D, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 5-HT receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 5-HT2A, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 5-HT receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 5-HT2B, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 5-HT receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 5-HT2C, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 5-HT receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 5-HT4, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 5-HT receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 5-HT6, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 5-HT receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 5-HT7, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Angiotensin receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type AT1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Cannabinoid receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type CB1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Endothelin receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type ETB, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Tachykinin receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type NK1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Tachykinin receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type NK2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(urotensin II, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Opioid receptors
RL: **BSU (Biological study, unclassified); BIOL**

(Biological study)
(κ-opioid, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Interleukin 8 receptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(α, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Adrenoceptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(α1A, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Adrenoceptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(α2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Adrenoceptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(α2A, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Interleukin 8 receptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(β, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Adrenoceptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(β1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Adrenoceptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(β2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Opioid receptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(δ-opioid, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Opioid receptors
RL: **BSU (Biological study, unclassified); BIOL**
(Biological study)
(μ-opioid, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 217645-38-0 219866-03-2 302347-94-0 325823-79-8 331756-51-5
342636-04-8 357612-05-6 365513-78-6 367506-61-4 373380-99-5
387825-78-7 387876-41-7 395679-53-5 **412008-22-1**
423722-34-3 444045-28-7 444683-11-8 457893-92-4 460047-71-6

485391-80-8 500013-54-7 515141-51-2 532994-25-5 538342-73-3
540765-44-4 562102-64-1 582325-54-0 583867-53-2 620610-83-5
626208-21-7 630052-65-2 642049-63-6 642443-00-3 643746-94-5
644974-13-0 645399-82-2 648884-40-6 652979-01-6 654010-68-1
758682-52-9 765887-47-6 782445-88-9 868056-59-1 868056-61-5
868056-63-7 868056-65-9 868056-67-1 868056-69-3 868056-71-7
868056-72-8 868056-73-9 868056-74-0 868056-75-1 868056-76-2
868056-77-3 868056-78-4 868056-80-8 868056-81-9 868056-83-1
868056-84-2 868056-86-4 868056-87-5 868056-89-7 868056-90-0
868056-91-1 868056-93-3 868056-94-4 868056-95-5 868056-96-6
868056-97-7 868056-98-8 868056-99-9 868057-00-5 868057-02-7
868057-06-1 868057-07-2 868057-08-3 868057-09-4 868057-11-8
868057-16-3 868057-21-0 868057-23-2 868057-25-4 868057-29-8
868057-32-3 868057-35-6 868057-37-8 868057-40-3 868057-41-4
868057-42-5
RL: **PAC (Pharmacological activity)**; PRP (Properties);
THU (Therapeutic use); **BIOL (Biological study)**;
USES (Uses)
(QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1004737 HCAPLUS
DOCUMENT NUMBER: 143:286695
TITLE: Preparation of peptides as caspase inhibitors
INVENTOR(S): Charrier, Jean-Damien; Durrant, Steven; Mortimore, Michael; O'Donnell, Michael; Rutherford, Alistair; Ramaya, Sharn; Studley, John R.; Trudeau, Martin; Looker, Adam
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 177 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085236	A2	20050915	WO 2005-US6540	20050228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005233979	A1	20051020	US 2005-69895	20050228

PRIORITY APPLN. INFO.: US 2004-548610P P 200402 27

US 2004-629661P P 200411 19

US 2004-629743P P 200411 19

OTHER SOURCE(S): MARPAT 143:286695

GI



I



II

AB The invention provides compds. I [Y is CH(CHO)CH2CO2H or 2-hydroxy-5-oxotetrahydro-3-furanyl or their ethers; ring A is 2-pyrrolidine or 2-piperidine or their cyclopropano or bicyclic derivs.; R is HCO, R3CO, R3SO2, R3O2C, R32NCO, etc., where R3 is alkyl, cycloalkyl, aryl, heterocyclyl, etc.; R2 is (un)substituted alkyl, aryl, heteroaryl or cycloalkyl] that are useful as caspase inhibitors, including processes for their prepn. and pharmaceutical compns. contg. these compds. for the **treatment** of **diseases** and disorders related to caspase-mediated **conditions.** Thus, peptide aldehyde II was prepd. via amidation reactions and showed Ki < 10 nM for inhibition of caspase-1 or caspase-8.

IT **864166-92-7P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of peptides as caspase inhibitors)

RN 864166-92-7 HCAPLUS

CN L-Prolinamide, N-[2-chloro-4-(2-thiazolylamino)benzoyl]-L-valyl-N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C07D405-00
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
IT **Inflammation**
(Crohn's **disease**; prepn. of peptides as caspase inhibitors)
IT Interleukin 1
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(disease mediated by; prepn. of peptides as caspase inhibitors)
IT Intestine, **disease**
(**inflammatory**; prepn. of peptides as caspase inhibitors)
IT Inflammation
Peritoneum, **disease**
(peritonitis, **inflammatory**; prepn. of peptides as caspase inhibitors)
IT Aging, animal
Alcoholism
Alopecia
Alzheimer's disease
Anti-Alzheimer's agents
Anti-infective agents
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antiparkinsonian agents
Antirheumatic agents
Antiviral agents
Apoptosis
Asthma
Atherosclerosis
Autoimmune disease
Bone, disease
Cell death
Diabetes mellitus
Encephalitis
Epilepsy
Graves' disease
Heart, disease
Hepatitis GB virus C/G
Human immunodeficiency virus
Infection
Inflammation
Kidney, disease
Leukemia
Liver, disease
Meningitis
Multiple myeloma

Multiple sclerosis
Myasthenia gravis
Myelodysplastic syndromes
Osteoarthritis
Osteoporosis
Parkinson's disease
Prion diseases
Psoriasis
Rheumatoid arthritis
Sepsis
Spinal muscular atrophy
Tuberculosis
(prepn. of peptides as caspase inhibitors)

IT Peptides, preparation
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of peptides as caspase inhibitors)

IT 122191-40-6, Caspase-1 179241-78-2, Caspase-8
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(prepn. of peptides as caspase inhibitors)

IT 864166-40-5P 864166-98-3P
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of peptides as caspase inhibitors)

IT 864166-41-6P 864166-42-7P 864166-43-8P 864166-44-9P
864166-45-0P 864166-46-1P 864166-47-2P 864166-48-3P
864166-49-4P 864166-50-7P 864166-51-8P 864166-52-9P
864166-53-0P 864166-54-1P 864166-55-2P 864166-56-3P
864166-57-4P 864166-58-5P 864166-59-6P 864166-60-9P
864166-61-0P 864166-62-1P 864166-63-2P 864166-64-3P
864166-65-4P 864166-66-5P 864166-67-6P 864166-68-7P
864166-69-8P 864166-70-1P 864166-71-2P 864166-72-3P
864166-73-4P 864166-74-5P 864166-75-6P 864166-76-7P
864166-77-8P 864166-78-9P 864166-79-0P 864166-80-3P
864166-81-4P 864166-82-5P 864166-83-6P 864166-84-7P
864166-85-8P 864166-86-9P 864166-87-0P 864166-88-1P
864166-89-2P 864166-90-5P 864166-91-6P **864166-92-7P**
864166-93-8P 864166-94-9P 864166-95-0P 864166-96-1P
864166-97-2P 864166-99-4P 864167-00-0P 864167-01-1P
864167-02-2P 864167-03-3P 864167-04-4P 864167-05-5P
864167-06-6P 864167-07-7P 864167-08-8P 864167-09-9P
864167-10-2P 864167-11-3P 864167-12-4P 864167-33-9P
864167-34-0P 864167-35-1P 864167-36-2P 864167-37-3P
864167-38-4P 864167-39-5P 864167-40-8P 864167-41-9P
864167-42-0P 864167-43-1P 864167-44-2P 864167-46-4P
864167-48-6P 864167-50-0P 864167-51-1P 864167-53-3P
864167-54-4P 864167-56-6P 864167-58-8P 864167-59-9P
864167-60-2P 864167-61-3P 864167-62-4P 864167-63-5P
864167-64-6P 864167-65-7P 864167-66-8P 864167-67-9P
864167-68-0P 864167-69-1P 864167-70-4P 864167-71-5P
864167-72-6P 864167-73-7P 864167-74-8P 864167-75-9P
864167-76-0P 864167-77-1P 864167-78-2P 864167-79-3P
864167-80-6P 864167-81-7P 864167-82-8P 864167-83-9P
864167-84-0P 864167-85-1P 864167-86-2P 864167-87-3P
864167-88-4P 864167-89-5P 864167-90-8P 864167-91-9P
864167-92-0P 864167-93-1P 864167-94-2P 864167-95-3P
864167-96-4P 864167-97-5P 864167-98-6P 864167-99-7P

864168-00-3P 864168-01-4P 864168-02-5P 864168-03-6P
864168-04-7P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of peptides as caspase inhibitors)

L32 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:673279 HCAPLUS
DOCUMENT NUMBER: 143:172865
TITLE: Preparation of thiazole derivatives as modulators of the phosphoinositide 3-kinases (PI3Ks)
INVENTOR(S): Quattropani, Anna; Rueckle, Thomas; Schwarz, Matthias; Dorbais, Jerome; Sauer, Wolfgang; Cleva, Christophe; Desforges, Gwenaelle
PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N. V., Neth. Antilles
SOURCE: PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068444	A2	20050728	WO 2005-EP50102	200501 11
WO 2005068444	A3	20050909		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2004-100083 A 200401 12

OTHER SOURCE(S): MARPAT 143:172865
GI



I



II

AB The title compds. I [R1 = NR5R6; R2, R3, R5 = H, alkyl, alkenyl, alkynyl; R4 = H, alkyl, alkenyl, alkynyl, NR8R9 (wherein R8, R9 = H, alkyl, alkenyl, etc.); R6 = alkyl, aryl, heteroaryl, etc.], useful in particular for the **treatment** and/or prophylaxis of autoimmune disorders and/or **inflammatory diseases**, cardiovascular **diseases**, neurodegenerative **diseases**, bacterial or viral infections, kidney **diseases**, platelet aggregation, cancer, transplantation, graft rejection or lung injuries, were prepd. and formulated. Thus, reacting 3-[(aminocarbonothioyl)amino]benzoic acid with N-[5-(bromoacetyl)-4-methyl-1,3-thiazol-2-yl]acetamide (prepn. given) afforded II.HBr which showed IC50 of 10 nM against PI3Kγ.

IT **860619-22-3P 860619-39-2P 860619-75-6P 860620-37-7P 860620-38-8P 860620-39-9P 860620-40-2P**
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

RN 860619-22-3 HCAPLUS

CN Benzoic acid, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 860619-39-2 HCAPLUS

CN Acetamide, N-[2-[(4-cyanophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-75-6 HCAPLUS
CN Benzamide, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 860620-37-7 HCAPLUS
CN Benzeneacetic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 860620-38-8 HCAPLUS
CN β-Alanine, N-[4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 860620-39-9 HCAPLUS
CN Glycine, N-[4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 860620-40-2 HCAPLUS
CN Benzenepropanoic acid, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT **307343-36-8P 315704-54-2P 315705-71-6P**
315705-72-7P 315705-74-9P 315705-75-0P
315705-76-1P 315705-77-2P 315705-78-3P
315705-79-4P 315705-80-7P 315705-81-8P
315705-82-9P 315705-86-3P 315705-87-4P
315705-90-9P 315705-91-0P 315705-92-1P
315705-94-3P 315705-95-4P 333746-64-8P
333746-84-2P 421580-61-2P 428836-20-8P
443747-65-7P 472980-88-4P 860619-26-7P
860619-40-5P 860619-41-6P 860619-50-7P
860619-51-8P 860619-52-9P 860619-63-2P
860619-65-4P 860619-68-7P 860619-69-8P
860619-77-8P 860619-78-9P 860619-79-0P
860619-80-3P 860619-81-4P 860619-82-5P
860619-83-6P 860619-84-7P 860619-85-8P
860619-87-0P 860619-89-2P 860620-05-9P
860620-08-2P 860620-09-3P 860620-10-6P
860620-12-8P 860620-13-9P 860620-18-4P
860620-20-8P 860620-29-7P 860620-30-0P
860620-34-4P 860620-36-6P 860620-41-3P
860620-43-5P 860620-47-9P 860620-48-0P
860620-50-4P 860620-51-5P 860620-52-6P
860620-53-7P 860620-75-3P 860620-78-6P
860620-89-9P 860621-21-2P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
RN 307343-36-8 HCAPLUS
CN Acetamide, N-[2-[[4-(aminosulfonyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315704-54-2 HCAPLUS
CN Propanamide, N-[4'-methyl-2-[[4-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]amino][4,5'-bithiazol]-2'-yl]-(9CI) (CA INDEX NAME)



RN 315705-71-6 HCAPLUS
CN Acetamide, N-[4'-methyl-2-(phenylamino)[4,5'-bithiazol]-2'-yl]-(9CI) (CA INDEX NAME)



RN 315705-72-7 HCAPLUS
CN Acetamide, N-[2-[(4-chlorophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-74-9 HCAPLUS
CN Acetamide, N-[2-[(4-bromophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-75-0 HCAPLUS
CN Acetamide, N-[2-[(2-methoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-76-1 HCAPLUS
CN Acetamide, N-[2-[(4-methoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-77-2 HCAPLUS
CN Acetamide, N-[2-[(3-hydroxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-78-3 HCAPLUS
CN Acetamide, N-[2-[(4-hydroxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-79-4 HCAPLUS
CN Acetamide, N-[2-[(4-ethoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-

yl]- (9CI) (CA INDEX NAME)



RN 315705-80-7 HCAPLUS
CN Acetamide, N-[2-[(3-acetylphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-81-8 HCAPLUS
CN Benzoic acid, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 315705-82-9 HCAPLUS
CN Benzoic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 315705-86-3 HCAPLUS
CN Acetamide, N-[2-[(4-aminophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-87-4 HCAPLUS

CN Acetamide, N-[2-[[4-(dimethylamino)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-90-9 HCAPLUS
CN Acetamide, N-[2-[[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-91-0 HCAPLUS
CN Acetamide, N-[2-[[4-[[(2,6-dimethoxy-4-pyrimidinyl)amino]sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-92-1 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[[4-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-94-3 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[(2-methylphenyl)amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-95-4 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[(4-methylphenyl)amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 333746-64-8 HCAPLUS
CN Acetamide, N-[2-[(2-ethylphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 333746-84-2 HCAPLUS
CN Acetamide, N-[2-[(2,5-dimethoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 421580-61-2 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[(3-nitrophenyl)amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 428836-20-8 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[(4-nitrophenyl)amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 443747-65-7 HCAPLUS
CN Propanamide, N-[2-[[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 472980-88-4 HCAPLUS
CN Benzoic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 860619-26-7 HCAPLUS
CN Benzamide, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 860619-40-5 HCAPLUS
CN Acetamide, N-[2-[(2-chlorophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-41-6 HCAPLUS
CN Acetamide, N-[2-[(3-chlorophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-50-7 HCAPLUS
CN Acetamide, N-[2-(5-benzofuranylamino)-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-51-8 HCAPLUS
CN Acetamide, N-[2-(5-benzofuranylamino)-4'-methyl[4,5'-bithiazol]-2'-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 860619-50-7
CMF C17 H14 N4 O2 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 860619-52-9 HCAPLUS
CN Acetamide, N-[2-[(3-cyanophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-63-2 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[[3-(5-oxazolyl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-65-4 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[[4-(1H-tetrazol-5-yl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-68-7 HCAPLUS
CN Acetamide, N-[2-[[3-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-69-8 HCAPLUS
CN Acetamide, N-[2-[[3-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 860619-68-7
CMF C17 H15 N7 O S3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 860619-77-8 HCAPLUS
CN Acetamide, N-[2-[[3-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 860619-78-9 HCAPLUS
CN Acetamide, N-[2-[[3-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]-, monoacetate (9CI) (CA

INDEX NAME)

CM 1

CRN 860619-77-8
CMF C19 H15 N5 O3 S3

Double bond geometry as shown.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 860619-79-0 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[[4-[(2-pyridinylamino)sulfonyl]phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-80-3 HCAPLUS
CN Acetamide, N-[2-[[2-(2-hydroxyethyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-81-4 HCAPLUS
CN Acetamide, N-[2-[[3-(hydroxymethyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-82-5 HCAPLUS
CN Acetamide, N-[2-[[4-(2-hydroxyethyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-83-6 HCAPLUS
CN Acetamide, N-[2-[[3-[(2-hydroxyethyl)sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-84-7 HCAPLUS
CN Acetamide, N-[2-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-85-8 HCAPLUS
CN Acetamide, N-[2-[[3-(aminosulfonyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-87-0 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[[4-[(methylamino)sulfonyl]phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-89-2 HCAPLUS
CN Acetamide, N-[2-[(2,3-dihydro-5-benzofuranyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-05-9 HCAPLUS
CN Acetamide, N-[2-[(2-hydroxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-08-2 HCAPLUS
CN Acetamide, N-[2-[(3-methoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-09-3 HCAPLUS
CN Benzamide, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 860620-10-6 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[(2-nitrophenyl)amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-12-8 HCAPLUS
CN Acetamide, N-[4'-methyl-2-(5-quinolinylamino)[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-13-9 HCAPLUS
CN Acetamide, N-[4'-methyl-2-(6-quinolinylamino)[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-18-4 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[[3-(methylsulfonyl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-20-8 HCAPLUS
CN Acetamide, N-[2-[(1,1-dioxidobenzo[b]thien-6-yl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-29-7 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[[4-(4-morpholinylsulfonyl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-30-0 HCAPLUS
CN Acetamide, N-[2-[[3-[(butylamino)sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-34-4 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[[2-(methylsulfonyl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-36-6 HCAPLUS
CN Acetamide, N-[2-[[3-(1-hydroxyethyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-41-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 860620-43-5 HCAPLUS
CN Benzeneacetic acid, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 860620-47-9 HCAPLUS
CN Urea, [4'-methyl-2-(phenylamino)[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-48-0 HCAPLUS
CN Urea, [2-[(4-hydroxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-50-4 HCAPLUS
CN Benzeneacetic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 860620-51-5 HCAPLUS
CN β-Alanine, N-[4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 860620-52-6 HCAPLUS
CN Glycine, N-[4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 860620-53-7 HCAPLUS
CN Benzenepropanoic acid, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 860620-75-3 HCAPLUS
CN Acetamide, N-[4'-methyl-2-[[3-(1H-tetrazol-5-yl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-78-6 HCAPLUS
CN Acetamide, N-[2-[[3-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-89-9 HCAPLUS
CN Acetamide, N-[2-[[3-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860621-21-2 HCAPLUS
CN Acetamide, N-[4-[[2'-(acetylamino)-5-methyl[4,5'-bithiazol]-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT **860620-90-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
RN 860620-90-2 HCAPLUS
CN Acetamide, N-[2-[[3-(1,3-dioxolan-2-yl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



IC ICM C07D277-46
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT Nervous system, **disease**
(Huntington's chorea, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Muscle, **disease**
(atrophy, **treating** or preventing skeletal muscle atrophy; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Lung, **disease**
(chronic obstructive pulmonary **disease**, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Nervous system, **disease**
(degeneration, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Kidney, **disease**
(fibrosis, **treating** or preventing progressive renal

fibrosis; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Inflammation
Kidney, **disease**
(glomerulonephritis, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Kidney, **disease**
(glomerulosclerosis, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Muscle, **disease**
(hypertrophy, **treating** or preventing skeletal muscle atrophy/hypertrophy; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Heart, **disease**
(hypertrophy, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Brain, **disease**
(infection, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Intestine, **disease**
(**inflammatory**, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Lung, **disease**
Reperfusion
(injury, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Inflammation
Lung, **disease**
(pneumonitis, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Brain, **disease**
(stroke, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Central nervous system, **disease**
(trauma, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT Allergy
Alzheimer's **disease**
Anaphylaxis
Angiogenesis
Asthma
Atherosclerosis
Autoimmune **disease**
Cardiovascular system, **disease**
Encephalitis
Fibrosis
Hypertension
Inflammation
Ischemia
Kidney, **disease**
Melanoma
Meningitis
Multiple sclerosis
Neoplasm
Platelet aggregation
Psoriasis
Rheumatoid arthritis

Sepsis
Thrombosis
Transplant and Transplantation
Transplant rejection
Vasoconstriction
(**treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 115926-52-8
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT **860619-22-3P 860619-39-2P** 860619-58-5P
860619-75-6P 860620-37-7P 860620-38-8P
860620-39-9P 860620-40-2P 860620-42-4P
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 32558-17-1P **307343-36-8P 315704-54-2P**
315705-71-6P 315705-72-7P 315705-74-9P
315705-75-0P 315705-76-1P 315705-77-2P
315705-78-3P 315705-79-4P 315705-80-7P
315705-81-8P 315705-82-9P 315705-83-0P
315705-86-3P 315705-87-4P 315705-90-9P
315705-91-0P 315705-92-1P 315705-94-3P
315705-95-4P 333746-52-4P 333746-55-7P **333746-64-8P 333746-84-2P** 412919-76-7P **421580-61-2P**
428836-20-8P 443747-65-7P 472980-88-4P
860619-23-4P 860619-24-5P 860619-25-6P **860619-26-7P**
860619-27-8P 860619-28-9P 860619-29-0P 860619-30-3P
860619-31-4P 860619-32-5P 860619-33-6P 860619-34-7P
860619-35-8P 860619-36-9P 860619-37-0P 860619-38-1P
860619-40-5P 860619-41-6P 860619-42-7P
860619-43-8P 860619-44-9P 860619-45-0P 860619-46-1P
860619-47-2P 860619-48-3P 860619-49-4P **860619-50-7P**
860619-51-8P 860619-52-9P 860619-53-0P
860619-54-1P 860619-55-2P 860619-56-3P 860619-57-4P
860619-59-6P 860619-60-9P 860619-61-0P 860619-62-1P
860619-63-2P 860619-64-3P **860619-65-4P**
860619-66-5P 860619-67-6P **860619-68-7P**
860619-69-8P 860619-70-1P 860619-71-2P 860619-72-3P
860619-73-4P 860619-74-5P 860619-76-7P **860619-77-8P**
860619-78-9P 860619-79-0P 860619-80-3P
860619-81-4P 860619-82-5P 860619-83-6P
860619-84-7P 860619-85-8P 860619-86-9P
860619-87-0P 860619-88-1P **860619-89-2P**
860619-90-5P 860619-91-6P 860619-92-7P 860619-93-8P
860619-94-9P 860619-95-0P 860619-96-1P 860619-98-3P
860620-00-4P 860620-02-6P 860620-03-7P 860620-04-8P
860620-05-9P 860620-06-0P 860620-07-1P
860620-08-2P 860620-09-3P 860620-10-6P
860620-11-7P **860620-12-8P 860620-13-9P**
860620-14-0P 860620-15-1P 860620-16-2P 860620-17-3P
860620-18-4P 860620-19-5P **860620-20-8P**
860620-21-9P 860620-22-0P 860620-23-1P 860620-24-2P
860620-25-3P 860620-26-4P 860620-27-5P 860620-28-6P
860620-29-7P 860620-30-0P 860620-31-1P
860620-32-2P 860620-33-3P **860620-34-4P** 860620-35-5P
860620-36-6P 860620-41-3P 860620-43-5P

860620-44-6P 860620-45-7P 860620-46-8P **860620-47-9P**
860620-48-0P 860620-49-1P **860620-50-4P**
860620-51-5P **860620-52-6P** **860620-53-7P**
860620-70-8P **860620-75-3P** 860620-76-4P 860620-77-5P
860620-78-6P 860620-83-3P 860620-84-4P 860620-86-6P
860620-87-7P 860620-88-8P **860620-89-9P** 860621-18-7P
860621-19-8P 860621-20-1P **860621-21-2P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 618-95-1P, Methyl 3-nitrobenzoate 926-59-0P 3043-28-5P, 3-Bromo-2,4-pentanedione 4138-35-6P, Methyl 3-aminopropanoate 14062-34-1P 32519-72-5P 32519-75-8P 39884-12-3P 53159-71-0P, 1-(2-Amino-1,3-thiazol-5-yl)ethanone 83725-80-8P, 5-(3-Nitrophenyl)-1,3,4-oxadiazol-2-ol 87005-15-0P 94284-63-6P, Ethyl 5-acetyl-2-amino-1,3-thiazole-4-carboxylate 115082-05-8P 167405-28-9P, 1-[2-Amino-4-(trifluoromethyl)-1,3-thiazol-5-yl]ethanone 191399-17-4P, 1-(2-Amino-4-methyl-1,3-oxazol-5-yl)ethanone 299441-33-1P, 5-(3-Aminophenyl)-1,3,4-thiadiazol-2-amine 440087-89-8P 696629-98-8P 860615-87-8P 860620-54-8P 860620-55-9P, N-(5-Acetyl-4-methyl-1,3-oxazol-2-yl)acetamide 860620-56-0P 860620-57-1P, N-(5-Acetyl-1,3-thiazol-2-yl)acetamide 860620-58-2P 860620-59-3P, N-[5-Acetyl-4-(trifluoromethyl)-1,3-thiazol-2-yl)acetamide 860620-60-6P 860620-61-7P, Ethyl 5-acetyl-2-(acetylamino)-1,3-thiazole-4-carboxylate 860620-62-8P 860620-63-9P 860620-64-0P, N-[3-(5-Amino-[1,3,4]thiadiazol-2-yl)phenyl]-2,2,2-trifluoro-acetamide 860620-81-1P 860620-82-2P 860620-85-5P **860620-90-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

L32 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:395267 HCAPLUS
DOCUMENT NUMBER: 142:463596
TITLE: Preparation of indole derivatives as PGD2 antagonists
INVENTOR(S): Middlemiss, David; Ashton, Mark Richard; Boyd, Edward Andrew; Brookfield, Frederick Arthur; Armer, Richard Edward
PATENT ASSIGNEE(S): Oxagen Limited, UK
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040112	A1	20050506	WO 2004-GB4337	20041013

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,

SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL,
PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

GB 2003-24083	A	200310 14
GB 2004-3334	A	200402 14
GB 2004-6963	A	200403 27

OTHER SOURCE(S): MARPAT 142:463596
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1, R2, R3, and R4 independently = H, halo, alkyl, etc.; R5 and R6 independently = H, alkyl or R5 and R6 together with carbon atom to which they are attached 3-7-membered cycloalkyl; R7 = H, alkyl; R8 = alkyl, alkenyl, alkynyl, etc.; R9 = H, alkyl, aryl, etc.] and their pharmaceutically acceptable salts, are prepd. and disclosed as PGD2 antagonists. Thus, e.g., II was prepd. by sulfonylation of (5-fluoro-1H-indol-3-yl)-acetic acid Et ester with 4-fluorobenzene sulfonyl chloride and subsequent hydrolysis of the Et ester. The activity of I towards CRTH2 receptors was evaluated in radioligand binding assays and it revealed that selected compds. of the invention displayed Ki values in the range of 15 up to 3050 nM. I as PGD2 antagonists should prove useful in the **treatment** of allergic **diseases** such as **asthma**, allergic rhinitis and atopic dermatitis. Pharmaceutical compns. comprising I are disclosed.

IT **851448-72-1P 851449-21-3P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of indole derivs. as PGD antagonists)

RN 851448-72-1 HCAPLUS
CN 1H-Indole-3-acetic acid, 5-fluoro-2-methyl-1-[[4-(2-thiazolylamino)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 851449-21-3 HCAPLUS

CN 1H-Indole-3-acetic acid, 5-fluoro-2-methyl-1-[[4-(methyl-2-thiazolylamino)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



IC ICM C07D209-18
ICS A61K031-404; A61P043-00; C07D403-12
CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63
IT **Inflammation**
(Crohn's **disease**; prepn. of indole derivs. as PGD antagonists)
IT Antibodies and Immunoglobulins
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(IgE, hyper syndrome; prepn. of indole derivs. as PGD antagonists)
IT Allergy
(allergic **asthma**; prepn. of indole derivs. as PGD antagonists)
IT **Asthma**
(allergic; prepn. of indole derivs. as PGD antagonists)
IT Intestine, **disease**
(**inflammatory**; prepn. of indole derivs. as PGD antagonists)
IT Acne
Antiasthmatics
Antirheumatic agents
Antitumor agents
Autoimmune disease
Combination chemotherapy
Food allergy
Human
Multiple sclerosis
Osteoarthritis
Psoriasis
Rheumatoid arthritis
(prepn. of indole derivs. as PGD antagonists)
IT Prostanoid receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(type DP2; prepn. of indole derivs. as PGD antagonists)
IT Prostanoid receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(type DP; prepn. of indole derivs. as PGD antagonists)
IT 6990-06-3, Fusidic acid 23593-75-1, Clotrimazole 79794-75-5, Loratidine 89365-50-4, Salmeterol 90566-53-3, Fluticasone 104987-11-3, Tacrolimus 111406-87-2, Zileuton 122320-73-4, Rosiglitazone 137071-32-0, Pimecrolimus 158966-92-8, Montelukast 242138-07-4, Omalizumab
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(claimed co-drugs; prepn. of indole derivs. as PGD antagonists)

IT 851447-47-7P 851447-48-8P 851447-49-9P 851447-50-2P
851447-51-3P 851447-52-4P 851447-53-5P 851447-54-6P
851447-55-7P 851447-56-8P 851447-57-9P 851447-58-0P
851447-59-1P 851447-60-4P 851447-61-5P 851447-62-6P
851447-63-7P 851447-64-8P 851447-65-9P 851447-66-0P
851447-67-1P 851447-68-2P 851447-69-3P 851447-70-6P
851447-71-7P 851447-72-8P 851447-73-9P 851447-74-0P
851447-75-1P 851447-76-2P 851447-77-3P 851447-78-4P
851447-79-5P 851447-80-8P 851447-81-9P 851447-82-0P
851447-83-1P 851447-84-2P 851447-85-3P 851447-86-4P
851447-87-5P 851447-88-6P 851447-89-7P 851447-90-0P
851447-91-1P 851447-92-2P 851447-93-3P 851447-94-4P
851447-95-5P 851447-96-6P 851447-97-7P 851447-98-8P
851447-99-9P 851448-00-5P 851448-01-6P 851448-02-7P
851448-03-8P 851448-04-9P 851448-05-0P 851448-06-1P
851448-07-2P 851448-08-3P 851448-09-4P 851448-10-7P
851448-11-8P 851448-14-1P 851448-15-2P 851448-16-3P
851448-17-4P 851448-18-5P 851448-19-6P 851448-20-9P
851448-21-0P 851448-22-1P 851448-23-2P 851448-24-3P
851448-25-4P 851448-26-5P 851448-27-6P 851448-28-7P
851448-29-8P 851448-30-1P 851448-31-2P 851448-32-3P
851448-33-4P 851448-34-5P 851448-35-6P 851448-36-7P
851448-37-8P 851448-38-9P 851448-39-0P 851448-40-3P
851448-41-4P 851448-42-5P 851448-43-6P 851448-44-7P
851448-45-8P 851448-46-9P 851448-47-0P 851448-48-1P
851448-49-2P 851448-50-5P 851448-51-6P 851448-52-7P
851448-53-8P 851448-54-9P 851448-55-0P 851448-56-1P
851448-57-2P 851448-58-3P 851448-59-4P 851448-60-7P
851448-61-8P 851448-62-9P 851448-63-0P 851448-64-1P
851448-65-2P 851448-66-3P 851448-67-4P 851448-68-5P
851448-69-6P 851448-70-9P 851448-71-0P **851448-72-1P**
851448-73-2P 851448-74-3P 851448-75-4P 851448-76-5P
851448-77-6P 851448-78-7P 851448-79-8P 851448-80-1P
851448-81-2P 851448-82-3P 851448-83-4P 851448-84-5P
851448-85-6P 851448-86-7P 851448-87-8P 851448-88-9P
851448-89-0P 851448-90-3P 851448-91-4P 851448-92-5P
851448-93-6P 851448-94-7P 851448-95-8P 851448-96-9P
851448-97-0P 851448-98-1P 851448-99-2P 851449-00-8P
851449-01-9P 851449-02-0P 851449-03-1P 851449-04-2P
851449-05-3P 851449-06-4P 851449-07-5P 851449-08-6P
851449-09-7P 851449-10-0P 851449-11-1P 851449-12-2P
851449-13-3P 851449-14-4P 851449-15-5P 851449-16-6P
851449-17-7P 851449-18-8P 851449-19-9P 851449-20-2P
851449-21-3P 851449-22-4P 851449-23-5P 851449-24-6P
851449-25-7P 851449-26-8P 851449-27-9P 851449-28-0P
851449-29-1P 851449-30-4P 851449-31-5P 851449-32-6P
851449-33-7P 851449-34-8P 851449-35-9P 851449-36-0P
851449-37-1P 851449-38-2P 851449-39-3P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of indole derivs. as PGD antagonists)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:369133 HCAPLUS
DOCUMENT NUMBER: 142:435774
TITLE: Compositions **treatment** of chronic **inflammatory diseases**
INVENTOR(S): Shapiro, Howard K.

PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 610,073, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005090553	A1	20050428	US 2004-924945		20040824
PRIORITY APPLN. INFO.:			US 1992-906909	B2	19920630
			US 1994-241603	B2	19940511
			US 1997-814291	B2	19970310
			US 2000-610073	B2	20000705

OTHER SOURCE(S): MARPAT 142:435774

AB This invention defines novel compns. that can be used for clin. **treatment** of a class of chronic **inflammatory diseases.** Increased generation of carbonyl substances, aldehydes and ketones, occurs at sites of chronic **inflammation** and is common to the etiologies of all of the clin. disorders addressed herein. Such carbonyl substances are cytotoxic and addnl. serve to perpetuate and disseminate the **inflammatory** process. This invention defines use of compns., the orally administered required primary agents of which are primary amine derivs. of benzoic acid capable of reacting with the carbonyl substances. P-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small mol. wt., is water sol., has a primary amine group which reacts with carbonyl-contg. substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a compn. comprising: (1) an orally consumed primary agent; (2) a previously known medicament co-agent recognized as effective to **treat** a chronic **inflammatory disease** addressed herein administered to the mammalian subject via the oral route, other systemic routes of administration or via the topical route; and (3) optionally 1 or more addnl. orally consumed co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents, so as to produce an additive or synergistic physiol. effect of an anti-**inflammatory** nature.

IT **110952-54-0**, 2-(2-Hydroxy-4-methylphenyl)aminothiazole hydrochloride
RL: **THU (Therapeutic use); BIOL (Biological study)**

; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

RN 110952-54-0 HCAPLUS

CN Phenol, 5-methyl-2-(2-thiazolylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IC ICM A61K031-195

INCL 514565000; 514567000

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

ST chronic **inflammatory disease**

IT **Inflammation**
(Crohn's **disease**; compns. **treatment** of chronic **inflammatory diseases**)

IT Intestine, **disease**
(Crohn's; compns. **treatment** of chronic **inflammatory diseases**)

IT Carbohydrates, biological studies
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**
; USES (Uses)
(amino sugars; compns. **treatment** of chronic **inflammatory diseases**)

IT Polysaccharides, biological studies
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**
; USES (Uses)
(aminodeoxy; compns. **treatment** of chronic **inflammatory diseases**)

IT **Inflammation**
Spinal column, **disease**
(ankylosing spondylitis; compns. **treatment** of chronic **inflammatory diseases**)

IT Autoimmune **disease**
Inflammation
Stomach, **disease**
(autoimmune gastritis, chronic; compns. **treatment** of chronic **inflammatory diseases**)

IT Lung, **disease**
(chronic obstructive pulmonary **disease**; compns. **treatment** of chronic **inflammatory diseases**)

IT **Inflammation**
(chronic; compns. **treatment** of chronic **inflammatory diseases**)

IT **Inflammation**
Intestine, **disease**
(colitis; compns. **treatment** of chronic **inflammatory diseases**)

IT Antioxidants

Arthritis
Edema
Epilepsy
Human
Ischemia
Multiple sclerosis
Myasthenia gravis
Myositis
Osteoarthritis
Pneumoconiosis
Psoriasis
Quillaja
Reperfusion
Rheumatoid arthritis
(compns. **treatment** of chronic **inflammatory diseases**)

IT Coal dust
RL: ADV (Adverse effect, including toxicity); **BIOL (Biological study)**
(compns. **treatment** of chronic **inflammatory diseases**)

IT Coal tar
RL: **THU (Therapeutic use)**; **BIOL (Biological study)** ; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

IT Collagens, biological studies
RL: **THU (Therapeutic use)**; **BIOL (Biological study)** ; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

IT Ginsenosides
RL: **THU (Therapeutic use)**; **BIOL (Biological study)** ; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

IT Macrolides
RL: **THU (Therapeutic use)**; **BIOL (Biological study)** ; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

IT Polysaccharides, biological studies
RL: **THU (Therapeutic use)**; **BIOL (Biological study)** ; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

IT Saponins
RL: **THU (Therapeutic use)**; **BIOL (Biological study)** ; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

IT Thiols, biological studies
RL: **THU (Therapeutic use)**; **BIOL (Biological study)** ; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

IT Ubiquinones
RL: **THU (Therapeutic use)**; **BIOL (Biological study)** ; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

IT Vitamins

RL: **THU (Therapeutic use)**; **BIOL (Biological study)**
; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

IT Bladder, **disease**
Inflammation
(cystitis, interstitial; compns. **treatment** of chronic **inflammatory diseases**)

IT Tendon
(**disease**, tendinitis; compns. **treatment** of chronic **inflammatory diseases**)

IT Tendon
(**disease**, tenosynovitis; compns. **treatment** of chronic **inflammatory diseases**)

IT Mandevilla velutina
(exts.; compns. **treatment** of chronic **inflammatory diseases**)

IT Drug delivery systems
(gels; compns. **treatment** of chronic **inflammatory diseases**)

IT Gingiva, **disease**
Inflammation
(gingivitis, chronic; compns. **treatment** of chronic **inflammatory diseases**)

IT **Inflammation**
Intestine, **disease**
(ileitis; compns. **treatment** of chronic **inflammatory diseases**)

IT Heart, **disease**
(infarction; compns. **treatment** of chronic **inflammatory diseases**)

IT Intestine, **disease**
(**inflammatory**; compns. **treatment** of chronic **inflammatory diseases**)

IT Drug delivery systems
(injections, i.m.; compns. **treatment** of chronic **inflammatory diseases**)

IT Drug delivery systems
(injections, i.v.; compns. **treatment** of chronic **inflammatory diseases**)

IT Kidney, **disease**
(ischemia; compns. **treatment** of chronic **inflammatory diseases**)

IT Drug delivery systems
(lotions; compns. **treatment** of chronic **inflammatory diseases**)

IT Streptomyces tsukubaensis
(macrolide from; compns. **treatment** of chronic **inflammatory diseases**)

IT Nerve, **disease**
(neuropathy, **inflammatory**; compns. **treatment** of chronic **inflammatory diseases**)

IT Natural products, pharmaceutical
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**
; USES (Uses)
(opium; compns. **treatment** of chronic **inflammatory diseases**)

IT Drug delivery systems
(oral; compns. **treatment** of chronic **inflammatory diseases**)

IT **Inflammation**
Periodontium, **disease**

(periodontitis, chronic; compns. **treatment** of chronic **inflammatory diseases**)
IT Nerve, **disease**
(peripheral nerve injury, carpal tunnel syndrome; compns. **treatment** of chronic **inflammatory diseases**)
IT Injury
(peripheral nerve, carpal tunnel syndrome; compns. **treatment** of chronic **inflammatory diseases**)
IT Ischemia
(renal; compns. **treatment** of chronic **inflammatory diseases**)
IT Brain, **disease**
(stroke; compns. **treatment** of chronic **inflammatory diseases**)
IT Lupus erythematosus
(systemic; compns. **treatment** of chronic **inflammatory diseases**)
IT Drug delivery systems
(tablets; compns. **treatment** of chronic **inflammatory diseases**)
IT **Inflammation**
(tendinitis; compns. **treatment** of chronic **inflammatory diseases**)
IT **Inflammation**
(tenosynovitis; compns. **treatment** of chronic **inflammatory diseases**)
IT Drug delivery systems
(topical; compns. **treatment** of chronic **inflammatory diseases**)
IT Central nervous system, **disease**
(trauma, acute; compns. **treatment** of chronic **inflammatory diseases**)
IT Injury
Spinal cord, **disease**
(trauma; compns. **treatment** of chronic **inflammatory diseases**)
IT Interferons
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(α-2a; compns. **treatment** of chronic **inflammatory diseases**)
IT Interferons
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(α-2b; compns. **treatment** of chronic **inflammatory diseases**)
IT Interferons
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(α-N3; compns. **treatment** of chronic **inflammatory diseases**)
IT Interferons
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(β; compns. **treatment** of chronic **inflammatory diseases**)
IT 24967-94-0, Dermatan sulfate
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(complex with heparinoids; compns. **treatment** of chronic

inflammatory diseases)

IT 7782-42-5, Graphite, biological studies 14807-96-6, Talc, biological studies
RL: ADV (Adverse effect, including toxicity); **BIOL (Biological study)**
(compns. **treatment** of chronic **inflammatory diseases**)

IT 50-02-2, Dexamethasone 50-03-3, Hydrocortisone acetate 50-06-6, Phenobarbital, biological studies 50-14-6, Vitamin D2 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-44-2, 6-Mercaptopurine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-53-3, Chlorpromazine, biological studies 51-06-9, Procainamide 51-34-3, Scopolamine 51-83-2, Carbachol 52-53-9, Verapamil 52-67-5, D-Penicillamine 52-90-4, L-Cysteine, biological studies 53-03-2, Prednisone 53-06-5, Cortisone 53-33-8, Paramethasone 53-36-1, Methylprednisolone acetate 53-86-1, Indomethacin 54-05-7, Chloroquine 54-21-7, Sodium salicylate 54-35-3, Penicillin G procaine 54-47-7, Pyridoxal 5-phosphate 54-85-3, Isoniazid 54-96-6, 3,4-Diaminopyridine 55-63-0, Trinitroglycerin 56-40-6, Glycine, biological studies 57-00-1, Creatine 57-41-0, Phenytoin 57-50-1D, Sucrose, esters with fatty acids 57-96-5, Sulfinpyrazone 58-05-9, Folinic acid 58-25-3, Chlordiazepoxide 58-32-2, Dipyridamole 58-73-1, Diphenhydramine 58-85-5, Vitamin H 58-95-7, (+)-α-Tocopheryl acetate 59-02-9, α-Tocopherol 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-43-8, Vitamin B1, biological studies 59-43-8D, Thiamine, salts 59-58-5, Thiamine propyl disulfide 59-66-5, Acetazolamide 59-67-6, Nicotinic acid, biological studies 59-96-1, Phenoxybenzamine 60-23-1, Cysteamine 60-54-8, Tetracycline 61-68-7, Mefenamic acid 63-68-3, L-Methionine, biological studies 65-22-5, Pyridoxal hydrochloride 66-72-8, Pyridoxal 67-16-3, Thiamine disulfide 67-73-2, Fluocinolone acetonide 67-78-7, Triamcinolone diacetate 67-97-0, Vitamin D3 68-19-9, Vitamin B12 68-26-8, Retinol 69-46-5, Calcium acetylsalicylate 69-72-7, Salicylic acid, biological studies 70-18-8, Glutathione, biological studies 74-31-7, N,N'-Diphenyl-p-phenylenediamine 76-25-5, Triamcinolone acetonide 76-57-3, Codeine 77-37-2, Procyclidine 77-67-8, Ethosuximide 77-92-9, Citric acid, biological studies 79-83-4, Pantothenic acid 80-08-0, Dapsone 81-81-2, Warfarin 83-43-2, Methylprednisolone 83-68-1, Vitamin K6 83-69-2, Vitamin K7 83-70-5, Vitamin K5 83-88-5, Vitamin B2, biological studies 83-89-6, Quinacrine 85-87-0, Pyridoxamine 86-42-0, Amodiaquine 87-33-2, Isosorbide dinitrate 89-57-6, 5-Aminosalicylic acid 91-53-2, Ethoxyquin 91-86-1, η-Tocopherol 92-43-3, Phenidone 98-92-0, Niacinamide 99-66-1, Valproic acid 107-35-7, Taurine 113-98-4, Penicillin G potassium 114-07-8, Erythromycin 116-31-4, Vitamin A aldehyde 117-39-5, Quercetin 118-42-3, Hydroxychloroquine 118-92-3, Vitamin L1 119-13-1, δ-Tocopherol 121-79-9, Propyl gallate 124-94-7, Triamcinolone 125-33-7, Primidone 127-47-9, Retinyl acetate 128-37-0, Butylated hydroxytoluene, biological studies 129-03-3, Cyproheptadine 129-20-4, Oxyphenbutazone 130-24-5, Vitamin K5 hydrochloride 130-40-5, Riboflavin 5'-phosphate ester monosodium salt 132-17-2, Benztropine mesylate 132-98-9, Penicillin V potassium 137-08-6, Pantothenic acid calcium salt 137-58-6, Lidocaine 138-14-7, Deferoxamine mesylate 144-11-6, Trihexyphenidyl 148-03-8, β-Tocopherol 153-18-4, Rutin 298-46-4, Carbamazepine 298-50-0, Propantheline 298-81-7, Methoxsalen 302-79-4, Vitamin A acid 305-03-3, Chlorambucil 309-36-4, Methohexital sodium 315-30-0, Allopurinol 317-34-0,

Aminophylline 327-97-9, Chlorogenic acid 352-97-6,
Guanidinoacetic acid 356-12-7, Fluocinonide 378-44-9,
Betamethasone 404-86-4, Capsaicin 432-70-2, α-Carotene
439-14-5, Diazepam 443-48-1, Metronidazole 444-27-9, Timonacic
446-72-0, Genistein 446-86-6, Azathioprine 458-37-7, Curcumin
462-20-4, Dihydrolipoic acid 472-93-5, γ-Carotene
476-66-4, Ellagic acid 480-16-0, Morin 480-17-1, Leucocyanidol
480-19-3, Isorhamnetin 481-46-9, Ginkgetin 489-35-0, Gossypetin
490-23-3, ε-Tocopherol 493-35-6, ζ2-Tocopherol
498-02-2, Apocynin 500-38-9, Nordihydroguaiaretic acid 501-30-4,
Kojic acid 502-65-8, ψ-,ψ-Carotene 504-24-5,
4-Aminopyridine 511-28-4, Vitamin D4 514-65-8, Biperiden
520-18-3, Kaempferol 520-36-5, Apigenin 521-32-4, Bilobetin
522-00-9, Ethopropazine 523-68-2, N-Acetyl vitamin K5 524-36-7,
Pyridoxamine dihydrochloride 525-66-6, Propranolol 528-48-3,
Fisetin 529-96-4, Pyridoxamine phosphate 530-78-9, Flufenamic
acid 532-11-6, Sulfarlem 532-40-1, Thiamine phosphate ester
chloride 532-43-4, Thiamine mononitrate 533-31-3, Sesamol
534-13-4, N,N'-Dimethylthiourea 540-05-6 541-15-1, L-Carnitine
548-19-6, Isoginkgetin 548-75-4, Quercetagetin-7-glucoside
552-66-9, Daidzin 552-94-3, Salsalate 564-25-0, Doxycycline
578-36-9, Potassium salicylate 599-79-1, Sulfasalazine 604-87-5
616-91-1, N-Acetylcysteine 635-97-2, Thiamine phosphoric acid
ester phosphate salt 637-07-0, Clofibrate 638-23-3,
S-Carboxymethylcysteine 644-62-2, Meclofenamic acid 644-62-2D,
Meclofenamic acid, salts 652-78-8, Gossypin 674-38-4,
Bethanechol 752-56-7, Riboflavin tetrabutyrate 768-94-5,
Amantadine 841-73-6, Bucolome 846-49-1, Lorazepam 867-81-2,
Pantothenic acid sodium salt 915-30-0, Diphenoxylate 992-46-1,
Thiamine disulfide phosphate 1077-28-7, Thioctic acid 1115-84-0,
Vitamin U 1134-47-0, Baclofen 1143-38-0, Anthralin 1166-52-5,
Dodecylgallate 1398-61-4D, Chitin, derivs. 1424-27-7,
Acetazolamide sodium 1505-95-9, Naphthypramide 1508-65-2,
Oxybutynin chloride 1524-88-5, Flurandrenolide 1538-09-6
1553-60-2, Ibufenac 1562-74-9, 5-Thiopyridoxine 1597-82-6,
Paramethasone 21-acetate 1622-61-3, Clonazepam 1721-51-3,
ζ1-Tocopherol 1948-33-0, tert-Butylhydroquinone 1953-02-2,
Tiopronin 2016-36-6, Choline salicylate, biological studies
2055-44-9, Perisoxal 2124-57-4, Vitamin K2(35) 2145-14-4,
Paramethasone disodium phosphate 2152-44-5, Betamethasone valerate
2319-84-8, Thioctic acid sodium salt 2447-54-3, Sanguinarine
2457-80-9, Vitamin L2 2487-39-0, Vitamin K-S(II) 2766-51-0,
Methylmethioninesulfonium bromide 3040-38-8, Acetyl-L-carnitine
3211-76-5, L-Selenomethionine 3286-46-2, Thiamine disulfide
O,O-di-isobutyrate 3380-34-5, Triclosan 3416-24-8, Glucosamine
3475-65-8, Thiamine triphosphoric acid ester 3570-15-8, Nicotinic
acid monoethanolamine salt 3930-20-9, Sotalol 4345-03-3
4394-00-7, Niflumic acid 4759-48-2, Isotretinoin 5003-48-5,
Benorylate 5011-34-7, Trimetazidine 5034-76-4, Indoxole
5104-49-4, Flurbiprofen 5355-16-8, Diaveridine 5593-20-4,
Betamethasone 17,21-dipropionate
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**
; USES (Uses)
(compns. **treatment** of chronic **inflammatory diseases**)

IT 5633-20-5, Oxybutynin 5728-52-9, Felbinac 5913-70-2, Pyridoxal
5-phosphate calcium salt 5934-23-6, Vitamin K2(30) dihydro
diacetate 5934-25-8, Vitamin K6 dihydrochloride 5934-26-9,
Vitamin K7 hydrochloride 5949-29-1, Citric acid monohydrate
6020-87-7, Creatine monohydrate 6027-13-0, Homocysteine
6035-45-6, Folinic acid calcium salt pentahydrate 6054-98-4,
Disodium azodisalicylate 6100-05-6 6223-35-4, Sodium

guaiazulene-3-sulfonate 6452-71-7, Oxprenolol 6493-05-6, Pentoxifylline 7085-45-2, Biperiden lactate 7235-40-7, β-Carotene 7512-17-6, N-AcetylGlucosamine 7616-22-0, γ-Tocopherol 7683-59-2, Isoproterenol 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 8069-87-2 9001-90-5D, Plasmin, streptokinase complex, acylated 9002-01-1, Streptokinase 9002-01-1D, Streptokinase, plasmin complex, acylated 9002-60-2, Corticotropin, biological studies 9002-89-5D, Poly(vinyl alcohol), derivs. 9003-39-8, Polyvinylpyrrolidone 9003-53-6D, Polystyrene, derivs. 9003-70-7D, Divinylbenzene-styrene copolymer, derivs. 9004-34-6D, Cellulose, derivs. 9004-57-3, Ethyl cellulose 9005-49-6, Heparin, biological studies 9014-67-9, Aloxiprin 9039-53-6D, Urokinase, acylated 9041-08-1, Heparin sodium 10118-90-8, Minocycline 10236-58-5, L-Selenocysteine 11032-49-8, Vitamin K2 11104-38-4, Vitamin K1 12192-57-3, Aurothioglucose 12244-57-4, Gold sodium thiomalate 13345-51-2D, Prostaglandin B1, oligomers 13422-55-4, Methyl vitamin B12 13523-86-9, Pindolol 13539-59-8, Azapropazone 13655-52-2, Alprenolol 13710-19-5, Tolfenamic acid 13739-02-1, Diacetylrhein 13993-65-2, Metiazinic acid 14402-89-2, Sodium nitroprusside 15307-86-5, Diclofenac 15475-56-6, Methotrexate sodium 15686-51-8, Clemastine 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 16051-77-7, Isosorbide 5-mononitrate 17969-20-9, Fenclozic acid 18471-20-0, Ditazol 18472-51-0, Chlorhexidine gluconate 18642-10-9, Thiamine disulfide hydrochloride 18694-40-1, Epirizole 18917-89-0, Magnesium salicylate 19771-63-2, L-2-Oxothiazolidine-4-carboxylic acid 19982-08-2, Memantine 20168-99-4, Cinmetacin 20554-84-1, Parthenolide 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4, Diflunisal 22760-18-5, Proquazone 23288-49-5, Probucol 23981-47-7, 6-Methoxy-2-naphthylacetic acid 24237-54-5, Tinoridine 25013-16-5, Butylated hydroxyanisole 25122-46-7, Clobetasol propionate 25451-15-4, Felbamate 25486-55-9, Vitamin K1 oxide 26171-23-3, Tolmetin 26589-39-9, Eudragit S 26787-78-0, Amoxicillin 26839-75-8, Timolol 27035-30-9, Oxametacin 27470-51-5, Suxibuzone 27686-36-8, Hypolaetin-8-glucoside 27696-41-9, Hypolaetin 28704-27-0, L-Alanine-L-glutamic acid-L-lysine-L-tyrosine copolymer 28841-62-5, D-myo-Inositol-1.2.6-trisphosphate 29031-19-4, Glucosamine sulfate 29098-15-5, Etoclofene 29122-68-7, Atenolol 29679-58-1, Fenoprofen 29908-03-0, S-Adenosylmethionine 30011-11-1, Bimetopyrol 30748-29-9, Feprazone 31793-07-4, Pirprofen 31842-01-0, Indoprofen 32808-51-8, Bucloxic acid 32839-30-8, Eicosapentaenoic acid 33005-95-7, Tiaprofenic acid 34031-32-8, Auranofin 34042-85-8, Sudoxicam 34148-01-1, Clidanac 34334-69-5, Cirsiliol 34461-73-9, Bumadizone calcium 34552-84-6, Isoxicam 34645-84-6, Fenclofenac 36322-90-4, Piroxicam 36330-85-5, Fenbufen 36364-49-5, Imidazole salicylate 36616-52-1, Fenclorac 36740-73-5, Flumizole 36894-69-6, Labetalol 36994-25-9, 2-(p-Bromophenyl)-9-dimethylaminopropyl-9H-imidazo[1,2-a]benzimidazole 37270-89-6, Heparin calcium 37517-30-9, Acebutolol 38194-50-2, Sulindac 38363-40-5, Penbutolol 38957-41-4, Emorfazone 40828-46-4, Suprofen 41340-25-4, Etodolac 42200-33-9, Nadolol 42399-41-7, Diltiazem 42924-53-8, Nabumetone 50270-32-1, 1-Isobutyl-3,4-diphenylpyrazole-5-acetic acid 50270-33-2, Isofezolac 51059-44-0, Oroxindin 51234-28-7, Benoxaprofen 51322-75-9, Tizanidine 51384-51-1, Metoprolol 51484-40-3, Difenpiramide 51579-82-9, Amfenac 51781-06-7, Carteolol 51803-78-2, Nimesulide 52263-84-0, (S)-(+)-Carprofen 52443-21-7, Glucametacin 53123-88-9, Rapamycin 53179-11-6D, Loperamide, diazo derivs. 53527-28-9, Scalaradial 53597-27-6, Fendosal 53716-49-7, Carprofen 54350-48-0,

Etretinate 55142-85-3, Ticlopidine 55242-55-2, Propentophylline
55366-56-8, Hibifolin 55453-87-7, Isoxepac 55837-18-8, Butibufen
55985-32-5, Nicardipine 56824-20-5, Amiprilose 57132-53-3,
Proglumetacin 58433-11-7, Tilomisole 58456-91-0,
2-Aminomethyl-4-tert-butyl-6-iodophenol 59122-46-2, Misoprostol
59804-37-4, Tenoxicam 59865-13-3, Cyclosporin A 59937-28-9,
Malotilate 60142-96-3, Gabapentin 60940-34-3, Ebselen
61941-57-9, Ethyl 2-amino-3-benzoylphenylacetate 62571-86-2,
Captopril 63329-53-3, Lobenzarit 63659-18-7, Betaxolol
64217-16-9, Phenytoin-phenobarbital mixt. 64224-21-1, Oltipraz
64294-95-7, Setastine 64425-90-7, Choline magnesium trisalicylate,
biological studies 65277-42-1, Ketoconazole 65666-07-1,
Silymarin 66734-13-2, Alclometasone dipropionate 66934-18-7,
Flunoxaprofen 68291-97-4, Zonisamide 68506-86-5, Vigabatrin
68767-14-6, Loxoprofen 69425-13-4, 2,6-Di-tert-butyl-4-[2'-
thenoyl]-phenol 70360-12-2, Sideritoflavone 71125-38-7,
Meloxicam 71320-77-9, Moclobemide 72509-76-3, Felodipine
74103-06-3, Ketorolac 74103-07-4, Ketorolac tromethamine
74469-00-4, Amoxicillin-clavulanate potassium mixt. 75060-92-3
75364-47-5 75695-93-1, Isradipine 75706-12-6, Leflunomide
75821-71-5, Lonazolac calcium 75847-73-3, Enalapril 76420-72-9,
Enalaprilat 76547-98-3, Lisinopril 76584-70-8, Divalproex sodium
76990-56-2, Milacemide 77086-21-6, Dizocilpine 77699-47-9,
Herbimycin 80474-14-2, Fluticasone propionate 80937-31-1,
6-(2,4-Difluorophenoxy)-5-methylsulfonylamino-1-indanone
81147-92-4, Esmolol 83919-23-7, Mometasone 17-(2-furoate)
84057-84-1, Lamotrigine 85441-61-8, Quinapril 86541-75-5,
Benazepril 87333-19-5, Ramipril 88150-42-9, Amlodipine
89149-10-0, 15-Deoxyspergualin 89796-99-6, Aceclofenac
90101-16-9, Droxicam 91418-71-2, Diacetylsplenopentin
98048-97-6, Fosinopril 98320-39-9, (10-Methoxy-4H-
benzo[4,5]cyclohepta[1,2-b]thiophene-4-ylidene)acetic acid
100827-28-9, Erbstatin 103475-41-8, Tepoxalin 110101-67-2,
Tirilazad mesylate **110952-54-0**, 2-(2-Hydroxy-4-
methylphenyl)aminothiazole hydrochloride 111406-87-2, Zileuton
117279-73-9 120072-59-5, 7-[3-(4-Acetyl-3-methoxy-2-propylphenoxy)-
propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid
120210-48-2, Tenidap 122726-03-8, Vitamin K2(35) dihydro diacetate
125697-92-9, Lavendustin A 129424-08-4 131420-91-2,
(Z)-3-[4-(Acetyloxy)-5-ethyl-3-methoxy-1-naphthalenyl]-2-methyl-2-
propenoic acid 132392-39-3, 5-[[3,5-Bis(1,1-dimethylethyl)-4-
hydroxyphenyl]methylene]-3-(dimethylamino)-4-thiazolidinone
132392-65-5, 5-[[3,5-Bis(1,1-dimethylethyl)-4-
hydroxyphenyl]methylene]-3-(methylamino)-4-thiazolidinone
133332-08-8, DL-2-(4-Hexyloxyphenyl)glycine octyl ester
133763-16-3, 1-p-Chlorobenzyl-2-dimethylaminomethyl-1,2-cyclohexene
135872-94-5, 1-[(4-Chlorophenyl)methyl]-2-methyl-5-
(quinolinylmethoxy)-1H-indole-3-acetic acid 136449-85-9
139639-23-9, Tissue plasminogen activator 143090-92-0, Anakinra
150977-36-9, Bromelain 151035-57-3, Quinapril-hydrochlorothiazide
mixt. 226721-96-6, Sodium 2-[4-(2-oxocyclopentylmethyl)phenyl]prop
ionate dihydrate 354124-52-0, Thioctic acid ethylenediamine
700346-94-7, Nicotinic acid sodium salt sesquihydrate 762210-30-0,
DL-2-[4-(5,5-Dimethylhexyloxy)phenyl]glycine octyl ester
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**
; USES (Uses)
(compns. **treatment** of chronic **inflammatory**
diseases)

IT 850785-97-6, Diphenoxylate-atropine sulfate mixt. 850785-98-7
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**
; USES (Uses)
(compns. **treatment** of chronic **inflammatory**

diseases)

L32 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:703129 HCAPLUS
DOCUMENT NUMBER: 141:218996
TITLE: Methods using Edg-7 **modulators** for **treating conditions** associated with an Edg-7 **receptor**
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004167192	A1	20040826	US 2004-760002		20040216
PRIORITY APPLN. INFO.:			US 2003-440321P	P	20030116
			US 2003-454881P	P	20030313

OTHER SOURCE(S): MARPAT 141:218996
AB The invention provides a method for modulating an Edg-7 **receptor** mediated biol. activity in a cell. A cell expressing the Edg-7 **receptor** is contacted with a **modulator** of the Edg-7 **receptor** which is capable of modulating an Edg-7 **receptor**-mediated biol. activity. The invention also provides a method for modulating an Edg-7 **receptor**-mediated biol. activity in a subject. A therapeutically effective amt. of a **modulator** of the Edg-7 **receptor** is administered to the subject. Prepn. of e.g. 4-Bromo-2-[2-(4-chlorophenylamino)-4-oxothiazolidin-5-ylidenemethyl]phenoxyacetic acid is described.
IT **353771-45-6P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
RN 353771-45-6 HCAPLUS
CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT **352694-02-1**
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
RN 352694-02-1 HCAPLUS
CN Acetic acid, [2-[[2-[(4-bromophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT **569656-05-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
RN 569656-05-9 HCAPLUS
CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IC ICM A61K031-4196
ICS A61K031-4172; A61K031-415; A61K031-41
INCL 514381000; 514383000; 514398000
CC 1-12 (Pharmacology)
Section cross-reference(s): 28

IT Animal cell line
(A431; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Animal cell line
(CAOV-3; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG (endothelial differentiation gene); Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-1 (endothelial differentiation gene 1); Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-2 (endothelial differentiation gene 2); Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-3 (endothelial differentiation gene 3); Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-4 (endothelial differentiation gene 4); Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-5 (endothelial differentiation gene 5); Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-6 (endothelial differentiation gene 6); Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-7 (endothelial differentiation gene 7); Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-8 (endothelial differentiation gene 8); Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Angiogenesis
Anti-**inflammatory** agents

Anti-ischemic agents
Antiasthmatics
Antitumor agents
Apoptosis
Asthma
Cardiovascular agents
Cardiovascular system, **disease**
Cell migration
Cell proliferation
Combination chemotherapy
Cytotoxic agents
Fibroblast
Human
Inflammation
Ischemia
Kidney, neoplasm
Lung, **disease**
Lung, neoplasm
Mammary gland, neoplasm
Myoblast
Neuron
Ovary, neoplasm
Pancreas, neoplasm
Peritoneum, neoplasm
Platelet (blood)
Platelet activation
Platelet activation
Prostate gland, neoplasm
Stomach, neoplasm
Thyroid gland, neoplasm
Uterus, neoplasm
Wound healing
(Edg-7 **modulators** for **treating** **conditions** assocd. with an Edg-7 **receptor**)

IT Carbohydrates, biological studies
Nucleic acids
Organic compounds, biological studies
Proteins
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(Edg-7 **modulators** for **treating** **conditions** assocd. with an Edg-7 **receptor**)

IT Animal cell line
(HT-1080; Edg-7 **modulators** for **treating** **conditions** assocd. with an Edg-7 **receptor**)

IT Animal cell line
(HTC; Edg-7 **modulators** for **treating** **conditions** assocd. with an Edg-7 **receptor**)

IT Animal cell line
(HUVEC; Edg-7 **modulators** for **treating** **conditions** assocd. with an Edg-7 **receptor**)

IT Animal cell line
(MDA-MB-231; Edg-7 **modulators** for **treating** **conditions** assocd. with an Edg-7 **receptor**)

IT Animal cell line
(MDA-MB-453; Edg-7 **modulators** for **treating** **conditions** assocd. with an Edg-7 **receptor**)

IT Animal cell line
(OV202; Edg-7 **modulators** for **treating** **conditions** assocd. with an Edg-7 **receptor**)

IT Respiratory distress syndrome
(adult; Edg-7 **modulators** for **treating**

conditions assocd. with an Edg-7 **receptor**)
IT Antiarteriosclerotics
(antiatherosclerotics; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Atherosclerosis
(atherogenesis; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Immune system
(autoimmune response; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Lysophosphatidic acids
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(cell proliferation stimulated by; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Carcinoma
Pheochromocytoma
(cell; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Uterus, neoplasm
(cervix; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Intestine, neoplasm
(colon; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Intestine, neoplasm
(colorectal; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Eye
(cornea, transcorneal freezing; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Burn
(cutaneous; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Uterus, neoplasm
(endometrium; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Epithelium
(epithelial cell; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Sarcoma
(fibrosarcoma, cell; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Carcinoma
(hepatocellular, cell; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Liver, neoplasm
(hepatoma, cell; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Phosphatidylinositols
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(hydrolysis; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Neoplasm
(invasiveness; Edg-7 **modulators** for **treating**

conditions assocd. with an Edg-7 **receptor**)
IT Ovary
(ovarian cell; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Actins
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(polymn.; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Intestine, neoplasm
(small; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Epithelium
(surface epithelial cell injury; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT Interleukin 8
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(synthesis; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT 26993-30-6, Sphingosine-1-phosphate
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT 312501-62-5P 331945-22-3P **353771-45-6P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT 49581-16-0 333772-21-7 352444-98-5 352683-56-8 **352694-02-1** 744198-30-9
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT 91-56-5, 1H-Indole-2,3-dione 108-31-6, Maleic anhydride, reactions 5242-26-2 **569656-05-9** 569656-06-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT 60-92-4, Cyclic AMP
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(formation, inhibition; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT 7440-70-2, Calcium, biological studies
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(mobilization; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)
IT 127464-60-2, Vascular endothelial growth factor
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(synthesis; Edg-7 **modulators** for **treating conditions** assocd. with an Edg-7 **receptor**)

L32 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:654774 HCAPLUS

DOCUMENT NUMBER: 141:190788
TITLE: A preparation of N-containing heterocyclic compounds, useful as vanilloid receptor ligands
INVENTOR(S): Doherty, Elizabeth M.; Fotsch, Christopher H.; Han, Nianhe; Hungate, Randall W.; Liu, Qingyian; Norman, Mark H.; Xi, Ning; Xu, Shimin
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 38 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004157845	A1	20040812	US 2004-775980	20040209
CA 2515215	AA	20040826	CA 2004-2515215	20040209
WO 2004072068	A1	20040826	WO 2004-US3908	20040209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1603905	A1	20051214	EP 2004-709532	20040209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2003-446511P P 20030210
WO 2004-US3908 W 20040209

OTHER SOURCE(S): MARPAT 141:190788
GI



I



II



III

AB The invention relates to a prepn. of N-contg. heterocyclic compds. of formula I [wherein: Q1, Q2, Q3, and Q4 are independently selected from N or C(R2); L is a substituted ethylene-1,2-diyl; X is NH, S, S(:O), SO2, or O; Y is NH, O, S, S(:O). or C(:O), etc.; R1 is halo, (halo)alkyl, -NH-alkyl, , or alkoxy, etc.; R2 is H, F, alkyl, or haloalkyl, etc.], useful as vanilloid receptor ligands (no biol. data). Compds. of formula I are useful for the **treatment** of **diseases** such as cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general **inflammation**, arthritis, rheumatic **diseases**, or osteoarthritis, etc. For instance, (pyridinylamino)thiazole deriv. II was prepd. via heterocyclization of 2-Cl-C6H4CH2C(:S)NH2 with Et bromopyruvate, hydrolysis of the obtained ester III (R3 = CO2Et), chlorination of the obtained acid III (R3 = CO2H), and subsequent amination of the obtained thiazole deriv. III [R3 = C(:O)Cl] by 3-amino-6-(trifluoromethyl)pyridine (example 1).

IT **736971-02-1P 736971-63-4P 736971-67-8P**
736971-83-8P 736972-70-6P 736972-72-8P
736972-73-9P 736972-75-1P 736972-76-2P
736972-78-4P 736972-80-8P 736972-82-0P
736972-83-1P 736972-84-2P 736972-86-4P
736972-87-5P 736972-89-7P 736972-91-1P
736972-93-3P 736972-94-4P 736972-96-6P
736972-98-8P 736973-00-5P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of heterocyclic compds., useful as vanilloid receptor ligands)

RN 736971-02-1 HCAPLUS

CN 4-Thiazolecarboxamide, 2-[(2,6-dimethylphenyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 736971-63-4 HCAPLUS
CN 4-Thiazolecarboxamide, 5-bromo-2-[(2,6-dichlorophenyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 736971-67-8 HCAPLUS
CN 2-Thiazolamine, N-(2,6-dichlorophenyl)-4-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 736971-83-8 HCAPLUS
CN 2-Thiazolamine, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-N-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 736972-70-6 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[(2-fluorophenyl)amino]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 736972-72-8 HCAPLUS
CN 4-Thiazolecarboxamide, N-(4-bromophenyl)-2-[(2-fluorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 736972-73-9 HCAPLUS
CN 4-Thiazolecarboxamide, N-(4-bromophenyl)-2-[(2,6-dichlorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 736972-75-1 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 736972-76-2 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[(2-fluorophenyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 736972-78-4 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 736972-80-8 HCAPLUS
CN 4-Thiazolecarboxamide, N-(6-bromo-3-pyridinyl)-2-[(2-chlorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 736972-82-0 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[(2-chlorophenyl)amino]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 736972-83-1 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[(2,6-dimethylphenyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 736972-84-2 HCAPLUS
CN 4-Thiazolecarboxamide, N-(4-bromophenyl)-2-[(2,6-dimethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 736972-86-4 HCAPLUS
CN 4-Thiazolecarboxamide, N-[4-(trifluoromethyl)phenyl]-2-[[2-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 736972-87-5 HCAPLUS
CN 4-Thiazolecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[[2-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 736972-89-7 HCAPLUS
CN 4-Thiazolecarboxamide, N-(4-bromophenyl)-2-[[2-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 736972-91-1 HCAPLUS
CN 4-Thiazolecarboxamide, N-(4-bromophenyl)-2-[[2-chloro-6-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 736972-93-3 HCAPLUS

CN 4-Thiazolecarboxamide, 2-[[2-chloro-6-(trifluoromethyl)phenyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 736972-94-4 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[[2-chloro-6-(trifluoromethyl)phenyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 736972-96-6 HCAPLUS
CN 2-Thiazolamine, 4-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 736972-98-8 HCAPLUS
CN 2-Thiazolamine, N-[2-chloro-6-(trifluoromethyl)phenyl]-4-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 736973-00-5 HCAPLUS
CN 2-Thiazolamine, 4-(5-bromo-1H-benzimidazol-2-yl)-N-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



IT **736971-65-6 736971-74-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of heterocyclic compds., useful as vanilloid receptor ligands)
RN 736971-65-6 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 736971-74-7 HCAPLUS
CN 4-Thiazolecarboxylic acid, 2-[(2,6-dichlorophenyl)amino]- (9CI) (CA INDEX NAME)



IT **736970-97-1P 736971-00-9P 736971-05-4P**
736971-07-6P 736971-69-0P 736971-71-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclic compds., useful as vanilloid receptor ligands)
RN 736970-97-1 HCAPLUS
CN 4-Thiazolecarboxylic acid, 2-[(2,6-dimethylphenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 736971-00-9 HCAPLUS
CN 4-Thiazolecarboxylic acid, 2-[(2,6-dimethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 736971-05-4 HCAPLUS
CN 4-Thiazolecarboxamide, N-[2-amino-4-(trifluoromethyl)phenyl]-2-[(2,6-dimethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 736971-07-6 HCAPLUS
CN 4-Thiazolecarboxamide, N-[2-amino-5-(trifluoromethyl)phenyl]-2-[(2,6-dimethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 736971-69-0 HCAPLUS
CN 4-Thiazolecarboxamide, N-[2-amino-5-(trifluoromethyl)phenyl]-2-[(2,6-dichlorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 736971-71-4 HCAPLUS
CN 4-Thiazolecarboxamide, N-[2-amino-4-(trifluoromethyl)phenyl]-2-[(2,6-dichlorophenyl)amino]- (9CI) (CA INDEX NAME)



IC ICM A61K031-53
ICS A61K031-52; A61K031-506
INCL 514242000; 514255050; 514252020; 514263200; 544182000; 544238000; 544277000; 544295000
CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT Allergy
Inflammation
Nose, **disease**
(allergic rhinitis, **treatment** of; prepn. of heterocyclic compds., useful as vanilloid receptor ligands)
IT Pain
Skin, **disease**
(allodynia, **treatment** of; prepn. of heterocyclic compds., useful as vanilloid receptor ligands)
IT Bladder, **disease**
Intestine, **disease**
(**inflammatory**, **treatment** of; prepn. of heterocyclic compds., useful as vanilloid receptor ligands)
IT Stomach, **disease**
(lesion, induced by necrotizing agent, **treatment** of; prepn. of heterocyclic compds., useful as vanilloid receptor ligands)
IT Capsaicin receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(ligand; prepn. of heterocyclic compds., useful as vanilloid receptor ligands)
IT Eye, **disease**
Inflammation
(ophthalmitis, **treatment** of; prepn. of heterocyclic compds., useful as vanilloid receptor ligands)
IT Arthritis
Asthma
Bronchi, **disease**
Burn
Diarrhea
Digestive tract, **disease**
Headache
Human herpesvirus
Inflammation
Osteoarthritis
Pruritus
Psoriasis
Rheumatic **diseases**
Vitiligo
Wound
(**treatment** of; prepn. of heterocyclic compds., useful as vanilloid receptor ligands)
IT 736970-85-7P 736970-94-8P **736971-02-1P** 736971-09-8P
736971-16-7P 736971-23-6P 736971-31-6P 736971-39-4P
736971-41-8P 736971-47-4P 736971-48-5P 736971-59-8P
736971-61-2P **736971-63-4P** **736971-67-8P**

736971-76-9P 736971-80-5P **736971-83-8P** 736971-88-3P
736971-98-5P 736972-05-7P 736972-11-5P 736972-13-7P
736972-15-9P 736972-17-1P 736972-19-3P 736972-21-7P
736972-23-9P 736972-25-1P 736972-27-3P 736972-29-5P
736972-31-9P 736972-32-0P 736972-34-2P 736972-37-5P
736972-39-7P 736972-40-0P 736972-42-2P 736972-43-3P
736972-45-5P 736972-47-7P 736972-49-9P 736972-51-3P
736972-53-5P 736972-56-8P 736972-58-0P 736972-60-4P
736972-62-6P 736972-64-8P 736972-65-9P 736972-66-0P
736972-68-2P **736972-70-6P 736972-72-8P**
736972-73-9P 736972-75-1P 736972-76-2P
736972-78-4P 736972-80-8P 736972-82-0P
736972-83-1P 736972-84-2P 736972-86-4P
736972-87-5P 736972-89-7P 736972-91-1P
736972-93-3P 736972-94-4P 736972-96-6P
736972-98-8P 736973-00-5P 736973-02-7P
736973-04-9P 736973-06-1P 736973-08-3P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of heterocyclic compds., useful as vanilloid receptor ligands)

IT 62-56-6, Thiourea, reactions 70-23-5, Ethyl bromopyruvate 95-76-1, 3,4-Dichloroaniline 99-88-7, 4-Isopropylaniline 105-39-5, Ethyl chloroacetate 106-40-1, 4-Bromoaniline 368-71-8, 4-(Trifluoromethyl)-1,2-phenylenediamine 455-14-1, 4-Trifluoromethylaniline 532-55-8, Benzoyl isothiocyanate 2104-89-4 2402-77-9, 2,3-Dichloropyridine 2856-63-5, 2-Chlorobenzyl cyanide 3215-64-3, 2,6-Dichlorophenylacetonitrile 3863-11-4 4755-81-1, Methyl 2-chloroacetoacetate 5348-42-5 6396-76-5 17518-49-9 22889-78-7, 4-Amino-3,5-dichloropyridine 54897-59-5 106877-33-2, 3-Amino-6-(trifluoromethyl)pyridine 263157-83-1 736971-27-0 **736971-65-6 736971-74-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of heterocyclic compds., useful as vanilloid receptor ligands)

IT 109-94-4P, Ethyl formate 5398-36-7P 5922-20-3P 6059-44-5P 263157-86-4P 673476-96-5P 736970-78-8P 736970-80-2P 736970-83-5P 736970-88-0P 736970-90-4P 736970-92-6P **736970-97-1P 736971-00-9P 736971-05-4P** **736971-07-6P** 736971-13-4P 736971-14-5P 736971-18-9P 736971-20-3P 736971-25-8P 736971-29-2P 736971-33-8P 736971-37-2P 736971-43-0P 736971-46-3P 736971-53-2P 736971-55-4P 736971-57-6P **736971-69-0P** **736971-71-4P** 736971-85-0P 736971-91-8P 736971-94-1P 736971-96-3P 736972-00-2P 736972-02-4P 736972-07-9P 736972-08-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclic compds., useful as vanilloid receptor ligands)

L32 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:648516 HCAPLUS
DOCUMENT NUMBER: 141:190785
TITLE: Preparation of thiazole derivatives as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 associated **diseases**
INVENTOR(S): Inoue, Takayuki; Tojo, Takashi; Morita, Masataka; Ohkubo, Mitsuru; Yoshihara, Kousei; Nagashima, Akira

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067521	A1	20040812	WO 2004-JP708	200401 27
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
CA 2514573	AA	20040812	CA 2004-2514573	200401 27
US 2004259923	A1	20041223	US 2004-764529	200401 27
EP 1587800	A1	20051026	EP 2004-705519	200401 27
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:		
US 2003-442509P	P	200301 27
US 2003-458369P	P	200303 31
US 2003-517377P	P	200311 06
WO 2004-JP708	W	200401 27

OTHER SOURCE(S): MARPAT 141:190785
GI



II

AB Title compds. of formula R1NHXYZ [I; wherein R1 = acyl; X = a bivalent (un)substituted thiazole; Y = a bond, alkylene, alkenylene, COHN; Z = 2-aminobenzimidazolyl, C6H4-R2; R2 = ABDE; A = a bond, alkylene, NH, SO2; B = a bond , alkylene, CO, O; D = a bond, alkylene, NH, CH2NH; E = (un)protected amino, N=CH2, dihydrothiazol-2-yl, dihydroimidazol-2-yl, C(=NH)R3; R3 = H, alkyl(thio), NHR4; R4 = H, NH2, alkyl; and pharmaceutically acceptable salts thereof] were prepd. as vascular adhesion protein-1 (VAP-1) inhibitors. For example, cycloaddn. of 3-chloro-2-oxopropyl acetate and thiourea in EtOH gave (2-amino-1,3-thiazol-4-yl)methyl acetate•HCl, which was amidated with acetyl chloride using pyridine in CH2Cl2. Deprotection of [2-(acetylamino)thiazol-4-yl]methyl acetate using K2CO3 in MeOH, followed by reaction of the resulting alc. with MnO2 in MeOH/CHCl3 provided N-(4-formylthiazol-2-yl)acetamide. Coupling of the aldehyde with 1-(bromomethyl)-4-nitrobenzene in the presence of PPh3 and t-BuOH in DMF gave N-[4-[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide, which was reduced to the amine with Pd/C in MeOH/THF/AcOH. Finally, coupling of the amine with cyanamide in the presence of HCl in EtOH/EtOAc afforded II. The latter inhibited VAP-1 enzyme (SSAO) activity in both human and rat plasma (IC50 = 0.15 μM and 0.012 μM, resp.), but not the enzyme activities of other amine oxidases (IC50 >100μM), such as human platelet monoamine oxidase (MAO) and cloned diamine oxidase (DAO, histaminase). **Treatment** of diabetic rats daily with II (10 mg/kg/ s.c. u.i.d.) improved their ocular permeability in comparison with the diabetic control group (vitreous/plasma ratio of fluorescein concns. = 5.39 ± 0.73 x10-3 and 8.93 ± 1.14 x10-3, resp.). Thus, I and their pharmaceutical compns. are useful for preventing or **treating** VAP-1 assocd. **diseases**, esp. macular edema (no data).

IT **183365-33-5P**, N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]thiazol-2-yl]acetamide **737822-89-8P**, N-[4-[(E)-2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethenyl]thiazol-2-yl]acetamide **737824-82-7P**, N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(VAP-1 inhibitor; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

RN 183365-33-5 HCAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737822-89-8 HCAPLUS

CN Acetamide, N-[4-[(1E)-2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 737824-82-7 HCAPLUS
CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



IC ICM C07D277-46
ICS C07D277-48; C07D277-56; C07D417-12; C07D417-06; A61K031-426; A61K031-427; A61K031-4439; A61K031-454; A61P027-02
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT **Inflammation**
(Crohn's **disease**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Intestine, **disease**
(Crohn's; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Blood vessel, **disease**
(Raynaud's phenomenon; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Arthritis
(Reiter's syndrome; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Cell adhesion molecules
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(VAP-1 (vascular adhesion protein-1); prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Granulomatous **disease**
(Wegener's granulomatosis; prepn. of thiazole derivs. as VAP-1

inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Cell differentiation
(adipocyte cell differation aberrations, **diseases**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Adipose tissue
(adipocyte, adipocyte cell differation aberrations, **diseases**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Respiratory distress syndrome
(adult; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Heart, **disease**
(angina pectoris; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT **Inflammation**
Spinal column, **disease**
(ankylosing spondylitis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Antiarteriosclerotics
(antiatherosclerotics; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT **Inflammation**
Mouth, **disease**
(aphthous stomatitis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Artery, **disease**
Inflammation
(arteritis, temporal; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Dermatitis
(atopic; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Ischemia
(cardiac; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT **Inflammation**
(central nervous system; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Lung, **disease**
(chronic obstructive pulmonary **disease**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Arthritis
(chronic; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Intestine, **disease**
(colon, spastic colon; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other

VAP-1 assocd. **diseases**)
IT Dermatitis
(contact; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Ulcer
(cutaneous, foot; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Eye, **disease**
(diabetic macular edema; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Lupus erythematosus
(discoid; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Joint, anatomical
(**disease**, degeneration; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Metabolism, animal
(disorder, carbohydrate metab.; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Blood vessel, **disease**
(endothelium; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Connective tissue, **disease**
Inflammation
(eosinophilic fasciitis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Kidney, **disease**
(failure; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Liver, **disease**
(fibrosis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Fibrosis
(hepatic; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Heart, **disease**
(infarction; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Central nervous system, **disease**
Connective tissue, **disease**
(**inflammation**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Intestine, **disease**
(**inflammatory**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Reperfusion
(injury; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd.

diseases)
IT Autoimmune **disease**
(insulin-dependent diabetes mellitus; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Diabetes mellitus
(insulin-dependent; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Intestine, **disease**
(irritable bowel syndrome; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Heart, **disease**
(ischemia; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT **Disease**, animal
(joint degeneration; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Rheumatoid arthritis
(juvenile; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Skin, **disease**
(lesion, allergic; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Skin, **disease**
(lichen planus; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Carbohydrates, biological studies
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(metab.; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Connective tissue, **disease**
(mixed connective tissue **disease**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Kidney, **disease**
(nephrotic syndrome; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Nerve, **disease**
(neuropathy; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Eye, **disease**
(non-diabetic macular edema; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Artery, **disease**
Inflammation
(periarteritis nodosa; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Artery, **disease**
(peripheral, occlusion; prepn. of thiazole derivs. as VAP-1

inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Skin, **disease**
(pityriasis versicolor; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT **Inflammation**
Lung, **disease**
(pneumonitis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Bone, **disease**
Inflammation
(polychondritis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Muscle, **disease**
(polymyalgia rheumatica; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Myositis
(polymyositis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Alzheimer's **disease**
Analgesics
Anti-Alzheimer's agents
Anti-**inflammatory** agents
Antianginal agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antihypertensives
Antiobesity agents
Antirheumatic agents
Arthritis
Asthma
Atherosclerosis
Behcet's syndrome
Blindness
Blood vessel, **disease**
Cardiovascular agents
Cardiovascular system, **disease**
Dermatitis
Dermatomyositis
Diabetes mellitus
Drug delivery systems
Gout
Human
Hypertension
Kidney, **disease**
Multiple sclerosis
Obesity
Osteoarthritis
Pain
Psoriasis
Rheumatoid arthritis
Sjogren's syndrome
Skin, **disease**
(prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Biliary tract, **disease**
(primary biliary cirrhosis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Arthritis
(psoriatic arthritis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Injury
(reperfusion; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Eye, **disease**
(retinopathy; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Connective tissue, **disease**
(scleroderma; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT **Inflammation**
Mouth, **disease**
(stomatitis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Brain, **disease**
Brain, **disease**
(stroke; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Lupus erythematosus
(systemic; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Thrombosis
(thromboangiitis obliterans; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Skin, **disease**
(ulcer, foot; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT **Inflammation**
Intestine, **disease**
(ulcerative colitis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Endothelium
(vascular, **disease**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT Blood vessel, **disease**
Inflammation
(vasculitis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
IT 737822-91-2P, Methyl N-[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]imidothiocarbamate hydroiodide 737823-19-7P, N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737823-37-9P, N-[4-[2-[4-[(Aminooxy)methyl]phenyl]ethyl]thiazol-2-yl]acetamide 737824-46-3P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737826-45-8P,

N-[4-[2-[4-(2-Aminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(VAP-1 inhibitor; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT **183365-33-5P**, N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]thiazol-2-yl]acetamide 737822-86-5P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide **737822-89-8P**, N-[4-[(E)-2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethenyl]thiazol-2-yl]acetamide 737822-94-5P, N-[4-[2-[4-[(4,5-Dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]thiazol-2-yl]acetamide 737822-95-6P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]-2-methylpropanamide 737823-01-7P, 2-(Acetylamino)-N-[4-[[amino(imino)methyl]amino]phenyl]thiazole-4-carboxamide 737823-04-0P, N-[4-[2-[4-(Ethanimidoylamino)phenyl]ethyl]thiazol-2-yl]acetamide 737823-05-1P, N-[4-[2-[4-[Amino(imino)methyl]phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737823-09-5P, N-[4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]phenyl]-2-[[amino(imino)methyl]amino]acetamide hydrochloride 737823-12-0P, N-[4-[4-[2-[[Amino(imino)methyl]amino]ethyl]phenyl]thiazol-2-yl]acetamide hydrochloride 737823-23-3P, Ethyl [4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]carbamate hydrochloride 737823-29-9P, N-[4-[2-[3-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-bromothiazol-2-yl]acetamide hydrochloride 737823-34-6P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-bromothiazol-2-yl]acetamide hydrochloride 737823-41-5P, N-[4-[2-[4-[[(Methyleneamino)oxy]methyl]phenyl]ethyl]thiazol-2-yl]acetamide 737823-42-6P, N-[5-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737823-47-1P, N-[4-[2-[4-[[(Imino)(methylamino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide 737823-48-2P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-chlorothiazol-2-yl]acetamide hydrochloride 737823-50-6P, N-[4-[2-[4-[[[Amino(imino)methyl]amino]methyl]phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737823-52-8P, Ethyl 2-(acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazole-5-carboxylate hydrochloride 737823-55-1P, N-[4-[2-[4-[[(Ethylamino)(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide 737823-56-2P 737823-62-0P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]benzamide hydrochloride 737823-67-5P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide hydrochloride 737823-78-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-methylthiazole-5-carboxamide hydrochloride 737823-84-6P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-phenylthiazole-5-carboxamide hydrochloride 737823-88-0P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N,N-dimethylthiazole-5-carboxamide hydrochloride 737823-92-6P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-benzylthiazole-5-carboxamide hydrochloride 737823-96-0P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-(4-nitrobenzyl)thiazole-5-carboxamide hydrochloride 737824-00-9P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(methylsulfonyl)benzyl]thiazole-5-carboxamide

hydrochloride 737824-05-4P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(trifluoromethyl)benzyl]thiazole-5-carboxamide hydrochloride 737824-09-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-(3-pyridinyl)thiazole-5-carboxamide dihydrochloride 737824-13-4P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-(4-phenoxybenzyl)thiazole-5-carboxamide hydrochloride 737824-15-6P, Ethyl 4-[[2-(acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-1-piperazinecarboxylate 737824-17-8P, N-[5-[(4-Acetyl-1-piperazinyl)carbonyl]-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide 737824-19-0P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]thiazol-2-yl]acetamide hydrochloride 737824-21-4P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-(4-thiomorpholinylcarbonyl)thiazol-2-yl]acetamide hydrochloride 737824-23-6P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]thiazol-2-yl]acetamide hydrochloride 737824-25-8P, Ethyl 1-[[2-(acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-4-piperidinecarboxylate hydrochloride 737824-27-0P, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-4-piperidinecarboxamide hydrochloride 737824-30-5P, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N-methyl-4-piperidinecarboxamide hydrochloride 737824-32-7P, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N,N-dimethyl-4-piperidinecarboxamide hydrochloride 737824-34-9P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-phenylthiazol-2-yl]acetamide hydrochloride 737824-40-7P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-benzylthiazol-2-yl]acetamide hydrochloride 737824-54-3P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-56-5P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride 737824-57-6P, N-[4-[2-[4-[[Hydrazino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-60-1P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(ethylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride 737824-70-3P, Ethyl [4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-2-yl]carbamate 737824-76-9P, N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-82-7P**, N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-83-8P, N-[4-[2-[4-[(4,5-Dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-84-9P, N-[4-[2-[4-(Ethanimidoylamino)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-85-0P, N-[4-[2-[4-[(Iminomethyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide 737824-86-1P, N-[4-[2-[4-[[Hydrazino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide 737824-87-2P, N-[4-[2-[4-(2-Amino-2-iminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737824-92-9P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylthio)benzyl]thiazol-2-yl]acetamide 737824-96-3P, N-[4-[4-[3-[[Amino(imino)methyl]amino]propyl]phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide hydrochloride 737825-09-1P, N-[4-[2-[4-[(Aminooxy)methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-15-9P, N-[4-[2-[4-[[[Amino(imino)methyl]amino]methyl]phenyl]ethyl]-5-[4-

(methylsulfonyl)phenyl]thiazol-2-yl]acetamide hydrochloride 737825-19-3P, Methyl 4-[[2-(acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoate hydrochloride 737825-30-8P, 4-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethylbenzamide hydrochloride 737825-35-3P, 4-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methylbenzamide hydrochloride 737825-38-6P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[(dimethylamino)methyl]thiazol-2-yl]acetamide dihydrochloride 737825-42-2P, N-[5-[(4-Acetyl-1-piperazinyl)methyl]-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide dihydrochloride 737825-45-5P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride 737825-49-9P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-(4-thiomorpholinylmethyl)thiazol-2-yl]acetamide dihydrochloride 737825-52-4P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-(dimethylamino)-2-oxoethyl]thiazole-5-carboxamide hydrochloride 737825-56-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]thiazole-5-carboxamide hydrochloride 737825-60-4P, 2-(Acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazole-5-carboxamide hydrochloride 737825-64-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]thiazole-5-carboxamide hydrochloride 737825-68-2P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-N-methylthiazole-5-carboxamide hydrochloride 737825-70-6P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-[benzyl(methyl)amino]-3-oxopropyl]thiazole-5-carboxamide hydrochloride 737825-72-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(dimethylamino)-4-oxobutyl]thiazole-5-carboxamide hydrochloride 737825-74-0P, (2R)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N,N-dimethyl-2-pyrrolidinecarboxamide hydrochloride 737825-76-2P, (2S)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N,N-dimethyl-2-pyrrolidinecarboxamide hydrochloride 737825-78-4P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-(methylsulfonyl)ethyl]thiazole-5-carboxamide hydrochloride 737825-80-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-(4-pyridinylmethyl)thiazole-5-carboxamide dihydrochloride 737825-82-0P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-(3-pyridinylmethyl)thiazole-5-carboxamide dihydrochloride 737825-84-2P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-[(2-phenylacetyl)amino]ethyl]thiazole-5-carboxamide hydrochloride 737825-86-4P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[5-(dimethylamino)-5-oxopentyl]thiazole-5-carboxamide hydrochloride 737825-88-6P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(benzylamino)-3-oxopropyl]thiazole-5-carboxamide hydrochloride 737825-90-0P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[6-(dimethylamino)-6-oxohexyl]thiazole-5-carboxamide hydrochloride 737825-92-2P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(4-morpholinyl)propyl]thiazole-5-carboxamide dihydrochloride 737825-94-4P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]thiazole-5-carboxamide hydrochloride 737825-96-6P, 2-(Acetylamino)-4-[2-[4-

[[amino(imino)methyl]amino]phenyl]ethyl]-N-hexylthiazole-5-carboxamide hydrochloride 737825-98-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-oxo-4-(1-piperidinyl)butyl]thiazole-5-carboxamide hydrochloride 737826-00-5P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(4-morpholinyl)-4-oxobutyl]thiazole-5-carboxamide hydrochloride 737826-02-7P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(methylsulfonyl)phenyl]thiazole-5-carboxamide hydrochloride 737826-05-0P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]thiazole-5-carboxamide hydrochloride 737826-07-2P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S)-1-benzyl-2-(dimethylamino)-2-oxoethyl]thiazole-5-carboxamide hydrochloride 737826-09-4P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-2-oxoethyl]thiazole-5-carboxamide hydrochloride 737826-11-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S,2S)-1-[(dimethylamino)carbonyl]-2-hydroxypropyl]thiazole-5-carboxamide hydrochloride 737826-13-0P, (2S)-2-[[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]amino]-N,N-dimethylpentanediamide hydrochloride 737826-15-2P, N-[4-[2-[4-[[(Imino)(methylamino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737826-16-3P, (2S)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-2-pyrrolidinecarboxamide dihydrochloride 737826-22-1P, 3-[[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl](methyl)amino]-N,N-dimethylpropanamide dihydrochloride 737826-27-6P, 4-[2-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]ethyl]-N,N-dimethylbenzamide hydrochloride 737826-33-4P, 4-[2-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]ethyl]-N-methylbenzamide hydrochloride 737826-36-7P, Methyl N-[4-[[2-(acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]phenyl]carbamate hydrochloride 737826-39-0P 737826-42-5P, 4-[2-[2-(Acetylamino)-5-[4-(methylsulfonyl)benzyl]thiazol-4-yl]ethyl]-N-[amino(imino)methyl]benzamide 737826-43-6P, tert-Butyl [2-[[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]phenyl]amino]-2-oxoethyl]carbamate 737826-44-7P, N-[4-[2-[2-(Acetylamino)-5-[4-(methylsulfonyl)benzyl]thiazol-4-yl]ethyl]phenyl]-2-aminoacetamide hydrochloride 737826-48-1P, N-[4-[2-[4-[2-[[Amino(imino)methyl]amino]ethyl]phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737826-50-5P, N-[4-[4-[[2-[[Amino(imino)methyl]amino]ethyl]sulfonyl]phenyl]thiazol-2-yl]acetamide hydrochloride 737826-59-4P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[3-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride 737826-71-0P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)methyl]thiazol-2-yl]acetamide dihydrochloride 737826-74-3P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-(4-morpholinylmethyl)thiazol-2-yl]acetamide dihydrochloride 737826-77-6P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[(3-oxo-1-piperazinyl)methyl]thiazol-2-yl]acetamide dihydrochloride 737826-80-1P, 4-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-1-piperazinecarboxamide dihydrochloride 737826-86-7P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride 737826-88-9P, N-[4-[2-[4-

[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride 737826-90-3P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]thiazol-2-yl]acetamide trihydrochloride 737826-92-5P, 3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]-N,N-dimethylpropanamide hydrochloride 737826-98-1P, 3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]-N-methylpropanamide hydrochloride 737827-00-8P, 3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]propanamide hydrochloride 737827-02-0P, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-4-piperidinecarboxamide dihydrochloride 737827-05-3P, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methyl-4-piperidinecarboxamide dihydrochloride 737827-07-5P, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-4-piperidinecarboxamide dihydrochloride 737827-09-7P, (3R)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-3-piperidinecarboxamide dihydrochloride 737827-14-4P, (3R)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methyl-3-piperidinecarboxamide dihydrochloride 737827-16-6P, (3S)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-3-piperidinecarboxamide dihydrochloride 737827-21-3P, (3S)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methyl-3-piperidinecarboxamide dihydrochloride 737827-23-5P, N-[4-[2-(2-Amino-1H-benzimidazol-6-yl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737827-26-8P, N-[4-[2-(2-Amino-1H-benzimidazol-6-yl)ethyl]thiazol-2-yl]acetamide 737827-29-1P, N-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methylacetamide hydrochloride 737827-34-8P, N-[4-[2-[4-[(2-Aminoethyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide dihydrochloride 737827-36-0P, N-[4-[3-[2-[[Amino(imino)methyl]amino]ethyl]phenyl]thiazol-2-yl]acetamide hydrochloride 737827-42-8P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737827-47-3P, N-[4-[2-[4-[2-[[Amino(imino)methyl]amino]ethyl]phenyl]ethyl]thiazol-2-yl]acetamide

RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(VAP-1 inhibitor; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT 2065-75-0P, 2-Bromomalonaldehyde 6362-58-9P, Methyl 2-oxo-3-phenylpropanoate 16444-13-6P, N-(4-Formylthiazol-2-yl)acetamide 28229-69-8P, 2-(3-Bromophenyl)ethanol 50602-38-5P, 2-(Acetylamino)thiazole-4-carboxylic acid 51307-38-1P, N-[4-(Hydroxymethyl)thiazol-2-yl]acetamide 62591-33-7P, Ethyl 2-(acetylamino)-4-(chloromethyl)thiazole-5-carboxylate 63077-41-8P, N-[2-[4-(2-Chloroacetyl)phenyl]ethyl]acetamide 77505-86-3P, Ethyl 2-amino-5-benzylthiazole-4-carboxylate 80625-18-9P, Methyl 2-amino-5-phenylthiazole-4-carboxylate 92819-12-0P, Ethyl 2-(acetylamino)thiazole-4-carboxylate 105512-85-4P, 4-[4-(Methylthio)phenyl]thiazol-2-amine 111608-67-4P, [2-(Acetylamino)thiazol-4-yl]methyl acetate 123392-44-9P, Methyl 3-[4-(methylthio)phenyl]propanoate 127942-30-7P, Ethyl 2-aminothiazole-4-carboxylate hydrobromide

183365-28-8P, N-[4-[(E)-2-(4-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide 183365-29-9P, N-[4-[2-(4-Aminophenyl)ethyl]thiazol-2-yl]acetamide 249937-07-3P, [2-(3-Bromophenyl)ethoxy](tert-butyl)dimethylsilane 252662-37-6P, N-(5-Formylthiazol-2-yl)acetamide 292858-05-0P, Ethyl 3-bromo-2-oxo-4-phenylbutanoate 737822-87-6P, (2-Aminothiazol-4-yl)methyl acetate hydrochloride 737822-88-7P, N-[4-[(Z)-2-(4-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737822-90-1P, N-[4-[(E)-2-(4-Aminophenyl)ethenyl]thiazol-2-yl]acetamide 737822-92-3P, N-[4-[2-[4-[[(Benzoylamino)carbonothioyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide 737822-93-4P, N-[4-[2-[4-[(Aminocarbonothioyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide 737822-96-7P, Ethyl 2-(isobutyrylamino)thiazole-4-carboxylate 737822-97-8P, N-[4-(Hydroxymethyl)thiazol-2-yl]-2-methylpropanamide 737822-98-9P, N-(4-Formylthiazol-2-yl)-2-methylpropanamide 737822-99-0P, 2-Methyl-N-[4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]propanamide 737823-00-6P, N-[4-[2-(4-Aminophenyl)ethyl]thiazol-2-yl]-2-methylpropanamide 737823-02-8P, tert-Butyl [4-[[[2-(acetylamino)thiazol-4-yl]carbonyl]amino]phenyl]carbamate 737823-03-9P, 2-(Acetylamino)-N-(4-aminophenyl)thiazole-4-carboxamide hydrochloride 737823-06-2P, N-[4-[(Z)-2-(4-Cyanophenyl)ethenyl]thiazol-2-yl]acetamide 737823-07-3P, N-[4-[2-(4-Cyanophenyl)ethyl]thiazol-2-yl]acetamide 737823-08-4P, 4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]benzenecarboximidic acid ethyl ester hydrochloride 737823-10-8P, tert-Butyl [2-[[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]amino]-2-oxoethyl]carbamate 737823-11-9P, N-[4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]phenyl]-2-aminoacetamide hydrochloride 737823-13-1P, N-[2-[4-(2-Aminothiazol-4-yl)phenyl]ethyl]acetamide hydrochloride 737823-14-2P, 4-[4-(2-Aminoethyl)phenyl]thiazol-2-amine dihydrochloride 737823-15-3P, tert-Butyl [2-[4-(2-aminothiazol-4-yl)phenyl]ethyl]carbamate 737823-16-4P, tert-Butyl [2-[4-[2-(acetylamino)thiazol-4-yl]phenyl]ethyl]carbamate 737823-17-5P, N-[4-[4-(2-Aminoethyl)phenyl]thiazol-2-yl]acetamide hydrochloride 737823-18-6P 737823-20-0P, N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737823-21-1P, N-[4-[2-[4-(Bromomethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737823-22-2P, N-[4-[2-[4-[(Diformylamino)methyl]phenyl]ethyl]thiazol-2-yl]acetamide 737823-24-4P, Ethyl [4-(hydroxymethyl)thiazol-2-yl]carbamate 737823-25-5P, Ethyl (4-formylthiazol-2-yl)carbamate 737823-26-6P, Ethyl [4-[2-(4-nitrophenyl)ethenyl]thiazol-2-yl]carbamate 737823-27-7P, Ethyl [4-[2-(4-aminophenyl)ethyl]thiazol-2-yl]carbamate 737823-28-8P 737823-30-2P, N-[4-[2-(3-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737823-31-3P, N-[4-[2-(3-Aminophenyl)ethyl]thiazol-2-yl]acetamide 737823-32-4P 737823-33-5P 737823-35-7P 737823-36-8P 737823-38-0P, Methyl 4-[(Z)-2-[2-(acetylamino)thiazol-4-yl]ethenyl]benzoate 737823-39-1P, Methyl 4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]benzoate 737823-40-4P, N-[4-[2-[4-[[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)oxy]methyl]phenyl]ethyl]thiazol-2-yl]acetamide 737823-44-8P, N-[5-[(Z)-2-(4-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737823-45-9P, N-[5-[2-(4-Aminophenyl)ethyl]thiazol-2-yl]acetamide 737823-46-0P 737823-49-3P 737823-51-7P 737823-53-9P, Ethyl 2-(acetylamino)-4-[(E)-2-(4-nitrophenyl)ethenyl]thiazole-5-carboxylate 737823-54-0P, Ethyl 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazole-5-carboxylate 737823-57-3P, Ethyl 2-[[(benzyloxy)carbonyl]amino]thiazole-4-carboxylate 737823-58-4P, Benzyl [4-(hydroxymethyl)thiazol-2-yl]carbamate 737823-59-5P, Benzyl (4-formylthiazol-2-yl)carbamate 737823-60-8P, Benzyl [4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]carbamate 737823-61-9P, Benzyl [4-[2-(4-aminophenyl)ethyl]thiazol-2-

yl]carbamate 737823-63-1P, 4-[(E)-2-(4-Nitrophenyl)ethenyl]thiazol-2-amine 737823-64-2P, N-[4-[(E)-2-(4-Nitrophenyl)ethenyl]thiazol-2-yl]benzamide 737823-65-3P, N-[4-[2-(4-Aminophenyl)ethyl]thiazol-2-yl]benzamide 737823-66-4P 737823-68-6P 737823-69-7P, 3-[4-(Methylsulfanyl)phenyl]-2-oxopropanoic acid 737823-70-0P, Methyl 3-[4-(methylsulfanyl)phenyl]-2-oxopropanoate 737823-71-1P, Methyl 2-amino-5-[4-(methylthio)phenyl]thiazole-4-carboxylate 737823-72-2P, Methyl 2-(acetylamino)-5-[4-(methylthio)phenyl]thiazole-4-carboxylate 737823-73-3P, N-[4-Formyl-5-[4-(methylthio)phenyl]thiazol-2-yl]acetamide 737823-74-4P, N-[5-[4-(Methylthio)phenyl]-4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737823-75-5P, N-[5-[4-(Methylsulfonyl)phenyl]-4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737823-76-6P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737823-77-7P 737823-79-9P, Ethyl 2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazole-5-carboxylate 737823-80-2P, 2-(Acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazole-5-carboxylic acid 737823-81-3P, tert-Butyl [4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737823-82-4P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-methylthiazole-5-carboxamide 737823-83-5P 737823-85-7P, tert-Butyl [4-[2-[2-(acetylamino)-5-(anilinocarbonyl)thiazol-4-yl]ethyl]phenyl]carbamate 737823-86-8P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-phenylthiazole-5-carboxamide 737823-87-9P 737823-89-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[(dimethylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737823-90-4P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N,N-dimethylthiazole-5-carboxamide 737823-91-5P 737823-93-7P, tert-Butyl [4-[2-[2-(acetylamino)-5-[(benzylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737823-94-8P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-benzylthiazole-5-carboxamide 737823-95-9P 737823-97-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[(4-nitrobenzyl)amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737823-98-2P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-(4-nitrobenzyl)thiazole-5-carboxamide 737823-99-3P 737824-01-0P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[[4-(methylthio)phenyl]methyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737824-02-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[[4-(methylsulfonyl)phenyl]methyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737824-03-2P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[4-(methylsulfonyl)benzyl]thiazole-5-carboxamide 737824-04-3P 737824-06-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737824-07-6P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[4-(trifluoromethyl)benzyl]thiazole-5-carboxamide 737824-08-7P 737824-10-1P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazole-5-carboxylic acid 737824-11-2P 737824-12-3P 737824-14-5P 737824-16-7P 737824-18-9P 737824-20-3P 737824-22-5P 737824-24-7P 737824-26-9P 737824-28-1P 737824-29-2P 737824-31-6P 737824-33-8P 737824-35-0P, Methyl 2-(acetylamino)-5-phenylthiazole-4-carboxylate 737824-36-1P, N-(4-Formyl-5-phenylthiazol-2-yl)acetamide 737824-37-2P 737824-38-3P, N-[4-[2-(4-Aminophenyl)ethyl]-5-phenylthiazol-2-yl]acetamide 737824-39-4P 737824-41-8P, Ethyl 2-(acetylamino)-5-benzylthiazole-4-carboxylate 737824-42-9P, N-(5-Benzyl-4-formylthiazol-2-yl)acetamide 737824-43-0P 737824-44-1P, N-[4-[2-(4-Aminophenyl)ethyl]-5-benzylthiazol-2-yl]acetamide 737824-45-2P 737824-47-4P, Ethyl 4-[4-(methylthio)phenyl]-2-oxobutanoate 737824-48-5P, Ethyl

3-bromo-4-[4-(methylthio)phenyl]-2-oxobutanoate 737824-49-6P, Ethyl 2-amino-5-[[4-(methylthio)phenyl]methyl]thiazole-4-carboxylate 737824-50-9P, Ethyl 2-(acetylamino)-5-[[4-(methylthio)phenyl]methyl]thiazole-4-carboxylate 737824-51-0P, N-[4-Formyl-5-[4-(methylthio)benzyl]thiazol-2-yl]acetamide 737824-52-1P 737824-53-2P 737824-55-4P 737824-58-7P, N-[4-[2-[4-[(Aminocarbonothioyl)amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-59-8P 737824-61-2P, Ethyl 3-[4-(ethylthio)phenyl]propanoate 737824-62-3P, Ethyl 4-[4-(ethylthio)phenyl]-2-oxobutanoate 737824-63-4P, Ethyl 3-bromo-4-[4-(ethylthio)phenyl]-2-oxobutanoate 737824-64-5P 737824-65-6P 737824-66-7P, N-[5-[4-(Ethylthio)benzyl]-4-formylthiazol-2-yl]acetamide 737824-67-8P 737824-68-9P 737824-69-0P 737824-71-4P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737824-72-5P, tert-Butyl [4-[2-[2-amino-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737824-73-6P, Ethyl [4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-2-yl]carbamate 737824-74-7P, Ethyl [4-[2-(4-aminophenyl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-2-yl]carbamate 737824-75-8P 737824-77-0P, Methyl 4-[(Z)-2-[2-(acetylamino)-5-[[4-(methylthio)phenyl]methyl]thiazol-4-yl]ethenyl]benzoate 737824-78-1P, Methyl 4-[(Z)-2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethenyl]benzoate 737824-79-2P, Methyl 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]benzoate 737824-80-5P, N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-81-6P, N-[4-[2-[4-(Chloromethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-88-3P, N-[4-[2-[4-(Chloromethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737824-89-4P, N-[4-[2-[4-(Cyanomethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737824-90-7P, 2-[4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]phenyl]ethanimidic acid methyl ester hydrochloride 737824-91-8P, N-[4-[2-[4-(2-Amino-2-iminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737824-93-0P 737824-94-1P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-(methylsulfinyl)benzyl]thiazol-2-yl]acetamide 737824-95-2P 737824-97-4P, Methyl 4-[[2-bromo-4-(methylthio)phenyl]acetyl]benzoate 737824-98-5P, Methyl 4-[2-amino-5-[4-(methylthio)phenyl]thiazol-4-yl]benzoate 737824-99-6P, [4-[2-Amino-5-[4-(methylthio)phenyl]thiazol-4-yl]phenyl]methanol 737825-00-2P, 4-[2-(Acetylamino)-5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]benzyl acetate 737825-01-3P, N-[4-[4-(Hydroxymethyl)phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-02-4P, N-[4-(4-Formylphenyl)-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-03-5P, Ethyl (2E)-3-[4-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]phenyl]-2-propenoate 737825-04-6P, N-[4-[4-(3-Hydroxypropyl)phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-05-7P, N-[4-[4-(3-Bromopropyl)phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-06-8P, N-[4-[4-[3-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-07-9P, N-[4-[4-(3-Aminopropyl)phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-08-0P 737825-10-4P, Methyl 4-[(E)-2-[2-(acetylamino)-5-[4-(methylthio)phenyl]thiazol-4-yl]ethenyl]benzoate 737825-11-5P, Methyl 4-[(E)-2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]ethenyl]benzoate 737825-12-6P, Methyl 4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]ethyl]benzoate 737825-13-7P,

N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-14-8P, N-[4-[2-[4-[[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)oxy]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-16-0P, N-[4-[2-[4-(Bromomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-17-1P, N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-18-2P 737825-20-6P, Ethyl 4-(4-iodophenyl)-2-oxobutanoate 737825-21-7P, Ethyl 3-bromo-4-(4-iodophenyl)-2-oxobutanoate 737825-22-8P, Ethyl 2-amino-5-(4-iodobenzyl)thiazole-4-carboxylate hydrobromide 737825-23-9P, Ethyl 2-(acetylamino)-5-(4-iodobenzyl)thiazole-4-carboxylate 737825-24-0P, N-[4-Formyl-5-(4-iodobenzyl)thiazol-2-yl]acetamide 737825-25-1P, N-[5-(4-Iodobenzyl)-4-[2-(4-nitrophenyl)vinyl]thiazol-2-yl]acetamide 737825-27-3P 737825-28-4P, Methyl 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]benzoate 737825-29-5P 737825-31-9P, Methyl 4-[[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoate 737825-32-0P, 4-[[2-(Acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoic acid 737825-33-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]phenyl]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-34-2P 737825-36-4P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]phenyl]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-37-5P 737825-39-7P 737825-40-0P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[(dimethylamino)methyl]thiazol-2-yl]acetamide 737825-41-1P 737825-43-3P 737825-44-4P 737825-46-6P 737825-48-8P 737825-50-2P 737825-51-3P 737825-53-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[2-(dimethylamino)-2-oxoethyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-54-6P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-(dimethylamino)-2-oxoethyl]thiazole-5-carboxamide hydrochloride 737825-55-7P 737825-57-9P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-58-0P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[3-(dimethylamino)-3-oxopropyl]thiazole-5-carboxamide hydrochloride 737825-59-1P 737825-61-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[2-(acetylamino)ethyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-62-6P, 2-(Acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-(4-aminophenyl)ethyl]thiazole-5-carboxamide hydrochloride 737825-63-7P 737825-65-9P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[2-[(methylsulfonyl)amino]ethyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-66-0P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]thiazole-5-carboxamide hydrochloride 737825-67-1P 737825-69-3P 737825-71-7P 737825-73-9P 737825-75-1P 737825-77-3P 737825-79-5P 737825-81-9P 737825-83-1P 737825-85-3P 737825-87-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT 737825-89-7P 737825-91-1P 737825-93-3P 737825-95-5P 737825-97-7P 737825-99-9P 737826-01-6P 737826-03-8P 737826-04-9P 737826-06-1P 737826-08-3P 737826-10-7P 737826-12-9P 737826-14-1P 737826-17-4P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[methoxy(methyl)amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737826-18-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-formylthiazol-4-yl]ethyl]phenyl]carbamate

737826-19-6P 737826-20-9P, (2S)-1-[[2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-2-pyrrolidinecarboxamide 737826-21-0P 737826-23-2P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[3-(N,N-dimethylamino)-3-oxopropyl]amino]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737826-24-3P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[3-(N,N-dimethylamino)-3-oxopropyl](methyl)amino]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737826-25-4P, 3-[[[2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl](methyl)amino]-N,N-dimethylpropanamide 737826-26-5P 737826-28-7P, Methyl 4-[2-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]vinyl]benzoate 737826-29-8P, Methyl 4-[2-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]ethyl]benzoate 737826-30-1P, 4-[2-[2-(Acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]ethyl]benzoic acid 737826-31-2P, tert-Butyl [4-[2-[2-(acetylamino)-5-[2-[4-[(methylamino)carbonyl]phenyl]ethyl]thiazol-4-yl]ethyl]phenyl]carbamate 737826-32-3P 737826-34-5P, tert-Butyl [4-[2-[2-(Acetylamino)-5-[2-[4-[(dimethylamino)carbonyl]phenyl]ethyl]thiazol-4-yl]ethyl]phenyl]carbamate 737826-35-6P 737826-37-8P, Methyl N-[4-[[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]phenyl]carbamate 737826-38-9P 737826-40-3P, Ethyl 1-[[2-(acetylamino)-4-[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-5-yl]methyl]-4-piperidinecarboxylate 737826-41-4P 737826-46-9P, tert-Butyl [2-[4-[2-(2-aminothiazol-4-yl)ethyl]phenyl]ethyl]carbamate 737826-47-0P, tert-Butyl [2-[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]ethyl]carbamate 737826-49-2P 737826-51-6P, N-[4-[4-(Methylthio)phenyl]thiazol-2-yl]acetamide 737826-52-7P, N-[4-[4-(Methylsulfinyl)phenyl]thiazol-2-yl]acetamide 737826-53-8P, [[4-[2-(Acetylamino)thiazol-4-yl]phenyl]thio]methyl acetate 737826-54-9P, [[4-[2-(Acetylamino)thiazol-4-yl]phenyl]sulfonyl]methyl acetate 737826-55-0P, Sodium 4-[2-(acetylamino)thiazol-4-yl]benzenesulfinate 737826-56-1P, N-[4-[4-[(2-Hydroxyethyl)sulfonyl]phenyl]thiazol-2-yl]acetamide 737826-57-2P, N-[4-[4-[(2-Aminoethyl)sulfonyl]phenyl]thiazol-2-yl]acetamide 737826-58-3P 737826-60-7P, N-Methoxy-N-methyl-3-(methylsulfonyl)benzamide 737826-61-8P, Methyl (2E)-3-[3-(methylsulfonyl)phenyl]-2-propenoate 737826-62-9P, Methyl 3-[3-(methylsulfonyl)phenyl]propanoate 737826-63-0P, Ethyl 4-[3-(methylsulfonyl)phenyl]-2-oxobutanoate 737826-64-1P, Ethyl 3-bromo-4-[3-(methylsulfonyl)phenyl]-2-oxobutanoate 737826-65-2P, Ethyl 2-amino-5-[[3-(methylsulfonyl)phenyl]methyl]thiazole-4-carboxylate 737826-66-3P, Ethyl 2-(acetylamino)-5-[[3-(methylsulfonyl)phenyl]methyl]thiazole-4-carboxylate 737826-67-4P, N-[4-Formyl-5-[3-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737826-68-5P 737826-69-6P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[3-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737826-70-9P 737826-72-1P 737826-73-2P 737826-75-4P 737826-76-5P 737826-78-7P 737826-79-8P 737826-81-2P, 9H-Fluoren-9-ylmethyl 4-[[2-(acetylamino)-4-[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-5-yl]methyl]-1-piperazinecarboxylate 737826-82-3P, 9H-Fluoren-9-ylmethyl 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]-1-piperazinecarboxylate 737826-83-4P 737826-84-5P 737826-85-6P 737826-87-8P 737826-89-0P 737826-91-4P 737826-93-6P, Ethyl 3-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]-2-propenoate 737826-94-7P, Ethyl 3-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]propanoate 737826-95-8P 737826-96-9P 737826-97-0P 737826-99-2P 737827-01-9P 737827-03-1P 737827-04-2P

737827-06-4P 737827-08-6P 737827-10-0P 737827-11-1P
737827-12-2P 737827-13-3P 737827-15-5P 737827-17-7P
737827-18-8P 737827-19-9P 737827-20-2P 737827-22-4P
737827-24-6P 737827-25-7P, N-[4-[2-(3,4-Diaminophenyl)ethyl]-5-[4-
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737827-27-9P
737827-28-0P, N-[4-[2-(3,4-Diaminophenyl)ethyl]thiazol-2-
yl]acetamide 737827-30-4P 737827-31-5P 737827-32-6P,
N-[[2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]-N-
methylacetamide 737827-33-7P 737827-35-9P, tert-Butyl
[2-[[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]amino]ethyl]carb
amate 737827-37-1P, 1-[3-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]ph
enyl]ethanone 737827-38-2P, N-[4-[3-(2-Hydroxyethyl)phenyl]thiazol-
2-yl]acetamide 737827-39-3P, 2-[3-[2-(Acetylamino)thiazol-4-
yl]phenyl]ethyl methanesulfonate 737827-40-6P,
N-[4-[3-(2-Aminoethyl)phenyl]thiazol-2-yl]acetamide 737827-41-7P
737827-43-9P, tert-Butyl N-[4-[2-[2-(acetylamino)-5-[(E)-2-[4-
(methylsulfonyl)phenyl]ethenyl]thiazol-4-yl]ethyl]phenyl]carbamate
737827-44-0P, tert-Butyl N-[4-[2-[2-(acetylamino)-5-[2-[4-
(methylsulfonyl)phenyl]ethyl]thiazol-4-yl]ethyl]phenyl]carbamate
737827-45-1P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[2-[4-
(methylsulfonyl)phenyl]ethyl]thiazol-2-yl]acetamide 737827-46-2P
740816-44-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)
(intermediate; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT 9001-53-0, Diamine oxidase 9001-66-5, Monoamine oxidase
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT 62-53-3, Aniline, reactions 70-23-5, Ethyl 3-bromo-2-oxopropanoate
79-30-1, Isobutyryl chloride 79-44-7, Dimethylcarbamyl chloride
95-92-1, Diethyl oxalate 100-11-8, 1-(Bromomethyl)-4-nitrobenzene
102-52-3, 1,1,3,3-Tetramethoxypropane 156-06-9,
2-Oxo-3-phenylpropanoic acid 501-53-1, Benzyloxycarbonyl chloride
524-38-9, 2-Hydroxy-1H-isoindole-1,3(2H)-dione 532-55-8, Benzoyl
isothiocyanate 543-24-8, (Acetylamino)acetic acid 555-16-8,
p-Nitrobenzaldehyde, reactions 591-08-2, 1-Acetyl-2-thiourea
638-07-3, Ethyl 4-chloro-3-oxobutanoate 877-95-2,
N-(2-Phenylethyl)acetamide 1074-82-4, Phthalimide potassium salt
1099-45-2, [(Carbethoxy)methylene]triphenylphosphorane 1253-46-9,
[4-(Methoxycarbonyl)benzyl]triphenylphosphonium bromide 1778-09-2,
1-[4-(Methylthio)phenyl]ethanone 1878-67-7, (3-Bromophenyl)acetic
acid 2605-67-6, Methyl 2-(triphenylphosphoranylidene)acetate
3446-89-7, 4-(Methylsulfanyl)benzaldehyde 3958-57-4,
1-(Bromomethyl)-3-nitrobenzene 4530-20-5, [(tert-
Butoxycarbonyl)amino]acetic acid 5345-27-7, 3-
(Methylsulfonyl)benzoic acid 5398-36-7, Ethyl 2-aminothiazole-4-
carboxylate 17201-43-3, 4-(Bromomethyl)benzonitrile 18162-48-6,
tert-Butyldimethylsilyl chloride 18600-42-5, (4-Nitrobenzyl)amine
hydrochloride 19975-56-5, 2-(Methylsulfanyl)-4,5-dihydrothiazole
39684-80-5, tert-Butyl (2-bromoethyl)carbamate 40235-68-5,
3-Chloro-2-oxopropyl acetate 51779-32-9, Di(tert-butyl)
iminodicarboxylate 63545-55-1, 3-(4-Mercaptophenyl)propanoic acid
64920-29-2, Ethyl 2-oxo-4-phenylbutanoate 71026-66-9, tert-Butyl
(4-aminophenyl)carbamate 77900-13-1 83171-39-5,
[4-(Methylthio)benzyl]amine 111608-52-7, Ethyl
[4-(chloromethyl)thiazol-2-yl]carbamate 149596-90-7,
(2S)-2-[(N,N-Dimethylamino)carbonyl]pyrrolidine hydrochloride

152120-54-2, N,N'-Bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboximidamide 157126-75-5, Ethyl 3-(4-iodophenyl)propanoate 162011-69-0, Methyl 4-[[4-(methylthio)phenyl]acetyl]benzoate 188814-80-4, Ethyl 2-(methylsulfanyl)-4,5-dihydro-1H-imidazole-1-carboxylate 737823-43-7 737825-26-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

L32 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:220328 HCAPLUS
DOCUMENT NUMBER: 140:270869
TITLE: Preparation of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase.
INVENTOR(S): Ritzeler, Olaf; Jaehne, Gerhard
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022553	A1	20040318	WO 2003-EP8629	20030805
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10237722	A1	20040819	DE 2002-10237722	20020817
CA 2498559	AA	20040318	CA 2003-2498559	20030805
EP 1530568	A1	20050518	EP 2003-793685	20030805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005539054	T2	20051222	JP 2004-533319	20030805
US 2005197353	A1	20050908	US 2003-642970	20030818
NO 2005001337	A	20050503	NO 2005-1337	

PRIORITY APPLN. INFO.: DE 2002-10237722 A 200503 15
DE 2002-10237722 A 200208 17
US 2002-434749P P 200212 19
WO 2003-EP8629 W 200308 05

OTHER SOURCE(S): MARPAT 140:270869

GI



I

AB Title compds. [I; X, M = N, CH; R1, R11 = H, F, Cl, Br, iodo, alkyl, cyano, CF3, OR5, NR5R6, COR5, SOxR5, etc.; x = 0-2; R3, R5, R6 = H, alkyl; R2 = (substituted) imidazolyl, imidazolidinyl, indazolyl, isothiazolyl, isoxazolyl, morpholinyl, piperazinyl, pyrazolyl, tetrazolyl, thiadiazolyl, thiazolyl, thiomorpholinyl, triazolyl, etc.; R4 = (substituted) (fused) pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, phthalazinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, etc.], were prepd. Thus, 2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-2-diphenylamino-1-hydrazinocarbonylethyl]amide (prepn. given) in CH2Cl2 was treated with phosgene followed by stirring for 15 h to give 76% 2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]-oxadiazol-2-yl)ethyl]amide. The latter inhibited IκB kinase with IC50 = 0.050 μM.

IT **33142-18-6P 673488-60-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

RN 33142-18-6 HCAPLUS

CN 2-Thiazolamine, N-phenyl- (9CI) (CA INDEX NAME)



RN 673488-60-3 HCAPLUS
CN Alanine, N,N-bis[(1,1-dimethylethoxy)carbonyl]-3-(phenyl-2-thiazolylamino)-, methyl ester (9CI) (CA INDEX NAME)



IC ICM C07D401-14
ICS C07D403-12
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
ST pyrimidinylindolecarboxamide pyrimidinylbenzimidazolecarboxamide prepn IkB kinase inhibitor; cancer gout septic shock viral infection **treatment** pyrimidinylindolecarboxamide pyrimidinylbenzimidazolecarboxamide; influenza hepatitis aids malaria leprosy **treatment** pyrimidinylindolecarboxamide pyrimidinylbenzimidazolecarboxamide prepn; fungal infection brain **inflammation** lung **disease treatment** pyrimidinylindolecarboxamide pyrimidinylbenzimidazolecarboxamide; chronic bronchitis **asthma** acute synovitis **treatment** pyrimidinylindolecarboxamide pyrimidinylbenzimidazolecarboxamide prepn; acute respiratory distress syndrome tuberculosis **psoriasis treatment** pyrimidinylindolecarboxamide pyrimidinylbenzimidazolecarboxamide
IT **Inflammation**
(Crohn's **disease, treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)
IT Intestine, **disease**
(Crohn's, **treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)
IT **Disease**, animal
(arthropathy, **treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)
IT Bronchi, **disease**
Inflammation
(chronic bronchitis, **treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)
IT Lung, **disease**
(chronic **inflammatory** lung **disease treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)
IT Muscle, **disease**
(degeneration, **treatment**; prepn. of

pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa
mides as inhibitors of IκB kinase)

IT Human adenovirus
Human herpesvirus
(**disease treatment**; prepn. of
pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa
mides as inhibitors of IκB kinase)

IT Joint, anatomical
(**disease, treatment**; prepn. of
pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa
mides as inhibitors of IκB kinase)

IT Heart, **disease**
(infarction, **treatment**; prepn. of
pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa
mides as inhibitors of IκB kinase)

IT Intestine, **disease**
(**inflammatory, treatment**; prepn. of
pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa
mides as inhibitors of IκB kinase)

IT Muscle, **disease**
Pain
(myalgia, **treatment**; prepn. of
pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa
mides as inhibitors of IκB kinase)

IT Tumor necrosis factors
RL: **BSU (Biological study, unclassified)**; **BIOL
(Biological study)**
(overexpression treatment; prepn. of
pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa
mides as inhibitors of IκB kinase)

IT Inflammation
Spinal column, **disease**
(spondylitis, **treatment**; prepn. of
pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa
mides as inhibitors of IκB kinase)

IT Artery, **disease**
(stenosis, **treatment**; prepn. of
pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa
mides as inhibitors of IκB kinase)

IT Arthritis
Synovial membrane, **disease**
(synovitis, **treatment**; prepn. of
pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa
mides as inhibitors of IκB kinase)

IT AIDS (**disease**)
Alzheimer's **disease**
Arthritis
Asthma
Atherosclerosis
Cachexia
Connective tissue, **disease**
Diabetes mellitus
Encephalitis
Gout
Hepatitis
Inflammation
Influenza
Leprosy
Malaria
Multiple sclerosis
Mycosis
Neoplasm

Osteoarthritis
Periodontium, **disease**
Psoriasis
Rheumatoid arthritis
Transplant rejection
Tuberculosis
Ulcer
(**treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT 159606-08-3, IκB Kinase
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(inhibitors; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT 669713-30-8P 669713-32-0P 673488-41-0P 673488-42-1P
673488-43-2P 673488-44-3P 673488-45-4P 673488-46-5P
673488-47-6P 673488-48-7P 673488-49-8P 673488-50-1P
673488-51-2P 673488-52-3P 673488-53-4P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT 22536-61-4P, 2-Chloro-5-methylpyrimidine 26054-60-4P
33142-18-6P 57356-49-7P, 2-Anilinopyrimidine 67751-23-9P
72358-70-4P 106157-94-2P 180869-38-9P 180869-39-0P
201338-62-7P 669713-33-1P 669713-34-2P 669713-35-3P
669713-36-4P 669713-38-6P 669713-39-7P 669713-40-0P
669713-43-3P 669713-45-5P 673488-54-5P 673488-55-6P
673488-56-7P 673488-57-8P 673488-58-9P 673488-59-0P
673488-60-3P 673488-61-4P 673488-62-5P 673488-63-6P
673488-64-7P 673488-65-8P 673488-66-9P 673488-67-0P
673488-68-1P 673488-69-2P 673488-70-5P 673488-71-6P
673488-72-7P 673488-73-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:220082 HCAPLUS
DOCUMENT NUMBER: 140:253556
TITLE: Preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors
INVENTOR(S): Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Doweyko, Arthur M. P.; Barrish, Joel C.; Wityak, John; Lombardo, Louis J.; Lee, Francis Y. F.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 184 pp., Cont.-in-part of U.S. 6,596,746.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004054186	A1	20040318	US 2003-395503	20030324
US 6596746	B1	20030722	US 2000-548929	20000413
US 2004024208	A1	20040205	US 2003-378372	20030303
US 6979694	B2	20051227		
US 2004073026	A1	20040415	US 2003-378461	20030303
US 2004077875	A1	20040422	US 2003-378373	20030303
CA 2519898	AA	20041007	CA 2004-2519898	20040323
WO 2004085388	A2	20041007	WO 2004-US8827	20040323
WO 2004085388	A3	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1610780	A2	20060104	EP 2004-758053	20040323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2005261305	A1	20051124	US 2005-138793	20050525
US 2005288303	A1	20051229	US 2005-138942	20050526
NO 2005004359	A	20051019	NO 2005-4359	20050920

PRIORITY APPLN. INFO.:	US 1999-129510P	P	19990415
	US 2000-548929	A2	20000413

US 2003-378373	A1	20030303
US 2003-395503	A	20030324
WO 2004-US8827	W	20040323

OTHER SOURCE(S): MARPAT 140:253556

GI



I



II

AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-assocd. disorders such as immunol. and oncol. disorders (no data), were prepd. E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day. The pharmaceutical compn. comprising the title compds. is claimed.

IT **302963-67-3P**
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

RN 302963-67-3 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3,4,5-trimethoxyphenyl)amino]- (9CI) (CA INDEX NAME)



IT **302961-94-0P 302961-95-1P 302961-96-2P**
302961-99-5P 302962-00-1P 302962-01-2P
302962-02-3P 302962-03-4P 302962-18-1P
302962-19-2P 302963-29-7P 302963-65-1P
302963-66-2P 302963-68-4P 302963-69-5P
302963-70-8P 302963-71-9P 302963-72-0P
302963-73-1P 302963-74-2P 302963-75-3P
302963-76-4P 302963-77-5P 302963-81-1P
302963-82-2P 302963-87-7P 302963-88-8P
302963-89-9P 302963-90-2P 302963-91-3P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

RN 302961-94-0 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-(phenylamino)-(9CI) (CA INDEX NAME)



RN 302961-95-1 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3-ethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 302961-96-2 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3,5-dimethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 302961-99-5 HCAPLUS
CN 5-Thiazolecarboxamide, 2-[(3-aminophenyl)amino]-N-(2-chloro-6-methylphenyl)- (9CI) (CA INDEX NAME)



RN 302962-00-1 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 302962-01-2 HCAPLUS
CN 5-Thiazolecarboxamide, 2-[(3-bromophenyl)amino]-N-(2-chloro-6-methylphenyl)- (9CI) (CA INDEX NAME)



RN 302962-02-3 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2,6-dimethylphenyl)-2-(phenylamino)- (9CI) (CA INDEX NAME)



RN 302962-03-4 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2,6-dimethylphenyl)-2-(methylphenylamino)-
(9CI) (CA INDEX NAME)



RN 302962-18-1 HCAPLUS
CN 5-Thiazolecarboxamide, 2-[(3-aminophenyl)amino]-N-(2,6-
dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 302962-19-2 HCAPLUS
CN 5-Thiazolecarboxamide, 2-[(3-bromophenyl)amino]-N-(2,6-
dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 302963-29-7 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-(2-naphthalenylamino)- (9CI) (CA INDEX NAME)



RN 302963-65-1 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[3-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-66-2 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[5-[[3-(1H-imidazol-1-yl)propyl]amino]-2-nitrophenyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-68-4 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 302963-69-5 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 302963-70-8 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 302963-71-9 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3,5-dimethoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 302963-72-0 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-(dimethylamino)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-73-1 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-74-2 HCAPLUS
CN Benzeneacetic acid, 3-[[5-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-75-3 HCAPLUS
CN Benzenebutanoic acid, 3-[[5-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-76-4 HCAPLUS
CN Benzeneacetic acid, 4-[[5-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-77-5 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-methyl-1H-benzimidazol-5-yl)amino]- (9CI) (CA INDEX NAME)



RN 302963-81-1 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(1-methyl-1H-benzimidazol-6-yl)amino]- (9CI) (CA INDEX NAME)



RN 302963-82-2 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(1-methyl-1H-benzimidazol-5-yl)amino]- (9CI) (CA INDEX NAME)



RN 302963-87-7 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[3-[3-(1H-imidazol-1-yl)propoxy]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-88-8 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-[3-(1H-imidazol-1-yl)propoxy]phenyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 302963-89-9 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-[2-(1H-imidazol-1-yl)ethoxy]-3-methoxyphenyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 302963-90-2 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[3-[[[3-(1H-imidazol-1-yl)propyl]amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 302963-91-3 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-[[[3-(1H-imidazol-1-yl)propyl]amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **302964-13-2P 302964-14-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

RN 302964-13-2 HCAPLUS

CN 5-Thiazolecarboxylic acid, 2-[(5-fluoro-2-nitrophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 302964-14-3 HCAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(5-fluoro-2-nitrophenyl)amino]- (9CI) (CA INDEX NAME)



IC ICM C07D041-02
ICS C07D043-02; C07D213-72; C07D207-22
INCL 546268100; 546304000; 548517000; 548557000; 548530000
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT Nervous system, **disease**
(Guillain-Barre syndrome, **treatment** of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)
IT Transcription factors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(IκB (inhibitor of NF-κB), co-administration with inhibitors of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)
IT Allergy
Inflammation
Nose, **disease**
(allergic rhinitis, **treatment** of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)
IT Autoimmune **disease**
Inflammation
Thyroid gland, **disease**
(autoimmune thyroiditis, **treatment** of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)
IT Lung, **disease**
(chronic obstructive pulmonary **disease**, **treatment** of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Tumor necrosis factors
RL: **THU (Therapeutic use); BIOL (Biological study)**
; USES (Uses)
(co-administration with TNF-α inhibitors; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT CD40 (antigen)
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(co-administration with agents blocking the interaction between CD40 and gp39; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT Tumor necrosis factor receptors
RL: **THU (Therapeutic use); BIOL (Biological study)**
; USES (Uses)
(co-administration with sol.; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT Antibodies and Immunoglobulins
Steroids, biological studies
RL: **THU (Therapeutic use); BIOL (Biological study)**
; USES (Uses)
(co-administration; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT Eye, **disease**
(diabetic retinopathy, **treatment** of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Macrolides
RL: **THU (Therapeutic use); BIOL (Biological study)**
; USES (Uses)
(epothilones, co-administration; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT Allergy
(hypersensitivity, **treatment** of T-cell mediated hypersensitivity **disease**; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Intestine, **disease**
(**inflammatory, treatment** of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Antibodies and Immunoglobulins
RL: **THU (Therapeutic use); BIOL (Biological study)**
; USES (Uses)
(monoclonal, co-administration with monoclonal antibody OKT3; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT T cell (lymphocyte)
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for **treating** T-cell mediated **diseases**)

IT Allergy
Asthma
Ischemia
Lupus erythematosus
Multiple sclerosis
Neoplasm
Psoriasis
Rheumatoid arthritis

Transplant rejection
(treatment of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 329900-75-6, Cyclooxygenase-2
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(co-administration with cyclooxygenase-2 inhibitors; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT 50-07-7, Mitomycin C 50-44-2, 6-Mercaptopurine 51-21-8, 5-Fluorouracil 54-62-6, Aminopterin 57-22-7, Vincristine 59-05-2, Methotrexate 147-94-4, Cytosine arabinoside 148-82-3, Melphalan 518-28-5, Podophyllotoxin 801-52-5, Porfiromycin 865-21-4, Vinblastine 2410-93-7, Methopterin 7440-57-5D, Gold, compds. 15228-71-4, Leurosidine 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 23360-92-1, Leurosine 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 50935-04-1 53123-88-9, Rapamycin 53643-48-4, Vindesine 59865-13-3, Cyclosporin A 95058-81-4, Gemcitabine 104987-11-3, FK506 114899-77-3, Ecteinascidin 743 117091-64-2, Etoposide phosphate 128794-94-5, Mycophenolate mofetil
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(co-administration; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT 79079-06-4, Her1 kinase 114051-78-4, Lck kinase 137632-09-8, Her2 kinase 140208-17-9, Lyn kinase 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes kinase 144941-32-2, Fgr kinase 144941-35-5, Blk kinase 145539-86-2, Hck kinase
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 21697-42-7P 302957-83-1P 302957-85-3P 302957-89-7P
302957-93-3P 302957-95-5P 302957-97-7P 302958-00-5P
302958-02-7P 302958-03-8P 302958-04-9P 302958-05-0P
302958-06-1P 302959-19-9P 302959-21-3P 302959-25-7P
302959-38-2P 302959-76-8P 302961-18-8P 302961-98-4P
302963-13-9P 302963-14-0P 302963-42-4P 302963-43-5P
302963-44-6P **302963-67-3P**
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 302957-87-5P 302957-91-1P 302957-94-4P 302957-96-6P
302957-99-9P 302958-01-6P 302958-07-2P 302958-08-3P
302958-09-4P 302958-10-7P 302958-11-8P 302958-12-9P
302958-13-0P 302958-14-1P 302958-15-2P 302958-16-3P
302958-17-4P 302958-18-5P 302958-19-6P 302958-20-9P
302958-21-0P 302958-22-1P 302958-23-2P 302958-24-3P
302958-25-4P 302958-26-5P 302958-27-6P 302958-28-7P
302958-29-8P 302958-30-1P 302958-31-2P 302958-32-3P
302958-33-4P 302958-34-5P 302958-35-6P 302958-36-7P
302958-37-8P 302958-38-9P 302958-39-0P 302958-40-3P
302958-41-4P 302958-42-5P 302958-43-6P 302958-44-7P
302958-45-8P 302958-46-9P 302958-47-0P 302958-48-1P
302958-49-2P 302958-50-5P 302958-51-6P 302958-52-7P

302958-53-8P 302958-54-9P 302958-55-0P 302958-56-1P
302958-57-2P 302958-58-3P 302958-59-4P 302958-60-7P
302958-61-8P 302958-62-9P 302958-63-0P 302958-64-1P
302958-65-2P 302958-66-3P 302958-67-4P 302958-68-5P
302958-69-6P 302958-70-9P 302958-71-0P 302958-72-1P
302958-73-2P 302958-74-3P 302958-75-4P 302958-76-5P
302958-77-6P 302958-78-7P 302958-79-8P 302958-80-1P
302958-81-2P 302958-82-3P 302958-83-4P 302958-84-5P
302958-85-6P 302958-86-7P 302958-87-8P 302958-88-9P
302958-89-0P 302958-90-3P 302958-91-4P 302958-92-5P
302958-93-6P 302958-94-7P 302958-95-8P 302958-96-9P
302958-97-0P 302958-98-1P 302958-99-2P 302959-00-8P
302959-01-9P 302959-02-0P 302959-03-1P 302959-04-2P
302959-05-3P 302959-06-4P 302959-07-5P 302959-08-6P
302959-09-7P 302959-10-0P 302959-11-1P 302959-12-2P
302959-13-3P 302959-14-4P 302959-15-5P 302959-16-6P
302959-17-7P 302959-18-8P 302959-20-2P 302959-23-5P
302959-24-6P 302959-27-9P 302959-29-1P 302959-31-5P
302959-34-8P 302959-35-9P 302959-37-1P 302959-39-3P
302959-41-7P 302959-42-8P 302959-43-9P 302959-44-0P
302959-45-1P 302959-46-2P 302959-47-3P 302959-48-4P
302959-49-5P 302959-50-8P 302959-51-9P 302959-52-0P
302959-53-1P 302959-54-2P 302959-55-3P 302959-56-4P
302959-57-5P 302959-58-6P 302959-59-7P 302959-60-0P
302959-61-1P 302959-62-2P 302959-63-3P 302959-64-4P
302959-65-5P 302959-66-6P 302959-67-7P 302959-68-8P
302959-69-9P 302959-70-2P 302959-71-3P 302959-72-4P
302959-73-5P 302959-74-6P 302959-75-7P 302959-77-9P
302959-78-0P 302959-79-1P 302959-80-4P 302959-81-5P
302959-82-6P 302959-83-7P 302959-84-8P 302959-85-9P
302959-86-0P 302959-87-1P 302959-88-2P 302959-89-3P
302959-90-6P 302959-91-7P 302959-92-8P 302959-93-9P
302959-94-0P 302959-95-1P 302959-96-2P 302959-97-3P
302959-98-4P 302959-99-5P 302960-00-5P 302960-01-6P
302960-02-7P 302960-03-8P 302960-04-9P 302960-05-0P
302960-06-1P 302960-07-2P 302960-08-3P 302960-09-4P
302960-10-7P 302960-11-8P 302960-12-9P 302960-13-0P
302960-14-1P 302960-15-2P 302960-16-3P 302960-17-4P
302960-18-5P 302960-19-6P 302960-20-9P 302960-21-0P
302960-22-1P 302960-23-2P 302960-24-3P 302960-25-4P
302960-26-5P 302960-27-6P 302960-28-7P 302960-29-8P
302960-30-1P 302960-31-2P 302960-32-3P 302960-33-4P
302960-34-5P 302960-35-6P 302960-36-7P 302960-37-8P
302960-38-9P 302960-39-0P 302960-40-3P 302960-41-4P
302960-42-5P 302960-43-6P 302960-44-7P 302960-45-8P
302960-46-9P 302960-47-0P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 302960-48-1P 302960-49-2P 302960-50-5P 302960-51-6P
302960-52-7P 302960-53-8P 302960-54-9P 302960-55-0P
302960-56-1P 302960-57-2P 302960-58-3P 302960-59-4P
302960-60-7P 302960-61-8P 302960-62-9P 302960-63-0P
302960-64-1P 302960-65-2P 302960-67-4P 302960-69-6P
302960-70-9P 302960-71-0P 302960-72-1P 302960-73-2P
302960-74-3P 302960-75-4P 302960-76-5P 302960-77-6P
302960-78-7P 302960-79-8P 302960-80-1P 302960-81-2P
302960-82-3P 302960-83-4P 302960-84-5P 302960-85-6P
302960-86-7P 302960-87-8P 302960-88-9P 302960-89-0P
302960-90-3P 302960-91-4P 302960-92-5P 302960-93-6P

302960-94-7P 302960-95-8P 302960-96-9P 302960-97-0P
302960-98-1P 302960-99-2P 302961-00-8P 302961-01-9P
302961-02-0P 302961-03-1P 302961-04-2P 302961-05-3P
302961-06-4P 302961-07-5P 302961-08-6P 302961-09-7P
302961-10-0P 302961-11-1P 302961-12-2P 302961-13-3P
302961-14-4P 302961-15-5P 302961-16-6P 302961-17-7P
302961-19-9P 302961-20-2P 302961-21-3P 302961-22-4P
302961-23-5P 302961-24-6P 302961-25-7P 302961-26-8P
302961-27-9P 302961-28-0P 302961-29-1P 302961-30-4P
302961-31-5P 302961-32-6P 302961-33-7P 302961-34-8P
302961-35-9P 302961-36-0P 302961-37-1P 302961-38-2P
302961-39-3P 302961-40-6P 302961-41-7P 302961-42-8P
302961-43-9P 302961-44-0P 302961-45-1P 302961-46-2P
302961-47-3P 302961-48-4P 302961-49-5P 302961-50-8P
302961-51-9P 302961-52-0P 302961-53-1P 302961-54-2P
302961-55-3P 302961-56-4P 302961-57-5P 302961-58-6P
302961-59-7P 302961-60-0P 302961-61-1P 302961-62-2P
302961-63-3P 302961-64-4P 302961-65-5P 302961-66-6P
302961-67-7P 302961-69-9P 302961-70-2P 302961-71-3P
302961-72-4P 302961-73-5P 302961-74-6P 302961-75-7P
302961-76-8P 302961-77-9P 302961-78-0P 302961-79-1P
302961-80-4P 302961-81-5P 302961-82-6P 302961-83-7P
302961-84-8P 302961-85-9P 302961-86-0P 302961-87-1P
302961-88-2P 302961-89-3P 302961-90-6P 302961-91-7P
302961-92-8P 302961-93-9P **302961-94-0P**
302961-95-1P 302961-96-2P 302961-97-3P
302961-99-5P 302962-00-1P 302962-01-2P
302962-02-3P 302962-03-4P 302962-04-5P
302962-05-6P 302962-06-7P 302962-07-8P 302962-08-9P
302962-09-0P 302962-10-3P 302962-11-4P 302962-12-5P
302962-13-6P 302962-14-7P 302962-15-8P 302962-16-9P
302962-17-0P **302962-18-1P 302962-19-2P**
302962-20-5P 302962-21-6P 302962-22-7P 302962-23-8P
302962-24-9P 302962-25-0P 302962-27-2P 302962-29-4P
302962-30-7P 302962-31-8P 302962-32-9P 302962-33-0P
302962-34-1P 302962-35-2P 302962-36-3P 302962-37-4P
302962-38-5P 302962-39-6P 302962-40-9P 302962-41-0P
302962-42-1P 302962-43-2P 302962-44-3P 302962-45-4P
302962-46-5P 302962-47-6P 302962-48-7P 302962-49-8P
302962-50-1P 302962-51-2P 302962-52-3P 302962-53-4P
302962-54-5P 302962-55-6P 302962-56-7P 302962-57-8P
302962-58-9P 302962-59-0P 302962-60-3P 302962-61-4P
302962-62-5P 302962-63-6P 302962-64-7P 302962-65-8P
302962-66-9P 302962-67-0P 302962-68-1P 302962-69-2P
302962-70-5P 302962-71-6P 302962-72-7P 302962-73-8P
302962-74-9P 302962-76-1P 302962-77-2P 302962-79-4P
302962-81-8P 302962-83-0P 302962-85-2P 302962-87-4P
302962-89-6P 302962-91-0P 302962-92-1P 302962-94-3P
302962-96-5P 302962-98-7P 302963-00-4P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 302963-02-6P 302963-04-8P 302963-05-9P 302963-07-1P
302963-09-3P 302963-11-7P 302963-15-1P 302963-16-2P
302963-18-4P 302963-20-8P 302963-22-0P 302963-23-1P
302963-24-2P 302963-25-3P 302963-26-4P 302963-27-5P
302963-28-6P **302963-29-7P** 302963-30-0P 302963-31-1P
302963-32-2P 302963-33-3P 302963-34-4P 302963-35-5P
302963-36-6P 302963-37-7P 302963-38-8P 302963-39-9P
302963-40-2P 302963-41-3P 302963-45-7P 302963-46-8P

302963-47-9P 302963-48-0P 302963-49-1P 302963-50-4P
302963-51-5P 302963-52-6P 302963-53-7P 302963-54-8P
302963-55-9P 302963-56-0P 302963-57-1P 302963-58-2P
302963-59-3P 302963-60-6P 302963-61-7P 302963-62-8P
302963-63-9P 302963-64-0P **302963-65-1P**
302963-66-2P 302963-68-4P 302963-69-5P
302963-70-8P 302963-71-9P 302963-72-0P
302963-73-1P 302963-74-2P 302963-75-3P
302963-76-4P 302963-77-5P 302963-78-6P
302963-79-7P 302963-80-0P **302963-81-1P**
302963-82-2P 302963-83-3P 302963-84-4P 302963-85-5P
302963-86-6P **302963-87-7P 302963-88-8P**
302963-89-9P 302963-90-2P 302963-91-3P
302963-93-5P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 3122-78-9P 3122-84-7P 129912-21-6P 210917-98-9P 244236-52-0P
302963-94-6P 302963-95-7P 302963-96-8P 302963-97-9P
302963-98-0P 302963-99-1P 302964-00-7P 302964-01-8P
302964-02-9P 302964-03-0P 302964-04-1P 302964-05-2P
302964-06-3P 302964-07-4P 302964-08-5P 302964-09-6P
302964-10-9P 302964-12-1P **302964-13-2P**
302964-14-3P 302964-15-4P 302964-16-5P 302964-17-6P
302964-18-7P 302964-19-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 138238-67-2, BCR-ABL kinase
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(wherein cancer is sensitive(or resistant) to treatment by an inhibitor of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating cancer)

L32 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:143145 HCAPLUS
DOCUMENT NUMBER: 140:199317
TITLE: Preparation of 2-(3-aminoaryl)amino-4-arylthiazoles as tyrosine phosphokinase c-kit inhibitors.
INVENTOR(S): Ciufolini, Marco; Wermuth, Camille; Gielthen, Bruno; Moussy, Alain
PATENT ASSIGNEE(S): Ab Science, Fr.
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014903	A1	20040219	WO 2003-IB3685	200307 31

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

CA 2494695	AA	20040219	CA 2003-2494695	200307 31
EP 1525200	A1	20050427	EP 2003-784419	200307 31
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013165	A	20050614	BR 2003-13165	200307 31
JP 2005539021	T2	20051222	JP 2004-527232	200307 31
US 2004110810	A1	20040610	US 2003-632101	200308 01
US 2005239852	A1	20051027	US 2005-523018	200502 02
NO 2005001115	A	20050302	NO 2005-1115	200503 02
PRIORITY APPLN. INFO.:			US 2002-400064P P	200208 02
			WO 2003-IB3685 W	200307 31

OTHER SOURCE(S): MARPAT 140:199317
GI



I



II

AB Title compds. [I; (substituted) alkyl, aryl, heteroaryl, CONHR, COR, CONRR'; R, R' = H, aryl, heteroaryl, alkyl, cycloalkyl; R2-R5 = H halo, alkyl, CF3, alkoxy; R6, R7 = (substituted) aryl, heteroaryl, H, halo, amino, NO2, etc.], were prepd. Thus, 2-(2-methyl-5-aminophenyl)-4-(3-pyridyl)thiazole (prepn. given) in CH2Cl2 was treated with Me3Al in PhMe at 0°; the mixt. was stirred 0.5 h at room temp. and Me 4-[(4-methylpiperazin-1-yl)methyl]benzoate in CH2Cl2 was added followed by reflux for 5 h to give 72% title compd. (II). Numerous I inhibited c-kit with IC50 <10 μM.

IT **660837-07-0P 660837-08-1P**
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

RN 660837-07-0 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 660837-08-1 HCAPLUS

CN 1,3-Benzenediamine, 4-methyl-N3-[4-(3-pyridinyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



IT **660836-74-8P 660836-76-0P 660836-78-2P**
660836-79-3P 660836-80-6P 660836-81-7P
660836-82-8P 660836-83-9P 660836-84-0P
660836-88-4P 660836-89-5P 660836-90-8P
660836-98-6P 660836-99-7P 660837-13-8P
660837-14-9P 660837-16-1P 660837-17-2P
660837-18-3P 660837-20-7P 660837-33-2P
660837-44-5P 660837-45-6P 660837-46-7P
660837-47-8P 660837-48-9P 660837-49-0P
660837-50-3P 660837-52-5P 660837-54-7P
660837-55-8P 660837-56-9P 660837-57-0P
660837-60-5P 660837-61-6P 660837-62-7P
660837-63-8P 660837-66-1P 660837-67-2P
660837-78-5P 660837-82-1P 660837-85-4P
660837-86-5P 660837-87-6P 660837-88-7P
660837-89-8P 660837-90-1P 660837-91-2P
660837-92-3P 660837-93-4P 660837-94-5P
660837-95-6P 660837-96-7P 660837-97-8P
660837-99-0P 660838-01-7P 660838-02-8P
660838-03-9P 660838-04-0P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

RN 660836-74-8 HCAPLUS
CN Benzamide, 4-[(diethylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-76-0 HCAPLUS
CN Benzamide, 4-[(dipropylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-78-2 HCAPLUS
CN Benzamide, 3-iodo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-

thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-79-3 HCAPLUS
CN Benzamide, 4-(hydroxymethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-80-6 HCAPLUS
CN Benzoic acid, 4-[[[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 660836-81-7 HCAPLUS
CN 2-Propynamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 660836-82-8 HCAPLUS
CN Benzamide, 4-amino-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-83-9 HCAPLUS
CN Benzamide, 2-iodo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-84-0 HCAPLUS
CN Benzamide, 4-iodo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-88-4 HCAPLUS
CN Carbamic acid, [[4-[[[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]amino]carbonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 660836-89-5 HCAPLUS
CN Benzamide, 4-hydroxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-90-8 HCAPLUS
CN Benzamide, 4-[[bis(1-methylethyl)amino]methyl]-N-[4-methyl-3-[[4-(3-

pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-98-6 HCAPLUS
CN Benzamide, 3-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-99-7 HCAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660837-13-8 HCAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[5-[(3-iodobenzoyl)amino]-2-methylphenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 660837-14-9 HCAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-methyl-5-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 660837-16-1 HCAPLUS
CN Benzamide, 3-bromo-N-[3-[[4-(4-chlorophenyl)-5-methyl-2-thiazolyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)



RN 660837-17-2 HCAPLUS
CN Carbamic acid, [3-[[4-(4-chlorophenyl)-5-methyl-2-thiazolyl]amino]-4-methylphenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 660837-18-3 HCAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[5-[(3-bromobenzoyl)amino]-2-methylphenyl]amino]-5-(4-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 660837-20-7 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[[5-[(3-bromobenzoyl)amino]-2-methylphenyl]amino]-5-(4-chlorophenyl)-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 660837-33-2 HCAPLUS
CN Benzamide, 3-bromo-4-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-44-5 HCAPLUS
CN Benzamide, 4-cyano-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-45-6 HCAPLUS
CN Benzamide, 4-fluoro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-46-7 HCAPLUS
CN Urea, N-(2-fluorophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-47-8 HCAPLUS
CN Urea, N-(2-chlorophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-48-9 HCAPLUS
CN Urea, N-(3-fluorophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-49-0 HCAPLUS
CN Urea, N-(4-methylphenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-50-3 HCAPLUS
CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-52-5 HCAPLUS
CN Benzamide, 3-fluoro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-54-7 HCAPLUS
CN Benzamide, 4-(dimethylamino)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-55-8 HCAPLUS
CN Benzamide, 2-fluoro-5-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-56-9 HCAPLUS
CN Benzamide, 4-(1,1-dimethylethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-57-0 HCAPLUS
CN Benzamide, 4-(1-methylethoxy)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-60-5 HCAPLUS
CN Benzamide, 3-cyano-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-61-6 HCAPLUS
CN Benzamide, 2-fluoro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 660837-62-7 HCAPLUS
CN Benzamide, 4-(aminomethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-63-8 HCAPLUS
CN Benzamide, 3-methoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-66-1 HCAPLUS
CN 4-Pyridinecarboxamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-67-2 HCAPLUS
CN 4-Pyridinecarboxamide, 2,6-dichloro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-78-5 HCAPLUS
CN Benzamide, 4-(1-methoxyethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-82-1 HCAPLUS
CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-85-4 HCAPLUS
CN Cyclohexanecarboxamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-86-5 HCAPLUS
CN Hexanoic acid, 6-[[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]amino]-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 660837-87-6 HCAPLUS
CN Cyclohexanecarboxamide, 1-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-88-7 HCAPLUS
CN Cyclohexanecarboxamide, 4-(1,1-dimethylethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-89-8 HCAPLUS
CN 4-Morpholinebutanamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-90-1 HCAPLUS
CN Carbamic acid, [4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 660837-91-2 HCAPLUS
CN Urea, N-(4-methoxyphenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-92-3 HCAPLUS
CN Urea, N-(4-bromophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-93-4 HCAPLUS
CN Urea, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 660837-94-5 HCAPLUS
CN Urea, N-(4-fluorophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-95-6 HCAPLUS

CN Urea, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-N'-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 660837-96-7 HCAPLUS
CN Benzoic acid, 4-[[[[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 660837-97-8 HCAPLUS
CN Urea, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-N'-2-thienyl- (9CI) (CA INDEX NAME)



RN 660837-99-0 HCAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660838-01-7 HCAPLUS
CN Urea, N-(3,5-dimethyl-4-isoxazolyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660838-02-8 HCAPLUS
CN Urea, N-(2-iodophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660838-03-9 HCAPLUS
CN Urea, N-[4-(difluoromethoxy)phenyl]-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660838-04-0 HCAPLUS
CN Urea, N-[4-(dimethylamino)phenyl]-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IC ICM C07D417-04
ICS C07D417-14; C07D277-42; C07D277-56; A61K031-426; A61K031-427; A61K031-4439; A61K031-497; A61P035-00; A61P037-00; A61P029-00
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
ST aminoarylaminoarylthiazole prepn tyrosine phosphokinase ckit inhibitor; nodular panarteritis **treatment**

arylaminothiazole prepn; Sjogrens syndrome polymyositis dermatomyositis cutaneous lupus **treatment** arylaminothiazole prepn; discoid systemic lupus erythematosus **treatment** thiazole arylamino prepn; rheumatoid arthritis polyarthritis **treatment** aminoarylaminoarylthiazole prepn; Crohns **disease** ulcerative colitis **psoriasis** multiple sclerosis **treatment** arylaminothiazole; autoimmune **disease** gouty arthritis osteoarthritis **treatment** arylaminothiazole; blood sucking parasitic infestation **treatment** arylaminothiazole; **inflammation** insect bite allergic contact dermatitis **treatment** arylaminothiazole prepn; atopic dermatitis angioedema urticaria anaphylactic syndrome **treatment** thiazole; allergic sinusitis rhinitis **asthma treatment** arylthiazole prepn; neoplasm mastocytosis mastocytoma small cell lung cancer **treatment** arylaminothiazole; gastrointestinal stromal tumor **treatment** arylthiazole prepn

IT **Inflammation**
(Crohn's **disease, treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Intestine, **disease**
(Crohn's, **treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Allergy
Inflammation
Nose, **disease**
(allergic rhinitis, **treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Intestine, **disease**
(autoimmune enteropathy **treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Eye, **disease**
Inflammation
(conjunctivitis, **treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT **Disease**, animal
(cutaneous necrotizing venulitis **treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Inflammation
Kidney, **disease**
(glomerulonephritis, proliferative glomerulonephritis **treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Intestine
(**inflammatory disease treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Skin, **disease**
(insect bite, insect bite skin **inflammation treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT **Disease**, animal
(nodular panarteritis **treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Connective tissue, **disease**

(scleroderma, local and systemic scleroderma **treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Inflammation
Respiratory system, **disease**
(sinusitis, allergic sinusitis **treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Allergy
Asthma
Autoimmune **disease**
Dermatomyositis
Gout
Inflammation
Multiple sclerosis
Myelodysplastic syndromes
Neoplasm
Osteoarthritis
Psoriasis
Rheumatoid arthritis
Sjogren's syndrome
Transplant rejection
Urticaria
(**treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT Inflammation
Intestine, **disease**
(ulcerative colitis, **treatment**; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT 138359-29-2, c-Kit kinase
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(inhibitors; prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT **660837-07-0P 660837-08-1P**
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

IT **660836-74-8P** 660836-75-9P **660836-76-0P**
660836-77-1P **660836-78-2P 660836-79-3P**
660836-80-6P 660836-81-7P 660836-82-8P
660836-83-9P 660836-84-0P 660836-85-1P
660836-86-2P 660836-87-3P **660836-88-4P**
660836-89-5P 660836-90-8P 660836-91-9P
660836-92-0P 660836-93-1P 660836-94-2P 660836-95-3P
660836-96-4P 660836-97-5P **660836-98-6P**
660836-99-7P 660837-00-3P 660837-01-4P 660837-02-5P
660837-03-6P 660837-04-7P 660837-05-8P 660837-06-9P
660837-09-2P 660837-10-5P 660837-11-6P 660837-12-7P
660837-13-8P 660837-14-9P 660837-15-0P
660837-16-1P 660837-17-2P 660837-18-3P
660837-20-7P 660837-24-1P 660837-28-5P 660837-29-6P
660837-30-9P 660837-31-0P **660837-33-2P** 660837-36-5P
660837-39-8P 660837-41-2P 660837-42-3P 660837-43-4P
660837-44-5P 660837-45-6P 660837-46-7P
660837-47-8P 660837-48-9P 660837-49-0P
660837-50-3P 660837-51-4P **660837-52-5P**
660837-53-6P **660837-54-7P 660837-55-8P**

660837-56-9P 660837-57-0P 660837-58-1P
660837-59-2P **660837-60-5P 660837-61-6P**
660837-62-7P 660837-63-8P 660837-64-9P
660837-65-0P **660837-66-1P 660837-67-2P**
660837-68-3P 660837-69-4P 660837-70-7P 660837-71-8P
660837-72-9P 660837-73-0P 660837-74-1P 660837-75-2P
660837-76-3P 660837-77-4P **660837-78-5P** 660837-79-6P
660837-80-9P 660837-81-0P **660837-82-1P** 660837-83-2P
660837-84-3P **660837-85-4P 660837-86-5P**
660837-87-6P 660837-88-7P 660837-89-8P
660837-90-1P 660837-91-2P 660837-92-3P
660837-93-4P 660837-94-5P 660837-95-6P
660837-96-7P 660837-97-8P 660837-98-9P
660837-99-0P 660838-00-6P **660838-01-7P**
660838-02-8P 660838-03-9P 660838-04-0P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of aminoarylaminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:591307 HCAPLUS
DOCUMENT NUMBER: 139:143997
TITLE: Methods using Edg **receptor modulators** for the **treatment** of Edg **receptor**-associated **conditions**
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): Ceretek LLC, USA
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062392	A2	20030731	WO 2003-US1881	200301 21
WO 2003062392	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473740	AA	20030731	CA 2003-2473740	200301 21

EP 1513522	A2	20050316	EP 2003-710713	200301 21
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519915	T2	20050707	JP 2003-562260	200301 21
US 2005261298	A1	20051124	US 2003-390428	200303 14
PRIORITY APPLN. INFO.:			US 2002-350445P	P 200201 18
			US 2002-350446P	P 200201 18
			US 2002-350447P	P 200201 18
			US 2002-350448P	P 200201 18
			WO 2003-US1881	W 200301 21
			US 2003-352579	B2 200301 27

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 **receptor**-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 **receptor** is contacted with a **modulator** of the Edg-2, Edg-3, Ed-4 or Edg 7 **receptor** sufficient to modulate **receptor** mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 **receptor** mediated biol. in a subject. A therapeutically effective amt. of a **modulator** of the Edg-2, Edg-3, Ed-4 or Edg7 **receptor** is administered to the subject. Prepn. of compds., e.g. 4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

IT **353771-45-6P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

RN 353771-45-6 HCAPLUS

CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT **569656-05-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
RN 569656-05-9 HCAPLUS
CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IC ICM C12N
CC 1-12 (Pharmacology)
Section cross-reference(s): 28
ST Edg **receptor modulator** therapeutic; phenylpyrazolylbutyramide deriv prepn Edg **receptor modulator** therapeutic
IT Animal cell line
(A431; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Animal cell line
(CAOV-3; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT **Inflammation**
(Crohn's **disease**; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Intestine, **disease**
(Crohn's; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-1 (endothelial differentiation gene 1); Edg **receptor modulators** for **treatment** of Edg

receptor-assocd. **conditions**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-2 (endothelial differentiation gene 2); Edg **receptor** **modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-3 (endothelial differentiation gene 3); Edg **receptor** **modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-5 (endothelial differentiation gene 5); Edg **receptor** **modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-6 (endothelial differentiation gene 6); Edg **receptor** **modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT G protein-coupled **receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(EDG-8 (endothelial differentiation gene 8); Edg **receptor** **modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Angiogenesis
Angiogenesis inhibitors
Anti-**inflammatory** agents
Anti-ischemic agents
Antiasthmatics
Antimigraine agents
Antirheumatic agents
Antitumor agents
Apoptosis
Asthma
Atherosclerosis
Behcet's syndrome
Cardiovascular agents
Cardiovascular system, **disease**
Cell migration
Cell proliferation
Cytotoxic agents
Fibroblast
Gastrointestinal agents
Human
Inflammation
Ischemia
Kidney, neoplasm
Lung, **disease**
Lung, neoplasm
Mammary gland, neoplasm
Neoplasm
Neuron
Ovary, neoplasm
Pancreas, neoplasm
Peritoneum, neoplasm

Platelet (blood)
Platelet activation
Platelet activation
Prostate gland, neoplasm
Psoriasis
Rheumatoid arthritis
Stomach, neoplasm
Thyroid gland, neoplasm
Uterus, neoplasm
Vasoconstriction
Vasodilators
Wound
Wound healing promoters
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Carbohydrates, biological studies
Nucleic acids
Organic compounds, biological studies
Peptides, biological studies
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT **Receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(Edg-4; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT **Receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(Edg-7; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT **Receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(Edg; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Animal cell line
(HT-1080; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Animal cell line
(HTC; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Animal cell line
(HUVEC; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Chemotaxis
(LPA-stimulated; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Animal cell line
(MDA-MB-231; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd.

conditions)
IT Animal cell line
(MDA-MB-453; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Animal cell line
(OV202; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Animal cell line
(SKOV3; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Respiratory distress syndrome
(adult; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Antiarteriosclerotics
(antiatherosclerotics; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Anemia (**disease**)
Autoimmune **disease**
(autoimmune hemolytic anemia; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Immunity
(autoimmunity; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Lysophosphatidic acids
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(cell proliferation stimulated by; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Carcinoma
Myoblast
Pheochromocytoma
(cell; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Artery
(cerebral, vasoconstriction; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Uterus, neoplasm
(cervix; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Resolution (separation)
(chromatog.; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT Infection
(chronic active hepatitis; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)
IT **Inflammation**
Kidney, **disease**
(chronic glomerulonephritis; Edg **receptor modulators** for **treatment** of Edg

receptor-assocd. conditions)
IT Temperature effects, biological
(cold, transcomeal freezing; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Intestine, neoplasm
(colon; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Intestine, neoplasm
(colorectal; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Burn
(cutaneous; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Meninges
(disease, subarachnoid hemorrhage; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Uterus, neoplasm
(endometrium; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Blood vessel
(endothelium; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Epithelium
(epithelial cell; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Carcinoma
(epithelioid; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Sarcoma
(fibrosarcoma, cell; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Carcinoma
(hepatocellular; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Liver, neoplasm
(hepatoma; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Phosphatidylinositols
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydrolysis; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Fatty acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(level of; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)
IT Receptors

RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(lysophosphatidic acid; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Neoplasm
(metastasis; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Headache
(migraine; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Kidney, **disease**
(non-glomerular nephrosis; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Blood vessel, **disease**
(occlusion; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Egg
(oocyte, Xenopus laevis; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Xenopus laevis
(oocyte; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Ovary
(ovarian cell; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Actins
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(polymn.; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Intestine, neoplasm
(small; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Blood vessel, **disease**
(spasm; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Brain, **disease**
(stroke; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Hemorrhage
(subarachnoid; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Injury
(surface epithelial cell; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Interleukin 8
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**

(synthesis; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Lupus erythematosus
(systemic; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Purpura (**disease**)
(thrombocytopenic, chronic; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT **Inflammation**
Intestine, **disease**
(ulcerative colitis; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Endothelium
(vascular; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT Hepatitis
(viral, chronic active; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 182762-25-0, GenBank X83864 218763-60-1, GenBank AJ000479
259476-69-2, GenBank AF233092 262400-57-7, GenBank AF233090
384729-36-6, GenBank U78192 385223-15-4, GenBank AF011466
390105-18-7, GenBank AF034780 390174-36-4, GenBank AF233365
390523-03-2, GenBank AF317676 392101-34-7, GenBank AF127138
RL: **BSU (Biological study, unclassified)**; PRP (Properties); **BIOL (Biological study)**
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 473390-98-6
RL: FMU (Formation, unclassified); **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; FORM (Formation, nonpreparative); USES (Uses)
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 353273-74-2P 569655-94-3P 569655-95-4P 569655-96-5P
569656-23-1P 569656-24-2P
RL: **PAC (Pharmacological activity)**; PUR (Purification or recovery); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 94835-69-5P
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 7741-53-9P 40622-01-3P 173275-26-8P 304650-31-5P
311799-07-2P 312501-62-5P 312519-16-7P 331945-22-3P
334498-72-5P 342384-25-2P 353253-35-7P **353771-45-6P**

355000-90-7P 569656-08-2P 569656-09-3P 569656-10-6P
569656-11-7P 569656-12-8P 569656-13-9P 569656-14-0P
569656-15-1P 569656-16-2P 569656-17-3P 569656-18-4P
569656-19-5P 569656-20-8P 569656-21-9P 569656-25-3P
569656-26-4P 569656-27-5P 569656-29-7P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 49843-94-9 90212-73-0 107235-67-6 136382-28-0 171286-07-0
177360-28-0 292076-38-1 306764-68-1 309282-30-2 311773-65-6
312594-43-7 321679-76-9 322662-05-5 327167-87-3 329350-38-1
330630-42-7 331274-84-1 332161-39-4 337349-59-4 337469-26-8
337498-14-3 346699-98-7 353463-50-0 353793-15-4 364051-15-0
383164-60-1 389079-78-1 400064-03-1 569655-97-6 569655-98-7
569656-22-0 569656-28-6
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 50-30-6, 2,6-Dichlorobenzoic acid 50-45-3, 2,3-Dichlorobenzoic acid 70-11-1, 2-Bromoacetophenone 79-19-6, Thiosemicarbazide 83-38-5, 2,6-Dichlorobenzaldehyde 91-56-5, 1H-Indole-2,3-dione 93-17-4, 3,4-Dimethoxyphenylacetonitrile 93-55-0, Propiophenone 98-59-9, p-Toluenesulfonyl chloride 98-88-4, Benzoyl chloride 98-95-3, Nitrobenzene, reactions 100-65-2, N-Phenylhydroxylamine 108-31-6, Maleic anhydride, reactions 108-38-3, 1,3-Dimethylbenzene, reactions 120-72-9, Indole, reactions 123-11-5, p-Anisaldehyde, reactions 140-75-0, 4-Fluorobenzylamine 302-01-2, Hydrazine, reactions 363-58-6 372-31-6, Ethyl 4,4,4-trifluoroacetoacetate 406-00-8, 4-Fluorophenylhydroxylamine 434-75-3, 2-Chloro-6-fluorobenzoic acid 533-18-6, o-Tolyl acetate 556-90-1, Pseudothiohydantoin 619-05-6, 3,4-Diaminobenzoic acid 619-41-0, 2-Bromo-4'-methylacetophenone 829-20-9 1226-42-2, 4,4'-Dimethoxybenzil 1468-83-3, 3-Acetylthiophene 1476-23-9, Allyl isocyanate 1572-10-7 2642-63-9, 3',4'-Dichloroacetophenone 4506-71-2 5242-26-2 5351-85-9 6629-60-3, Ethylhydrazine oxalate 13100-05-5 13380-67-1 19541-95-8 23448-86-4 23821-37-6 36817-57-9 39151-19-4 64900-65-8, 2-Chlorobenzenesulfonyl isocyanate 72411-52-0 82799-44-8 89570-85-4 96799-03-0 96799-04-1 569656-04-8 **569656-05-9** 569656-06-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 5351-91-7P 5467-70-9P 6292-74-6P 7420-34-0P 7741-54-0P
43071-45-0P 76293-13-5P 82799-45-9P 86358-85-2P 91912-53-7P
112612-58-5P 113054-02-7P 149246-80-0P 149246-86-6P
208519-10-2P 208519-15-7P 329069-72-9P 502132-61-8P
569655-99-8P 569656-00-4P 569656-01-5P 569656-02-6P
569656-03-7P 569656-07-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 26993-30-6, Sphingosine-1-phosphate
RL: **BSU (Biological study, unclassified)**; **BIOL**

(Biological study)
(calcium mobilization stimulated by; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 60-92-4, Cyclic AMP
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(formation inhibition; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 7440-70-2, Calcium, biological studies
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(mobilization; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

IT 127464-60-2, Vascular endothelial growth factor
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(synthesis; Edg **receptor modulators** for **treatment** of Edg **receptor**-assocd. **conditions**)

L32 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:888719 HCAPLUS
DOCUMENT NUMBER: 137:384854
TITLE: Preparation of diaryl ureas as antiinflammatory agents
INVENTOR(S): Cirillo, Pier F.; Goldberg, Daniel R.; Hammach, Abdelhakim; Moss, Neil; Regan, John Robinson
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092576	A1	20021121	WO 2002-US14733	20020508
W: AE, AU, BG, BR, CA, CN, CO, CZ, EC, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2445003	AA	20021121	CA 2002-2445003	20020508
EP 1392661	A1	20040303	EP 2002-734324	20020508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
JP 2004530690	T2	20041007	JP 2002-589462	20020508
US 2003008868	A1	20030109	US 2002-143322	200205

US 6852717 B2 20050208 10
PRIORITY APPLN. INFO.: US 2001-291425P P 200105 16
WO 2002-US14733 W 200205 08

GI



I

AB The title diaryl ureas, useful in pharmaceutic compns. for **treating** a cytokine mediated **diseases** or **conditions** involving **inflammation** such as chronic **inflammatory diseases**, were prepd. Thus, **treating** 4-(2-chloropyrimidin-4-yloxy)naphthalen-1-ylamine with Et3N in DMF followed by addn. of Et4NCN, and **treatment** of the resulting nitrile with phosgene, and reacting the intermediate with 5-tert-butyl-o-anisidine afforded the urea I.

IT **476011-68-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of diaryl ureas as antiinflammatory agents)

RN 476011-68-4 HCAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[5-(1,1-dimethylethyl)-2-methoxy-3-nitrophenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IC ICM C07D239-34
ICS A61K031-505; C07D251-42; C07D239-47; C07D417-12; C07D401-12; C07D231-40; A61P029-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT **Inflammation**
(Crohn's **disease**, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)

IT Intestine, **disease**
(Crohn's, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)

IT Nervous system, **disease**

(Guillain-Barre syndrome, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)
IT Lung, **disease**
(chronic obstructive pulmonary **disease**, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)
IT Inflammation
Intestine, **disease**
(enterocolitis, **treatment** of necrotizing; prepn. of diaryl ureas as antiinflammatory agents)
IT Heart, **disease**
(failure, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)
IT Inflammation
Kidney, **disease**
(glomerulonephritis, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)
IT Heart, **disease**
(infarction, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)
IT Tumor necrosis factors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(inhibitors of TNF prodn.; prepn. of diaryl ureas as antiinflammatory agents)
IT Brain, **disease**
(stroke, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)
IT Bone resorption
Bone resorption inhibitors
(**treatment** of bone resorption **diseases**; prepn. of diaryl ureas as antiinflammatory agents)
IT Cytokines
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(**treatment** of cytokine mediated **disease** or **condition**; prepn. of diaryl ureas as antiinflammatory agents)
IT Skin, **disease**
(**treatment** of dermatoses with acute **inflammatory** components; prepn. of diaryl ureas as antiinflammatory agents)
IT Alzheimer's **disease**
Asthma
Atherosclerosis
Diabetes mellitus
Multiple organ failure
Multiple sclerosis
Pain
Psoriasis
Rheumatoid arthritis
Sepsis
(**treatment** of; prepn. of diaryl ureas as antiinflammatory agents)
IT Inflammation
Intestine, **disease**
(ulcerative colitis, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)
IT 285983-44-0P 473269-90-8P 473269-96-4P 473271-63-5P
473271-65-7P 473271-70-4P 473271-82-8P 473271-86-2P
473271-87-3P 473271-90-8P 473271-91-9P 473271-96-4P
473272-06-9P 473272-08-1P 473272-09-2P 473272-15-0P

473272-16-1P 476009-04-8P 476009-05-9P 476009-07-1P
476009-08-2P 476009-10-6P 476009-12-8P 476009-16-2P
476009-18-4P 476009-19-5P 476009-21-9P 476009-22-0P
476009-23-1P 476009-25-3P 476009-27-5P 476009-28-6P
476009-30-0P 476009-34-4P 476009-38-8P 476009-40-2P
476009-42-4P 476009-43-5P 476009-46-8P 476009-48-0P
476009-49-1P 476009-52-6P 476009-54-8P 476009-56-0P
476009-58-2P 476009-60-6P 476009-62-8P 476009-63-9P
476009-65-1P 476009-66-2P 476009-67-3P 476009-68-4P
476009-70-8P 476009-71-9P 476009-72-0P 476009-74-2P
476009-78-6P 476009-80-0P 476009-82-2P 476009-84-4P
476009-87-7P 476009-89-9P 476009-91-3P 476009-93-5P
476009-95-7P 476009-97-9P 476010-05-6P 476010-09-0P
476010-11-4P 476010-14-7P 476010-16-9P 476010-17-0P
476010-19-2P 476010-20-5P 476010-22-7P 476010-24-9P
476010-26-1P 476010-28-3P 476010-30-7P 476010-32-9P
476010-34-1P 476010-36-3P 476010-38-5P 476010-40-9P
476010-42-1P 476010-44-3P 476010-46-5P 476010-48-7P
476010-50-1P 476010-52-3P 476010-53-4P 476010-54-5P
476010-56-7P 476010-58-9P 476010-60-3P 476010-62-5P
476010-64-7P 476010-65-8P 476010-68-1P 476010-72-7P
476010-74-9P 476010-77-2P 476010-79-4P 476010-81-8P
476010-84-1P 476010-86-3P 476010-88-5P 476010-90-9P
476010-92-1P 476010-96-5P 476010-98-7P 476010-99-8P
476011-01-5P 476011-03-7P 476011-05-9P 476011-06-0P
476011-08-2P 476011-10-6P 476011-12-8P 476011-14-0P
476011-16-2P 476011-18-4P 476011-20-8P 476011-22-0P
476011-24-2P 476011-26-4P 476011-28-6P 476011-30-0P
476011-32-2P 476011-34-4P 476011-36-6P 476011-37-7P
476011-39-9P 476011-41-3P 476011-43-5P 476011-45-7P
476011-47-9P 476011-49-1P 476011-51-5P 476011-53-7P
476011-55-9P 476012-73-4P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of diaryl ureas as antiinflammatory agents)

IT 341-92-4P, 1-Fluoro-4-nitronaphthalene 341-95-7P, 4-Nitro-1-naphthalenediazonium tetrafluoroborate 473269-91-9P
473269-92-0P 476011-58-2P 476011-59-3P 476011-60-6P
476011-62-8P 476011-64-0P 476011-66-2P 476011-67-3P
476011-68-4P 476011-71-9P 476011-73-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of diaryl ureas as antiinflammatory agents)

L32 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:814851 HCAPLUS
DOCUMENT NUMBER: 137:310930
TITLE: Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
INVENTOR(S): Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 426 pp., Cont.-in-part of U.S. Ser. No. 663,780.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002156081	A1	20021024	US 2001-815310	20010322
US 6921763	B2	20050726		
US 6660744	B1	20031209	US 2000-663780	20000915
CA 2440724	AA	20021017	CA 2002-2440724	20020322
WO 2002080926	A1	20021017	WO 2002-US9104	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1385524	A1	20040204	EP 2002-746301	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1520298	A	20040811	CN 2002-810250	20020322
JP 2004531513	T2	20041014	JP 2002-578965	20020322
BR 2002005889	A	20041109	BR 2002-5889	20020322
ZA 2003006886	A	20040716	ZA 2003-6886	20030903
NO 2003004176	A	20031121	NO 2003-4176	20030919
BG 108269	A	20041230	BG 2003-108269	20031014
PRIORITY APPLN. INFO.:			US 1999-154620P P	19990917
			US 2000-663780 A2	20000915
			US 2001-815310 A	20010322

WO 2002-US9104 W
200203
22

OTHER SOURCE(S): MARPAT 137:310930
GI



I II

AB Title compds. I [wherein G = (un)substituted 5-6 membered (azahetero)aryl; R2 = H or (un)substituted trityl, cycloalkenyl, azaheteroaryl, or C6H4-4-CH2E; E = (un)substituted alkyl-OR, alkyl-CO2R, alkylheteroaryl, alkylheterocycloalkyl, or alkyl-NR2; R = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); R3 = independently H, OH, or (un)substituted alkyl, alkyl-CO, (hetero)aryl-CO, or alkoxy; or racemic diastereomeric mixts., optical isomers, pharmaceutically acceptable salts, prodrugs, and/or biol. active metabolites thereof] were prepd. For example, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine was coupled with 4-fluorobenzaldehyde in the presence of NaH in DMF to give 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde. **Treatment** of the 3-iodopyrazolopyrimidine with N-[2-methoxy-4-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide, Pd(PPh3)4, and Na2CO3 in H2O afforded the N-[4-(pyrazolopyrimidin-3-yl)phenyl]benzamide. Addn. of morpholine to the benzaldehyde in the presence of Na(AcO)3BH in dichloroethane produced II. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concn. of ≤ 50 μM. Certain compds. of the invention also significantly inhibited cdc2 or cellular VEGF-induced KDR tyrosine kinase phosphorylation at concns. of ≤ 50 μM. Thus, I are useful for the **treatment** of a wide variety of **disease** states ameliorated by the inhibition of protein tyrosine kinase activity essential for angiogenic processes (no data).

IT **330793-97-0P**, N-(4-Bromophenyl)-N-(4-ethyl-1,3-thiazol-2-yl)amine **330793-98-1P**, N-(4-Ethyl-1,3-thiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT (Reactant or reagent)
(intermediate; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

RN 330793-97-0 HCAPLUS
CN 2-Thiazolamine, N-(4-bromophenyl)-4-ethyl- (9CI) (CA INDEX NAME)



RN 330793-98-1 HCAPLUS
CN 2-Thiazolamine, 4-ethyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (9CI) (CA INDEX NAME)



IC ICM A61K031-519
ICS C07D487-04
INCL 514247000
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT **Inflammation**
(Crohn's **disease**; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Tyrosine kinase receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(Tie, TIE-2; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Tyrosine kinase receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(Tie-1; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(VEGF, VEGF-B, VEGF-C, VEGF-D, or VEGF-E, combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Antibodies and Immunoglobulins
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(antiiodotypic, combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
RL: **BSU (Biological study, unclassified)**; **BIOL**

(Biological study)
(c-fgr; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Angiogenic factors
Hepatocyte growth factor
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(fyn; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(gene hck; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(gene lyn; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Intestine, **disease**
(**inflammatory**; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(p62c-yes; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Anemia (disease)
Angiogenesis
Angiogenesis inhibitors
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Antibacterial agents
Antidiabetic agents
Antiglaucoma agents
Antirheumatic agents
Antitumor agents
Antiulcer agents
Asthma
Atherosclerosis
Cardiovascular agents
Cardiovascular system, disease
Cirrhosis
Contraceptives
Eye, disease
Fibrosis
Fungicides
Glaucoma (disease)
Hematopoiesis
Hodgkin's disease
Human
Human herpesvirus
Human immunodeficiency virus 1

Hypoxia
Ischemia
Leukemia
Lyme disease
Lymphoma
Melanoma
Multiple myeloma
Multiple sclerosis
Mycosis
Necrosis
Neoplasm
Osteoarthritis
Parapoxvirus
Preeclampsia
Protozoa
Protozoacides
Psoriasis
Radiation
Rheumatoid arthritis
Sarcoidosis
Sarcoma
Sepsis
Sickle cell anemia
Transplant rejection
Ulcer
Wound
(prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Hepatocyte growth factor receptors
Insulin-like growth factor I receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Fibroblast growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 1; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type VEGFR-1; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type VEGFR-2; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type VEGFR-3; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Platelet-derived growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(α; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Platelet-derived growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(β; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 106096-92-8, FGF-1 106096-93-9, FGF-2
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330793-90-3P 330793-91-4P, cis-4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzaldehyde 330793-95-8P, N-(6-Chloro-1,3-benzothiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-96-9P **330793-97-0P**, N-(4-Bromophenyl)-N-(4-ethyl-1,3-thiazol-2-yl)amine **330793-98-1P**, N-(4-Ethyl-1,3-thiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-99-2P, 4-Amino-1-(4-nitrophenyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 330794-00-8P, 3-Iodo-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-01-9P, 4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzaldehyde 330794-02-0P, 1-Bromo-2-fluoro-5-methoxy-4-nitrobenzene 330794-03-1P, 4-Bromo-5-fluoro-2-methoxyaniline 330794-04-2P, tert-Butyl N-(4-bromo-5-fluoro-2-methoxyphenyl)carbamate 330794-05-3P, tert-Butyl N-[5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 330794-06-4P, 3-Iodo-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-08-6P, trans-tert-Butyl N-[2-[[[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]]anilino]methyl]phenyl]carbamate acetate 330794-09-7P, tert-Butyl N-(4-bromo-2-chlorophenyl)carbamate 330794-10-0P, tert-Butyl N-[2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 330794-11-1P, Trans-tert-Butyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]carbamate 330794-12-2P, Trans-3-(4-Amino-3-chlorophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-13-3P, 1-(4-Bromophenyl)-3-methyl-5-phenyl-4,5-dihydro-1H-pyrazole 330794-14-4P, 3-Methyl-5-phenyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-4,5-dihydro-1H-pyrazole 330794-15-5P 330794-17-7P, tert-Butyl N-[3-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-oxopropyl]-N-(2-hydroxyethyl)carbamate 330794-18-8P, tert-Butyl N-[3-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-oxopropyl]-N-(2-hydroxyethyl)carbamate 330794-19-9P, tert-Butyl 2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetate 330794-20-2P, Benzyl 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 330794-21-3P, Benzyl 4-[4-amino-3-[4-[(tert-butoxycarbonyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-22-4P, Benzyl 4-[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-23-5P, Trans-Benzyl 4-[4-amino-3-[3-methoxy-4-[[(2-phenylcyclopropyl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-24-6P, Benzyl 4-[4-amino-3-[3-methoxy-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-25-7P, tert-Butyl 4-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-4-hydroxy-1-piperidinecarboxylate 330794-26-8P, tert-Butyl

4-[[4-amino-3-[4-[[(benzyloxy)carbonyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-27-9P, tert-Butyl 4-[[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-28-0P, Trans-tert-Butyl 4-[[4-amino-3-[3-methoxy-4-[[(2-phenylcyclopropyl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-29-1P 461696-99-1P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde 461697-00-7P 461697-02-9P, 2-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-ethanol 461697-03-0P, [2-[4-Amino-3-[3-methoxy-4-[[(1-methyl-1H-indol-2-yl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl] methanesulfonate 461697-30-3P, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-methyl-1H-2-indolecarboxamide 461697-31-4P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-34-7P, N-[4-[4-Amino-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-36-9P, N-[4-[4-Amino-1-[2-[(2-hydroxyethyl)amino]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-38-1P, N-[4-[4-Amino-1-[2-(dimethylamino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-40-5P, N-[4-[4-Amino-1-[2-(1H-1-imidazolyl)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-53-0P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-cyclopenten-1-ol 461697-57-4P, tert-Butyl 4-[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461697-66-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-98-3P, 3-Iodo-1-(1-methyl-3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-01-1P, 3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-02-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethyl)benzamide 461698-04-4P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethoxy)benzamide 461698-10-2P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylcarbonyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide 461698-14-6P 461698-21-5P 461698-24-8P 461698-45-3P, tert-Butyl 4-[4-amino-3-(4-aminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461698-46-4P, tert-Butyl 4-[4-amino-3-[4-[[(benzyloxy)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461698-79-3P, 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-1H-benzo[d]isothiazole-1,1-dione 461698-84-0P, N-(4-Bromophenyl)-2-fluoro-1-benzenecarbothioamide 461698-85-1P 461698-86-2P, N-(Benzo[d]isoxazol-3-yl)-N-(4-bromophenyl)amine 461698-87-3P, N-(Benzo[d]isoxazol-3-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 461698-94-2P, Benzenecarboximidic acid, N-(4-bromophenyl)-2-fluoro-, hydrazide 461698-95-3P, N-(4-Bromophenyl)-N-(1H-3-indazolyl)amine 461698-96-4P, N-(1H-3-Indazolyl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 461698-99-7P, N-(4-Bromophenyl)-2-fluoro-4-(trifluoromethyl)benzamide 461699-00-3P, N-(4-Bromophenyl)-2-fluoro-4-(trifluoromethyl)-1-benzenecarbothioamide 461699-01-4P, Benzenecarboximidic acid, N-(4-bromophenyl)-2-fluoro-4-(trifluoromethyl)-, hydrazide 461699-02-5P, N-(4-Bromophenyl)-N-[6-(trifluoromethyl)benzo[d]isoxazol-3-yl]amine 461699-03-6P,

N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-N-[6-(trifluoromethyl)benzo[d]isoxazol-3-yl]amine 461699-05-8P, 3-Iodo-1-[1-(2-methoxyethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-06-9P 461699-09-2P, 3-Iodo-1-(3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 461699-13-8P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 461699-14-9P, tert-Butyl 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461699-18-3P, 3-Iodo-1-(3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dihydrochloride 461699-19-4P, 9H-Fluoren-9-ylmethyl N-[2-[3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidino]-1,1-dimethyl-2-oxoethyl]-N-methylcarbamate 461699-20-7P 461699-22-9P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)azetane-1-carboxylate 461699-23-0P, tert-Butyl 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]azetane-1-carboxylate 461699-27-4P, 1-(3-Azetanyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461699-28-5P, 3-Iodo-1-(1-methyl-3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-30-9P, 2-(4-Bromoanilino)-1,3-benzoxazole-5-carbonitrile 461699-31-0P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-1,3-benzoxazole-5-carbonitrile 461699-34-3P, 2-Amino-4-(trifluoromethoxy)phenol 461699-35-4P, N-(4-Bromophenyl)-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-36-5P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-38-7P, N-(4-Bromophenyl)-5-ethyl-1,3-benzoxazol-2-amine 461699-39-8P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-ethyl-1,3-benzoxazol-2-amine 461699-41-2P, Cis-1-[4-(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-42-3P, trans-1-[4-(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-46-7P, N-(4-Bromophenyl)-5-chloro-1,3-benzoxazol-2-amine 461699-47-8P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-chloro-1,3-benzoxazol-2-amine 461699-48-9P, N-(4-Bromophenyl)-5-methyl-1,3-benzoxazol-2-amine 461699-49-0P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-methyl-1,3-benzoxazol-2-amine 461699-50-3P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-51-4P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-52-5P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-(methylamino)cyclohexyl]- 461699-61-6P, N-(4-Bromophenyl)-N-(5,7-dimethyl-1,3-benzothiazol-2-yl)amine 461699-78-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461699-82-1P, 2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline bismaleate 461701-01-9P, 3-Iodo-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monohydrochloride 461701-02-0P, 3-Iodo-1-(1-methyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-03-1P, N-(4-Bromophenyl)-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-05-3P, 3-Iodo-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-07-5P, N-(4-Bromo-2-fluorophenyl)-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-08-6P, N-[2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-10-0P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]imidazo[1,2-a]pyridine 461701-12-2P, 1-[3-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydro-1H-pyrrol-1-yl]-2-(dimethylamino)-1-ethanone 461701-14-4P, 9H-Fluoren-9-ylmethyl N-[2-[3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydro-1H-pyrrol-1-yl]-1,1-dimethyl-2-oxoethyl]-

N-methylcarbamate 461701-15-5P 461701-17-7P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinecarboxylate 461701-18-8P, tert-Butyl 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinecarboxylate 461701-21-3P, N-(4-Bromophenyl)-7-isopropyl-1,3-benzoxazol-2-amine 461701-22-4P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-7-isopropyl-1,3-benzoxazol-2-amine 461701-38-2P, 4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzaldehyde 461701-54-2P 461702-08-9P, 1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-benzo[d]imidazole 461702-16-9P, N-[4-[4-Amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-21-6P 461702-22-7P, N-[4-[4-Amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-24-9P, N-[4-[4-Amino-1-[1-(2,2-difluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-39-6P, 1-(3-Bromopropyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-40-9P, 3-Iodo-1-[3-(4-methylpiperazino)propyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-42-1P, 3-Iodo-1-(3-morpholinopropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-44-3P, 1-[3-(1H-1-Imidazolyl)propyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-55-6P, Cyclohexanecarboxylic acid, 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-, ethyl ester, cis- 461702-59-0P, N-(4-Bromophenyl)-N-(2-pyrimidinyl)amine 461702-62-5P, 1-(2-Chloro-4-pyridyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-63-6P 461702-66-9P, (S)-tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 461702-68-1P 461702-69-2P, (S)-3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-98-7P, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-3-indolecarboxamide 471925-68-5P, 3-(4-Phenoxyphenyl)-1-(3-propylidenecyclobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-82-3P 471925-83-4P, N-[4-[4-Amino-1-[1-(1-methyl-4-piperidyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]aniline 471925-90-3P, 1-[1-(1H-2-Imidazolylmethyl)-4-piperidyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-91-4P, tert-Butyl N-[4-[4-amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 471925-92-5P, 3-(4-Amino-3-methoxyphenyl)-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-99-2P, 2-Fluoro-6-[(2-methoxyethyl)amino]benzonitrile 471927-37-4P, 5-Ethoxy-3-methyl-1-[4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl]-1H-pyrazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 144697-17-6 144941-35-5, Blk protein kinase
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-88-1P, 1-(1-Benzyl-4-piperidinyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or

reagent); USES (Uses)
(protein kinase inhibitor.; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330788-71-1P 330788-72-2P 330788-73-3P 330788-74-4P
330788-75-5P 330788-76-6P 330788-77-7P 330788-78-8P
330788-79-9P 330788-80-2P 330788-81-3P 330788-82-4P
330788-83-5P 330788-84-6P 330788-85-7P 330788-86-8P
330788-87-9P 330788-88-0P 471925-84-5P
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent)
(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-90-5P, 3-(4-Phenoxyphenyl)-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-11-3P 330786-13-5P, 4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanone 330786-15-7P, tert-Butyl cis-4-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]-1-piperazinecarboxylate 330786-16-8P, tert-Butyl trans-4-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]-1-piperazinecarboxylate 330786-24-8P, 3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-58-8P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-63-5P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-67-9P 330787-59-2P 330787-63-8P 330787-67-2P, 3-[4-(Benzyloxy)phenyl]-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-88-7P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzonitrile 330787-91-2P, Cis-3-[4-[2-(Aminomethyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-01-7P 330788-03-9P, 1-(3-Azetanyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-11-9P, Cis-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 330788-15-3P, Trans-1-[3-[(Benzyloxy)methyl]cyclobutyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-68-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide 330788-92-6P, Ethyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330789-03-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 330789-23-6P, cis-3-[4-(Benzyloxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-29-2P, trans-3-[4-(Benzyloxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-32-7P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-75-8P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1-phenyl-1-ethanone diacetate 330790-07-3P, Methyl 5-[4-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]-2-furoate 330790-15-3P, Cis-2-[3-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzaldehyde 330790-20-0P 330790-21-1P 330790-70-0P, Trans-2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]acetic acid

330790-74-4P 330790-88-0P, Methyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330790-98-2P, Ethyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330790-99-3P, Methyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330791-04-3P, Methyl 4-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanoate 330791-51-0P, tert-Butyl N-[4-[4-amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330791-57-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine dihydrochloride 330791-68-9P 330791-88-3P, tert-Butyl N-[4-[4-amino-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330791-99-6P, trans-3-(4-Amino-2-fluoro-5-methoxyphenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-01-3P, tert-Butyl N-[4-[4-amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330792-23-9P, Trans-3-[4-[(2-Aminobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-33-1P, Trans-3-[4-(5-Ethoxy-1H-1-pyrazolyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-43-3P, 2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetic acid 330792-49-9P, 3-[3-Methoxy-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461697-04-1P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-42-7P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-45-0P, Cis-Ethyl 3-[[4-[4-amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoate 461697-46-1P, Trans-Ethyl 3-[[4-[4-amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoate 461697-49-4P, N-[4-(4-Amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-50-7P, N-[4-(4-Amino-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-52-9P, N-[4-[4-Amino-1-(4-hydroxy-2-cyclopentenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461698-20-4P 461698-28-2P, trans-3-[4-[[(2-Methoxy-3-pyridyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461699-12-7P 461701-33-7P, 3-(4-Amino-3-methoxyphenyl)-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-35-9P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide 461702-45-4P, N-[4-[4-Amino-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-54-5P, cis-Ethyl 4-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylate 471926-42-8P 471927-18-1P, trans-tert-Butyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]carbamate
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL**

(Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-92-7P, 1-[1-(1-Methyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330785-96-1P, 1-[1-(1-Isopropyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330785-98-3P, 1-[1-(4-Piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-02-2P, 1-[trans-4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-06-6P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-08-8P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide dimaleate 330786-18-0P, Cis-3-(4-Phenoxyphenyl)-1-(4-piperazinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-20-4P, Trans-3-(4-Phenoxyphenyl)-1-(4-piperazinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-25-9P, 4-Amino-1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine 330786-27-1P, 3-(4-Phenoxyphenyl)-1-(tetrahydropyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 330786-29-3P 330786-30-6P 330786-33-9P 330786-36-2P, Cis-3-(4-Anilinophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-40-8P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-45-3P, Trans-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate dimaleate 330786-47-5P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzamide dimaleate 330786-49-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-phenylsulfamide dimaleate 330786-51-1P 330786-53-3P 330786-55-5P 330786-57-7P 330786-59-9P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-61-3P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-64-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-66-8P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-69-1P 330786-71-5P 330786-72-6P 330786-73-7P 330786-75-9P 330786-77-1P 330786-78-2P, Cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide 330786-79-3P, Cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzoic acid 330786-81-7P 330786-83-9P 330786-85-1P, cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide diacetate 330786-86-2P, Cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzoic acid 330786-88-4P 330786-89-5P, Cis-N-[3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzyl]benzamide 330786-91-9P 330786-93-1P, Cis-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo-[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate dimaleate 330786-95-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-

1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-benzylurea acetate 330786-97-5P, Cis-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330786-99-7P 330787-03-6P, Trans-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330787-05-8P, Trans-3-[4-[(2,6-Dimethoxybenzyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-07-0P, Trans-3-[4-[(2-Chloro-6-fluorobenzyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-09-2P, Cis-3-[4-(Benzylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-11-6P, Cis-3-[4-[(2-Methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-13-8P 330787-14-9P, Cis-3-[4-[(2-Chlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-15-0P, Cis-3-[4-[(2-Bromobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-16-1P, Cis-3-[4-[(2-Ethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-17-2P, Cis-3-[4-[[2-(Difluoromethoxy)benzyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-19-4P 330787-21-8P 330787-23-0P, Cis-2-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]benzonitrile diacetate 330787-24-1P, Cis-3-[4-[(2,6-Difluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-26-3P, Cis-3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330787-27-4P, Cis-3-[4-[[2-Fluoro-6-(trifluoromethyl)benzyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-29-6P, Cis-3-[4-[(2-Fluoro-6-methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-30-9P, Cis-3-[4-[(2,6-Dichlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-32-1P, Cis-3-[4-[(2,6-Dimethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-34-3P, Cis-3-[4-[(2-Fluoro-4-methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-38-7P, Cis-3-[4-[[(1-Methyl-1H-indol-2-yl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-40-1P, Trans-3-[4-(Benzylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330787-42-3P, Trans-3-[4-[(2-Methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-44-5P, Trans-3-[4-[(2,6-Dimethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-46-7P, Trans-3-[4-[(2-Chlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-48-9P, Trans-3-[4-[(2-Bromobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330787-50-3P 330787-52-5P 330787-53-6P 330787-55-8P, Cis-3-[4-[Benzyl(methyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-57-0P, Cis-3-[4-[Benzyl(ethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine

diacetate 330787-61-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(phenethylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-65-0P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(3-phenylpropyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-66-1P, 1-Cyclopentyl-3-[4-(3-methoxyphenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-68-3P, 1-Cyclopentyl-3-[4-(4-fluorophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-69-4P, 1-Cyclopentyl-3-[4-[3-(trifluoromethyl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-70-7P, 1-Cyclopentyl-3-[4-(3-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-71-8P, 1-Cyclopentyl-3-[4-[4-(trifluoromethoxy)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-72-9P, 1-Cyclopentyl-3-[4-[4-(trifluoromethyl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-73-0P, 3-[3-(Benzyloxy)phenyl]-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-75-2P, Cis-3-[4-[(3-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-77-4P, Cis-3-[4-[(2-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-79-6P, Cis-3-[4-[(4-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-81-0P, Cis-3-[4-[(3-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-83-2P, Cis-3-[4-[(4-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-84-3P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(3-pyridylmethyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-85-4P, Cis-3-[4-[(2-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-87-6P, Cis-3-[3-(Benzylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-90-1P, Cis-2-[3-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide triacetate 330787-93-4P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-95-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-96-7P, Cis-3-[4-(2-Aminophenoxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-97-8P, [2-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-phenoxyphenyl]methanol 330787-99-0P 330788-02-8P 330788-04-0P, 2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanol 330788-06-2P, 1-[1-(2-Methoxyethyl)-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330788-07-3P, 1-[1-[2-(2-Methoxyethoxy)ethyl]-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-08-4P, 1-[1-(1-Methyl-4-piperidyl)-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-09-5P, 1-[1-[(1-Methyl-1H-imidazol-2-yl)methyl]-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-10-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanone 330788-12-0P, Trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 330788-14-2P 330788-16-4P, trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclobutanemethanol 330788-18-6P 330788-19-7P 330788-20-0P 330788-21-1P 330788-23-3P 330788-24-4P 330788-25-5P 330788-26-6P 330788-27-7P

330788-28-8P 330788-29-9P 330788-30-2P 330788-31-3P 330788-32-4P 330788-34-6P, cis-3-[4-[(4-Bromobenzyl)amino]-3-fluorophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330788-46-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(2,4-difluorophenyl)urea 330788-47-1P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methoxyphenyl)urea 330788-48-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methoxyphenyl)urea monoacetate 330788-50-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-51-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-52-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N-ethyl-N'-(3-methylphenyl)urea 330788-53-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N-benzyl-N'-(2,4-difluorophenyl)urea 330788-54-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-N'-(3-methylphenyl)urea 330788-55-1P, N-[4-[4-Amino-1-[1-[2-(dimethylamino)acetyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-57-3P, N-[4-[4-Amino-1-[1-[3-(diethylamino)propanoyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-58-4P, N-[4-[4-Amino-1-[1-[2-(methylamino)acetyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-60-8P, N-[4-[4-Amino-1-[1-[3-[(2-hydroxyethyl)amino]propanoyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-61-9P 330788-62-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-2-carboxamide 330788-63-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-1H-indene-2-carboxamide 330788-64-2P 330788-65-3P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 330788-66-4P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-3-carboxamide 330788-67-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330788-69-7P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide trimaleate 330788-70-0P 330788-89-1P 330788-90-4P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(phenethylamino)(phenyl)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-91-5P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-93-7P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330788-94-8P, N-[4-[4-Amino-1-[2-cyano-4-(4-methylpiperazino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330788-95-9P, cis-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-96-0P, trans-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-97-1P,

cis-N-Benzyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-98-2P, cis-N-Phenethyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-99-3P, cis-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 330789-00-9P, cis-N-Phenethyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 330789-02-1P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide trimaleate 330789-04-3P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide trimaleate 330789-06-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide trimaleate 330789-08-7P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide trimaleate 330789-09-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-13-4P, 1-[1-(1H-Imidazol-2-ylmethyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-15-6P, 1-[1-(1-Methyl-4-piperidyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330789-16-7P, N-[4-[4-Amino-1-[1-(1H-imidazol-2-ylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-24-7P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile 330789-26-9P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(4-methylphenyl)sulfanyl]benzonitrile trimaleate 330789-28-1P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-(2-pyridylsulfanyl)benzonitrile dimaleate 330789-31-6P, trans-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile trimaleate 330789-33-8P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide trimaleate 330789-34-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N-methyl-3-phenylpropanamide 330789-35-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide trimaleate 330789-37-2P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino](4-methylpiperazino)methanone dimaleate 330789-39-4P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide trimaleate 330789-40-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethyl)benzamide 330789-41-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethoxy)benzamide 330789-42-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethoxy)benzamide 330789-43-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-

methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 330789-44-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethyl)benzamide 330789-46-3P 330789-48-5P, Cis-3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330789-50-9P 330789-52-1P, Trans-3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330789-56-5P, Cis-2-[2-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]phenoxy]acetic acid diacetate 330789-58-7P, Cis-3-[4-[(2-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-60-1P, Cis-3-[4-[[(5-Methyl-2-furyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-62-3P, Cis-3-[4-[(3-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-64-5P 330789-66-7P

, Trans-3-[4-[(2-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-68-9P, 3-[4-[[(5-Methyl-2-furyl)methyl]amino]phenyl]-1-[1-(1-methyl-4-piperidyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330789-70-3P 330789-71-4P 330789-77-0P 330789-79-2P 330789-81-6P 330789-83-8P 330789-85-0P 330789-86-1P 330789-88-3P 330789-90-7P 330789-92-9P 330789-93-0P 330789-96-3P 330789-98-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-2-methyl-2-phenylpropanamide diacetate 330790-00-6P 330790-02-8P 330790-03-9P 330790-05-1P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzoxazol-2-amine diacetate 330790-06-2P, 2-[4-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]acetamide 330790-08-4P, 5-[4-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]-2-furoic acid 330790-09-5P, 1-Cyclopentyl-3-[4-(3-thienyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330790-11-9P 330790-12-0P, Cis-3-[3-[Di(2-furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330790-14-2P 330790-18-6P, (2S)-3-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]propane-1,2-diol 330790-19-7P, (2R)-3-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]propane-1,2-diol 330790-22-2P 330790-23-3P, N-Methyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-24-4P, N,N-Dimethyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-25-5P, N-Isopropyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-26-6P, N-(3-Hydroxypropyl)-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-27-7P 330790-28-8P, N-Benzyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-30-2P, 2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-morpholino-1-ethanone 330790-31-3P, N-(3-Methyl-5-isoxazolyl)-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-34-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-hydroxyethyl)amino]-1-ethanone 330790-35-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-

1-azetanyl]-2-[(2-methoxyethyl)amino]-1-ethanone 330790-36-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(3-hydroxypropyl)amino]-1-ethanone 330790-37-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2,3-dihydroxypropyl)amino]-1-ethanone 330790-38-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(tetrahydro-2-furanylmethyl)amino]-1-ethanone 330790-39-1P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-piperidinoethyl)amino]-1-ethanone 330790-40-4P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[2-(dimethylamino)ethyl](methyl)amino]-1-ethanone 330790-42-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[2-(dimethylamino)ethyl]amino]-1-ethanone acetate 330790-43-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[methyl(1-methyl-4-piperidyl)amino]-1-ethanone 330790-44-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-morpholinoethyl)amino]-1-ethanone
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330790-45-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(3-morpholinopropyl)amino]-1-ethanone 330790-46-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[3-(1H-1-imidazolyl)propyl]amino]-1-ethanone 330790-47-1P, 1-[3-[[2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-oxoethyl]amino]propyl]-2-pyrrolidinone 330790-48-2P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(4-hydroxypiperidino)-1-ethanone 330790-49-3P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(hydroxymethyl)piperidino]-1-ethanone 330790-51-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-morpholino-1-ethanone 330790-52-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(4-methylpiperazino)-1-ethanone 330790-53-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(piperid-1-yl)piperidino]-1-ethanone 330790-54-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(1H-4-imidazolyl)-1-ethanone 330790-56-2P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(methylamino)-1-ethanone acetate 330790-58-4P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(dimethylamino)-1-ethanone acetate 330790-59-5P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-(diethylamino)-1-propanone 330790-61-9P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(methylamino)-1-ethanone acetate 330790-62-0P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-64-2P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-(diethylamino)-1-propanone acetate 330790-66-4P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-morpholino-1-ethanone acetate 330790-68-6P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(4-methylpiperazino)-1-ethanone acetate 330790-69-7P, Cis-2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-

hydroxycyclohexyl]acetic acid 330790-71-1P, [3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-(hydroxymethyl)cyclobutyl]methanol 330790-72-2P 330790-73-3P 330790-75-5P 330790-76-6P 330790-77-7P 330790-79-9P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-5-chloro-2-thiophenesulfonamide maleate 330790-80-2P, 1-[4-[4-Amino-3-[4-(1,3-benzoxazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-81-3P, 1-[4-[4-Amino-3-[4-(1,3-benzothiazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-82-4P, N-[4-[4-Amino-1-(2-morpholino-2-oxoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330790-83-5P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)-2-oxoethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330790-84-6P, N-((1R,2S)-2-Hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-85-7P, N-((1S,2S)-2-Hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-86-8P 330790-87-9P 330790-89-1P, 2-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetic acid 330790-90-4P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-91-5P, N-[2-(Diethylamino)ethyl]-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-92-6P, 2-(Dimethylamino)ethyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330790-93-7P, N-[3-(Dimethylamino)propyl]-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-94-8P, 2-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-96-0P, N-[4-[4-Amino-1-(2-morpholino-2-oxoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330790-97-1P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)-2-oxoethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330791-00-9P, 2-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 330791-01-0P 330791-02-1P 330791-03-2P, Ethyl 4-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanoate 330791-05-4P, 4-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanamide 330791-06-5P 330791-07-6P 330791-08-7P, 2-[4-Amino-3-[4-(1,3-benzoxazol-2-ylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-5-(4-methylpiperazino)benzonitrile 330791-09-8P, Ethyl 2-[4-amino-3-[4-(1,3-benzothiazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330791-10-1P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzoxazol-2-amine 330791-11-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzothiazol-2-amine 330791-12-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzothiazol-2-amine 330791-13-4P, Trans-N-[4-[4-Amino-1-[4-(4-

methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzoxazol-2-amine 330791-14-5P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzoxazol-2-amine 330791-15-6P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzothiazol-2-amine 330791-16-7P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-methyl-1,3-benzoxazol-2-amine 330791-17-8P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-chloro-1,3-benzoxazol-2-amine 330791-18-9P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-1,3-benzoxazol-2-amine 330791-19-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 330791-20-3P 330791-21-4P 330791-23-6P 330791-24-7P 330791-25-8P 330791-26-9P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzyl]-N'-(3-methylphenyl)urea 330791-27-0P 330791-28-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 330791-30-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide trimaleate 330791-32-7P 330791-33-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]thiophene-2-carboxamide 330791-34-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-thiophenecarboxamide 330791-35-0P 330791-37-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-3-phenylbutanamide trimaleate 330791-38-3P 330791-39-4P 330791-40-7P 330791-43-0P 330791-44-1P 330791-46-3P 330791-48-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide trimaleate 330791-50-9P 330791-52-1P, 3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[1-(1-methyl-4-piperidinyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330791-54-3P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenylcyclopropane-1-carboxamide dimaleate 330791-58-7P 330791-59-8P 330791-60-1P 330791-61-2P 330791-62-3P 330791-63-4P 330791-64-5P 330791-65-6P 330791-66-7P 330791-67-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzyl]-5-methyl-1,3-thiazol-2-amine 330791-69-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dichloro-1,3-benzoxazol-2-amine 330791-70-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-methyl-1,3-benzoxazol-2-amine 330791-71-4P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-chloro-1,3-benzoxazol-2-amine 330791-72-5P 330791-73-6P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 330791-74-7P, N-[4-[4-Amino-1-[2-cyano-4-(4-methylpiperazino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330791-75-8P, cis-N-[4-[4-Amino-1-[4-(4-

methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-chloro-1,3-benzothiazol-2-amine 330791-76-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-methoxy-1,3-benzothiazol-2-amine 330791-77-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-ethyl-1,3-thiazol-2-amine 330791-78-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4,5-dimethyl-1,3-thiazol-2-amine 330791-79-2P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-phenyl-1,3-thiazol-2-amine 330791-80-5P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-(4-methylphenyl)-1,3-thiazol-2-amine 330791-81-6P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-4-phenyl-1,3-thiazol-2-amine 330791-83-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-phenylbutanamide trimaleate 330791-85-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamidetrimaleat 330791-87-2P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3S)-3-phenylbutanamide trimaleate 330791-89-4P, 4-Amino-3-(4-amino-3-methoxyphenyl)-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidine 330791-91-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 330791-93-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide dimaleate 330791-94-1P, 3-Phenyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330791-95-2P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-phenylbutanamide 330791-96-3P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]methanol 330791-97-4P, 1-[4-[(4-Methylpiperazino)methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-00-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide 330792-03-5P, Trans-3-[4-[(2-Chlorobenzyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-05-7P, Trans-3-[3-Methoxy-4-[(1,3-thiazol-2-ylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-09-1P, Trans-3-[3-Methoxy-4-[(2-thienylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-11-5P, Trans-3-[3-Methoxy-4-[[(5-methyl-2-thienyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-13-7P, Trans-3-[4-[[(5-Chloro-2-thienyl)methyl]amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-15-9P, Trans-3-[3-Methoxy-4-[[(2-methyl-1,3-thiazol-4-yl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-19-3P, Trans-3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-25-1P 330792-27-3P 330792-29-5P 330792-31-9P, Trans-3-[4-(3-Methyl-5-phenyl-1H-1-pyrazolyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-35-3P 330792-37-5P, 2-(2-Amino-1H-1-

imidazolyl)-1-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanone acetate 330792-38-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-[(2-hydroxyethyl)amino]-1-propanone 330792-40-0P, 2-(2-Amino-1H-1-imidazolyl)-1-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-1-ethanone acetate 330792-41-1P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-[(2-hydroxyethyl)amino]-1-ethanone 330792-42-2P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-[(2-hydroxyethyl)amino]-1-propanone 330792-46-6P, Trans-N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide maleate 330792-48-8P, trans-N-[4-[4-Amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide 330792-50-2P, 3-[3-Methoxy-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-52-4P, trans-N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylcyclopropane-1-carboxamide 330792-54-6P 330792-55-7P 330792-56-8P, 1-(Aminomethyl)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 461697-05-2P, N-[4-[4-Amino-1-[4-(morpholinomethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-07-4P, N-[4-[4-Amino-1-[4-[(4-hydroxypiperidino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-08-5P, N-[4-[4-Amino-1-[4-[[4-(2-hydroxyethyl)piperazino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-10-9P, N-[4-[4-Amino-1-[4-[[4-(2-hydroxyethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461697-12-1P, N-[4-[4-Amino-1-[4-[[3-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-14-3P, N-[4-[4-Amino-1-[4-[[2-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-15-4P, N-[4-[4-Amino-1-[4-[[(2-morpholinoethyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-17-6P, N-[4-[4-Amino-1-[4-[[4-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461697-18-7P, N-[4-[4-Amino-1-[4-[[4-(2-methoxyethyl)piperazino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-19-8P 461697-20-1P 461697-21-2P, N-[4-[4-Amino-1-[4-[[[3-(1H-1-imidazolyl)propyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-22-3P, N-[4-[4-Amino-1-[4-[[(4-hydroxybutyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-23-4P, N-[4-[4-Amino-1-[4-[[(3-methoxypropyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-25-6P, N-[4-[4-Amino-1-[4-[[[3-(dimethylamino)propyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-26-7P, L-Histidine, N-[[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]methyl]-, methyl ester 461697-27-8P, N-[4-[4-Amino-1-[4-[[(2-

methoxyethyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-28-9P, N-[4-[4-Amino-1-[4-[[[2-(dimethylamino)ethyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-29-0P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-32-5P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide trimaleate 461697-35-8P, N-[4-[4-Amino-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461697-37-0P, N-[4-[4-Amino-1-[2-[(2-hydroxyethyl)amino]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide monomaleate 461697-39-2P, N-[4-[4-Amino-1-[2-(dimethylamino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide monomaleate 461697-41-6P 461697-43-8P, Cis-N-[4-[4-Amino-1-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-44-9P, Trans-N-[4-[4-Amino-1-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-47-2P, Cis-3-[[4-[4-Amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoic acid 461697-48-3P, Trans-3-[[4-[4-Amino-3-[3-methoxy-4-[(2-methoxy-4-trifluoromethylbenzoyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoic acid 461697-51-8P, N-[4-(4-Amino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-54-1P, N-[4-[4-Amino-1-(3-hydroxycyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-56-3P, 1H-Indole-1-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461697-59-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(trifluoromethoxy)-, monoacetate 461697-61-0P, Benzenebutanamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461697-63-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methyl-, monoacetate 461697-65-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methoxy-, monoacetate 461697-67-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, monoacetate 461697-69-8P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)-, monoacetate 461697-71-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461697-73-4P
, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methoxy-, monoacetate 461697-75-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-fluoro-, monoacetate 461697-77-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-chloro-, monoacetate 461697-79-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-chloro-, monoacetate 461697-81-4P,

1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-methoxy-, monoacetate 461697-83-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-ethyl-, monoacetate 461697-85-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methyl-, monoacetate 461697-87-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-nitro-, monoacetate 461697-89-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenyl-, monoacetate 461697-91-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-ethyl-, monoacetate 461697-93-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-(2-propenyl)-, monoacetate 461697-95-0P, 1H-Indole-1-acetic acid, 2-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, monoacetate 461697-97-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(1-methyl-3-piperidinyl)-3-(4-phenoxyphenyl)-, acetate 461698-00-0P, 1-[1-(2-Methoxyethyl)-3-piperidyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-03-3P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazol[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethyl)benzamide dimaleate 461698-05-5P 461698-07-7P, Trans-3-[3-Chloro-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-09-9P 461698-11-3P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylcarbonyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide monomaleate 461698-13-5P, Cyclopropanecarboxamide, N-[4-[4-amino-1-[cis-4-(2-aminoethyl)-4-hydroxycyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-, (1R,2R)-rel-, acetate (salt) 461698-15-7P 461698-17-9P 461698-19-1P, 2-Pyrrolidinecarboxamide, N-[4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, (2R)-, monoacetate 461698-22-6P, 3-(4-Phenoxyphenyl)-1-(4-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-23-7P, N-[4-[4-Amino-1-(4-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461698-25-9P, 1-(6-Amino-3-pyridyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-26-0P, 3-(4-Phenoxyphenyl)-1-(2-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-30-6P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(1H-indol-2-ylmethyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-32-8P, Trans-3-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]-1,2-dihydro-2-pyridinone diacetate 461698-34-0P, Trans-5-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyanilino]methyl]-4-chloro-1,3-thiazol-2-amine diacetate 461698-36-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[3-methoxy-4-[[(5-methyl-3-isoxazolyl)methyl]amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-38-4P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[3-methoxy-4-[(4-thiazolylmethyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-40-8P, Trans-3-[4-[(4,6-Dichloro-2,3-dihydrobenzo[b]furan-3-yl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 461698-42-0P,

1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(4-chloro-2,3-dihydro-3-benzofuranyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-44-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(4,6-dichloro-2,3-dihydro-3-benzofuranyl)amino]-3-methoxyphenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-48-6P, 3-[4-[[(Benzo[b]furan-2-yl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-50-0P, 3-[4-[[(2-Methoxy-3-pyridyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-52-2P, 3-[4-[[(5-Methyl-2-thienyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-54-4P, 3-[4-[(2-Furylmethyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-56-6P, 3-[4-(Benzylamino)phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-58-8P, 3-[4-[(2-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-60-2P, 3-[4-[(3-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-62-4P, 3-[4-[(4-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-64-6P 461698-66-8P 461698-68-0P, 3-[4-[[(2-Methyl-1,3-thiazol-4-yl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-70-4P, 3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-72-6P 461698-74-8P, 3-[4-[[(Benzo[b]furan-2-yl)methyl]amino]-3-methoxyphenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461698-76-0P, 3-[4-[(2,3-Dihydrobenzo[b]furan-3-yl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-78-2P, trans-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1H-benzo[d]isothiazole-1,1-dione monoacetate 461698-81-7P, Cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1H-benzo[d]isothiazole-1,1-dione diacetate 461698-83-9P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]benzo[d]isoxazol-3-amine monoacetate 461698-89-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]benzo[d]isoxazol-3-amine diacetate 461698-91-9P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(1,2-benzisoxazol-3-ylamino)phenyl]-1-(4-piperidinyl)-, acetate 461698-93-1P, Trans-3-[4-(1H-3-Indazolylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-98-6P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-(trifluoromethyl)benzo[d]isoxazol-3-amine monoacetate 461699-04-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-07-0P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-08-1P, N-[4-[4-Amino-1-(1-methyl-3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-10-5P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-16-1P, Piperidine, 3-[4-amino-3-[4-[(5,7-

dimethyl-2-benzoxazolyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-[(dimethylamino)acetyl]-, acetate 461699-17-2P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-methyl-2-(methylamino)-1-propanone 461699-21-8P, N-4-[4-Amino-1-(3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-24-1P, N-[4-[4-Amino-1-(1-methyl-3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-29-6P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carbonitrile 461699-33-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-37-6P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-1,3-benzoxazol-2-amine 461699-40-1P, Cis-N-[4-[4-Amino-1-[4-(dimethylamino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-45-6P, trans-N-[4-[4-Amino-1-[4-(dimethylamino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-53-6P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-54-7P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-55-8P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-56-9P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-57-0P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5-chloro-2-benzoxazolyl)amino]phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-58-1P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-(methylamino)cyclohexyl]- 461699-59-2P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-(2-nitrophenyl)-1,3-thiazol-2-amine 461699-60-5P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzothiazol-2-amine 461699-62-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,6-dihydro-4H-cyclopenta[d][1,3]thiazol-2-amine 461699-63-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-phenyl-1,3-thiazol-2-amine 461699-64-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine 461699-65-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-isopropyl-4-phenyl-1,3-thiazol-2-amine 461699-66-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-phenyl-5-propyl-1,3-thiazol-2-amine 461699-67-2P, 3-[4-(1,3-Benzoxazol-2-ylmethyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-68-3P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-(1,3-benzoxazol-2-ylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 461699-69-4P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(4-methylphenyl)-1,3-thiazol-2-amine 461699-71-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(2-methylphenyl)-1,3-thiazol-2-amine 461699-72-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-

yl]phenyl]-5-ethyl-4-(3-methylphenyl)-1,3-thiazol-2-amine 461699-73-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide bismaleate 461699-76-3P 461699-79-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461699-84-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-fluoro-4-(trifluoromethyl)-, acetate 461699-86-5P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461699-88-7P, Benzenepropanamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461699-90-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-cyclopentylpropanamide diacetate 461699-92-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1,3-dimethyl-1H-5-pyrazolecarboxamide diacetate 461699-94-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(2-thienyl)acetamide diacetate 461699-95-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylacetamide 461699-96-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(3,4-dimethoxyphenyl)acetamide 461699-97-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenoxypropanamide 461699-99-0P, 5-Isoxazolecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-01-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-pyridinecarboxamide triacetate 461700-03-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,4-difluorobenzamide diacetate 461700-05-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,5-difluoro-, acetate 461700-07-2P, 2-Furancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-08-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethylpropanamide 461700-09-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-cyanobenzamide 461700-11-8P, Cyclopropanecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-13-0P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-methyl-, acetate 461700-14-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-fluoro-3-methylbenzamide 461700-15-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(dimethylamino)benzamide 461700-16-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,3-difluoro-4-methylbenzamide 461700-18-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]isonicotinamide diacetate 461700-20-9P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-22-1P, 1H-Pyrrole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, acetate 461700-24-3P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-methyl-, acetate 461700-26-5P, Pyrazinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-28-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-

methoxyphenyl]-4-iodobenzamide diacetate 461700-29-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-bromobenzamide 461700-30-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-phenoxybenzamide 461700-31-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-fluorobenzamide 461700-32-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-chlorobenzamide 461700-33-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methoxybenzamide 461700-34-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 461700-35-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-nitrobenzamide 461700-36-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]thiophene-2-carboxamide 461700-37-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide 461700-38-9P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methylbenzamide 461700-40-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(1,1-dimethylethyl)-, acetate 461700-42-5P, Benzoic acid, 4-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, methyl ester, acetate 461700-43-6P, 4-[[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyanilino]carbonyl]benzoic acid 461700-45-8P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-chloro-, acetate 461700-47-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-bromo-, acetate 461700-49-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-methoxy-, acetate 461700-50-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylbenzamide 461700-52-7P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethyl)-, acetate 461700-54-9P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethoxy)-, acetate 461700-55-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methoxybenzamide 461700-56-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethyl)benzamide 461700-58-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-3-(trifluoromethyl)-, acetate 461700-60-7P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-6-(trifluoromethyl)-, acetate 461700-62-9P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-5-(trifluoromethyl)-, acetate 461700-63-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-5-methylbenzamide 461700-64-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-chloro-2-fluorobenzamide 461700-65-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-benzoylbenzamide 461700-66-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-acetylbenzamide 461700-67-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-isopropylbenzamide 461700-69-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-ethyl-, acetate 461700-71-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-

pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-propyl-, acetate 461700-73-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-cyclohexyl-, acetate 461700-75-4P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-ethoxy-, acetate 461700-77-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(methylsulfonyl)-, acetate 461700-79-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-isopropoxybenzamide diacetate 461700-81-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(1H-imidazol-1-yl)-, acetate 461700-83-4P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-, acetate 461700-84-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methoxybenzo[b]furan-2-carboxamide 461700-86-7P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-bromo-, acetate 461700-87-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methylbenzo[b]furan-2-carboxamide 461700-88-9P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methylbenzo[b]furan-2-carboxamide 461700-89-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-nitrobenzo[b]furan-2-carboxamide 461700-91-4P, 2-Benzofurancarboxamide, 5-amino-N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-93-6P, 2-Benzofurancarboxamide, 5-(acetylamino)-N-[4-[4-(acetylamino)-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-95-8P, 2-Benzofurancarboxamide, 5-(acetylamino)-N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-97-0P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methyl-, acetate 461700-99-2P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methoxy-, acetate 461701-00-8P, N-[4-[4-Amino-1-(1-methyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-04-2P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-06-4P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-09-7P, Cis-3-[4-(Imidazo[1,2-a]pyridin-2-yl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-11-1P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]tetrahydro-1H-pyrrol-1-yl]-2-(dimethylamino)-1-ethanone 461701-13-3P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]tetrahydro-1H-pyrrol-1-yl]-2-methyl-2-(methylamino)-1-propanone 461701-16-6P, N-[4-[4-Amino-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-20-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-isopropyl-1,3-benzoxazol-2-amine diacetate 461701-23-5P 461701-25-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-1,3-benzoxazol-2-amine monoacetate 461701-26-8P 461701-28-0P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-1,3-benzoxazol-2-amine monoacetate

461701-30-4P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-chloro-1,3-benzoxazol-2-amine monoacetate 461701-32-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimesylate 461701-34-8P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]trans-2-phenyl-1-cyclopropanecarboxamide 461701-36-0P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 461701-37-1P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(1,3-oxazol-5-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-39-3P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 461701-40-6P 461701-41-7P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-1-ethanol 461701-42-8P
, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-2-methyl-1-propanol 461701-43-9P, 4-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-1-butanol 461701-44-0P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N',N'-dimethyl-1,2-ethanediamine 461701-45-1P, 1-[4-[[(3-Methoxypropyl)amino]methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-46-2P, 1-[4-[[(2-Methoxyethyl)amino]methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-47-3P, 3-(4-Phenoxyphenyl)-1-[4-(1,3-thiazolan-3-ylmethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-48-4P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl](2-hydroxyethyl)amino]-1-ethanol 461701-49-5P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N,N',N'-trimethyl-1,2-ethanediamine 461701-50-8P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-4-piperidinol 461701-51-9P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N,N',N'-trimethyl-1,3-propanediamine 461701-52-0P, [1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-4-piperidyl]methanol 461701-53-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide dimaleate 461701-55-3P, N-[4-[4-Amino-1-(1-ethyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-56-4P, N-[4-[4-Amino-1-[1-(cyclopropylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-58-6P, Benzamide, N-[4-[4-amino-1-[1-(1H-pyrrol-1-ylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-59-7P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-61-1P, Benzamide, N-[4-[4-amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-63-3P, Benzamide, N-[4-[4-amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-65-5P, Benzamide, N-[4-[4-amino-1-[1-[(4-methyl-1H-imidazol-5-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-66-6P, N-[4-[4-Amino-1-[1-(1,3-thiazol-2-ylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-

(trifluoromethyl)benzamide 461701-67-7P, N-[4-[4-Amino-1-[1-[[5-(hydroxymethyl)-2-furyl]methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-68-8P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-69-9P, N-[4-[4-Amino-1-(1-isopropyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-71-3P, Benzamide, N-[4-[4-amino-1-[1-(2-methylpropyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-72-4P, N-[4-[4-Amino-1-[1-(2-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-73-5P, N-[4-[4-Amino-1-[1-(3-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-74-6P, Benzamide, N-[4-[4-amino-1-[1-(1H-imidazol-1-ylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-75-7P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-76-8P, tert-Butyl 4-[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidyl]-1-piperidinecarboxylate 461701-77-9P, N-[4-[4-Amino-1-[1-(tetrahydrothiophen-3-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-78-0P, N-[4-[4-Amino-1-(1-benzyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-80-4P, Benzamide, N-[4-[4-amino-1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-81-5P 461701-82-6P 461701-84-8P, Benzamide, N-[4-[4-amino-1-[1-[(1-methyl-1H-pyrrol-2-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-86-0P , Benzamide, N-[4-[4-amino-1-[1-[(5-methyl-2-furanyl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-87-1P, N-[4-[4-Amino-1-[1-(2-thienylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-89-3P 461701-91-7P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461701-92-8P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-thiopyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-93-9P, 4-[[4-[4-Amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]methyl]-1-pyridine-N-oxide 461701-94-0P, N-[4-[4-Amino-1-[1-(2-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-95-1P, N-[4-[4-Amino-1-[1-(3-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-96-2P, N-[4-[4-Amino-1-[1-(4-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-97-3P, N-[4-[4-Amino-1-[1-[3-(methylsulfanyl)propyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-98-4P, N-[4-[4-Amino-1-[1-[(5-methyl-2-thienyl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-

fluoro-4-(trifluoromethyl)benzamide 461701-99-5P, N-[4-[4-Amino-1-[1-(3-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-00-1P, N-[4-[4-Amino-1-[1-(4-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-01-2P, N-[4-[4-Amino-1-[1-(2-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-02-3P, N-[4-[4-Amino-1-[1-(4-methoxybenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-03-4P, N-[4-[4-Amino-1-[1-(1-acetylpiperidin-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-05-6P, Benzamide, N-[4-[4-amino-1-[1-[(3-methyl-1H-pyrazol-1-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461702-06-7P, Methyl 2-[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetate 461702-07-8P 461702-10-3P, Benzamide, N-[4-[4-amino-1-[1-(2-methoxyethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461702-11-4P, N-[4-[4-Amino-1-[1-(cyanomethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-13-6P, 1-Piperidineacetamide, 4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-, acetate 461702-15-8P 461702-17-0P, N-[4-[4-Amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-20-5P 461702-23-8P, N-[4-[4-Amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-25-0P, N-[4-[4-Amino-1-[1-(2,2-difluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-28-3P, N-[4-[4-Amino-1-(1-ethyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-31-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-[1-[(3-methyl-1H-pyrazol-1-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, acetate 461702-33-0P, N-[4-[4-Amino-1-[1-(3-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide

RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461702-35-2P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-36-3P, N-[4-[4-Amino-1-[1-(1-acetylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 461702-37-4P 461702-38-5P, N-[4-[4-Amino-1-[3-(4-methylpiperazino)propyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-41-0P, N-[4-[4-Amino-1-(3-morpholinopropyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-43-2P, N-[4-[4-Amino-1-[3-(1H-1-imidazolyl)propyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-46-5P, N-[4-[4-Amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]tetrahydro-1H-

pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-47-6P, N-[4-[4-Amino-1-(1-isopropyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-48-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-49-8P, N-[4-[4-Amino-1-[1-(1H-imidazol-4-ylmethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-50-1P, N-[4-[4-Amino-1-[1-[(3-methyl-1H-pyrazol-4-yl)methyl]tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-51-2P 461702-52-3P 461702-53-4P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-isopropyl-1,3-benzoxazol-2-amine 461702-56-7P, cis-Methyl 4-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylate 461702-57-8P, cis-4-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylic acid 461702-58-9P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-61-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461702-64-7P 461702-65-8P, (S)-N-[4-[4-Amino-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461702-72-7P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carboxamide triacetate 461702-75-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)-, monoacetate 461702-77-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(methylsulfonyl)-, monoacetate 461702-79-4P, 1H-Indole-5-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461702-81-8P, 1H-Indole-6-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461702-83-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(phenylmethoxy)-, monoacetate 461702-85-2P, β-Alanine, N-[3-[4-[(1H-indol-2-ylcarbonyl)amino]-3-methoxyphenyl]-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, monoacetate 461702-87-4P, 1H-Indole-1-propanoic acid, 2-[[[4-[4-[(2-carboxyethyl)amino]-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, monoacetate 461702-89-6P, 1H-Indole-1-acetamide, 2-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-N,N-dimethyl-, monoacetate 461702-91-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-hydroxy-1H-2-indolecarboxamide monoacetate 461702-93-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-hydroxy-1H-2-indolecarboxamide monoacetate 461702-95-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-amino-1H-2-indolecarboxamide monoacetate 461702-97-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-3-indolecarboxamide monoacetate 461703-00-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-4-indolecarboxamide monoacetate 471925-60-7P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine maleate 471925-63-0P,

Cis-3-[4-[(1H-4-Imidazolylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 471925-65-2P, Cis-3-[4-[(1H-2-Indolylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471925-69-6P 471925-70-9P 471925-71-0P 471925-72-1P 471925-73-2P 471925-74-3P 471925-75-4P 471925-76-5P 471925-77-6P 471925-78-7P 471925-79-8P 471925-80-1P 471925-81-2P 471925-87-8P 471925-88-9P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide trimaleate 471925-93-6P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(2-methoxyphenyl)propanamide 471925-94-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-methoxyphenyl)propanamide 471925-95-8P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(3-methoxyphenyl)propanamide 471925-96-9P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-methylphenyl)propanamide 471925-97-0P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-fluorophenyl)propanamide 471925-98-1P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(3,4-difluorophenyl)propanamide 471926-08-6P, Trans-3-[3-Methoxy-4-[(5-methyl-2-furyl)methyl]aminophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 471926-09-7P 471926-14-4P, Cis-3-[3-[2-(1H-2-Imidazolyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471926-16-6P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-anilinoacetamide 471926-23-5P, N,N-Methoxymethyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 471926-25-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-(1H-4-imidazolyl)-1-propanone 471926-26-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(2-methoxyethyl)piperidino]-1-ethanone 471926-61-1P 471926-74-6P 471926-76-8P 471926-82-6P 471927-20-5P, Trans-3-[3-Methoxy-4-[[(3-methyl-1H-4-pyrazolyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-25-0P, Trans-3-[4-[(1H-7-Indolylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-28-3P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[[(5-methyl-1H-4-pyrazolyl)methyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-44-3P, N-(1H-2-Imidazolyl)-2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetamide 471927-45-4P, trans-N-[4-[4-Amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide 471927-46-5P, Trans-N-[4-[4-Amino-1-[(4-hydroxy-4-piperidyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide

RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

L32 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:793426 HCAPLUS
DOCUMENT NUMBER: 137:310925
TITLE: Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
INVENTOR(S): Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.
PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 867 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080926	A1	20021017	WO 2002-US9104	200203 22
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002156081	A1	20021024	US 2001-815310	200103 22
US 6921763	B2	20050726		
CA 2440724	AA	20021017	CA 2002-2440724	200203 22
EP 1385524	A1	20040204	EP 2002-746301	200203 22
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531513	T2	20041014	JP 2002-578965	200203 22
BR 2002005889	A	20041109	BR 2002-5889	200203 22
NO 2003004176	A	20031121	NO 2003-4176	200309 19

PRIORITY APPLN. INFO.:	US 2001-815310	A	200103 22
	US 1999-154620P	P	199909 17

US 2000-663780 A2
200009
15

WO 2002-US9104 W
200203
22

OTHER SOURCE(S): MARPAT 137:310925

GI



AB Title compds. I [wherein G = (un)substituted 5-6 membered (azahetero)aryl; R2 = H or (un)substituted trityl, cycloalkenyl, azaheteroaryl, or C6H4-4-CH2E; E = (un)substituted alkyl-OR, alkyl-CO2R, alkylheteroaryl, alkylheterocycloalkyl, or alkyl-NR2; R = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); R3 = independently H, OH, or (un)substituted alkyl, alkyl-CO, (hetero)aryl-CO, or alkoxy; or racemic diastereomeric mixts., optical isomers, pharmaceutically acceptable salts, prodrugs, and/or biol. active metabolites thereof] were prepd. For example, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine was coupled with 4-fluorobenzaldehyde in the presence of NaH in DMF to give 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde. **Treatment** of the 3-iodopyrazolopyrimidine with N-[2-methoxy-4-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide, Pd(PPh3)4, and Na2CO3 in H2O afforded the N-[4-(pyrazolopyrimidin-3-yl)phenyl]benzamide. Addn. of morpholine to the benzaldehyde in the presence of Na(AcO)3BH in dichloroethane produced II. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concn. of ≤ 50 μM. Certain compds. of the invention also significantly inhibited cdc2 or cellular VEGF-induced KDR tyrosine kinase phosphorylation at concns. of ≤ 50 μM. Thus, I are useful for the **treatment** of a wide variety of **disease** states ameliorated by the inhibition of protein tyrosine kinase activity essential for angiogenic processes (no

data).

IT **330793-97-0P**, N-(4-Bromophenyl)-N-(4-ethyl-1,3-thiazol-2-yl)amine **330793-98-1P**, N-(4-Ethyl-1,3-thiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

RN 330793-97-0 HCAPLUS
CN 2-Thiazolamine, N-(4-bromophenyl)-4-ethyl- (9CI) (CA INDEX NAME)



RN 330793-98-1 HCAPLUS
CN 2-Thiazolamine, 4-ethyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (9CI) (CA INDEX NAME)



IC ICM A61K031-519
ICS C07D487-04

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT **Inflammation**
(Crohn's **disease**; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Tyrosine kinase receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(Tie, TIE-2; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Tyrosine kinase receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(Tie-1; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(VEGF, VEGF-B, VEGF-C, VEGF-D, or VEGF-E, combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Antibodies and Immunoglobulins
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(antiiodotypic, combination therapy agent; prepn. of

[(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(c-fgr; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Angiogenic factors
Hepatocyte growth factor
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(fyn; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(gene hck; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(gene lyn; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Intestine, **disease**
(**inflammatory**; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(p62c-yes; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Anemia (disease)
Angiogenesis
Angiogenesis inhibitors
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Antibacterial agents
Antidiabetic agents
Antiglaucoma agents
Antirheumatic agents
Antitumor agents
Antiulcer agents
Asthma
Atherosclerosis
Cardiovascular agents
Cardiovascular system, disease
Cirrhosis
Contraceptives
Eye, disease
Fibrosis
Fungicides
Glaucoma (disease)
Hematopoiesis

Hodgkin's disease
Human
Human herpesvirus
Human immunodeficiency virus 1
Hypoxia
Ischemia
Leukemia
Lyme disease
Lymphoma
Melanoma
Multiple myeloma
Multiple sclerosis
Mycosis
Necrosis
Neoplasm
Osteoarthritis
Parapoxvirus
Preeclampsia
Protozoa
Protozoacides
Psoriasis
Radiation
Rheumatoid arthritis
Sarcoidosis
Sarcoma
Sepsis
Sickle cell anemia
Transplant rejection
Ulcer
Wound
(prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Hepatocyte growth factor receptors
Insulin-like growth factor I receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Fibroblast growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type 1; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type VEGFR-1; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type VEGFR-2; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(type VEGFR-3; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Platelet-derived growth factor receptors

RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(α; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Platelet-derived growth factor receptors
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(β; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 106096-92-8, FGF-1 106096-93-9, FGF-2
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330793-90-3P 330793-91-4P, cis-4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzaldehyde 330793-95-8P, N-(6-Chloro-1,3-benzothiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-96-9P **330793-97-0P**, N-(4-Bromophenyl)-N-(4-ethyl-1,3-thiazol-2-yl)amine **330793-98-1P**, N-(4-Ethyl-1,3-thiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-99-2P, 4-Amino-1-(4-nitrophenyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 330794-00-8P, 3-Iodo-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-01-9P, 4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzaldehyde 330794-02-0P, 1-Bromo-2-fluoro-5-methoxy-4-nitrobenzene 330794-03-1P, 4-Bromo-5-fluoro-2-methoxyaniline 330794-04-2P, tert-Butyl N-(4-bromo-5-fluoro-2-methoxyphenyl)carbamate 330794-05-3P, tert-Butyl N-[5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 330794-06-4P, 3-Iodo-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-08-6P, trans-tert-Butyl N-[2-[[[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]]anilino]methyl]phenyl]carbamate acetate 330794-09-7P, tert-Butyl N-(4-bromo-2-chlorophenyl)carbamate 330794-10-0P, tert-Butyl N-[2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 330794-11-1P, Trans-tert-Butyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]carbamate 330794-12-2P, Trans-3-(4-Amino-3-chlorophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-13-3P, 1-(4-Bromophenyl)-3-methyl-5-phenyl-4,5-dihydro-1H-pyrazole 330794-14-4P, 3-Methyl-5-phenyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-4,5-dihydro-1H-pyrazole 330794-15-5P 330794-17-7P, tert-Butyl N-[3-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-oxopropyl]-N-(2-hydroxyethyl)carbamate 330794-18-8P, tert-Butyl N-[3-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-oxopropyl]-N-(2-hydroxyethyl)carbamate 330794-19-9P, tert-Butyl 2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetate 330794-20-2P, Benzyl 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 330794-21-3P, Benzyl 4-[4-amino-3-[4-[(tert-butoxycarbonyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-22-4P, Benzyl 4-[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-23-5P, Trans-Benzyl 4-[4-amino-3-[3-methoxy-4-[[(2-phenylcyclopropyl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-24-6P, Benzyl 4-[4-amino-3-[3-methoxy-4-[[(5-methyl-2-

furyl)methyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-25-7P, tert-Butyl 4-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-4-hydroxy-1-piperidinecarboxylate 330794-26-8P, tert-Butyl 4-[[4-amino-3-[4-[[(benzyloxy)carbonyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-27-9P, tert-Butyl 4-[[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-28-0P, Trans-tert-Butyl 4-[[4-amino-3-[3-methoxy-4-[[(2-phenylcyclopropyl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-29-1P 461696-99-1P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde 461697-00-7P 461697-02-9P, 2-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-ethanol 461697-03-0P, [2-[4-Amino-3-[3-methoxy-4-[[(1-methyl-1H-indol-2-yl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl] methanesulfonate 461697-30-3P, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-methyl-1H-2-indolecarboxamide 461697-31-4P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-34-7P, N-[4-[4-Amino-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-36-9P, N-[4-[4-Amino-1-[2-[(2-hydroxyethyl)amino]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-38-1P, N-[4-[4-Amino-1-[2-(dimethylamino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-40-5P, N-[4-[4-Amino-1-[2-(1H-1-imidazolyl)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-53-0P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-cyclopenten-1-ol 461697-57-4P, tert-Butyl 4-[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461697-66-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-98-3P, 3-Iodo-1-(1-methyl-3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-01-1P, 3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-02-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethyl)benzamide 461698-04-4P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethoxy)benzamide 461698-10-2P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylcarbonyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide 461698-14-6P 461698-21-5P 461698-24-8P 461698-45-3P, tert-Butyl 4-[4-amino-3-(4-aminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461698-46-4P, tert-Butyl 4-[4-amino-3-[4-[[(benzyloxy)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461698-79-3P, 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-1H-benzo[d]isothiazole-1,1-dione 461698-84-0P, N-(4-Bromophenyl)-2-fluoro-1-benzenecarbothioamide 461698-85-1P 461698-86-2P, N-(Benzo[d]isoxazol-3-yl)-N-(4-bromophenyl)amine 461698-87-3P, N-(Benzo[d]isoxazol-3-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 461698-94-2P, Benzenecarboximidic acid, N-(4-bromophenyl)-2-fluoro-, hydrazide 461698-95-3P, N-(4-Bromophenyl)-N-(1H-3-indazolyl)amine 461698-96-4P, N-(1H-3-Indazolyl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 461698-99-7P, N-(4-Bromophenyl)-2-fluoro-4-(trifluoromethyl)benzamide 461699-00-3P, N-(4-Bromophenyl)-2-

fluoro-4-(trifluoromethyl)-1-benzenecarbothioamide 461699-01-4P, Benzenecarboximidic acid, N-(4-bromophenyl)-2-fluoro-4-(trifluoromethyl)-, hydrazide 461699-02-5P, N-(4-Bromophenyl)-N-[6-(trifluoromethyl)benzo[d]isoxazol-3-yl]amine 461699-03-6P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-N-[6-(trifluoromethyl)benzo[d]isoxazol-3-yl]amine 461699-05-8P, 3-Iodo-1-[1-(2-methoxyethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-06-9P 461699-09-2P, 3-Iodo-1-(3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 461699-13-8P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 461699-14-9P, tert-Butyl 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461699-18-3P, 3-Iodo-1-(3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dihydrochloride 461699-19-4P, 9H-Fluoren-9-ylmethyl N-[2-[3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidino]-1,1-dimethyl-2-oxoethyl]-N-methylcarbamate 461699-20-7P 461699-22-9P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)azetane-1-carboxylate 461699-23-0P, tert-Butyl 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]azetane-1-carboxylate 461699-27-4P, 1-(3-Azetanyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461699-28-5P, 3-Iodo-1-(1-methyl-3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-30-9P, 2-(4-Bromoanilino)-1,3-benzoxazole-5-carbonitrile 461699-31-0P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-1,3-benzoxazole-5-carbonitrile 461699-34-3P, 2-Amino-4-(trifluoromethoxy)phenol 461699-35-4P, N-(4-Bromophenyl)-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-36-5P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-38-7P, N-(4-Bromophenyl)-5-ethyl-1,3-benzoxazol-2-amine 461699-39-8P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-ethyl-1,3-benzoxazol-2-amine 461699-41-2P, Cis-1-[4-(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-42-3P, trans-1-[4-(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-46-7P, N-(4-Bromophenyl)-5-chloro-1,3-benzoxazol-2-amine 461699-47-8P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-chloro-1,3-benzoxazol-2-amine 461699-48-9P, N-(4-Bromophenyl)-5-methyl-1,3-benzoxazol-2-amine 461699-49-0P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-methyl-1,3-benzoxazol-2-amine 461699-50-3P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-51-4P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-52-5P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-(methylamino)cyclohexyl]- 461699-61-6P, N-(4-Bromophenyl)-N-(5,7-dimethyl-1,3-benzothiazol-2-yl)amine 461699-78-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461699-82-1P, 2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline bismaleate 461701-01-9P, 3-Iodo-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monohydrochloride 461701-02-0P, 3-Iodo-1-(1-methyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-03-1P, N-(4-Bromophenyl)-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-05-3P, 3-Iodo-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-07-5P, N-(4-Bromo-2-fluorophenyl)-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-08-6P, N-[2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-10-0P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]imidazo[1,2-a]pyridine 461701-12-2P,

1-[3-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydro-1H-pyrrol-1-yl]-2-(dimethylamino)-1-ethanone 461701-14-4P, 9H-Fluoren-9-ylmethyl N-[2-[3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydro-1H-pyrrol-1-yl]-1,1-dimethyl-2-oxoethyl]-N-methylcarbamate 461701-15-5P 461701-17-7P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinecarboxylate 461701-18-8P, tert-Butyl 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinecarboxylate 461701-21-3P, N-(4-Bromophenyl)-7-isopropyl-1,3-benzoxazol-2-amine 461701-22-4P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-7-isopropyl-1,3-benzoxazol-2-amine 461701-38-2P, 4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzaldehyde 461701-54-2P 461702-08-9P, 1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-benzo[d]imidazole 461702-16-9P, N-[4-[4-Amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-21-6P 461702-22-7P, N-[4-[4-Amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-24-9P, N-[4-[4-Amino-1-[1-(2,2-difluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-39-6P, 1-(3-Bromopropyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-40-9P, 3-Iodo-1-[3-(4-methylpiperazino)propyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-42-1P, 3-Iodo-1-(3-morpholinopropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-44-3P, 1-[3-(1H-1-Imidazolyl)propyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-55-6P, Cyclohexanecarboxylic acid, 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-, ethyl ester, cis- 461702-59-0P, N-(4-Bromophenyl)-N-(2-pyrimidinyl)amine 461702-62-5P, 1-(2-Chloro-4-pyridyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-63-6P 461702-66-9P, (S)-tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 461702-68-1P 461702-69-2P, (S)-3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-98-7P, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-3-indolecarboxamide 471925-68-5P, 3-(4-Phenoxyphenyl)-1-(3-propylidenecyclobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-82-3P 471925-83-4P, N-[4-[4-Amino-1-[1-(1-methyl-4-piperidyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]aniline 471925-90-3P, 1-[1-(1H-2-Imidazolylmethyl)-4-piperidyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-91-4P, tert-Butyl N-[4-[4-amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 471925-92-5P, 3-(4-Amino-3-methoxyphenyl)-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-99-2P, 2-Fluoro-6-[(2-methoxyethyl)amino]benzonitrile 471927-37-4P, 5-Ethoxy-3-methyl-1-[4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl]-1H-pyrazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 144697-17-6 144941-35-5, Blk protein kinase
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**
(prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-88-1P, 1-(1-Benzyl-4-piperidinyl)-3-(4-phenoxyphenyl)-1H-

pyrazolo[3,4-d]pyrimidin-4-amine
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase inhibitor.; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330788-71-1P 330788-72-2P 330788-73-3P 330788-74-4P
330788-75-5P 330788-76-6P 330788-77-7P 330788-78-8P
330788-79-9P 330788-80-2P 330788-81-3P 330788-82-4P
330788-83-5P 330788-84-6P 330788-85-7P 330788-86-8P
330788-87-9P 330788-88-0P 471925-84-5P
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent)
(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-90-5P, 3-(4-Phenoxyphenyl)-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-11-3P 330786-13-5P, 4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanone 330786-15-7P, tert-Butyl cis-4-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]-1-piperazinecarboxylate 330786-16-8P, tert-Butyl trans-4-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]-1-piperazinecarboxylate 330786-24-8P, 3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-58-8P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-63-5P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-67-9P 330787-59-2P 330787-63-8P 330787-67-2P, 3-[4-(Benzyloxy)phenyl]-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-88-7P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzonitrile 330787-91-2P, Cis-3-[4-[2-(Aminomethyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-01-7P 330788-03-9P, 1-(3-Azetanyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-11-9P, Cis-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 330788-15-3P, Trans-1-[3-[(Benzyloxy)methyl]cyclobutyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-68-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide 330788-92-6P, Ethyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330789-03-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 330789-23-6P, cis-3-[4-(Benzyloxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-29-2P, trans-3-[4-(Benzyloxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-32-7P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-75-8P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1-phenyl-1-ethanone diacetate 330790-07-3P, Methyl 5-[4-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]-2-furoate 330790-15-3P,

Cis-2-[3-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzaldehyde 330790-20-0P 330790-21-1P 330790-70-0P, Trans-2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]acetic acid 330790-74-4P 330790-88-0P, Methyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330790-98-2P, Ethyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330790-99-3P, Methyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330791-04-3P, Methyl 4-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanoate 330791-51-0P, tert-Butyl N-[4-[4-amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330791-57-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine dihydrochloride 330791-68-9P 330791-88-3P, tert-Butyl N-[4-[4-amino-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330791-99-6P, trans-3-(4-Amino-2-fluoro-5-methoxyphenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-01-3P, tert-Butyl N-[4-[4-amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330792-23-9P, Trans-3-[4-[(2-Aminobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-33-1P, Trans-3-[4-(5-Ethoxy-1H-1-pyrazolyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-43-3P, 2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetic acid 330792-49-9P, 3-[3-Methoxy-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461697-04-1P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-42-7P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-45-0P, Cis-Ethyl 3-[[4-[4-amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoate 461697-46-1P, Trans-Ethyl 3-[[4-[4-amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoate 461697-49-4P, N-[4-(4-Amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-50-7P, N-[4-(4-Amino-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-52-9P, N-[4-[4-Amino-1-(4-hydroxy-2-cyclopentenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461698-20-4P 461698-28-2P, trans-3-[4-[[(2-Methoxy-3-pyridyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461699-12-7P 461701-33-7P, 3-(4-Amino-3-methoxyphenyl)-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-35-9P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide 461702-45-4P, N-[4-[4-Amino-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-54-5P, cis-Ethyl 4-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylate 471926-42-8P 471927-18-1P, trans-tert-Butyl N-[4-[4-amino-1-[4-(4-

methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]carbamate
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-92-7P, 1-[1-(1-Methyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330785-96-1P, 1-[1-(1-Isopropyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330785-98-3P, 1-[1-(4-Piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-02-2P, 1-[trans-4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-06-6P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-08-8P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide dimaleate 330786-18-0P, Cis-3-(4-Phenoxyphenyl)-1-(4-piperazinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-20-4P, Trans-3-(4-Phenoxyphenyl)-1-(4-piperazinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-25-9P, 4-Amino-1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine 330786-27-1P, 3-(4-Phenoxyphenyl)-1-(tetrahydropyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 330786-29-3P 330786-30-6P 330786-33-9P 330786-36-2P, Cis-3-(4-Anilinophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-40-8P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-45-3P, Trans-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate dimaleate 330786-47-5P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzamide dimaleate 330786-49-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-phenylsulfamide dimaleate 330786-51-1P 330786-53-3P 330786-55-5P 330786-57-7P 330786-59-9P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-61-3P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-64-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-66-8P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-69-1P 330786-71-5P 330786-72-6P 330786-73-7P 330786-75-9P 330786-77-1P 330786-78-2P, Cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide 330786-79-3P, Cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzoic acid 330786-81-7P 330786-83-9P 330786-85-1P, cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide diacetate 330786-86-2P, Cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzoic acid 330786-88-4P 330786-89-5P, Cis-N-[3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-

yl]phenoxy]benzyl]benzamide 330786-91-9P 330786-93-1P, Cis-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo-[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate dimaleate 330786-95-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-benzylurea acetate 330786-97-5P, Cis-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330786-99-7P 330787-03-6P, Trans-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330787-05-8P, Trans-3-[4-[(2,6-Dimethoxybenzyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-07-0P, Trans-3-[4-[(2-Chloro-6-fluorobenzyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-09-2P, Cis-3-[4-(Benzylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-11-6P, Cis-3-[4-[(2-Methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-13-8P 330787-14-9P, Cis-3-[4-[(2-Chlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-15-0P, Cis-3-[4-[(2-Bromobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-16-1P, Cis-3-[4-[(2-Ethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-17-2P, Cis-3-[4-[[2-(Difluoromethoxy)benzyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-19-4P 330787-21-8P 330787-23-0P, Cis-2-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]benzonitrile diacetate 330787-24-1P, Cis-3-[4-[(2,6-Difluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-26-3P, Cis-3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330787-27-4P, Cis-3-[4-[[2-Fluoro-6-(trifluoromethyl)benzyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-29-6P, Cis-3-[4-[(2-Fluoro-6-methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-30-9P, Cis-3-[4-[(2,6-Dichlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-32-1P, Cis-3-[4-[(2,6-Dimethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-34-3P, Cis-3-[4-[(2-Fluoro-4-methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-38-7P, Cis-3-[4-[[(1-Methyl-1H-indol-2-yl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-40-1P, Trans-3-[4-(Benzylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330787-42-3P, Trans-3-[4-[(2-Methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-44-5P, Trans-3-[4-[(2,6-Dimethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-46-7P, Trans-3-[4-[(2-Chlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-48-9P, Trans-3-[4-[(2-Bromobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330787-50-3P 330787-52-5P 330787-53-6P

330787-55-8P, Cis-3-[4-[Benzyl(methyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-57-0P, Cis-3-[4-[Benzyl(ethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-61-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(phenethylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-65-0P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(3-phenylpropyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-66-1P, 1-Cyclopentyl-3-[4-(3-methoxyphenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-68-3P, 1-Cyclopentyl-3-[4-(4-fluorophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-69-4P, 1-Cyclopentyl-3-[4-[3-(trifluoromethyl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-70-7P, 1-Cyclopentyl-3-[4-(3-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-71-8P, 1-Cyclopentyl-3-[4-[4-(trifluoromethoxy)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-72-9P, 1-Cyclopentyl-3-[4-[4-(trifluoromethyl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-73-0P, 3-[3-(Benzyloxy)phenyl]-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-75-2P, Cis-3-[4-[(3-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-77-4P, Cis-3-[4-[(2-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-79-6P, Cis-3-[4-[(4-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-81-0P, Cis-3-[4-[(3-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-83-2P, Cis-3-[4-[(4-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-84-3P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(3-pyridylmethyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-85-4P, Cis-3-[4-[(2-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-87-6P, Cis-3-[3-(Benzylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-90-1P, Cis-2-[3-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide triacetate 330787-93-4P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-95-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-96-7P, Cis-3-[4-(2-Aminophenoxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-97-8P, [2-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-phenoxyphenyl]methanol 330787-99-0P 330788-02-8P 330788-04-0P, 2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanol 330788-06-2P, 1-[1-(2-Methoxyethyl)-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330788-07-3P, 1-[1-[2-(2-Methoxyethoxy)ethyl]-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-08-4P, 1-[1-(1-Methyl-4-piperidyl)-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-09-5P, 1-[1-[(1-Methyl-1H-imidazol-2-yl)methyl]-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-10-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanone 330788-12-0P, Trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol

330788-14-2P 330788-16-4P, trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclobutanemethanol 330788-18-6P 330788-19-7P 330788-20-0P 330788-21-1P 330788-23-3P 330788-24-4P 330788-25-5P 330788-26-6P 330788-27-7P 330788-28-8P 330788-29-9P 330788-30-2P 330788-31-3P 330788-32-4P 330788-34-6P, cis-3-[4-[(4-Bromobenzyl)amino]-3-fluorophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330788-46-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(2,4-difluorophenyl)urea 330788-47-1P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methoxyphenyl)urea 330788-48-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methoxyphenyl)urea monoacetate 330788-50-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-51-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-52-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N-ethyl-N'-(3-methylphenyl)urea 330788-53-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N-benzyl-N'-(2,4-difluorophenyl)urea 330788-54-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-N'-(3-methylphenyl)urea 330788-55-1P, N-[4-[4-Amino-1-[1-[2-(dimethylamino)acetyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-57-3P, N-[4-[4-Amino-1-[1-[3-(diethylamino)propanoyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-58-4P, N-[4-[4-Amino-1-[1-[2-(methylamino)acetyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-60-8P, N-[4-[4-Amino-1-[1-[3-[(2-hydroxyethyl)amino]propanoyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-61-9P 330788-62-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-2-carboxamide 330788-63-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-1H-indene-2-carboxamide 330788-64-2P 330788-65-3P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 330788-66-4P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-3-carboxamide 330788-67-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330788-69-7P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide trimaleate 330788-70-0P 330788-89-1P 330788-90-4P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(phenethylamino)(phenyl)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-91-5P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-93-7P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330788-94-8P, N-[4-[4-Amino-1-[2-cyano-4-(4-methylpiperazino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330788-95-9P,

cis-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-96-0P, trans-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-97-1P, cis-N-Benzyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-98-2P, cis-N-Phenethyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-99-3P, cis-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 330789-00-9P, cis-N-Phenethyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 330789-02-1P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide trimaleate 330789-04-3P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide trimaleate 330789-06-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide trimaleate 330789-08-7P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide trimaleate 330789-09-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-13-4P, 1-[1-(1H-Imidazol-2-ylmethyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-15-6P, 1-[1-(1-Methyl-4-piperidyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330789-16-7P, N-[4-[4-Amino-1-[1-(1H-imidazol-2-ylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-24-7P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile 330789-26-9P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(4-methylphenyl)sulfanyl]benzonitrile trimaleate 330789-28-1P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-(2-pyridylsulfanyl)benzonitrile dimaleate 330789-31-6P, trans-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile trimaleate 330789-33-8P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide trimaleate 330789-34-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N-methyl-3-phenylpropanamide 330789-35-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide trimaleate 330789-37-2P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino](4-methylpiperazino)methanone dimaleate 330789-39-4P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide trimaleate 330789-40-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethyl)benzamide 330789-41-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethoxy)benzamide 330789-42-9P,

cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethoxy)benzamide 330789-43-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 330789-44-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethyl)benzamide 330789-46-3P 330789-48-5P, Cis-3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330789-50-9P 330789-52-1P, Trans-3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330789-56-5P, Cis-2-[2-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]phenoxy]acetic acid diacetate 330789-58-7P, Cis-3-[4-[(2-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-60-1P, Cis-3-[4-[[(5-Methyl-2-furyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-62-3P, Cis-3-[4-[(3-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-64-5P 330789-66-7P
, Trans-3-[4-[(2-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-68-9P, 3-[4-[[(5-Methyl-2-furyl)methyl]amino]phenyl]-1-[1-(1-methyl-4-piperidyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330789-70-3P 330789-71-4P 330789-77-0P 330789-79-2P 330789-81-6P 330789-83-8P 330789-85-0P 330789-86-1P 330789-88-3P 330789-90-7P 330789-92-9P 330789-93-0P 330789-96-3P 330789-98-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-2-methyl-2-phenylpropanamide diacetate 330790-00-6P 330790-02-8P 330790-03-9P 330790-05-1P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzoxazol-2-amine diacetate 330790-06-2P, 2-[4-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]acetamide 330790-08-4P, 5-[4-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]-2-furoic acid 330790-09-5P, 1-Cyclopentyl-3-[4-(3-thienyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330790-11-9P 330790-12-0P, Cis-3-[3-[Di(2-furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330790-14-2P 330790-18-6P, (2S)-3-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]propane-1,2-diol 330790-19-7P, (2R)-3-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]propane-1,2-diol 330790-22-2P 330790-23-3P, N-Methyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-24-4P, N,N-Dimethyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-25-5P, N-Isopropyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-26-6P, N-(3-Hydroxypropyl)-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-27-7P 330790-28-8P, N-Benzyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-30-2P, 2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-morpholino-1-ethanone 330790-31-3P, N-(3-Methyl-5-isoxazolyl)-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-

pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-34-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-hydroxyethyl)amino]-1-ethanone 330790-35-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-methoxyethyl)amino]-1-ethanone 330790-36-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(3-hydroxypropyl)amino]-1-ethanone 330790-37-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2,3-dihydroxypropyl)amino]-1-ethanone 330790-38-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(tetrahydro-2-furanylmethyl)amino]-1-ethanone 330790-39-1P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-piperidinoethyl)amino]-1-ethanone 330790-40-4P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[2-(dimethylamino)ethyl](methyl)amino]-1-ethanone 330790-42-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[2-(dimethylamino)ethyl]amino]-1-ethanone acetate 330790-43-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[methyl(1-methyl-4-piperidyl)amino]-1-ethanone 330790-44-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-morpholinoethyl)amino]-1-ethanone

RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330790-45-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(3-morpholinopropyl)amino]-1-ethanone 330790-46-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[3-(1H-1-imidazolyl)propyl]amino]-1-ethanone 330790-47-1P, 1-[3-[[2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-oxoethyl]amino]propyl]-2-pyrrolidinone 330790-48-2P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(4-hydroxypiperidino)-1-ethanone 330790-49-3P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(hydroxymethyl)piperidino]-1-ethanone 330790-51-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-morpholino-1-ethanone 330790-52-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(4-methylpiperazino)-1-ethanone 330790-53-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(piperid-1-yl)piperidino]-1-ethanone 330790-54-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(1H-4-imidazolyl)-1-ethanone 330790-56-2P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(methylamino)-1-ethanone acetate 330790-58-4P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(dimethylamino)-1-ethanone acetate 330790-59-5P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-(diethylamino)-1-propanone 330790-61-9P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(methylamino)-1-ethanone acetate 330790-62-0P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-64-2P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-(diethylamino)-1-propanone acetate 330790-66-4P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-morpholino-1-ethanone

acetate 330790-68-6P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(4-methylpiperazino)-1-ethanone acetate 330790-69-7P, Cis-2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]acetic acid 330790-71-1P, [3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-(hydroxymethyl)cyclobutyl]methanol 330790-72-2P 330790-73-3P 330790-75-5P 330790-76-6P 330790-77-7P 330790-79-9P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-5-chloro-2-thiophenesulfonamide maleate 330790-80-2P, 1-[4-[4-Amino-3-[4-(1,3-benzoxazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-81-3P, 1-[4-[4-Amino-3-[4-(1,3-benzothiazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-82-4P, N-[4-[4-Amino-1-(2-morpholino-2-oxoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330790-83-5P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)-2-oxoethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330790-84-6P, N-((1R,2S)-2-Hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-85-7P, N-((1S,2S)-2-Hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-86-8P 330790-87-9P 330790-89-1P, 2-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetic acid 330790-90-4P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-91-5P, N-[2-(Diethylamino)ethyl]-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-92-6P, 2-(Dimethylamino)ethyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330790-93-7P, N-[3-(Dimethylamino)propyl]-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-94-8P, 2-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-96-0P, N-[4-[4-Amino-1-(2-morpholino-2-oxoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330790-97-1P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)-2-oxoethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330791-00-9P, 2-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 330791-01-0P 330791-02-1P 330791-03-2P, Ethyl 4-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanoate 330791-05-4P, 4-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanamide 330791-06-5P 330791-07-6P 330791-08-7P, 2-[4-Amino-3-[4-(1,3-benzoxazol-2-ylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-5-(4-methylpiperazino)benzonitrile 330791-09-8P, Ethyl 2-[4-amino-3-[4-(1,3-benzothiazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330791-10-1P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzoxazol-2-amine 330791-11-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-

fluorophenyl]-1,3-benzothiazol-2-amine 330791-12-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzothiazol-2-amine 330791-13-4P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzoxazol-2-amine 330791-14-5P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzoxazol-2-amine 330791-15-6P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzothiazol-2-amine 330791-16-7P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-methyl-1,3-benzoxazol-2-amine 330791-17-8P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-chloro-1,3-benzoxazol-2-amine 330791-18-9P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-1,3-benzoxazol-2-amine 330791-19-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 330791-20-3P 330791-21-4P 330791-23-6P 330791-24-7P 330791-25-8P 330791-26-9P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzyl]-N'-(3-methylphenyl)urea 330791-27-0P 330791-28-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 330791-30-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide trimaleate 330791-32-7P 330791-33-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]thiophene-2-carboxamide 330791-34-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-thiophenecarboxamide 330791-35-0P 330791-37-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-3-phenylbutanamide trimaleate 330791-38-3P 330791-39-4P 330791-40-7P 330791-43-0P 330791-44-1P 330791-46-3P 330791-48-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide trimaleate 330791-50-9P 330791-52-1P, 3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[1-(1-methyl-4-piperidinyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330791-54-3P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenylcyclopropane-1-carboxamide dimaleate 330791-58-7P 330791-59-8P 330791-60-1P 330791-61-2P 330791-62-3P 330791-63-4P 330791-64-5P 330791-65-6P 330791-66-7P 330791-67-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzyl]-5-methyl-1,3-thiazol-2-amine 330791-69-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dichloro-1,3-benzoxazol-2-amine 330791-70-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-methyl-1,3-benzoxazol-2-amine 330791-71-4P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-chloro-1,3-benzoxazol-2-amine 330791-72-5P 330791-73-6P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-

pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 330791-74-7P, N-[4-[4-Amino-1-[2-cyano-4-(4-methylpiperazino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330791-75-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-chloro-1,3-benzothiazol-2-amine 330791-76-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-methoxy-1,3-benzothiazol-2-amine 330791-77-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-ethyl-1,3-thiazol-2-amine 330791-78-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4,5-dimethyl-1,3-thiazol-2-amine 330791-79-2P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-phenyl-1,3-thiazol-2-amine 330791-80-5P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-(4-methylphenyl)-1,3-thiazol-2-amine 330791-81-6P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-4-phenyl-1,3-thiazol-2-amine 330791-83-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-phenylbutanamide trimaleate 330791-85-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide trimaleate 330791-87-2P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3S)-3-phenylbutanamide trimaleate 330791-89-4P, 4-Amino-3-(4-amino-3-methoxyphenyl)-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidine 330791-91-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 330791-93-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide dimaleate 330791-94-1P, 3-Phenyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330791-95-2P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-phenylbutanamide 330791-96-3P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]methanol 330791-97-4P, 1-[4-[(4-Methylpiperazino)methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-00-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide 330792-03-5P, Trans-3-[4-[(2-Chlorobenzyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-05-7P, Trans-3-[3-Methoxy-4-[(1,3-thiazol-2-ylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-09-1P, Trans-3-[3-Methoxy-4-[(2-thienylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-11-5P, Trans-3-[3-Methoxy-4-[[(5-methyl-2-thienyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-13-7P, Trans-3-[4-[[(5-Chloro-2-thienyl)methyl]amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-15-9P, Trans-3-[3-Methoxy-4-[[(2-methyl-1,3-thiazol-4-yl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-19-3P, Trans-3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine

diacetate 330792-25-1P 330792-27-3P 330792-29-5P 330792-31-9P, Trans-3-[4-(3-Methyl-5-phenyl-1H-1-pyrazolyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-35-3P 330792-37-5P, 2-(2-Amino-1H-1-imidazolyl)-1-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanone acetate 330792-38-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-[(2-hydroxyethyl)amino]-1-propanone 330792-40-0P, 2-(2-Amino-1H-1-imidazolyl)-1-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-1-ethanone acetate 330792-41-1P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-[(2-hydroxyethyl)amino]-1-ethanone 330792-42-2P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-[(2-hydroxyethyl)amino]-1-propanone 330792-46-6P, Trans-N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide maleate 330792-48-8P, trans-N-[4-[4-Amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide 330792-50-2P, 3-[3-Methoxy-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-52-4P, trans-N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylcyclopropane-1-carboxamide 330792-54-6P 330792-55-7P 330792-56-8P, 1-(Aminomethyl)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 461697-05-2P, N-[4-[4-Amino-1-[4-(morpholinomethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-07-4P, N-[4-[4-Amino-1-[4-[(4-hydroxypiperidino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-08-5P, N-[4-[4-Amino-1-[4-[[4-(2-hydroxyethyl)piperazino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-10-9P, N-[4-[4-Amino-1-[4-[[4-(2-hydroxyethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461697-12-1P, N-[4-[4-Amino-1-[4-[[3-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-14-3P, N-[4-[4-Amino-1-[4-[[2-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-15-4P, N-[4-[4-Amino-1-[4-[[(2-morpholinoethyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-17-6P, N-[4-[4-Amino-1-[4-[[4-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461697-18-7P, N-[4-[4-Amino-1-[4-[[4-(2-methoxyethyl)piperazino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-19-8P 461697-20-1P 461697-21-2P, N-[4-[4-Amino-1-[4-[[[3-(1H-1-imidazolyl)propyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-22-3P, N-[4-[4-Amino-1-[4-[[(4-hydroxybutyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-23-4P, N-[4-[4-Amino-1-[4-[[(3-methoxypropyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-25-6P, N-[4-[4-Amino-1-[4-[[[3-(dimethylamino)propyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-

(trifluoromethyl)benzamide monoacetate 461697-26-7P, L-Histidine, N-[[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]methyl]-, methyl ester 461697-27-8P, N-[4-[4-Amino-1-[4-[[(2-methoxyethyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-28-9P, N-[4-[4-Amino-1-[4-[[[2-(dimethylamino)ethyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-29-0P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-32-5P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide trimaleate 461697-35-8P, N-[4-[4-Amino-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461697-37-0P, N-[4-[4-Amino-1-[2-[(2-hydroxyethyl)amino]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide monomaleate 461697-39-2P, N-[4-[4-Amino-1-[2-(dimethylamino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide monomaleate 461697-41-6P 461697-43-8P, Cis-N-[4-[4-Amino-1-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-44-9P, Trans-N-[4-[4-Amino-1-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-47-2P, Cis-3-[[4-[4-Amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoic acid 461697-48-3P, Trans-3-[[4-[4-Amino-3-[3-methoxy-4-[(2-methoxy-4-trifluoromethylbenzoyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoic acid 461697-51-8P, N-[4-(4-Amino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-54-1P, N-[4-[4-Amino-1-(3-hydroxycyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-56-3P, 1H-Indole-1-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461697-59-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(trifluoromethoxy)-, monoacetate 461697-61-0P, Benzenebutanamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461697-63-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methyl-, monoacetate 461697-65-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methoxy-, monoacetate 461697-67-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, monoacetate 461697-69-8P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)-, monoacetate 461697-71-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461697-73-4P
, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methoxy-, monoacetate 461697-75-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-fluoro-, monoacetate 461697-77-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-

pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-chloro-, monoacetate 461697-79-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-chloro-, monoacetate 461697-81-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-methoxy-, monoacetate 461697-83-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-ethyl-, monoacetate 461697-85-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methyl-, monoacetate 461697-87-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-nitro-, monoacetate 461697-89-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenyl-, monoacetate 461697-91-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-ethyl-, monoacetate 461697-93-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-(2-propenyl)-, monoacetate 461697-95-0P, 1H-Indole-1-acetic acid, 2-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, monoacetate 461697-97-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(1-methyl-3-piperidinyl)-3-(4-phenoxyphenyl)-, acetate 461698-00-0P, 1-[1-(2-Methoxyethyl)-3-piperidyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-03-3P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazol[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethyl)benzamide dimaleate 461698-05-5P 461698-07-7P, Trans-3-[3-Chloro-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-09-9P 461698-11-3P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylcarbonyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide monomaleate 461698-13-5P, Cyclopropanecarboxamide, N-[4-[4-amino-1-[cis-4-(2-aminoethyl)-4-hydroxycyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-, (1R,2R)-rel-, acetate (salt) 461698-15-7P 461698-17-9P 461698-19-1P, 2-Pyrrolidinecarboxamide, N-[4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, (2R)-, monoacetate 461698-22-6P, 3-(4-Phenoxyphenyl)-1-(4-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-23-7P, N-[4-[4-Amino-1-(4-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461698-25-9P, 1-(6-Amino-3-pyridyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-26-0P, 3-(4-Phenoxyphenyl)-1-(2-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-30-6P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(1H-indol-2-ylmethyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-32-8P, Trans-3-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]-1,2-dihydro-2-pyridinone diacetate 461698-34-0P, Trans-5-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyanilino]methyl]-4-chloro-1,3-thiazol-2-amine diacetate 461698-36-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[3-methoxy-4-[[(5-methyl-3-isoxazolyl)methyl]amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-38-4P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[3-methoxy-4-[(4-thiazolylmethyl)amino]phenyl]-1-[trans-4-(4-

methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-40-8P, Trans-3-[4-[(4,6-Dichloro-2,3-dihydrobenzo[b]furan-3-yl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 461698-42-0P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(4-chloro-2,3-dihydro-3-benzofuranyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-44-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(4,6-dichloro-2,3-dihydro-3-benzofuranyl)amino]-3-methoxyphenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-48-6P, 3-[4-[[(Benzo[b]furan-2-yl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-50-0P, 3-[4-[[(2-Methoxy-3-pyridyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-52-2P, 3-[4-[[(5-Methyl-2-thienyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-54-4P, 3-[4-[(2-Furylmethyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-56-6P, 3-[4-(Benzylamino)phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-58-8P, 3-[4-[(2-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-60-2P, 3-[4-[(3-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-62-4P, 3-[4-[(4-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-64-6P 461698-66-8P 461698-68-0P, 3-[4-[[(2-Methyl-1,3-thiazol-4-yl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-70-4P, 3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-72-6P 461698-74-8P, 3-[4-[[(Benzo[b]furan-2-yl)methyl]amino]-3-methoxyphenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate

RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461698-76-0P, 3-[4-[(2,3-Dihydrobenzo[b]furan-3-yl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-78-2P, trans-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1H-benzo[d]isothiazole-1,1-dione monoacetate 461698-81-7P, Cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1H-benzo[d]isothiazole-1,1-dione diacetate 461698-83-9P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]benzo[d]isoxazol-3-amine monoacetate 461698-89-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]benzo[d]isoxazol-3-amine diacetate 461698-91-9P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(1,2-benzisoxazol-3-ylamino)phenyl]-1-(4-piperidinyl)-, acetate 461698-93-1P, Trans-3-[4-(1H-3-Indazolylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-98-6P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-(trifluoromethyl)benzo[d]isoxazol-3-amine monoacetate 461699-04-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-07-0P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-08-1P, N-[4-[4-Amino-1-(1-methyl-3-piperidyl)-1H-

pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-10-5P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-16-1P, Piperidine, 3-[4-amino-3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-[(dimethylamino)acetyl]-, acetate 461699-17-2P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-methyl-2-(methylamino)-1-propanone 461699-21-8P, N-4-[4-Amino-1-(3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-24-1P, N-[4-[4-Amino-1-(1-methyl-3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-29-6P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carbonitrile 461699-33-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-37-6P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-1,3-benzoxazol-2-amine 461699-40-1P, Cis-N-[4-[4-Amino-1-[4-(dimethylamino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-45-6P, trans-N-[4-[4-Amino-1-[4-(dimethylamino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-53-6P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-54-7P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-55-8P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-56-9P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-57-0P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5-chloro-2-benzoxazolyl)amino]phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-58-1P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-(methylamino)cyclohexyl]- 461699-59-2P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-(2-nitrophenyl)-1,3-thiazol-2-amine 461699-60-5P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzothiazol-2-amine 461699-62-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,6-dihydro-4H-cyclopenta[d][1,3]thiazol-2-amine 461699-63-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-phenyl-1,3-thiazol-2-amine 461699-64-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine 461699-65-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-isopropyl-4-phenyl-1,3-thiazol-2-amine 461699-66-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-phenyl-5-propyl-1,3-thiazol-2-amine 461699-67-2P, 3-[4-(1,3-Benzoxazol-2-ylmethyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-68-3P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-(1,3-benzoxazol-2-ylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 461699-69-4P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(4-methylphenyl)-1,3-thiazol-2-amine

461699-71-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(2-methylphenyl)-1,3-thiazol-2-amine 461699-72-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(3-methylphenyl)-1,3-thiazol-2-amine 461699-73-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide bismaleate 461699-76-3P 461699-79-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461699-84-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-fluoro-4-(trifluoromethyl)-, acetate 461699-86-5P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461699-88-7P, Benzenepropanamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461699-90-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-cyclopentylpropanamide diacetate 461699-92-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1,3-dimethyl-1H-5-pyrazolecarboxamide diacetate 461699-94-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(2-thienyl)acetamide diacetate 461699-95-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylacetamide 461699-96-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(3,4-dimethoxyphenyl)acetamide 461699-97-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenoxypropanamide 461699-99-0P, 5-Isoxazolecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-01-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-pyridinecarboxamide triacetate 461700-03-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,4-difluorobenzamide diacetate 461700-05-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,5-difluoro-, acetate 461700-07-2P, 2-Furancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-08-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethylpropanamide 461700-09-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-cyanobenzamide 461700-11-8P, Cyclopropanecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-13-0P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-methyl-, acetate 461700-14-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-fluoro-3-methylbenzamide 461700-15-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(dimethylamino)benzamide 461700-16-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,3-difluoro-4-methylbenzamide 461700-18-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]isonicotinamide diacetate 461700-20-9P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-22-1P, 1H-Pyrrole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, acetate 461700-24-3P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-

methoxyphenyl]-6-methyl-, acetate 461700-26-5P, Pyrazinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-28-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-iodobenzamide diacetate 461700-29-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-bromobenzamide 461700-30-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-phenoxybenzamide 461700-31-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-fluorobenzamide 461700-32-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-chlorobenzamide 461700-33-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methoxybenzamide 461700-34-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 461700-35-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-nitrobenzamide 461700-36-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]thiophene-2-carboxamide 461700-37-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide 461700-38-9P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methylbenzamide 461700-40-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(1,1-dimethylethyl)-, acetate 461700-42-5P, Benzoic acid, 4-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, methyl ester, acetate 461700-43-6P, 4-[[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyanilino]carbonyl]benzoic acid 461700-45-8P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-chloro-, acetate 461700-47-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-bromo-, acetate 461700-49-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-methoxy-, acetate 461700-50-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylbenzamide 461700-52-7P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethyl)-, acetate 461700-54-9P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethoxy)-, acetate 461700-55-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methoxybenzamide 461700-56-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethyl)benzamide 461700-58-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-3-(trifluoromethyl)-, acetate 461700-60-7P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-6-(trifluoromethyl)-, acetate 461700-62-9P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-5-(trifluoromethyl)-, acetate 461700-63-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-5-methylbenzamide 461700-64-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-chloro-2-fluorobenzamide 461700-65-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-benzoylbenzamide 461700-66-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-acetylbenzamide 461700-67-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-

d]pyrimidin-3-yl]-2-methoxyphenyl]-4-isopropylbenzamide
461700-69-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-ethyl-, acetate
461700-71-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-propyl-, acetate
461700-73-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-cyclohexyl-,
acetate 461700-75-4P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-
1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-ethoxy-,
acetate 461700-77-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-
1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-
(methylsulfonyl)-, acetate 461700-79-8P, N-[4-[4-Amino-1-(4-
piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-
isopropoxybenzamide diacetate 461700-81-2P, Benzamide,
N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
methoxyphenyl]-4-(1H-imidazol-1-yl)-, acetate 461700-83-4P,
Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-, acetate
461700-84-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methoxybenzo[b]furan-2-
carboxamide 461700-86-7P, 2-Benzofurancarboxamide,
N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
methoxyphenyl]-5-bromo-, acetate 461700-87-8P,
N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
methoxyphenyl]-5-methylbenzo[b]furan-2-carboxamide 461700-88-9P,
N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
methoxyphenyl]-3-methylbenzo[b]furan-2-carboxamide 461700-89-0P,
N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
methoxyphenyl]-5-nitrobenzo[b]furan-2-carboxamide 461700-91-4P,
2-Benzofurancarboxamide, 5-amino-N-[4-[4-amino-1-(4-piperidinyl)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate
461700-93-6P, 2-Benzofurancarboxamide, 5-(acetylamino)-N-[4-[4-
(acetylamino)-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
methoxyphenyl]-, acetate 461700-95-8P, 2-Benzofurancarboxamide,
5-(acetylamino)-N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-97-0P,
2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methyl-, acetate
461700-99-2P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-
piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-
methoxy-, acetate 461701-00-8P, N-[4-[4-Amino-1-(1-
methyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-
yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-04-2P,
N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-
amine 461701-06-4P, Cis-N-[4-[4-Amino-1-[4-(4-
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
fluorophenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-09-7P,
Cis-3-[4-(Imidazo[1,2-a]pyridin-2-yl)phenyl]-1-[4-(4-
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine
461701-11-1P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-
yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]tetrahydro-1H-
pyrrol-1-yl]-2-(dimethylamino)-1-ethanone 461701-13-3P,
1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-
1H-pyrazolo[3,4-d]pyrimidin-1-yl]tetrahydro-1H-pyrrol-1-yl]-2-methyl-
2-(methylamino)-1-propanone 461701-16-6P, N-[4-[4-Amino-1-
(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-
5,7-dimethyl-1,3-benzoxazol-2-amine 461701-20-2P,
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-isopropyl-1,3-benzoxazol-2-
amine diacetate 461701-23-5P 461701-25-7P, N-[4-[4-Amino-1-[1-(2-
methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-

3-yl]phenyl]-5-ethyl-1,3-benzoxazol-2-amine monoacetate 461701-26-8P 461701-28-0P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-1,3-benzoxazol-2-amine monoacetate 461701-30-4P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-chloro-1,3-benzoxazol-2-amine monoacetate 461701-32-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimesylate 461701-34-8P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]trans-2-phenyl-1-cyclopropanecarboxamide 461701-36-0P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 461701-37-1P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(1,3-oxazol-5-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-39-3P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 461701-40-6P 461701-41-7P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-1-ethanol 461701-42-8P

, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-2-methyl-1-propanol 461701-43-9P, 4-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-1-butanol 461701-44-0P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N',N'-dimethyl-1,2-ethanediamine 461701-45-1P, 1-[4-[[(3-Methoxypropyl)amino]methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-46-2P, 1-[4-[[(2-Methoxyethyl)amino]methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-47-3P, 3-(4-Phenoxyphenyl)-1-[4-(1,3-thiazolan-3-ylmethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-48-4P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl](2-hydroxyethyl)amino]-1-ethanol 461701-49-5P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N,N',N'-trimethyl-1,2-ethanediamine 461701-50-8P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-4-piperidinol 461701-51-9P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N,N',N'-trimethyl-1,3-propanediamine 461701-52-0P, [1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-4-piperidyl]methanol 461701-53-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide dimaleate 461701-55-3P, N-[4-[4-Amino-1-(1-ethyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-56-4P, N-[4-[4-Amino-1-[1-(cyclopropylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-58-6P, Benzamide, N-[4-[4-amino-1-[1-(1H-pyrrol-1-ylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-59-7P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-61-1P, Benzamide, N-[4-[4-amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-63-3P, Benzamide, N-[4-[4-amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-65-5P, Benzamide, N-[4-[4-amino-1-[1-[(4-methyl-1H-imidazol-5-yl)methyl]-4-

piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-66-6P, N-[4-[4-Amino-1-[1-(1,3-thiazol-2-ylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-67-7P, N-[4-[4-Amino-1-[1-[[5-(hydroxymethyl)-2-furyl]methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-68-8P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-69-9P, N-[4-[4-Amino-1-(1-isopropyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-71-3P, Benzamide, N-[4-[4-amino-1-[1-(2-methylpropyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-72-4P, N-[4-[4-Amino-1-[1-(2-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-73-5P, N-[4-[4-Amino-1-[1-(3-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-74-6P, Benzamide, N-[4-[4-amino-1-[1-(1H-imidazol-1-ylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-75-7P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-76-8P, tert-Butyl 4-[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidyl]-1-piperidinecarboxylate 461701-77-9P, N-[4-[4-Amino-1-[1-(tetrahydrothiophen-3-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-78-0P, N-[4-[4-Amino-1-(1-benzyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-80-4P, Benzamide, N-[4-[4-amino-1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-81-5P 461701-82-6P 461701-84-8P, Benzamide, N-[4-[4-amino-1-[1-[(1-methyl-1H-pyrrol-2-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-86-0P , Benzamide, N-[4-[4-amino-1-[1-[(5-methyl-2-furanyl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-87-1P, N-[4-[4-Amino-1-[1-(2-thienylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-89-3P 461701-91-7P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461701-92-8P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-thiopyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-93-9P, 4-[[4-[4-Amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]methyl]-1-pyridine-N-oxide 461701-94-0P, N-[4-[4-Amino-1-[1-(2-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-95-1P, N-[4-[4-Amino-1-[1-(3-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-96-2P, N-[4-[4-Amino-1-[1-(4-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-97-3P, N-[4-[4-Amino-1-[1-[3-

(methylsulfanyl)propyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-98-4P, N-[4-[4-Amino-1-[1-[(5-methyl-2-thienyl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-99-5P, N-[4-[4-Amino-1-[1-(3-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-00-1P, N-[4-[4-Amino-1-[1-(4-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-01-2P, N-[4-[4-Amino-1-[1-(2-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-02-3P, N-[4-[4-Amino-1-[1-(4-methoxybenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-03-4P, N-[4-[4-Amino-1-[1-(1-acetylpiperidin-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-05-6P, Benzamide, N-[4-[4-amino-1-[1-[(3-methyl-1H-pyrazol-1-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461702-06-7P, Methyl 2-[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetate 461702-07-8P 461702-10-3P, Benzamide, N-[4-[4-amino-1-[1-(2-methoxyethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461702-11-4P, N-[4-[4-Amino-1-[1-(cyanomethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-13-6P, 1-Piperidineacetamide, 4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-, acetate 461702-15-8P 461702-17-0P, N-[4-[4-Amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-20-5P 461702-23-8P, N-[4-[4-Amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-25-0P, N-[4-[4-Amino-1-[1-(2,2-difluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-28-3P, N-[4-[4-Amino-1-(1-ethyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-31-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-[1-[(3-methyl-1H-pyrazol-1-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, acetate 461702-33-0P, N-[4-[4-Amino-1-[1-(3-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide

RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461702-35-2P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-36-3P, N-[4-[4-Amino-1-[1-(1-acetylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 461702-37-4P 461702-38-5P, N-[4-[4-Amino-1-[3-(4-methylpiperazino)propyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-41-0P, N-[4-[4-Amino-1-(3-morpholinopropyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-

1-methyl-1H-2-indolecarboxamide 461702-43-2P, N-[4-[4-Amino-1-[3-(1H-1-imidazolyl)propyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-46-5P, N-[4-[4-Amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-47-6P, N-[4-[4-Amino-1-(1-isopropyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-48-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-49-8P, N-[4-[4-Amino-1-[1-(1H-imidazol-4-ylmethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-50-1P, N-[4-[4-Amino-1-[1-[(3-methyl-1H-pyrazol-4-yl)methyl]tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-51-2P 461702-52-3P 461702-53-4P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-isopropyl-1,3-benzoxazol-2-amine 461702-56-7P, cis-Methyl 4-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylate 461702-57-8P, cis-4-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylic acid 461702-58-9P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-61-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461702-64-7P 461702-65-8P, (S)-N-[4-[4-Amino-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461702-72-7P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carboxamide triacetate 461702-75-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)-, monoacetate 461702-77-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(methylsulfonyl)-, monoacetate 461702-79-4P, 1H-Indole-5-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461702-81-8P, 1H-Indole-6-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461702-83-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(phenylmethoxy)-, monoacetate 461702-85-2P, β-Alanine, N-[3-[4-[(1H-indol-2-ylcarbonyl)amino]-3-methoxyphenyl]-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, monoacetate 461702-87-4P, 1H-Indole-1-propanoic acid, 2-[[[4-[4-[(2-carboxyethyl)amino]-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, monoacetate 461702-89-6P, 1H-Indole-1-acetamide, 2-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-N,N-dimethyl-, monoacetate 461702-91-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-hydroxy-1H-2-indolecarboxamide monoacetate 461702-93-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-hydroxy-1H-2-indolecarboxamide monoacetate 461702-95-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-amino-1H-2-indolecarboxamide monoacetate 461702-97-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-3-indolecarboxamide monoacetate 461703-00-4P,

N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-4-indolecarboxamide monoacetate 471925-60-7P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine maleate 471925-63-0P, Cis-3-[4-[(1H-4-Imidazolylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 471925-65-2P, Cis-3-[4-[(1H-2-Indolylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471925-69-6P 471925-70-9P 471925-71-0P 471925-72-1P 471925-73-2P 471925-74-3P 471925-75-4P 471925-76-5P 471925-77-6P 471925-78-7P 471925-79-8P 471925-80-1P 471925-81-2P 471925-87-8P 471925-88-9P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide trimaleate 471925-93-6P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(2-methoxyphenyl)propanamide 471925-94-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-methoxyphenyl)propanamide 471925-95-8P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(3-methoxyphenyl)propanamide 471925-96-9P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-methylphenyl)propanamide 471925-97-0P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-fluorophenyl)propanamide 471925-98-1P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(3,4-difluorophenyl)propanamide 471926-08-6P, Trans-3-[3-Methoxy-4-[(5-methyl-2-furyl)methyl]aminophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 471926-09-7P 471926-14-4P, Cis-3-[3-[2-(1H-2-Imidazolyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471926-16-6P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-anilinoacetamide 471926-23-5P, N,N-Methoxymethyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 471926-25-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-(1H-4-imidazolyl)-1-propanone 471926-26-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(2-methoxyethyl)piperidino]-1-ethanone 471926-61-1P 471926-74-6P 471926-76-8P 471926-82-6P 471927-20-5P, Trans-3-[3-Methoxy-4-[[(3-methyl-1H-4-pyrazolyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-25-0P, Trans-3-[4-[(1H-7-Indolylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-28-3P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[[(5-methyl-1H-4-pyrazolyl)methyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-44-3P, N-(1H-2-Imidazolyl)-2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetamide 471927-45-4P, trans-N-[4-[4-Amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide 471927-46-5P, Trans-N-[4-[4-Amino-1-[(4-hydroxy-4-piperidyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-

d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 18 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:658109 HCAPLUS
DOCUMENT NUMBER: 137:201312
TITLE: Preparation of N-(piperidin-4-yl) amides for **treating** a chemokine mediated **diseases**
INVENTOR(S): Brough, Stephen; McInally, Thomas; Perry, Matthew; Springthorpe, Brian
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066460	A1	20020829	WO 2002-SE269	20020218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1363902	A1	20031126	EP 2002-711619	20020218
EP 1363902	B1	20040915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518742	T2	20040624	JP 2002-565975	20020218
AT 276246	E	20041015	AT 2002-711619	20020218
US 2004102483	A1	20040527	US 2003-468179	20030818
US 6958350	B2	20051025		
PRIORITY APPLN. INFO.:			GB 2001-4050 A	20010219
			WO 2002-SE269 W	20020218

OTHER SOURCE(S): MARPAT 137:201312
GI



I



II

AB The title compds. [I; R1 = (un)substituted Ph; R2-R4 = H, alkyl; R5 = alkyl, aryl, heteroaryl, etc.; X = (CH2)n; n = 1-4; Y = 2,4-, 2,5- or 3,5-linking 5-membered heteroaryl comprising 2-3 heteroatoms selected from N, O, and S], useful in therapy, esp. for the **treatment** of **chemokine receptor** related **diseases** and **conditions**, were prepd. Thus, a 2-step synthesis of the propionamide II, starting with 1-(3,4-dichlorobenzyl)piperidin-4-ylamine and Me 3-chlorocarbonylpropionate, was given. The exemplified compds. I were found to be antagonists of the eotaxin mediated [Ca+2]i in human eosinophils and/or antagonists of the MIP-1α mediated [Ca+2]i in human monocytes (no data). Certain exemplified compds. I were found to be antagonists of the eotaxin mediated human eosinophil chemotaxis (no data).

IT **453524-35-1P 453524-38-4P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of N-(piperidin-4-yl) amides for **treating** a chemokine mediated **diseases**)

RN 453524-35-1 HCAPLUS
CN 4-Thiazoleacetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-2-(phenylamino)- (9CI) (CA INDEX NAME)



RN 453524-38-4 HCAPLUS
CN 4-Thiazoleacetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-5-methyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



IT **259654-76-7 453524-57-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-(piperidin-4-yl) amides for **treating** a chemokine mediated **diseases**)
RN 259654-76-7 HCAPLUS
CN 4-Thiazoleacetic acid, 5-methyl-2-(phenylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 453524-57-7 HCAPLUS
CN 4-Thiazoleacetic acid, 2-(phenylamino)-, ethyl ester (9CI) (CA INDEX NAME)



IC ICM C07D401-12
ICS C07D401-14; C07D405-12; C07D405-14; C07D411-12; C07D411-14; C07D413-12; C07D413-14; C07D417-12; C07D417-14; C07D419-12; C07D419-14; A61K031-4525; A61K031-4535; A61K031-4545; A61P011-00; A61P017-00; A61P029-00; A61P037-00
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
IT Eotaxin
Macrophage inflammatory protein 1α
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(prepn. of N-(piperidin-4-yl) amides as antagonists of the eotaxin mediated [Ca+2]i in human eosinophils and/or antagonists of the MIP-1α mediated [Ca+2]i in human monocytes)
IT Human
(prepn. of N-(piperidin-4-yl) amides for **treating** a chemokine mediated **diseases**)
IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(prepn. of N-(piperidin-4-yl) amides for **treating** a **chemokine** mediated **diseases**)
IT 453524-44-2P

RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of N-(piperidin-4-yl) amides for **treating** a chemokine mediated **diseases**)

IT 453523-76-7P 453523-78-9P 453523-80-3P 453523-82-5P
453523-84-7P 453523-86-9P 453523-88-1P 453523-90-5P
453523-92-7P 453523-94-9P 453523-96-1P 453523-98-3P
453523-99-4P 453524-00-0P 453524-01-1P 453524-02-2P
453524-03-3P 453524-04-4P 453524-05-5P 453524-06-6P
453524-07-7P 453524-08-8P 453524-09-9P 453524-10-2P
453524-11-3P 453524-12-4P 453524-13-5P 453524-14-6P
453524-15-7P 453524-16-8P 453524-17-9P 453524-18-0P
453524-19-1P 453524-20-4P 453524-21-5P 453524-22-6P
453524-23-7P 453524-24-8P 453524-25-9P 453524-26-0P
453524-27-1P 453524-28-2P 453524-29-3P 453524-32-8P
453524-35-1P 453524-38-4P 453524-41-9P
453524-45-3P 453524-46-4P 453524-47-5P 453524-48-6P
453524-49-7P 453524-50-0P 453524-51-1P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of N-(piperidin-4-yl) amides for **treating** a chemokine mediated **diseases**)

IT 100-52-7, Benzaldehyde, reactions 103-72-0, Isothiocyanatobenzene 1490-25-1, Methyl 3-chlorocarbonylpropionate 2740-81-0, 1-Chloro-2-isothiocyanatobenzene 36239-09-5, Ethyl malonyl chloride 50541-93-0, 1-(Phenylmethyl)-4-piperidinamine 92539-28-1 160358-08-7 **259654-76-7 453524-57-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-(piperidin-4-yl) amides for **treating** a chemokine mediated **diseases**)

IT 453524-52-2P 453524-53-3P 453524-54-4P 453524-55-5P
453524-56-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-(piperidin-4-yl) amides for **treating** a chemokine mediated **diseases**)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:504649 HCAPLUS
DOCUMENT NUMBER: 137:83638
TITLE: Concomitant drugs of p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents
INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Miwatashi, Seiji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002051442 A1 20020704 WO 2001-JP11353
200112
25
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2436739 AA 20020704 CA 2001-2436739
200112
25
JP 2002302458 A2 20021018 JP 2001-392778
200112
25
EP 1354603 A1 20031022 EP 2001-271876
200112
25
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004097555 A1 20040520 US 2003-451839
200306
25
PRIORITY APPLN. INFO.: JP 2000-396220 A
200012
26
JP 2001-27572 A
200102
02
WO 2001-JP11353 W
200112
25

OTHER SOURCE(S): MARPAT 137:83638

AB Drugs comprising a combination of one or more p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with one or more agents selected from the group consisting of: (1) nonsteroidal anti-**inflammatory** agents; (2) **disease**-modification antirheumatics; (3) anti-cytokine drugs; (4) immunomodulators; (5) steroidal drugs; and (6) c-JUN N-terminal kinase inhibitors. These concomitant drugs are useful as preventives and remedies for **diseases** such as rheumatism and arthritis and other **diseases.** For example, tablets contg. [4-(3,5-dimethylphenyl)-5-(2-phenylmethyloxy-4-pyridyl)-1,3-thiazol-2-yl]amine 50 mg/tablet are administered with tablets contg. rofecoxib 5 mg/tablet.

IT **97422-54-3P 97422-55-4P 97422-56-5P**
224038-79-3P 224038-87-3P
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

RN 97422-54-3 HCAPLUS

CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 97422-55-4 HCAPLUS
CN 2-Thiazolamine, N-phenyl-5-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)-(9CI) (CA INDEX NAME)



RN 97422-56-5 HCAPLUS
CN Phenol, 4-[2-(phenylamino)-5-(3-pyridinyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 224038-79-3 HCAPLUS
CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 224038-87-3 HCAPLUS
CN Acetamide, N-[4-(4-methoxyphenyl)-5-(4-pyridinyl)-2-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



IC ICM A61K045-06
ICS A61K031-4439; A61K031-4545; A61K031-497; A61K031-506; A61K031-5377; A61P001-04; A61P001-16; A61P003-10; A61P007-06; A61P009-02; A61P009-04; A61P009-10; A61P011-00; A61P011-06; A61P013-12; A61P017-04; A61P017-06; A61P019-02; A61P019-10

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT **Inflammation**
(Crohn's **disease**; combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT Addison's disease
Allergy
Allergy inhibitors
Alzheimer's disease
Anti-Alzheimer's agents
Anti-inflammatory agents
Antianginal agents
Antiarteriosclerotics
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antihypertensives
Antihypotensives
Antiparkinsonian agents
Antitumor agents
Antiviral agents
Arteriosclerosis
Arthritis
Asthma
Cachexia
Cardiovascular agents
Diabetes mellitus
Hypertension
Immunomodulators
Meningitis
Multiple sclerosis
Neoplasm
Osteoarthritis
Osteoporosis
Parkinson's disease
Psoriasis
Rheumatic diseases
Silicosis
Transplant rejection
Tuberculosis
(combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT Tumor necrosis factors
RL: **BSU (Biological study, unclassified); BIOL**

(Biological study)
(combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT Steroids, biological studies
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT Cytokines
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(inhibitors; combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT 165245-96-5, p38 Kinase
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT 97422-32-7P 97422-44-1P 97422-45-2P 99478-69-0P 99478-80-5P
224038-59-9P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT 303162-57-4 303162-58-5 303162-59-6 303162-60-9 303162-61-0
303162-62-1
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT 97422-27-0P 97422-28-1P 97422-29-2P 97422-30-5P 97422-31-6P
97422-33-8P 97422-34-9P 97422-35-0P 97422-36-1P 97422-37-2P
97422-38-3P 97422-39-4P 97422-41-8P 97422-42-9P 97422-43-0P
97422-46-3P 97422-47-4P 97422-48-5P 97422-49-6P 97422-50-9P
97422-51-0P 97422-52-1P 97422-53-2P **97422-54-3P**
97422-55-4P **97422-56-5P** 97422-57-6P
97422-58-7P 97422-59-8P 97422-60-1P 97422-61-2P 97422-62-3P
97422-63-4P 97422-64-5P 97422-65-6P 97422-66-7P 97422-67-8P
97422-68-9P 97422-69-0P 97422-70-3P 97422-71-4P 97422-72-5P
97422-73-6P 97422-74-7P 97422-75-8P 97422-76-9P 97422-77-0P
97422-78-1P 97422-79-2P 97422-80-5P 97422-81-6P 97422-82-7P
97422-83-8P 97422-84-9P 97422-85-0P 97422-86-1P 97422-87-2P
97422-88-3P 97422-89-4P 97443-15-7P 97443-16-8P 97443-17-9P
99478-71-4P 99478-73-6P 99478-74-7P 99478-75-8P 99478-76-9P
99478-78-1P 99478-79-2P 99478-81-6P 99478-82-7P 99478-83-8P
99478-84-9P 99478-85-0P 99478-86-1P 99478-87-2P 99478-88-3P
99478-89-4P 99496-91-0P 99496-92-1P 99496-93-2P 223914-57-6P
223914-58-7P 223914-59-8P 223914-63-4P 224037-86-9P
224037-87-0P 224037-88-1P 224037-89-2P 224037-90-5P
224037-91-6P 224037-92-7P 224037-93-8P 224037-94-9P
224037-95-0P 224037-96-1P 224037-98-3P 224037-99-4P
224038-00-0P 224038-01-1P 224038-02-2P 224038-03-3P
224038-04-4P 224038-05-5P 224038-06-6P 224038-07-7P
224038-08-8P 224038-09-9P 224038-11-3P 224038-13-5P 224038-1
4-6P 224038-15-7P 224038-16-8P 224038-17-9P 224038-18-0P
224038-19-1P 224038-20-4P 224038-21-5P 224038-22-6P
224038-23-7P 224038-24-8P 224038-25-9P 224038-26-0P
224038-27-1P 224038-28-2P 224038-29-3P 224038-30-6P
224038-31-7P 224038-32-8P 224038-33-9P 224038-34-0P
224038-35-1P 224038-36-2P 224038-38-4P 224038-39-5P
224038-40-8P 224038-41-9P 224038-42-0P 224038-43-1P

224038-44-2P 224038-45-3P 224038-46-4P 224038-47-5P
224038-48-6P 224038-49-7P 224038-50-0P 224038-51-1P
224038-52-2P 224038-53-3P 224038-54-4P 224038-55-5P
224038-56-6P 224038-57-7P 224038-58-8P 224038-60-2P
224038-61-3P 224038-62-4P 224038-63-5P 224038-64-6P
224038-65-7P 224038-66-8P 224038-67-9P 224038-68-0P
224038-69-1P 224038-70-4P 224038-71-5P 224038-72-6P
224038-73-7P 224038-74-8P 224038-75-9P 224038-76-0P
224038-77-1P 224038-78-2P **224038-79-3P** 224038-80-6P
224038-81-7P 224038-82-8P 224038-83-9P 224038-84-0P
224038-85-1P 224038-86-2P **224038-87-3P** 224038-88-4P
224038-89-5P 224038-90-8P 224038-91-9P 224038-92-0P
224038-93-1P 224038-94-2P 224038-95-3P 224038-96-4P
224038-97-5P 224038-98-6P 224038-99-7P 224039-00-3P
224039-01-4P 224039-02-5P 224039-03-6P 224039-04-7P
224039-05-8P 224039-06-9P 224039-07-0P 224039-08-1P
224039-09-2P 224039-10-5P 224039-11-6P 224039-12-7P
224039-13-8P 224039-14-9P 224039-15-0P 224039-16-1P
224039-18-3P 224039-19-4P 224039-20-7P 224039-21-8P
224039-22-9P 224039-23-0P 224039-24-1P 224039-25-2P
224039-26-3P 224039-27-4P 224039-28-5P 224039-30-9P
224039-31-0P 224039-32-1P 224039-33-2P 224039-34-3P
224039-36-5P 224039-37-6P 224039-38-7P 224039-39-8P
224039-40-1P 224039-42-3P 224039-44-5P 224039-46-7P
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT 224039-49-0P 224039-51-4P 224039-54-7P 224039-55-8P
224039-56-9P 224039-57-0P 224039-58-1P 224039-59-2P
224039-60-5P 224039-61-6P 224039-63-8P 224039-64-9P
224039-65-0P 224039-66-1P 224039-67-2P 224039-68-3P
224039-70-7P 224039-72-9P 224039-73-0P 224039-74-1P
224039-76-3P 224039-77-4P 224039-78-5P 224039-79-6P
224039-81-0P 224039-82-1P 224039-83-2P 224039-85-4P
224039-86-5P 224039-87-6P 224039-88-7P 224039-90-1P
224039-91-2P 224039-92-3P 224039-93-4P 224039-95-6P
224039-96-7P 224039-97-8P 224039-99-0P 224040-00-0P
224040-01-1P 224040-02-2P 224040-03-3P 224040-04-4P
224040-06-6P 224040-07-7P 224040-08-8P 224040-10-2P
224040-11-3P 224040-12-4P 224040-13-5P 224040-14-6P
224040-16-8P 224040-17-9P 224040-18-0P 224040-19-1P
224040-21-5P 224040-22-6P 224040-23-7P 224040-24-8P
224040-26-0P 224040-27-1P 224040-28-2P 224040-30-6P
224040-31-7P 224040-33-9P 224040-34-0P 224040-36-2P
224040-37-3P 224040-38-4P 224040-40-8P 224040-41-9P
224040-42-0P 224040-43-1P 224040-44-2P 224040-45-3P
224040-46-4P 224040-47-5P 224040-57-7P 252198-63-3P
252198-66-6P 252198-74-6P 252198-75-7P 252198-97-3P
284486-00-6P 303162-67-6P 303162-68-7P 303162-69-8P
303162-70-1P 303162-71-2P 303162-72-3P 303162-73-4P
303162-74-5P 303162-75-6P 303162-76-7P 303162-77-8P
303162-78-9P 303162-79-0P 303162-80-3P 303162-81-4P
303162-82-5P 303162-84-7P 303162-85-8P 303162-86-9P
303162-87-0P 303162-88-1P 303162-89-2P 303162-90-5P
303162-91-6P 303162-92-7P 303162-93-8P 303162-94-9P
303162-95-0P 303162-96-1P 303162-97-2P 303162-98-3P
303162-99-4P 303163-00-0P 303163-01-1P 303163-02-2P
303163-03-3P 303163-04-4P 303163-05-5P 303163-06-6P
303163-07-7P 303163-08-8P 303163-09-9P 303163-10-2P
303163-11-3P 303163-12-4P 303163-13-5P 303163-14-6P
303163-15-7P 303163-16-8P 303163-17-9P 303163-18-0P

303163-19-1P 303163-20-4P 303163-21-5P 303163-22-6P
303163-23-7P 303163-24-8P 303163-25-9P 303163-26-0P
303163-27-1P 303163-28-2P 303163-29-3P 303163-30-6P
303163-31-7P 303163-32-8P 303163-33-9P 303163-34-0P
303163-35-1P 303163-36-2P 303163-37-3P 303163-38-4P
303163-39-5P 303163-40-8P 303163-41-9P 303163-42-0P
303163-43-1P 303163-44-2P 303787-77-1P 303787-98-6P
325767-68-8P 325767-69-9P 325767-71-3P 325767-72-4P
325767-73-5P 325767-74-6P 325767-75-7P 325767-76-8P
325767-77-9P 325767-79-1P 325767-80-4P 325767-81-5P
325767-82-6P 325767-83-7P 325767-84-8P 325767-85-9P
325767-86-0P 325767-87-1P 325767-88-2P 325767-89-3P
325767-90-6P 325767-91-7P 325767-92-8P 325767-93-9P
325767-94-0P 325767-95-1P 325767-96-2P 325767-97-3P
325767-99-5P 325768-00-1P 325768-02-3P 325768-03-4P
325768-04-5P 325768-05-6P 325768-06-7P 325768-07-8P
325768-08-9P 325768-09-0P 325768-10-3P 325768-11-4P
325768-12-5P 325768-13-6P 325768-14-7P 325768-15-8P
325768-16-9P 325768-17-0P 325768-18-1P 325768-19-2P
325768-20-5P 325768-21-6P 325768-22-7P 325768-23-8P
325768-24-9P 325768-25-0P 325768-27-2P 325768-28-3P
325768-29-4P 325768-30-7P 325768-31-8P 325768-32-9P
325768-33-0P 325768-34-1P 325768-35-2P 325768-36-3P
325768-37-4P 325768-38-5P 325768-40-9P 325768-41-0P
325768-42-1P 325768-43-2P 325768-44-3P
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**;
BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination drugs contg. p38MAP kinase inhibitors and/or
TNF-α prodn. inhibitors with other specified agents)

IT 325768-45-4P 325768-46-5P 325768-47-6P 325768-48-7P
325768-49-8P 325768-50-1P 325768-51-2P 325768-52-3P
325768-53-4P 325768-54-5P 325768-55-6P 325768-56-7P
325768-57-8P 325768-58-9P 325768-59-0P 325768-60-3P
325768-61-4P 325768-62-5P 325768-63-6P 325768-64-7P
325768-65-8P 325768-66-9P 325768-67-0P 325768-68-1P
325768-69-2P 325768-70-5P 325768-71-6P 325768-72-7P
325768-73-8P 325768-75-0P 325768-76-1P 325768-77-2P
325768-78-3P 325768-79-4P 325768-80-7P 325768-81-8P
325768-82-9P 325768-83-0P 325768-84-1P 325768-85-2P
325768-86-3P 325768-87-4P 325768-88-5P 325768-89-6P
325768-90-9P 325768-91-0P 325768-92-1P 325768-93-2P
325768-94-3P 325768-95-4P 325768-96-5P 325768-97-6P
325768-98-7P 325768-99-8P 325769-00-4P 325769-01-5P
325769-02-6P 325769-03-7P 325769-04-8P 325769-05-9P
325769-06-0P 325769-07-1P 325769-08-2P 325769-09-3P
325769-10-6P 325769-11-7P 325769-12-8P 325769-13-9P
325769-14-0P 325769-15-1P 325769-16-2P 325769-17-3P
325769-18-4P 325769-19-5P 325769-20-8P 325769-21-9P
325769-22-0P 325769-23-1P 325769-25-3P 325769-26-4P
325769-27-5P 325769-28-6P 325769-29-7P 325769-30-0P
325769-31-1P 325769-32-2P 325769-33-3P 325769-34-4P
325769-35-5P 325769-36-6P 325769-37-7P 325769-38-8P
325769-39-9P 325769-40-2P 325769-41-3P 325769-42-4P
325769-43-5P 325769-44-6P 325769-45-7P 325769-46-8P
325769-47-9P 325769-48-0P 325769-49-1P 325769-50-4P
325769-51-5P 325769-52-6P 325769-53-7P 325769-54-8P
325769-55-9P 325769-56-0P 325769-57-1P 325769-58-2P
325769-59-3P 325769-60-6P 325769-61-7P 325769-62-8P
325769-63-9P 325769-64-0P 325769-65-1P 325769-66-2P
325769-67-3P 325769-68-4P 325769-69-5P 325769-70-8P
325769-71-9P 325769-73-1P 325769-74-2P 325769-75-3P
325769-76-4P 325769-77-5P 325769-78-6P 325769-79-7P

325769-80-0P 325769-81-1P 325769-82-2P 325769-83-3P
325769-84-4P 325769-85-5P 325769-86-6P 325769-87-7P
325769-88-8P 325769-89-9P 325769-91-3P 325769-92-4P
325769-93-5P 325769-95-7P 325769-96-8P 325769-97-9P
325769-98-0P 325769-99-1P 325770-00-1P 325770-01-2P
325770-02-3P 325770-03-4P 325770-09-0P 325770-10-3P
325770-11-4P 325770-12-5P 325770-13-6P 325770-14-7P
325770-15-8P 325770-16-9P 325770-18-1P 325770-19-2P
325770-20-5P 325770-21-6P 325770-22-7P 325770-23-8P
325770-24-9P 325770-25-0P 325770-26-1P 325770-27-2P
325770-28-3P 325770-29-4P 325770-30-7P 439914-34-8P
439914-35-9P 439914-36-0P 439914-37-1P 439914-40-6P
439914-41-7P 439914-43-9P
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT 162011-90-7, Rofecoxib 303162-64-3 439914-42-8 439914-44-0
439914-45-1 439914-46-2 439914-47-3 439914-49-5 439914-51-9
439914-53-1 439914-55-3 439914-58-6 439914-60-0 439914-61-1
439914-62-2 439914-64-4 439914-66-6 439914-68-8 439914-69-9
439914-70-2 439914-72-4 439914-74-6 439914-76-8 439914-78-0
439914-80-4 439914-81-5 439914-83-7 439914-84-8 439914-85-9
439914-86-0
RL: **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

IT 289898-51-7, c-JUN N-terminal kinase
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(inhibitors; combination drugs contg. p38MAP kinase inhibitors and/or TNF-α prodn. inhibitors with other specified agents)

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:293390 HCAPLUS
DOCUMENT NUMBER: 136:304071
TITLE: Modulation of **CCR4** function for disease therapy
INVENTOR(S): Collins, Tassie; Dairaghi, Daniel J.; Mahmud, Hoosen; McMaster, Brian E.; Medina, Julio C.; Schall, Thomas J.; Xu, Feng; Wang, Xuemei
PATENT ASSIGNEE(S): Tularik Inc., USA; Chemocentryx, Inc.
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030358	A2	20020418	WO 2001-US42625	200110 11

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2425259	AA	20020418	CA 2001-2425259	200110 11
AU 2002013467	A5	20020422	AU 2002-13467	200110 11
US 2002173524	A1	20021121	US 2001-975566	200110 11
EP 1578341	A2	20050928	EP 2001-981850	200110 11

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

WO 2002094264	A1	20021128	WO 2002-US16393	200205 22

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003018022	A1	20030123	US 2002-155605	200205 22
US 2004039035	A1	20040226	US 2003-654112	200309 02

PRIORITY APPLN. INFO.:	US 2000-240022P	P	200010 11
	US 2001-293781P	P	200105 23
	US 2001-975566	B3	200110 11
	WO 2001-US42625	W	200110 11

OTHER SOURCE(S): MARPAT 136:304071

AB The present invention is directed to compds. which are modulators of **CCR4 chemokine receptor** function and are useful in the prevention or **treatment** of inflammatory

conditions and **diseases** such as allergic **diseases, psoriasis**, atopic dermatitis and **asthma.** The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or **treatment** of **diseases** in which **CCR4 chemokine receptors** are involved. Compds. and compns. are provided that bind to the **CCR4 chemokine receptor** and which are useful for **treating diseases** assocd. with **CCR4** activity, such as contact hypersensitivity.

IT **1619-51-8P 219314-97-3P 284668-45-7P**
301236-29-3P 339201-47-7P 339204-07-8P
339204-08-9P 412008-20-9P 412008-21-0P
412008-22-1P 412008-23-2P 412008-24-3P
412008-25-4P 412008-27-6P 412008-28-7P
412008-30-1P 412008-31-2P 412008-32-3P
412008-33-4P 412008-34-5P 412008-36-7P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases, psoriasis**, atopic dermatitis, and **asthma**)

RN 1619-51-8 HCAPLUS
CN 2-Thiazolamine, 4-[4-(1,1-dimethylethyl)phenyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 219314-97-3 HCAPLUS
CN 2-Thiazolamine, N-(3-chloro-2-methylphenyl)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 284668-45-7 HCAPLUS

CN 2-Thiazolamine, 4-(4-chlorophenyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 301236-29-3 HCAPLUS
CN 2-Thiazolamine, 4-(4-methylphenyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 339201-47-7 HCAPLUS
CN 2-Thiazolamine, N-2-naphthalenyl-4-phenyl-5-propyl- (9CI) (CA INDEX NAME)



RN 339204-07-8 HCAPLUS
CN 2-Thiazolamine, N-(4-methylphenyl)-4-phenyl-5-propyl- (9CI) (CA INDEX NAME)



RN 339204-08-9 HCAPLUS
CN 2-Thiazolamine, N-(4-chlorophenyl)-4-phenyl-5-propyl- (9CI) (CA INDEX NAME)



RN 412008-20-9 HCAPLUS
CN 2-Thiazolamine, 4-(1-methylethyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 412008-21-0 HCAPLUS
CN 2-Thiazolamine, 4-(1,1-dimethylethyl)-N-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 412008-22-1 HCAPLUS
CN 2-Thiazolamine, N-(4-chloro-1-naphthalenyl)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 412008-23-2 HCAPLUS
CN 2-Thiazolamine, 4-(1,1-dimethylethyl)-N-1-naphthalenyl-5-propyl-
(9CI) (CA INDEX NAME)



RN 412008-24-3 HCAPLUS
CN 2-Thiazolamine, 4-(1,1-dimethylethyl)-5-methyl-N-1-naphthalenyl-
(9CI) (CA INDEX NAME)



RN 412008-25-4 HCAPLUS
CN 2-Thiazolamine, 4-(1,1-dimethylethyl)-N-[2-(4-morpholinyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 412008-27-6 HCAPLUS
CN 4-Thiazolepropanoic acid, β,β-dimethyl-2-(1-naphthalenylamino)-, ethyl ester (9CI) (CA INDEX NAME)



RN 412008-28-7 HCAPLUS
CN 2-Thiazolamine, 4-(1,1-dimethylethyl)-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 412008-30-1 HCAPLUS
CN 2-Thiazolamine, 4-(2,2-dimethylpropyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 412008-31-2 HCAPLUS
CN 4-Thiazolemethanamine, N,N-bis(2-methylpropyl)-2-(1-naphthalenylamino)- (9CI) (CA INDEX NAME)



RN 412008-32-3 HCAPLUS
CN 2-Thiazolamine, N-(3-bromo-2-methylphenyl)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 412008-33-4 HCAPLUS
CN 4-Thiazolemethanamine, α-methyl-N,N-bis(2-methylpropyl)-2-(1-naphthalenylamino)- (9CI) (CA INDEX NAME)



RN 412008-34-5 HCAPLUS
CN 5-Quinolinamine, N-[4-(1,1-dimethylethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 412008-36-7 HCAPLUS
CN 2-Thiazolamine, 4-(4-ethylphenyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



IT **412008-18-5**
RL: **PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study)**; USES (Uses)
(modulators of **CCR4 chemokine**

receptor function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

RN 412008-18-5 HCAPLUS

CN 2-Thiazolamine, 5-methyl-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



IT **21917-60-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

RN 21917-60-2 HCAPLUS

CN 2-Thiazolamine, 4-(chloromethyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



IC ICM A61K

CC 1-7 (Pharmacology)

ST **chemokine receptor CCR4** modulator disease therapy

IT **Chemokine receptors**

RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**

(**CCR4**; modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

IT Dermatitis

(atopic; modulators of **CCR4 chemokine receptor** function for prevention and **treatment**

of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

IT Dermatitis
(contact; modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

IT Intestine, **disease**
(inflammatory; modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

IT Anti-AIDS agents
Anti-inflammatory agents
Antiasthmatics
Antirheumatic agents
Antitumor agents
Chemotaxis
Human
Human immunodeficiency virus 1
Lupus erythematosus
Psoriasis
T cell (lymphocyte)
(modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

IT Shock (circulatory collapse)
(septic; modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

IT Antidiabetic agents
(type I diabetes; modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

IT **1619-51-8P 219314-97-3P 284668-45-7P**
301236-29-3P 339201-47-7P 339204-07-8P
339204-08-9P 412008-20-9P 412008-21-0P
412008-22-1P 412008-23-2P 412008-24-3P
412008-25-4P 412008-26-5P **412008-27-6P**
412008-28-7P 412008-29-8P **412008-30-1P**
412008-31-2P 412008-32-3P 412008-33-4P
412008-34-5P 412008-35-6P **412008-36-7P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

IT 81191-20-0 411207-58-4 411207-59-5 411207-60-8 411207-61-9
412008-18-5 412008-19-6
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic**

use); **BIOL (Biological study)**; USES (Uses)
(modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

IT 78-81-9, Isobutylamine 78-84-2 108-18-9, Diisopropylamine 134-32-7, 1-Aminonaphthalene 3622-23-9 104860-16-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

IT **21917-60-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(modulators of **CCR4 chemokine receptor** function for prevention and **treatment** of inflammatory **conditions** and **diseases** such as allergic **diseases**, **psoriasis**, atopic dermatitis, and **asthma**)

L32 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:293389 HCAPLUS
DOCUMENT NUMBER: 136:304070
TITLE: Compounds and methods for modulating **CCR4** function for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**
INVENTOR(S): Dairaghi, Daniel J.; McMaster, Brian E.; Schall, Thomas J.
PATENT ASSIGNEE(S): Chemocentryx, Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030357	A2	20020418	WO 2001-US42624	20011011
WO 2002030357	A3	20030515		
WO 2002030357	C2	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002013466	A5	20020422	AU 2002-13466	20011011
US 2002132836	A1	20020919	US 2001-975567	

					200110 11
US 2004039035	A1	20040226	US 2003-654112		200309 02
PRIORITY APPLN. INFO.:			US 2000-240022P	P	200010 11
			US 2001-293781P	P	200105 23
			US 2001-975566	B3	200110 11
			WO 2001-US42624	W	200110 11

OTHER SOURCE(S): MARPAT 136:304070

AB The present invention is directed to compns. and methods useful in modulating **CCR4 chemokine receptor** activity. The compds., compns. and methods described herein are useful in the prevention or **treatment** of certain inflammatory and immunoregulatory disorders and **diseases**, including **asthma** and allergic **diseases**, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.

IT **1957-01-3**
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

RN 1957-01-3 HCAPLUS

CN 2-Thiazolamine, 4-methyl-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



IC ICM A61K

CC 1-7 (Pharmacology)
Section cross-reference(s): 15

ST autoimmune disease **chemokine receptor** **CCR4** modulator

IT **Chemokine receptors**
RL: **BSU (Biological study, unclassified)**; **BIOL (Biological study)**
(**CCR4**; modulators of **CCR4** functions for

prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Allergy
(allergic contact dermatitis; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Dermatitis
(allergic contact; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Allergy
Inflammation
Nose, **disease**
(allergic rhinitis; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Antiarteriosclerotics
(antiatherosclerotics; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Dermatitis
(atopic; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Ischemia
(cardiac; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Respiratory system, **disease**
(hyperresponsiveness, allergic; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Heart, **disease**
(infarction; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Intestine, **disease**
(inflammatory; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Drug delivery systems
(injections, i.v.; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Reperfusion
(injury; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Autoimmune **disease**
(insulin-dependent diabetes mellitus; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Diabetes mellitus
(insulin-dependent; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Heart, **disease**
(ischemia; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Keratosis
(keratolytic agent; modulators of **CCR4** functions for

prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
IT Anti-AIDS agents
Anti-ischemic agents
Antianginal agents
Antiasthmatics
Antihistamines
Antirheumatic agents
Antitumor agents
Atherosclerosis
Autoimmune **disease**
Human
Human immunodeficiency virus 1
Lupus erythematosus
Photodynamic therapy
Psoriasis
UV A radiation
(modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
IT Corticosteroids, biological studies
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
IT Cosmetics
(moisturizers; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
IT Drug delivery systems
(oral; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
IT Injury
(reperfusion; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
IT Artery, **disease**
(restenosis; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
IT Shock (circulatory collapse)
(septic; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
IT Multiple sclerosis
(therapeutic agents; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
IT 66-97-7, Psoralen 67-97-0, Vitamin D3 1143-38-0, Anthralin **1957-01-3** 81191-20-0 411207-58-4 411207-59-5 411207-60-8 411207-61-9
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; USES (Uses)
(modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

L32 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:232516 HCAPLUS
DOCUMENT NUMBER: 134:275760

TITLE: Medicine compositions for **treatment** of integrin α4-mediated cell adhesion-associated **diseases**
INVENTOR(S): Sircar, Ila; Gudmundsson, Kristjan S.; Martin, Richard
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 88 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001089368	A2	20010403	JP 2000-216898	200007 18
PRIORITY APPLN. INFO.:			JP 1999-204581 A	199907 19

OTHER SOURCE(S): MARPAT 134:275760
GI



I

AB The medicine compns. (I; A = arom. hydrocarbon ring; Q = binding linkage; N = 0, 1, 2; W = O, S, -CH=CH-, -N=CH-; Z = O, S; R1, R2, R3 = H, halogen, (substituted)low alkyl; R4 = tetrazolyl, carboxyl, etc.; R5 = H, nitro, (substituted)amino, OH low alkanoyl, etc.; R6 = (substituted)phenyl, etc.) and their pharmacol. acceptable salts are claimed for **treatment** of integrin 4-mediated cell adhesion-assocd. **diseases**, including **asthma**, diabetes, rheumatoid arthritis, **inflammatory** bowel **disease**, and digestive tract and other **diseases** assocd. with leukocyte infiltration in the epithelium (e.g. skin, urethra, bronchiole, synovial membrane and transplanted kidney, liver, heart, blood vessel, and nerve tissues, and pancreas and other **diseases** including **psoriasis**, atopic dermatitis, contact dermatitis, systemic lupus erythematosus, etc.). I were prepd., and their inhibitory effects on cell adhesion were tested in vitro.

IT **232274-66-7P**
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd.

diseases)
RN 232274-66-7 HCAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, α-[[2-chloro-4-[(4,5-dihydro-2-thiazolyl)amino]benzoyl]amino]-2'-methoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **232275-57-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)
RN 232275-57-9 HCAPLUS
CN Benzoic acid, 2-chloro-4-[(4,5-dihydro-2-thiazolyl)amino]- (9CI) (CA INDEX NAME)



IC ICM A61K031-198
ICS A61K031-27; A61K031-275; A61K031-343; A61K031-381; A61K031-40; A61K031-426; A61K031-44; A61K031-445; A61K031-495; A61K031-4965; A61K031-5375; A61K031-54; A61P001-04; A61P003-10; A61P011-06; A61P017-02; A61P017-06; A61P029-00; A61P037-00
CC 1-7 (Pharmacology)
Section cross-reference(s): 25, 26
IT Dermatitis
(atopic; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)
IT Transplant and Transplantation
(blood vessel; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)
IT Dermatitis
(contact; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)
IT Transplant and Transplantation
(heart; phenylalanine analogs as medicine compns. for

treatment of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT Intestine, **disease**
(**inflammatory**; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT Transplant and Transplantation
(kidney; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT Transplant and Transplantation
(liver; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT Transplant and Transplantation
(neural; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT Transplant and Transplantation
(pancreas; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT Adhesion, biological
Antiasthmatics
Antidiabetic agents
Antirheumatic agents
Psoriasis
Transplant and Transplantation
(phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT Lupus erythematosus
(systemic; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT Blood vessel
Heart
Kidney
Liver
Nerve
Pancreas
(transplant; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT Integrins
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); **BSU (Biological study, unclassified)**; **BIOL (Biological study)**; PROC (Process)
(α4; phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT 232274-04-3P
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(delphenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT 232271-13-5P 232271-15-7P 232271-17-9P, N-(2,6-Dichlorobenzoyl)-4-(2-methoxyphenyl)-D-phenylalanine 232271-20-4P 232271-21-5P 232271-22-6P 232271-23-7P 232271-24-8P 232271-25-9P

232271-26-0P 232271-27-1P, N-(2,6-Dichlorobenzoyl)-4-[2-[N-(tert-butyl)sulfamoyl]phenyl]-L-phenylalanine 232271-28-2P
232271-29-3P 232271-30-6P 232271-31-7P 232271-32-8P
232271-33-9P 232271-34-0P 232271-35-1P 232271-36-2P
232271-37-3P 232271-38-4P 232271-39-5P 232271-40-8P
232271-41-9P 232271-42-0P 232271-43-1P 232271-44-2P
232271-45-3P 232271-46-4P 232271-47-5P 232271-48-6P
232271-49-7P 232271-50-0P 232271-51-1P 232271-52-2P
232271-53-3P 232271-54-4P 232271-55-5P 232271-56-6P
232271-57-7P 232271-58-8P 232271-59-9P 232271-61-3P
232271-62-4P 232271-63-5P 232271-64-6P 232271-65-7P
232271-66-8P 232271-67-9P 232271-68-0P 232271-69-1P
232271-70-4P 232271-71-5P 232271-72-6P 232271-73-7P
232271-74-8P 232271-75-9P 232271-76-0P 232271-77-1P
232271-78-2P 232271-79-3P 232271-80-6P 232271-81-7P
232271-82-8P 232271-83-9P 232271-84-0P 232271-85-1P
232271-86-2P 232271-87-3P 232271-88-4P 232271-89-5P
232271-90-8P 232271-91-9P 232271-92-0P 232271-93-1P
232271-94-2P 232271-95-3P 232271-96-4P 232271-97-5P
232271-98-6P 232271-99-7P 232272-01-4P 232272-02-5P
232272-04-7P 232272-06-9P 232272-08-1P 232272-10-5P
232272-11-6P 232272-12-7P 232272-14-9P 232272-16-1P
232272-17-2P 232272-18-3P 232272-19-4P 232272-21-8P
232272-22-9P 232272-24-1P 232272-25-2P 232272-26-3P
232272-27-4P 232272-28-5P 232272-30-9P 232272-32-1P
232272-34-3P 232272-36-5P 232272-38-7P 232272-39-8P
232272-41-2P 232272-43-4P 232272-45-6P 232272-47-8P
232272-49-0P 232272-50-3P 232272-51-4P 232272-52-5P
232272-53-6P 232272-54-7P 232272-56-9P 232272-58-1P
232272-60-5P 232272-62-7P 232272-64-9P 232272-65-0P
232272-67-2P 232272-68-3P 232272-70-7P 232272-72-9P
232272-74-1P 232272-76-3P 232272-78-5P 232272-81-0P
232272-83-2P 232272-85-4P 232272-87-6P 232272-89-8P
232272-91-2P 232272-92-3P 232272-93-4P 232272-94-5P
232272-95-6P 232272-96-7P 232272-98-9P 232272-99-0P
232273-00-6P 232273-01-7P 232273-02-8P 232273-03-9P
232273-04-0P 232273-05-1P 232273-06-2P 232273-07-3P
232273-08-4P 232273-09-5P 232273-10-8P 232273-11-9P
232273-12-0P 232273-13-1P 232273-14-2P 232273-15-3P
232273-16-4P 232273-17-5P 232273-18-6P 232273-21-1P
232273-22-2P 232273-23-3P 232273-24-4P 232273-25-5P
232273-26-6P 232273-27-7P 232273-28-8P 232273-29-9P
232273-30-2P 232273-31-3P 232273-32-4P 232273-33-5P
232273-34-6P 232273-35-7P 232273-36-8P 232273-37-9P
232273-38-0P 232273-39-1P 232273-40-4P 232273-41-5P
232273-42-6P 232273-43-7P 232273-44-8P 232273-45-9P
232273-46-0P 232273-47-1P 232273-48-2P 232273-49-3P
232273-50-6P 232273-51-7P 232273-52-8P 232273-53-9P
232273-54-0P 232273-55-1P 232273-56-2P 232273-57-3P
232273-59-5P 232273-60-8P 232273-61-9P 232273-63-1P
232273-64-2P 232273-65-3P 232273-66-4P 232273-68-6P
232273-70-0P 232273-72-2P 232273-74-4P 232273-76-6P,
[1,1'-Biphenyl]-4-propanoic acid, α-[(2,6-dichlorobenzoyl)amino]-2'-(1-methylethoxy)-, (αS)-
232273-78-8P 232273-80-2P 232273-81-3P 232273-82-4P
232273-84-6P 232273-86-8P 232273-88-0P 232274-02-1P
232274-03-2P 232274-05-4P 232274-06-5P 232274-07-6P
232274-08-7P 232274-09-8P 232274-10-1P 232274-11-2P
232274-13-4P 232274-17-8P 232274-20-3P 232274-24-7P
232274-27-0P
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT 232274-28-1P 232274-31-6P 232274-37-2P 232274-38-3P
232274-39-4P 232274-40-7P 232274-41-8P 232274-42-9P
232274-43-0P 232274-44-1P 232274-45-2P 232274-46-3P
232274-47-4P 232274-48-5P 232274-49-6P 232274-50-9P
232274-51-0P 232274-52-1P 232274-53-2P 232274-54-3P
232274-55-4P 232274-56-5P 232274-57-6P 232274-58-7P
232274-59-8P 232274-60-1P 232274-61-2P 232274-62-3P
232274-63-4P 232274-64-5P 232274-65-6P **232274-66-7P**
232274-67-8P 232274-68-9P 232274-69-0P 232274-70-3P
232274-71-4P 232274-72-5P 232274-73-6P 232274-74-7P
232274-75-8P 232274-76-9P 232274-77-0P 232274-80-5P
232274-81-6P 232274-82-7P 232274-83-8P 232274-84-9P
232274-85-0P 232274-88-3P 232274-90-7P 232274-91-8P
232274-92-9P 232274-93-0P 232274-94-1P 232274-95-2P
232274-96-3P 232274-97-4P 232274-99-6P 232275-00-2P
232275-01-3P 232275-02-4P 232275-03-5P 232275-04-6P
232275-05-7P 232275-06-8P 232275-07-9P 232275-08-0P
232275-09-1P 232275-10-4P 232275-11-5P 232275-12-6P
232275-13-7P 232275-14-8P 232275-15-9P 232275-16-0P
232275-17-1P 232275-18-2P 232275-19-3P 232275-20-6P
232275-21-7P 232275-22-8P 232275-23-9P 232275-24-0P
232275-25-1P 232275-26-2P 232275-27-3P 232275-28-4P
232275-29-5P 232275-30-8P 232275-31-9P 232275-91-1P
232275-99-9P 332391-52-3P 332391-77-2P 332391-92-1P
332392-28-6P 332392-88-8P 332392-90-2P 332393-45-0P
332393-47-2P 332393-49-4P 332393-52-9P 332393-55-2P
332393-57-4P 332393-60-9P 332393-62-1P 332393-65-4P
332393-77-8P 332394-03-3P
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation); **THU (Therapeutic use); BIOL (Biological study)**;
PREP (Preparation); USES (Uses)
(phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT 121-43-7 349-55-3, 3-Methoxy-5-trifluoromethylaniline 626-17-5, 1.3-Dicyanobenzene 1530-32-1, Ethyl triphenylphosphonium bromide 10272-07-8, 3,5-Dimethoxyaniline 13330-65-9, 2,4-Dimethoxyphenol 18791-98-5, 3-Bromothiophene-2-carbonitrile 19393-92-1, 1-Bromo-2,6-dichlorobenzene 22509-50-8 29668-44-8 31558-40-4, 4-Bromo-3,5-dimethoxybenzaldehyde
RL: RCT (Reactant); RACT (Reactant or reagent)
(phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

IT 4641-38-7P 5204-46-6P, 4-Amino-2,6-dichlorobenzoic acid 73852-17-2P, 2,6-Dichlorobenzeneboronic acid 80257-12-1P
158580-15-5P 232275-35-3P 232275-36-4P 232275-37-5P
232275-39-7P 232275-40-0P 232275-41-1P 232275-42-2P
232275-44-4P 232275-45-5P 232275-46-6P 232275-51-3P
232275-52-4P 232275-55-7P **232275-57-9P** 232275-62-6P
232275-65-9P 232275-67-1P 232275-69-3P 232275-71-7P
232275-75-1P 232275-77-3P 232275-83-1P 232275-85-3P
232275-88-6P 232276-76-5P 332394-13-5P 332394-16-8P
332394-20-4P 332394-23-7P 332394-26-0P 332394-29-3P
332394-32-8P 332394-34-0P 332394-37-3P 332394-40-8P
332394-46-4P 332394-52-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phenylalanine analogs as medicine compns. for **treatment** of integrin α4-mediated cell adhesion-assocd. **diseases**)

L32 ANSWER 23 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:115147 HCAPLUS
DOCUMENT NUMBER: 134:163031
TITLE: Preparation of thiazole derivatives as p38MAP kinase inhibitors and inhibitors of TNF-α production
INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Kimura, Hiroyuki; Miwatashi, Seiji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010865	A1	20010215	WO 2000-JP5198	20000803
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2381215	AA	20010215	CA 2000-2381215	20000803
EP 1205478	A1	20020515	EP 2000-951874	20000803
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2001114690	A2	20010424	JP 2000-242761	20000804
US 6962933	B1	20051108	US 2002-48937	20020206

PRIORITY APPLN. INFO.:	JP 1999-224651	A	19990806
	WO 2000-JP5198	W	20000803

OTHER SOURCE(S): MARPAT 134:163031
AB Claimed are p38MAP kinase inhibitors contg. 1,3-thiazole compds. (substituted by optionally substituted pyridyl at the 5-position), or salts or prodrugs thereof. Compds. of this invention in vitro

showed IC50 values of 0.086 μM to 0.63 μM against p38MAP kinase. Formulations are given.

IT **97422-54-3P 97422-55-4P 97422-56-5P 224038-79-3P 224038-87-3P**
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF-α prodn.)

RN 97422-54-3 HCAPLUS
CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 97422-55-4 HCAPLUS
CN 2-Thiazolamine, N-phenyl-5-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 97422-56-5 HCAPLUS
CN Phenol, 4-[2-(phenylamino)-5-(3-pyridinyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 224038-79-3 HCAPLUS
CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 224038-87-3 HCAPLUS
CN Acetamide, N-[4-(4-methoxyphenyl)-5-(4-pyridinyl)-2-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



IC ICM C07D417-04
ICS C07D417-14; A61K031-4439; A61K031-5377; A61P043-00; A61P011-06; A61P011-00; A61P037-08; A61P029-00; A61P007-06; A61P009-10; A61P025-28; A61P025-16; A61P021-00; A61P003-10; A61P019-02; A61P019-10; A61P039-02; A61P001-04; A61P031-06
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT Lung, **disease**
(**inflammation**; prepn. and effect of thiazole derivs. with activity against p38MAP kinase and TNF prodn.)
IT Addison's disease
Alzheimer's disease
Atherosclerosis
Cachexia
Diabetes mellitus
Hepatitis
Hypotension
Lung, disease
Lupus erythematosus
Multiple sclerosis
Osteoarthritis
Osteoporosis
Parkinson's disease
Psoriasis
Rheumatoid arthritis
Sarcoidosis
Septicemia
Silicosis
Thrombosis
Transplant and Transplantation
Tuberculosis
(prepn. and effect of thiazole derivs. with activity against p38MAP kinase and TNF prodn.)
IT Tumor necrosis factors

RL: BPR (Biological process); **BSU (Biological study, unclassified)**; **BIOL (Biological study)**; PROC (Process)
(thiazole derivs. with activity against p38MAP kinase and TNF prodn.)

IT

97422-27-0P	97422-28-1P	97422-29-2P	97422-30-5P	97422-31-6P
97422-32-7P	97422-33-8P	97422-34-9P	97422-35-0P	97422-36-1P
97422-37-2P	97422-38-3P	97422-39-4P	97422-40-7P	97422-41-8P
97422-42-9P	97422-43-0P	97422-44-1P	97422-45-2P	97422-46-3P
97422-47-4P	97422-48-5P	97422-49-6P	97422-50-9P	97422-51-0P
97422-52-1P	97422-53-2P	**97422-54-3P**	**97422-55-4P**	
97422-56-5P	97422-57-6P	97422-58-7P	97422-59-8P	
97422-60-1P	97422-61-2P	97422-62-3P	97422-63-4P	97422-64-5P
97422-65-6P	97422-66-7P	97422-67-8P	97422-68-9P	97422-69-0P
97422-70-3P	97422-71-4P	97422-72-5P	97422-73-6P	97422-74-7P
97422-75-8P	97422-76-9P	97422-77-0P	97422-78-1P	97422-79-2P
97422-80-5P	97422-81-6P	97422-82-7P	97422-83-8P	97422-84-9P
97422-85-0P	97422-86-1P	97422-87-2P	97422-88-3P	97422-89-4P
97443-15-7P	97443-16-8P	97443-17-9P	99478-69-0P	99478-71-4P
99478-73-6P	99478-74-7P	99478-75-8P	99478-76-9P	99478-77-0P
99478-78-1P	99478-79-2P	99478-80-5P	99478-81-6P	99478-82-7P
99478-83-8P	99478-84-9P	99478-85-0P	99478-86-1P	99478-87-2P
99478-88-3P	99478-89-4P	99496-91-0P	99496-92-1P	99496-93-2P
223914-57-6P	223914-58-7P	223914-59-8P	223914-63-4P	
224037-86-9P	224037-87-0P	224037-88-1P	224037-89-2P	
224037-90-5P	224037-91-6P	224037-92-7P	224037-93-8P	
224037-94-9P	224037-95-0P	224037-96-1P	224037-98-3P	
224037-99-4P	224038-00-0P	224038-01-1P	224038-02-2P	
224038-03-3P	224038-04-4P	224038-05-5P	224038-06-6P	
224038-07-7P	224038-08-8P	224038-09-9P	224038-11-3P	
224038-13-5P	224038-14-6P	224038-15-7P	224038-16-8P	
224038-17-9P	224038-18-0P	224038-19-1P	224038-20-4P	
224038-21-5P	224038-22-6P	224038-23-7P	224038-24-8P	
224038-25-9P	224038-26-0P	224038-27-1P	224038-28-2P	
224038-29-3P	224038-30-6P	224038-31-7P	224038-32-8P	
224038-33-9P	224038-34-0P	224038-35-1P	224038-36-2P	
224038-37-3P	224038-38-4P	224038-39-5P	224038-40-8P	
224038-41-9P	224038-42-0P	224038-43-1P	224038-44-2P	
224038-45-3P	224038-46-4P	224038-47-5P	224038-48-6P	
224038-49-7P	224038-50-0P	224038-51-1P	224038-52-2P	
224038-53-3P	224038-54-4P	224038-55-5P	224038-56-6P	
224038-57-7P	224038-58-8P	224038-59-9P	224038-60-2P	
224038-61-3P	224038-62-4P	224038-63-5P	224038-64-6P	
224038-65-7P	224038-66-8P	224038-67-9P	224038-68-0P	
224038-69-1P	224038-70-4P	224038-71-5P	224038-72-6P	
224038-73-7P	224038-74-8P	224038-75-9P	224038-76-0P	
224038-77-1P	224038-78-2P	**224038-79-3P**	224038-80-6P	
224038-81-7P	224038-82-8P	224038-83-9P	224038-84-0P	
224038-85-1P	224038-86-2P	**224038-87-3P**	224038-88-4P	
224038-89-5P	224038-90-8P	224038-91-9P	224038-92-0P	
224038-93-1P	224038-94-2P	224038-95-3P	224038-96-4P	
224038-97-5P	224038-98-6P	224038-99-7P	224039-00-3P	
224039-01-4P	224039-02-5P	224039-03-6P	224039-04-7P	
224039-05-8P	224039-06-9P	224039-07-0P	224039-08-1P	
224039-09-2P	224039-10-5P	224039-11-6P	224039-12-7P	
224039-13-8P	224039-14-9P	224039-15-0P	224039-16-1P	
224039-17-2P	224039-18-3P	224039-19-4P	224039-20-7P	
224039-21-8P	224039-22-9P	224039-23-0P	224039-24-1P	
224039-25-2P	224039-26-3P	224039-27-4P	224039-28-5P	
224039-30-9P				

RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF-α prodn.)

IT 224039-31-0P 224039-32-1P 224039-33-2P 224039-34-3P
224039-36-5P 224039-37-6P 224039-38-7P 224039-39-8P
224039-40-1P 224039-42-3P 224039-44-5P 224039-46-7P
224039-49-0P 224039-51-4P 224039-54-7P 224039-55-8P
224039-56-9P 224039-57-0P 224039-58-1P 224039-59-2P
224039-60-5P 224039-61-6P 224039-63-8P 224039-64-9P
224039-65-0P 224039-66-1P 224039-67-2P 224039-68-3P
224039-70-7P 224039-71-8P 224039-72-9P 224039-73-0P
224039-74-1P 224039-76-3P 224039-77-4P 224039-78-5P
224039-79-6P 224039-81-0P 224039-82-1P 224039-83-2P
224039-85-4P 224039-86-5P 224039-87-6P 224039-88-7P
224039-90-1P 224039-91-2P 224039-92-3P 224039-93-4P
224039-95-6P 224039-96-7P 224039-97-8P 224039-99-0P
224040-00-0P 224040-01-1P 224040-02-2P 224040-03-3P
224040-04-4P 224040-06-6P 224040-07-7P 224040-08-8P
224040-10-2P 224040-11-3P 224040-12-4P 224040-13-5P
224040-14-6P 224040-16-8P 224040-17-9P 224040-18-0P
224040-19-1P 224040-21-5P 224040-22-6P 224040-23-7P
224040-24-8P 224040-26-0P 224040-27-1P 224040-28-2P
224040-30-6P 224040-31-7P 224040-33-9P 224040-34-0P
224040-36-2P 224040-37-3P 224040-38-4P 224040-39-5P
224040-40-8P 224040-41-9P 224040-42-0P 224040-43-1P
224040-44-2P 224040-45-3P 224040-46-4P 224040-47-5P
224040-57-7P 252198-66-6P 252198-74-6P 252198-75-7P
252198-97-3P 284486-00-6P 303787-77-1P 303787-98-6P
325767-68-8P 325767-69-9P 325767-70-2P 325767-71-3P
325767-72-4P 325767-73-5P 325767-74-6P 325767-75-7P
325767-76-8P 325767-77-9P 325767-79-1P 325767-80-4P
325767-81-5P 325767-82-6P 325767-83-7P 325767-84-8P
325767-85-9P 325767-86-0P 325767-87-1P 325767-88-2P
325767-89-3P 325767-90-6P 325767-91-7P 325767-92-8P
325767-93-9P 325767-94-0P 325767-95-1P 325767-96-2P
325767-97-3P 325767-98-4P 325767-99-5P 325768-00-1P
325768-02-3P 325768-03-4P 325768-04-5P 325768-05-6P
325768-06-7P 325768-07-8P 325768-08-9P 325768-09-0P
325768-10-3P 325768-11-4P 325768-12-5P 325768-13-6P
325768-14-7P 325768-15-8P 325768-16-9P 325768-17-0P
325768-18-1P 325768-19-2P 325768-20-5P 325768-21-6P
325768-22-7P 325768-23-8P 325768-24-9P 325768-25-0P
325768-27-2P 325768-28-3P 325768-29-4P 325768-30-7P
325768-31-8P 325768-32-9P 325768-33-0P 325768-34-1P
325768-35-2P 325768-36-3P 325768-37-4P 325768-38-5P
325768-39-6P 325768-40-9P 325768-41-0P 325768-42-1P
325768-43-2P 325768-44-3P 325768-45-4P 325768-46-5P
325768-47-6P 325768-48-7P 325768-49-8P 325768-50-1P
325768-51-2P 325768-52-3P 325768-53-4P 325768-54-5P
325768-55-6P 325768-56-7P 325768-57-8P 325768-58-9P
325768-59-0P 325768-60-3P 325768-61-4P 325768-62-5P
325768-63-6P 325768-64-7P 325768-65-8P 325768-66-9P
325768-67-0P 325768-68-1P 325768-69-2P 325768-70-5P
325768-71-6P 325768-72-7P 325768-73-8P 325768-75-0P
325768-76-1P 325768-77-2P 325768-78-3P 325768-79-4P
325768-80-7P 325768-81-8P 325768-82-9P 325768-83-0P
325768-84-1P 325768-85-2P 325768-86-3P 325768-87-4P
325768-88-5P 325768-89-6P 325768-90-9P 325768-91-0P
325768-92-1P 325768-93-2P 325768-94-3P 325768-95-4P
325768-96-5P 325768-97-6P 325768-98-7P 325768-99-8P
325769-00-4P 325769-01-5P 325769-02-6P 325769-03-7P

325769-04-8P
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF-α prodn.)

IT 325769-05-9P 325769-06-0P 325769-07-1P 325769-08-2P
325769-09-3P 325769-10-6P 325769-11-7P 325769-12-8P
325769-13-9P 325769-14-0P 325769-15-1P 325769-16-2P
325769-17-3P 325769-18-4P 325769-19-5P 325769-20-8P
325769-21-9P 325769-22-0P 325769-23-1P 325769-25-3P
325769-26-4P 325769-27-5P 325769-28-6P 325769-29-7P
325769-30-0P 325769-31-1P 325769-32-2P 325769-33-3P
325769-34-4P 325769-35-5P 325769-36-6P 325769-37-7P
325769-38-8P 325769-39-9P 325769-40-2P 325769-41-3P
325769-42-4P 325769-43-5P 325769-44-6P 325769-45-7P
325769-46-8P 325769-47-9P 325769-48-0P 325769-49-1P
325769-50-4P 325769-51-5P 325769-52-6P 325769-53-7P
325769-54-8P 325769-55-9P 325769-56-0P 325769-57-1P
325769-58-2P 325769-59-3P 325769-60-6P 325769-61-7P
325769-62-8P 325769-63-9P 325769-64-0P 325769-65-1P
325769-66-2P 325769-67-3P 325769-68-4P 325769-69-5P
325769-70-8P 325769-71-9P 325769-73-1P 325769-74-2P
325769-75-3P 325769-76-4P 325769-77-5P 325769-78-6P
325769-79-7P 325769-80-0P 325769-81-1P 325769-82-2P
325769-83-3P 325769-84-4P 325769-85-5P 325769-86-6P
325769-87-7P 325769-88-8P 325769-89-9P 325769-91-3P
325769-92-4P 325769-93-5P 325769-94-6P 325769-95-7P
325769-96-8P 325769-97-9P 325769-98-0P 325769-99-1P
325770-00-1P 325770-01-2P 325770-02-3P 325770-03-4P
325770-04-5P 325770-05-6P 325770-06-7P 325770-07-8P
325770-08-9P 325770-09-0P 325770-10-3P 325770-11-4P
325770-12-5P 325770-13-6P 325770-14-7P 325770-15-8P
325770-16-9P 325770-18-1P 325770-19-2P 325770-20-5P
325770-21-6P 325770-22-7P 325770-23-8P 325770-24-9P
325770-25-0P 325770-26-1P 325770-27-2P 325770-28-3P
325770-29-4P 325770-30-7P
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF-α prodn.)

IT 165245-96-5, p38 Mitogen-activated protein kinase
RL: BPR (Biological process); **BSU (Biological study, unclassified)**; **BIOL (Biological study)**; PROC (Process)
(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF-α prodn.)

IT 9036-21-9, Phosphodiesterase IV
RL: BPR (Biological process); **BSU (Biological study, unclassified)**; **BIOL (Biological study)**; PROC (Process)
(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF-α prodn. and phosphodiesterase IV inhibitors)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:464267 HCAPLUS
DOCUMENT NUMBER: 131:116517
TITLE: Preparation of N-acyl-phenylalanine derivatives as inhibitors of α4-mediated cell adhesion
INVENTOR(S): Sircar, Ila; Gudmundsson, Kristjan S.; Martin, Richard
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9936393	A1	19990722	WO 1999-US993	19990119
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2318527	AA	19990722	CA 1999-2318527	19990119
AU 9924584	A1	19990802	AU 1999-24584	19990119
AU 749568	B2	20020627		
BR 9907040	A	20001017	BR 1999-7040	19990119
EP 1049662	A1	20001108	EP 1999-904115	19990119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002509131	T2	20020326	JP 2000-540111	19990119
JP 3634749	B2	20050330		
NZ 506081	A	20030228	NZ 1999-506081	19990119
TW 591007	B	20040611	TW 1999-88100776	19990119
US 6521666	B1	20030218	US 2000-619712	20000719
US 2003191118	A1	20031009	US 2002-286777	20021104
US 6855843	B2	20050215		
JP 2005002116	A2	20050106	JP 2004-202046	

			200407 08
PRIORITY APPLN. INFO.:	US 1998-71840P	P	199801 20
	JP 2000-540111	A3	199901 19
	WO 1999-US993	W	199901 19
	US 2000-619712	A3	200007 19

OTHER SOURCE(S): MARPAT 131:116517

GI For diagram(s), see printed CA Issue.

AB The present invention relates to a pharmaceutical compn. comprising as an active ingredient a compd. of formula [I; wherein ring A is an arom. or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene optionally substituted by HO or Ph, lower alkenylene, or -O-(lower alkylene)-; n is 0, 1 or 2; Z is oxygen or sulfur; W is oxygen, sulfur, -CH:CH-, -NH- or -N:CH-; R1, R2 and R3 are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, CO2H or an amide or an ester thereof, cyano, lower alkylthio, lower alkanesulfonyl, substituted or unsubstituted SO2NH2, etc.; R4 is tetrazolyl, carboxyl group, amide or ester; R5 is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl, etc.; R6 is selected from (a) a substituted or unsubstituted Ph group, (b) a substituted or unsubstituted pyridyl group, (c) a substituted or unsubstituted thienyl group, (d) a substituted or unsubstituted benzofuranyl group, etc.; or a pharmaceutically acceptable salt thereof]. These phenylalanine derivs. are useful for **treating** or preventing **conditions** caused by α4-mediated cell adhesion such as rheumatoid arthritis, **asthma**, **psoriasis**, eczema, contact dermatitis and other skin **inflammatory diseases**, diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), **inflammatory** bowel **disease** including ulcerative colitis and Crohn's **disease**, and other **diseases** involving leukocyte infiltration of the gastrointestinal tract, or other epithelial lined tissues, such as skin, urinary tract, respiratory airway, and joint synovium. N-(tert-butoxycarbonyl)-O-(trifluoromethanesulfonyl)-L-tyrosine Me ester (prepn. given) was coupled with 2-methoxybenzene boronic acid in toluene/DMF in the presence of K2CO3 and Pd(PPh3)4 at 80 °C for 24 h to give N-(tert-butoxycarbonyl)-4-(2-methoxyphenyl)-L-phenylalanine Me ester. The latter compd. was **treated** with CF3CO2H in CH2Cl2 for 1.5 h to remove the Boc group and then condensed with 2,6-dichlorobenzoyl chloride in the presence of diisopropylethylamine at room temp. for 24 h to give N-(2,6-dichlorobenzoyl)-4-(2-methoxyphenyl)-L-phenylalanine Me ester (II) which was sapond. with LiOH in THF/MeOH at room temp. for 3 h, evapd., **treated** with H2O, adjusted Ph 2, and extd. with EtOAc to give N-(2,6-dichlorobenzoyl)-4-(2-methoxyphenyl)-L-phenylalanine (III). II and III in vitro inhibited at IC50 of 1≥ and 0.3≥ μM, resp., β7-mediated cell

adhesion which measured the adhesive interactions of a B-cell line, RPMI, known to express α4β7, to the alternatively spliced region of fibronectin referred to as CS-1, in the presence of test compds.

IT **232274-66-7P**
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)

RN 232274-66-7 HCAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, α-[[2-chloro-4-[(4,5-dihydro-2-thiazolyl)amino]benzoyl]amino]-2'-methoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **232275-57-9P 232275-58-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)

RN 232275-57-9 HCAPLUS

CN Benzoic acid, 2-chloro-4-[(4,5-dihydro-2-thiazolyl)amino]- (9CI) (CA INDEX NAME)



RN 232275-58-0 HCAPLUS

CN Benzoic acid, 2-chloro-4-[(4,5-dihydro-2-thiazolyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



IC ICM C07C233-87
ICS C07C237-30; C07C271-28; C07C311-09; C07D295-14; C07D333-34; A61K031-245; A61K031-33
CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
ST acylphenylalanine deriv prepn inhibitor 4 mediated cell adhesion; rheumatoid arthritis **treatment** prevention
acylphenylalanine; **asthma treatment** prevention
acylphenylalanine; **psoriasis treatment** prevention acylphenylalanine; eczema **treatment** prevention
acylphenylalanine; contact dermatitis **treatment** prevention
acylphenylalanine; skin **inflammatory disease treatment** prevention acylphenylalanine; diabetes **treatment** prevention acylphenylalanine; multiple sclerosis prevention **treatment** acylphenylalanine; systemic lupus erythematosus **treatment** prevention acylphenylalanine; **inflammatory** bowel **disease treatment** prevention acylphenylalanine; ulcerative colitis **treatment** prevention acylphenylalanine; Crohn **disease treatment** prevention acylphenylalanine; leukocyte infiltration prevention **treatment** acylphenylalanine
IT Intestine, **disease**
(Crohn's; prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)
IT Dermatitis
(contact; prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)
IT Intestine, **disease**
(**inflammatory**; prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)
IT Cell migration
(leukocyte infiltration, **diseases** caused by; prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)
IT Antiasthmatics
Antidiabetic agents
Cell adhesion
Dermatitis
Eczema
Multiple sclerosis
Psoriasis
Rheumatoid arthritis
(prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by

α4-mediated cell adhesion)

IT Amino acids, preparation
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)

IT Lupus erythematosus
(systemic; prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)

IT Intestine, **disease**
(ulcerative colitis; prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)

IT 232275-30-8P 232275-31-9P 232275-99-9P 232277-16-6P
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)

IT 232271-13-5P 232271-14-6P 232271-15-7P 232271-16-8P
232271-17-9P 232271-18-0P 232271-19-1P 232271-20-4P
232271-21-5P 232271-22-6P 232271-23-7P 232271-24-8P
232271-25-9P 232271-26-0P 232271-27-1P 232271-28-2P
232271-29-3P 232271-30-6P 232271-31-7P 232271-32-8P
232271-33-9P 232271-34-0P 232271-35-1P 232271-36-2P
232271-37-3P 232271-38-4P 232271-39-5P 232271-40-8P
232271-41-9P 232271-42-0P 232271-43-1P 232271-44-2P
232271-45-3P 232271-46-4P 232271-47-5P 232271-48-6P
232271-49-7P 232271-50-0P 232271-51-1P 232271-52-2P
232271-53-3P 232271-54-4P 232271-55-5P 232271-56-6P
232271-57-7P 232271-58-8P 232271-59-9P 232271-60-2P
232271-61-3P 232271-62-4P 232271-63-5P 232271-64-6P
232271-65-7P 232271-66-8P 232271-67-9P 232271-68-0P
232271-69-1P 232271-70-4P 232271-71-5P 232271-72-6P
232271-73-7P 232271-74-8P 232271-75-9P 232271-76-0P
232271-77-1P 232271-78-2P 232271-79-3P 232271-80-6P
232271-81-7P 232271-82-8P 232271-83-9P 232271-84-0P
232271-85-1P 232271-86-2P 232271-87-3P 232271-88-4P
232271-89-5P 232271-90-8P 232271-91-9P 232271-92-0P
232271-93-1P 232271-94-2P 232271-95-3P 232271-96-4P
232271-97-5P 232271-98-6P 232271-99-7P 232272-00-3P
232272-01-4P 232272-02-5P 232272-04-7P 232272-06-9P
232272-08-1P 232272-10-5P 232272-11-6P 232272-12-7P
232272-14-9P 232272-16-1P 232272-17-2P 232272-18-3P
232272-19-4P 232272-21-8P 232272-22-9P 232272-24-1P
232272-25-2P 232272-26-3P 232272-27-4P 232272-28-5P
232272-30-9P 232272-32-1P 232272-34-3P 232272-36-5P
232272-38-7P 232272-39-8P 232272-41-2P 232272-43-4P
232272-45-6P 232272-47-8P 232272-49-0P 232272-50-3P
232272-51-4P 232272-52-5P 232272-53-6P 232272-54-7P
232272-56-9P 232272-58-1P 232272-60-5P 232272-62-7P

232272-64-9P 232272-65-0P 232272-67-2P 232272-68-3P
232272-70-7P 232272-72-9P 232272-74-1P 232272-76-3P
232272-78-5P 232272-81-0P 232272-83-2P 232272-85-4P
232272-87-6P 232272-89-8P 232272-91-2P 232272-92-3P
232272-93-4P 232272-94-5P 232272-95-6P 232272-96-7P
232272-97-8P 232272-98-9P 232272-99-0P 232273-00-6P
232273-01-7P 232273-02-8P 232273-03-9P 232273-04-0P
232273-05-1P 232273-06-2P 232273-07-3P 232273-08-4P
232273-09-5P 232273-10-8P 232273-11-9P 232273-12-0P
232273-13-1P 232273-14-2P 232273-15-3P 232273-16-4P
232273-17-5P 232273-18-6P 232273-19-7P 232273-20-0P
232273-21-1P 232273-22-2P 232273-23-3P 232273-24-4P
232273-25-5P 232273-26-6P 232273-27-7P 232273-28-8P
232273-29-9P 232273-30-2P 232273-31-3P 232273-32-4P
232273-33-5P 232273-34-6P 232273-35-7P 232273-36-8P
232273-37-9P 232273-38-0P 232273-39-1P 232273-40-4P
232273-41-5P 232273-42-6P 232273-43-7P 232273-44-8P
232273-45-9P 232273-46-0P 232273-47-1P 232273-48-2P
232273-49-3P 232273-50-6P 232273-51-7P 232273-52-8P
232273-53-9P 232273-54-0P 232273-55-1P 232273-56-2P
232273-57-3P 232273-59-5P 232273-60-8P 232273-61-9P
232273-62-0P 232273-63-1P 232273-64-2P 232273-65-3P
232273-66-4P 232273-68-6P 232273-70-0P 232273-72-2P
232273-74-4P 232273-76-6P 232273-78-8P 232273-80-2P
232273-81-3P 232273-82-4P 232273-84-6P 232273-86-8P
232273-88-0P 232273-90-4P 232273-92-6P 232273-94-8P
232273-96-0P
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)

IT 232273-97-1P 232273-98-2P 232273-99-3P 232274-00-9P
232274-01-0P 232274-02-1P 232274-03-2P 232274-04-3P
232274-05-4P 232274-06-5P 232274-07-6P 232274-08-7P
232274-09-8P 232274-10-1P 232274-11-2P 232274-13-4P
232274-17-8P 232274-20-3P 232274-24-7P 232274-27-0P
232274-28-1P 232274-31-6P 232274-34-9P 232274-37-2P
232274-38-3P 232274-39-4P 232274-40-7P 232274-41-8P
232274-42-9P 232274-43-0P 232274-44-1P 232274-45-2P
232274-46-3P 232274-47-4P 232274-48-5P 232274-49-6P
232274-50-9P 232274-51-0P 232274-52-1P 232274-53-2P
232274-54-3P 232274-55-4P 232274-56-5P 232274-57-6P
232274-58-7P 232274-59-8P 232274-60-1P 232274-61-2P
232274-62-3P 232274-63-4P 232274-64-5P 232274-65-6P
232274-66-7P 232274-67-8P 232274-68-9P 232274-69-0P
232274-70-3P 232274-71-4P 232274-72-5P 232274-73-6P
232274-74-7P 232274-75-8P 232274-76-9P 232274-77-0P
232274-78-1P 232274-79-2P 232274-80-5P 232274-81-6P
232274-82-7P 232274-83-8P 232274-84-9P 232274-85-0P
232274-86-1P 232274-87-2P 232274-88-3P 232274-89-4P
232274-90-7P 232274-91-8P 232274-92-9P 232274-93-0P
232274-94-1P 232274-95-2P 232274-96-3P 232274-97-4P
232274-99-6P 232275-00-2P 232275-01-3P 232275-02-4P
232275-03-5P 232275-04-6P 232275-05-7P 232275-06-8P
232275-07-9P 232275-08-0P 232275-09-1P 232275-10-4P
232275-11-5P 232275-12-6P 232275-13-7P 232275-14-8P
232275-15-9P 232275-16-0P 232275-17-1P 232275-18-2P
232275-19-3P 232275-20-6P 232275-21-7P 232275-22-8P

232275-23-9P 232275-24-0P 232275-25-1P 232275-26-2P
232275-27-3P 232275-28-4P 232275-29-5P 232275-32-0P
232275-33-1P 232275-34-2P 232277-14-4P
RL: BAC (Biological activity or effector, except adverse); **BSU (Biological study, unclassified)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and **treatment** of **diseases** caused by α4-mediated cell adhesion)

IT 50-00-0, Formaldehyde, reactions 59-92-7, 3,4-Dihydroxy-L-phenylalanine, reactions 62-53-3, Benzenamine, reactions 67-63-0, 2-Propanol, reactions 68-12-2, reactions 74-88-4, reactions 74-89-5, Methylamine, reactions 75-36-5, Acetyl chloride 75-65-0, reactions 79-22-1, Methyl chloroformate 96-32-2, Methyl bromoacetate 98-80-6, Benzeneboronic acid 98-88-4, Benzoyl chloride 100-46-9, Benzyl amine, reactions 106-95-6, Allyl bromide, reactions 107-21-1, 1,2-Ethanediol, reactions 107-30-2, Chloromethyl methyl ether 108-24-7, Acetic anhydride 108-46-3, Resorcinol, reactions 108-93-0, Cyclohexanol, reactions 109-01-3, N-Methylpiperazine 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 121-43-7, Trimethyl borate 123-56-8, Succinimide 123-90-0, Thiomorpholine 124-63-0, Mesyl chloride 151-10-0, 1,3-Dimethoxybenzene 151-18-8, 2-Cyanoethylamine 349-55-3, 3-Methoxy-5-(trifluoromethyl)aniline 358-23-6, Triflic anhydride 407-25-0, Trifluoroacetic anhydride 421-83-0, Trifluoromethanesulfonyl chloride 541-41-3, Ethyl chloroformate 556-61-6, Methyl isothiocyanate 590-17-0, Bromoacetonitrile 593-56-6, Methoxyamine hydrochloride 614-68-6, 2-Methylphenyl isocyanate 616-04-6, 1-Methylhydantoin 624-83-9, Methyl isocyanate 626-17-5, 1,3-Dicyanobenzene 661-69-8, Hexamethylditin 696-59-3, 2,5-Dimethoxytetrahydrofuran 705-76-0, 3,5-Dimethoxybenzyl alcohol 927-68-4, 2-Bromoethyl acetate 1189-71-5, Chlorosulfonyl isocyanate 1530-32-1, Ethyltriphenylphosphonium bromide 1762-95-4, Ammonium thiocyanate 1943-83-5, 2-Chloroethyl isocyanate 2148-56-3, 2-Amino-6-chlorobenzoic acid 2457-76-3, 4-Amino-2-chlorobenzoic acid 2605-67-6, (Triphenylphosphoranylidene)acetic acid methyl ester 3144-09-0, Methanesulfonamide 3722-78-9 3728-20-9, D-Tyrosine methyl ester hydrochloride 4326-36-7 4635-59-0, 4-Chlorobutyryl chloride 4659-45-4, 2,6-Dichlorobenzoyl chloride 4670-10-4, (3,5-Dimethoxy)phenylacetic acid 5191-60-6 5470-11-1, Hydroxylamine hydrochloride 5720-06-9, 2-Methoxybenzene boronic acid 6099-88-3, 2-Chloroethyl isothiocyanate 6160-65-2, 1,1'-Thiocarbonyldiimidazole 6165-68-0, 2-Thienylboronic acid 6575-24-2, (2,6-Dichlorophenyl)acetic acid 6652-32-0, 3,5-Dimethoxybenzyl chloride 7073-36-1, 2-Chloro-4-nitrobenzoyl chloride 7311-34-4, 3,5-Dimethoxybenzaldehyde 7782-24-3, (S)-2-Phenylpropionic acid 10272-07-8, 3,5-Dimethoxyaniline 13330-65-9, 2,4-Dimethoxyphenol 13360-57-1, N,N-Dimethylsulfamoyl chloride 16649-50-6, tert-Butylhydroxylamine 18063-02-0, 2,6-Difluorobenzoyl chloride 18791-98-5 19179-31-8, 3,5-Dimethoxybenzonitrile 19393-92-1, 1-Bromo-2,6-dichlorobenzene 22509-50-8 24424-99-5, Di-tert-butyl dicarbonate 25784-91-2, 2-Chloro-5-nitrobenzoyl chloride 29668-44-8 31558-40-4, 4-Bromo-3,5-dimethoxybenzaldehyde 32483-30-0 34128-16-0, 2-Chloro-3-nitrobenzoyl chloride 40138-16-7, 2-Formylbenzeneboronic acid 46004-37-9, Methyl 4-amino-2-chlorobenzoate 55737-77-4 57260-71-6, N-(tert-Butoxycarbonyl)piperazine 58479-61-1, tert-Butyl-diphenylsilyl

chloride 62129-39-9 64248-56-2, 1-Bromo-2,6-difluorobenzene
107264-06-2 115377-94-1 121359-48-6 135884-31-0 150587-19-2
150691-04-6 173979-01-6 188978-71-4 206347-30-0,
7-Bromo-2,3-dihydrobenzo[b]furan 220497-50-7 220848-45-3
232277-15-5 232277-17-7 232277-19-9 232277-20-2 232277-21-3
232277-22-4 232277-23-5 232277-24-6 232277-25-7 232277-26-8
232277-27-9 232277-28-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-acyl-phenylalanine derivs. as inhibitors of
α4-mediated cell adhesion for prevention and
treatment of **diseases** caused by
α4-mediated cell adhesion)

IT 349-56-4P 532-55-8P, Benzoyl isothiocyanate 2012-78-4P
4641-38-7P, 2,6-Dichloro-4-hydroxybenzoic acid 7101-51-1P
7417-20-1P 10288-72-9P, 6-Hydroxy-1,4-benzodioxan 23112-96-1P
29668-45-9P, 6-Methoxy-1,4-benzodioxan 37169-36-1P 41395-10-2P
54551-83-6P 57234-29-4P 73852-17-2P, 2,6-Dichlorobenzeneboronic
acid 80257-12-1P 104202-36-0P 112766-18-4P 115130-81-9P
123796-61-2P 139887-64-2P 153037-34-4P 153037-35-5P
158152-56-8P 158580-15-5P 158580-33-7P 192211-90-8P
193420-30-3P 193420-35-8P 204972-82-7P 232275-35-3P
232275-36-4P 232275-37-5P 232275-38-6P 232275-39-7P 232275-4
0-0P 232275-41-1P 232275-42-2P 232275-43-3P 232275-44-4P
232275-45-5P 232275-46-6P 232275-47-7P 232275-48-8P
232275-49-9P 232275-50-2P 232275-51-3P 232275-52-4P
232275-53-5P 232275-54-6P 232275-55-7P 232275-56-8P
232275-57-9P 232275-58-0P 232275-59-1P
232275-60-4P 232275-61-5P 232275-62-6P 232275-63-7P
232275-64-8P 232275-65-9P 232275-66-0P 232275-67-1P
232275-68-2P 232275-69-3P 232275-70-6P 232275-71-7P
232275-72-8P 232275-73-9P 232275-74-0P 232275-75-1P
232275-76-2P 232275-77-3P 232275-78-4P 232275-79-5P
232275-80-8P 232275-81-9P 232275-82-0P 232275-83-1P
232275-84-2P 232275-85-3P 232275-86-4P 232275-87-5P
232275-88-6P 232275-89-7P 232275-90-0P 232275-91-1P
232275-92-2P 232275-93-3P 232275-94-4P 232275-95-5P
232275-96-6P 232275-97-7P 232275-98-8P 232276-00-5P
232276-01-6P 232276-02-7P 232276-03-8P 232276-04-9P
232276-06-1P 232276-07-2P 232276-08-3P 232276-09-4P
232276-10-7P 232276-11-8P 232276-12-9P 232276-13-0P
232276-14-1P 232276-15-2P 232276-16-3P 232276-17-4P
232276-18-5P 232276-19-6P 232276-20-9P 232276-21-0P
232276-22-1P 232276-23-2P 232276-24-3P 232276-25-4P
232276-26-5P 232276-27-6P 232276-28-7P 232276-29-8P
232276-30-1P 232276-31-2P 232276-33-4P 232276-34-5P
232276-35-6P 232276-36-7P 232276-37-8P 232276-38-9P
232276-39-0P 232276-40-3P 232276-42-5P 232276-43-6P
232276-44-7P 232276-45-8P 232276-46-9P 232276-47-0P
232276-48-1P 232276-49-2P 232276-50-5P 232276-51-6P
232276-52-7P 232276-53-8P 232276-54-9P 232276-55-0P
232276-56-1P 232276-57-2P 232276-58-3P 232276-59-4P
232276-60-7P 232276-61-8P 232276-62-9P 232276-63-0P
232276-64-1P 232276-65-2P 232276-66-3P 232276-67-4P
232276-68-5P 232276-69-6P 232276-70-9P 232276-71-0P
232276-72-1P 232276-73-2P 232276-74-3P 232276-75-4P
232276-76-5P 232276-77-6P 232276-78-7P 232276-79-8P
232276-80-1P 232276-81-2P 232276-82-3P 232276-83-4P
232276-84-5P 232276-85-6P 232276-86-7P 232276-87-8P
232276-88-9P 232276-89-0P 232276-90-3P 232276-91-4P
232276-92-5P 232276-93-6P 232276-94-7P 232276-95-8P
232276-96-9P 232276-97-0P 232276-98-1P 232276-99-2P
232277-00-8P 232277-01-9P 232277-02-0P 232277-03-1P

232277-04-2P 232277-05-3P 232277-06-4P 232277-07-5P
232277-08-6P 232277-09-7P 232277-10-0P 232277-11-1P
232277-12-2P 232277-13-3P 232277-18-8P 232277-29-1P
232277-30-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)
(prepn. of N-acyl-phenylalanine derivs. as inhibitors of
α4-mediated cell adhesion for prevention and
treatment of **diseases** caused by
α4-mediated cell adhesion)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>